CONTEMPORARY ENDOCRINOLOGY ™
Transgenics in Endocrinology Edited by
Martin M. Matzuk, MD, PhD Chester W. Brown, MD, Ph...
50 downloads
1911 Views
4MB Size
Report
This content was uploaded by our users and we assume good faith they have the permission to share this book. If you own the copyright to this book and it is wrongfully on our website, we offer a simple DMCA procedure to remove your content from our site. Start by pressing the button below!
Report copyright / DMCA form
CONTEMPORARY ENDOCRINOLOGY ™
Transgenics in Endocrinology Edited by
Martin M. Matzuk, MD, PhD Chester W. Brown, MD, PhD T. Rajendra Kumar, PhD
HUMANA PRESS
Contents
i
TRANSGENICS IN ENDOCRINOLOGY
ii
Contents
CONTEMPORARY ENDOCRINOLOGY P. Michael Conn, SERIES EDITOR Difficult Cases in Endocrinology, edited by MARK E. MOLITCH, 2002 Selective Estrogen Receptor Modulators: Research and Clinical Applications, edited by ANDREA MANNI AND MICHAEL F. VERDERAME, 2002 Transgenics in Endocrinology, edited by MARTIN MATZUK, CHESTER W. BROWN, AND T. RAJENDRA KUMAR, 2001 Assisted Fertilization and Nuclear Transfer in Mammals, edited by DON P. WOLF AND MARY ZELINSKI-WOOTEN, 2001 Adrenal Disorders, edited by ANDREW N. MARGIORIS AND GEORGE P. CHROUSOS, 2001 Endocrine Oncology, edited by STEPHEN P. ETHIER, 2000 Endocrinology of the Lung: Development and Surfactant Synthesis, edited by CAROLE R. MENDELSON, 2000 Sports Endocrinology, edited by MICHELLE P. WARREN AND NAAMA W. CONSTANTINI, 2000 Gene Engineering in Endocrinology, edited by MARGARET A. SHUPNIK, 2000 Endocrinology of Aging, edited by JOHN E. MORLEY AND LUCRETIA VAN DEN BERG, 2000 Human Growth Hormone: Research and Clinical Practice, edited by ROY G. SMITH AND MICHAEL O. THORNER, 2000 Hormones and the Heart in Health and Disease, edited by LEONARD SHARE, 1999 Menopause: Endocrinology and Management, edited by DAVID B. SEIFER AND ELIZABETH A. KENNARD, 1999 The IGF System: Molecular Biology, Physiology, and Clinical Applications, edited by RON G. ROSENFELD AND CHARLES T. ROBERTS, JR., 1999 Neurosteroids: A New Regulatory Function in the Nervous System, edited by ETIENNEEMILE BAULIEU, MICHAEL SCHUMACHER, AND PAUL ROBEL, 1999 Autoimmune Endocrinopathies, edited by ROBERT VOLPÉ, 1999 Hormone Resistance Syndromes, edited by J. LARRY JAMESON, 1999 Hormone Replacement Therapy, edited by A. WAYNE MEIKLE, 1999 Insulin Resistance: The Metabolic Syndrome X, edited by GERALD M. REAVEN AND AMI LAWS, 1999 Endocrinology of Breast Cancer, edited by ANDREA MANNI, 1999 Molecular and Cellular Pediatric Endocrinology, edited by STUART HANDWERGER, 1999 Gastrointestinal Endocrinology, edited by GEORGE H. GREELEY, JR., 1999 The Endocrinology of Pregnancy, edited by FULLER W. BAZER, 1998 Clinical Management of Diabetic Neuropathy, edited by ARISTIDIS VEVES, 1998 G Proteins, Receptors, and Disease, edited by ALLEN M. SPIEGEL, 1998 Natriuretic Peptides in Health and Disease, edited by WILLIS K. SAMSON AND ELLIS R. LEVIN, 1997 Endocrinology of Critical Disease, edited by K. PATRICK OBER, 1997 Diseases of the Pituitary: Diagnosis and Treatment, edited by MARGARET E. WIERMAN, 1997 Diseases of the Thyroid, edited by LEWIS E. BRAVERMAN, 1997 Endocrinology of the Vasculature, edited by JAMES R. SOWERS, 1996
Contents
iii
TRANSGENICS IN ENDOCRINOLOGY Edited by
MARTIN M. MATZUK, MD, PhD CHESTER W. BROWN, MD, PhD and
T. RAJENDRA KUMAR, PhD Baylor College of Medicine, Houston, TX
HUMANA PRESS TOTOWA, NEW JERSEY
iv
Contents
© 2001 Humana Press Inc. 999 Riverview Drive, Suite 208 Totowa, New Jersey 07512 www.humanapress.com All rights reserved. No part of this book may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording, or otherwise without written permission from the Publisher. Cover design by Patricia F. Cleary. Production Editor: Kim Hoather-Potter. All articles, comments, opinions, conclusions, or recommendations are those of the author(s), and do not necessarily reflect the views of the publisher. Due diligence has been taken by the publishers, editors, and authors of this book to assure the accuracy of the information published and to describe generally accepted practices. The contributors herein have carefully checked to ensure that the drug selections and dosages set forth in this text are accurate and in accord with the standards accepted at the time of publication. Notwithstanding, as new research, changes in government regulations, and knowledge from clinical experience relating to drug therapy and drug reactions constantly occurs, the reader is advised to check the product information provided by the manufacturer of each drug for any change in dosages or for additional warnings and contraindications. This is of utmost importance when the recommended drug herein is a new or infrequently used drug. It is the responsibility of the treating physician to determine dosages and treatment strategies for individual patients. Further it is the responsibility of the health care provider to ascertain the Food and Drug Administration status of each drug or device used in their clinical practice. The publisher, editors, and authors are not responsible for errors or omissions or for any consequences from the application of the information presented in this book and make no warranty, express or implied, with respect to the contents in this publication. This publication is printed on acid-free paper. ' ANSI Z39.48-1984 (American National Standards Institute) Permanence of Paper for Printed Library Materials. Photocopy Authorization Policy: Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by Humana Press Inc., provided that the base fee of US $10.00 per copy, plus US $00.25 per page, is paid directly to the Copyright Clearance Center at 222 Rosewood Drive, Danvers, MA 01923. For those organizations that have been granted a photocopy license from the CCC, a separate system of payment has been arranged and is acceptable to Humana Press Inc. The fee code for users of the Transactional Reporting Service is: [0-89603-764-9/01 $10.00 + $00.25]. Printed in the United States of America. 10 9 8 7 6 5 4 3 2 1 Library of Congress Cataloging-in-Publication Data Transgenics in endocrinology/edited by Martin M. Matzuk, Chester W. Brown, and T. Rajendra Kumar. p. cm. — (Contemporary endocrinology) Includes bibliographical references and index. ISBN 0-89603-764-9 (alk. paper) 1. Molecular endocrinology. 2. Transgenic mice. 3. Transgenic organisms. 4. Endocrinology—Research—Methodology. I. Matzuk, Martin M. II. Brown, Chester W. III. Kumar, T. Rajendra. IV. Contemporary endocrinology (Totowa, N.J.) QP187.3.M64 T73 2001 573.4'19—dc21 00-067291
Contents P REFACE
v
“Man’s mind stretched to a new idea, never goes back to its original dimensions.” Oliver Wendell Holmes The latter part of the 20th century has seen an amazing change in how we view and synthesize endocrinology. Prior to the 1980s, we understood endocrine disorders and the field of endocrinology through patients with genetic mutations, protein purification, physiological experiments in humans and whole animals, tissue culture cells, and radioimmunoassays. Little did we know that the field of endocrinology (and all of genetics) would move by leaps and bounds because of a simple mammalian model—a mouse that grew twice as fast as its fellow littermates. As students at the time, we were fascinated by these mice, glorified by their appearance on the 1982 and 1983 covers of Nature and Science. These transgenic mice, created by Drs. Ralph Brinster and Richard Palmiter and colleagues, were the first endocrine models created by genetic manipulation—mice carrying a mouse metallothionein I promoter driving the expression of either rat growth hormone (1982) or human growth hormone (1983). The expression of the foreign growth hormone genes (transgenes) resulted in “gigantic mice” because of the growth hormone excess. Clearly, for our field and all of biology, the phrase “a picture is worth a thousand words” rang true on those autumn days in 1982 and 1983 and generated a movement that revolutionized our thinking. Little did we realize that a second revolution was already evolving that would take hold of the field in the decade to follow. In the early 1980s, Dr. Martin Evans’ laboratory first isolated cell lines from the inner cell mass of mouse blastocysts that could be propagated in culture, maintain their pluripotency, and contribute to the germline. These so-called embryonic stem (ES) cell lines, first used with retroviral infection in an attempt to model the human Lesch-Nyhan syndrome, became valuable genetic conduits to mimic and better understand endocrine disorders and systems. In parallel with the development of ES cells, Oliver Smithies and colleagues showed in 1985 that they could achieve homologous recombination to correct a mutation in the human `-globin locus in mammalian tissue culture cells. Although this was heralded as a major breakthrough for the possible correction of human genetic diseases, it more importantly suggested that germline mutations of endogenous mammalian genes could be created. Homologous recombination in ES cell lines along with the so-called positive–negative selection strategy developed in the laboratory of Dr. Mario Capecchi, laid the foundation for “knockout” technology with more far-reaching implications than were envisioned at the early stages. The first knockout models were subsequently created with great excitement in the early 1990s including mice lacking the endocrine factors insulin-like growth factor II (1990), transforming growth factor-`1 (1992), and inhibin (1992). As you will see in the following chapters, thousands of transgenics have been created to study and manipulate the endocrine system. Some of these models have given expected results, whereas analysis of the phenotype of others has revealed novel functions for these endocrine factors. Clearly, transgenesis has given endocrinologists a new tool for understanding structure/function relationships in vivo. In closing, we graciously thank all of the authors of Transgenics in Endocrinology for accepting our challenge to write state-of-the-art chapters on their specific topics. Writing v
vi vi
Contents Preface
reviews of ever-changing fields is not an easy task, but we honestly believe each chapter to be a work of art. Because all of the authors are experts in their respective areas, it has been a pleasure to read these bodies of work and to be part of the editorial process. We would also like to thank Michael Conn for having enough confidence in us to edit this volume of diverse topics, the first of its kind for the three of us. A great deal of thanks also goes to Ms. Shirley Baker who coordinated the correspondences with the authors and incorporated all of our editorial scribbles. Lastly, to all of the readers of this book, enjoy the chapters and the immense body of literature that has been published in the field of transgenics and endocrinology over the last two decades. We hope that Transgenics in Endocrinology will instill much excitement and insight into your endocrine research endeavors in the 21st century. Martin M. Matzuk, MD, PhD Chester W. Brown, MD, PhD T. Rajendra Kumar, PhD
Contents C ONTENTS
vii
Preface ........................................................................................................ v Contributors .............................................................................................. ix 1
2
3
4 5
6
7
8
Germline Genetic Engineering Techniques in Endocrinology ........ 1 Albert S. Y. Chang, Michael J. Reardon, and Francesco J. DeMayo The Transgenic Mouse in Studies of Mammalian Sexual Differentiation ............................................................................. 19 Deanne J. Whitworth and Richard R. Behringer The In Vivo Function of Müllerian-Inhibiting Substance During Mammalian Sexual Development ................................. 41 Yuji Mishina Control of Ovarian Function ........................................................... 61 Julia A. Elvin and Martin M. Matzuk Mouse Models to Study the Pituitary-Testis Interplay Leading to Regulated Gene Expression ................................................... 91 Emiliana Borrelli, T. Rajendra Kumar, and Paolo Sassone-Corsi Functional Analysis of the Bcl2 Gene Family in Transgenic Mice ................................................................... 115 Andrea J. Ross and Grant R. MacGregor The Role of C-Kit/Kit Ligand Axis in Mammalian Gametogenesis ................................................. 147 Peter J. Donovan and Maria P. de Miguel Gene Knockout Approaches to Steroidogenesis .......................... 165 Tomonobu Hasegawa, Liping Zhao, Kathleen M. Caron, Morag Young, and Keith L. Parker
9
The Progesterone Receptor Knockout Mouse Model: New Insights into Progesterone Action In Vivo ....................... 173 John P. Lydon, Selma Soyal, Bert W. O’Malley, and Preeti M. Ismail
10
Knockout and Transgenic Mouse Models that Have Contributed to the Understanding of Normal Mammary Gland Development .................................................................. 205 Tiffany N. Seagroves and Jeffrey M. Rosen Prolactin and the Prolactin Receptor ............................................ 231 Nelson D. Horseman Transgenic Models for Oxytocin and Vasopressin ...................... 245 Larry J. Young and Thomas R. Insel
11 12
vii
viii
Contents
viii
Contents
13
Glycoprotein Hormones: Transgenic Mice as Tools to Study Regulation and Function ........................................... 261 Ruth A. Keri and John H. Nilson
14
Genetic Approaches to the Study of Pituitary Follicle-Stimulating Hormone Regulation .............................. 297 Daniel J. Bernard and Teresa K. Woodruff
15
Transgenic Analysis of the Proopiomelanocortin Neuroendocrine System .......................................................... 319 Malcolm J. Low, Marcelo Rubinstein, and E. Cheng Chan
16
Overexpression and Targeted Disruption of Genes Involved in the Control of Growth, Food Intake, and Obesity .............................................................................. 339 Andrzej Bartke and Michael Michalkiewicz Insulin and Insulin-Like Growth Factors: Targeted Deletion of the Ligands and Receptors ................................... 371 Carolyn A. Bondy and Domenico Accili
17
18
Use of Transgenic Animals in Skeleton Biology ........................ 385 Thomas Günther, Mary Jo Doherty, and Gerard Karsenty
19
Transgenic Mouse Models of Prostate Cancer............................ 401 Robert J. Matusik, Naoya Masumori, Tania Thomas, Thomas Case, Manik Paul, Susan Kasper, and Scott B. Shappell
20
Neural- and Endocrine-Cell-Specific Immortalization Using Transgenic Approaches ................................................ 427 T. Rajendra Kumar
Index...................................................................................................... 469
Contents C ONTRIBUTORS
ix
DOMENICO ACCILI, MD, Developmental Endocrinology Branch, NIH-NICHD, Bethesda, MD ANDRZEJ BARTKE, PhD, Department of Physiology, Southern Illinois University School of Medicine, Carbondale, IL RICHARD R. BEHRINGER, PhD, Department of Molecular Genetics, University of Texas MD Anderson Cancer Center, Houston, TX DANIEL J. BERNARD, PhD, Department of Neurobiology and Physiology, Northwestern University, Evanston, IL CAROLYN A. BONDY, MD, Developmental Endocrinology Branch, NIH-NICHD, Bethesda, MD EMILIANA BORRELLI, PhD, Institut de Genetique et de Biologie Moleculaire et Cellulaire, Strasbourg, France CHESTER W. BROWN, MD, PhD, Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX KATHLEEN M. CARON, PhD, Department of Human Genetics, University of North Carolina-Chapel Hill, Chapel Hill, NC THOMAS CASE, BS, Vanderbilt University Medical Center, Nashville, TN E. CHENG CHAN, PhD, University of New Castle, Australia ALBERT S. Y. CHANG, MD, Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX FRANCESCO J. DEMAYO, PhD, Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX MARIA P. DE MIGUEL, PhD, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA MARY JO DOHERTY, PhD, Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX PETER J. DONOVAN, PhD, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA JULIA A. ELVIN, PhD, Departments of Pathology, and Molecular and Human Genetics, Baylor College of Medicine, Houston, TX THOMAS GÜNTHER, PhD, Department of Obstetrics and Gynecology, Freiburg University Medical Center, Freiburg, Germany TOMONOBU HASEGAWA, MD, PhD, Department of Pediatrics, Keio University, Tokyo, Japan NELSON D. HORSEMAN, PHD, Department of Molecular and Cellular Physiology, University of Cincinnati, Cincinnati, OH THOMAS R. INSEL, PhD, Emory University, Atlanta, GA PREETI M. ISMAIL, PhD, Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX GERARD KARSENTY, MD, PhD, Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX SUSAN KASPER, PhD, Vanderbilt University Medical Center, Nashville, TN RUTH A. KERI, PhD, Department of Pharmacology, Case Western Reserve Medical School, Cleveland, OH T. RAJENDRA KUMAR, PhD, Departments of Pathology, and Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX ix
x
Contributors Contents
MALCOLM J. LOW, MD, PhD, Vollum Institute, Oregon Health Sciences University, Portland, OR JOHN P. LYDON, PhD, Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX GRANT R. MACGREGOR, DPhil, Center for Molecular Medicine, Emory University School of Medicine, Atlanta, GA NAOYA MASUMORI, MD, PhD, Sapporo Medical University School of Medicine, Sapporo, Japan ROBERT J. MATUSIK, PhD, Department of Urologic Surgery,Vanderbilt University Medical Center, Nashville, TN MARTIN M. MATZUK, MD, PhD, Departments of Pathology, Molecular and Cellular Biology, and Molecular and Human Genetics, Baylor College of Medicine, Houston, TX MICHAEL MICHALKIEWICZ, DVM, PhD, West Virginia University Health Sciences Center, Morgantown, WV YUJI MISHINA, PhD, National Institute of Environmental Health Sciences/NIH, Research Triangle Park, NC JOHN H. NILSON, PhD, Department of Pharmacology, Case Western Reserve Medical School, Cleveland, OH BERT W. O’MALLEY, MD, Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX KEITH L. PARKER, MD, PhD, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX MANIK PAUL, BS, Vanderbilt University Medical Center, Nashville, TN MICHAEL J. REARDON, MD, Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX JEFFREY M. ROSEN, PhD, Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX ANDREA J. ROSS, PhD, Center for Molecular Medicine, Emory University School of Medicine, Atlanta, GA MARCELO RUBENSTEIN, PhD, Universidad de Buenos Aires, Buenos Aires, Argentina PAOLO SASSONE-CORSI, PhD, Institut de Genetique et de Biologie Moleculaire et Cellulaire, Strasbourg, France TIFFANY N. SEAGROVES, PhD, Department of Molecular and Cellular Biology, University of California, San Diego, CA SCOTT B. SHAPPELL, MD, PhD, Vanderbilt University Medical Center, Nashville, TN SELMA SOYAL, PhD, Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX TANIA THOMAS, PhD, Vanderbilt University Medical Center, Nashville, TN DEANNE J. WHITWORTH, PhD, Department of Molecular Genetics, University of Texas MD Anderson Cancer Center, Houston, TX TERESA K. WOODRUFF, PhD, Department of Neurobiology and Physiology, Northwestern University, Evanston, IL LARRY J. YOUNG, PhD, Center for Behavioral Neuroscience, Emory University School of Medicine, Atlanta, GA MORAG YOUNG, PhD, Baker Medical Research Institute, Melbourne, Australia LIPING ZHAO, PhD, Departments of Internal Medicine and Pharmacology, UT Southwestern Medical Center, Dallas, TX
Chapter 1/Germline Genetic Engineering Techniques
1
1
Germline Genetic Engineering Techniques in Endocrinology Albert S. Y. Chang, MD, Michael J. Reardon, MD, and Francesco J. DeMayo, PHD CONTENTS INTRODUCTION INTRODUCTION OF GENETIC ELEMENTS INTO THE MURINE GENOME MODIFICATION OF ENDOGENOUS MURINE GENES NEW TECHNOLOGIES FOR GENETIC ALTERATION OF THE MURINE GENOME ACKNOWLEDGMENTS REFERENCES
INTRODUCTION The latter half of the twentieth century exhibited great progress in the ability to understand and control the mammalian reproductive cycle and endocrinology. A direct result of the advancements in reproductive endocrinology was the ability to manipulate the mammalian genome. The advancements in reproductive endocrinology allowed foreign genes to be introduced in a regulated manner into the genome. Genes can now be ablated or mutated in subtle and specific ways, and entire genomes have been replicated—a process termed “cloning.” Advances in reproductive endocrinology, combined with developments in molecular biology, led to an explosion in biotechnology at the end of the twentieth century. Although the advances in molecular biology were at the core of this explosion, the true power of the molecular techniques could not have been realized without the ability to generate living mammalian organisms with the appropriate genetic manipulations. This allowed the manipulations to be investigated in a model that met the constraints of developmental and physiological regulation. Using the combination of the advances in the disciplines of endocrinology and molecular biology, new models for development, physiology, and disease could be generated. The goal of this chapter is to review the technologies involved in the introduction, manipulation, and replication of the mammalian genome. This chapter examines these technologies and addresses the nuances and limitations of these approaches. Because the mouse is the easiest mammalian model to manipulate, this chapter will focus on the mouse model. From: Contemporary Endocrinology: Transgenics in Endocrinology Edited by: M. Matzuk, C. W. Brown, and T. R. Kumar © Humana Press Inc., Totowa, NJ
1
2
Chang, Reardon, and DeMayo
INTRODUCTION OF GENETIC ELEMENTS INTO THE MURINE GENOME Success in the introduction of foreign DNA into a genome depends upon the ability to ensure that the DNA integrates into the germline. This allows the stable integration of the foreign DNA into the genome, and the transmission of the manipulation to future generations, thus establishing a new and novel strain of the organism. Therefore, techniques to introduce foreign DNA into a genome have centered on introducing the DNA into either the preimplantation embryo or the gamete. The most successful of these approaches has been the introduction of DNA into the male pronucleus of the one-cell mouse embryo (1). However, recent advances in sperm freeze-drying and intracellular sperm injection (ICSI) of mouse oocytes may lead to the development of this technology for future use (2). Introduction of DNA into the preimplantation embryo ensures a high probability that the foreign DNA will incorporate into as many of the developing cells as possible. With introduction into these earlier cleavage stages, the probability of the integration of the DNA into the germline is higher. Two techniques have been successfully utilized to accomplish this goal. One approach utilizes murine retroviruses to infect eight-cell mouse embryos (3). This approach has been very effective in generating animals with incorporation of the viral DNA into the murine genome. Because it involves a very hearty stage of preimplantation development, the eight-cell mouse embryo is very easily manipulated in vitro, and embryo transfer of these manipulated embryos results in a high percentage of mice born per embryo transferred. Because retroviral infection is very efficient with this approach, it holds a great deal of promise. However, there are two major flaws in this approach. First, since infection occurs at the eight-cell stage, the animals developed from such manipulations have been mosaic—the virus integrates at different sites in the different blastomeres of the eight-cell mouse embryo. Therefore, the integration sites needed to be sorted out in the first few generations of the newly established strain (4). However, the fatal flaw in this approach was that one could not achieve reproducible expression of the foreign DNA. This was a result of the constraints of packaging the foreign DNA construction into the virus, in addition to still undefined reasons why the viral genome may have inhibited transgene expression when integrated into the murine genome (5). Because of the limitations of the retroviral approach and the success of introducing DNA directly into the murine genome by microinjection of the one-cell mouse embryo, the latter approach has dominated the field, and has become the standard process for the generation of transgenic mice. The ability to introduce foreign DNA into the murine genome by microinjection of DNA into the one-celled embryo was first reported by Gordon and colleagues in 1981 (6). This technique has changed little in the 20 yr since its first report. The approach requires the ability to manipulate the one-cell mouse embryo, and is demanding in terms of skill and equipment. However, it confers the ability to reproducibly generate transgenic mice that express the transgene of interest. This approach has expanded many lines of research. First, it has made possible the investigation of elements that are responsible for the appropriate spatial and temporal regulation of gene expression in vivo. This has allowed the identification of tissue-specific promoters that will direct gene expression in an appropriate manner. Second, investigators can utilize these promoters to direct the expression of regulatory genes to desired tissues, allowing the analysis of the role these
Chapter 1/Germline Genetic Engineering Techniques
3
Fig. 1. Schematic for the generation of transgenic mice by DNA microinjection techniques. For embryo collection, female mice are treated with a superovulatory regimen of gonadotropins, consisting of pregnant mare serum gonadotropin (PMSG) followed by human chorionic gonadotropin (hCG) 48 h later. The donor females are then placed with a male mouse, and the embryos are collected the following morning. Embryos are harvested, processed, and readied for injection. Approximately 2 pl of DNA [2 ng/µL] is injected into the one-cell embryo and transferred to a synchronized, psuedopregnant female recipient mouse. The recipients are allowed to gestate to birth, and the offspring are screened for the presence of the transgene using Southern blot analysis or PCR.
proteins play in tissue development when their expression is disrupted. Finally, as a result of transgene integration, regulatory genes are sometimes disrupted. These insertional mutations have allowed the identification of genes involved in limb formation, which occurs at a low frequency, as well as the regulation of left/right asymmetry and other processes. Although the ability to generate transgenic mice by pronuclear microinjection is laborious, the power of the approach has proven the technology worthwhile (1). Hogan and colleagues have described the procedure for the generation of transgenic mice in detail (7). Figure 1 describes the general schematic for the generation of transgenic mice by DNA microinjection, which consists of the preparation of the transgene, collection, injection, and transfer of the embryos, and identification of the transgenic offspring.
Preparation of Transgene DNA In order to ensure maximum efficiency in the development of transgenic mice, the DNA fragment to be injected must be pure and accurately quantitated. The DNA to
4
Chang, Reardon, and DeMayo
be injected must be digested with the appropriate restriction endonuclease(s) to free the transgene from prokaryotic vector sequences (8). The incorporation of prokaryotic sequences inhibits expression of transgenes in the murine genome. The transgene is usually separated from the vector sequences by agarose-gel electrophoresis. The appropriate fragment is excised, purified, and quantitated by measuring the optical density (OD) of the sample at 260 nm. The purity of the fragment is estimated by measuring the OD at 280 nm and comparing the ratio of OD 260:OD 280. Once the isolated DNA is verified as the correct fragment and quantitated, the DNA is diluted to 2 ng/µL in TE buffer (10 mM Tris pH 7.5, 0.25 mM ethylenediaminetetraacetic acid [EDTA]). The DNA is then microinjected into the male pronucleus of one-cell mouse embryos. This buffer and concentration has been shown to be optimal for incorporation of the transgene into the murine genome (8).
Embryo Collection, Microinjection, and Embryo Transfer The strain of the mouse is important for the success of microinjection. Theoretically, transgenic mice can be made in any reproductively viable stain. However, to maximize the chance of obtaining transgenic mice, it is best to collect a large number of fertilized one-cell mouse embryos after treating female mice with a superovulatory regimen of gonadotropins and mating with an intact male mouse. The ability to collect these embryos is dependent upon strain, age, and dose of gonadotropins (7). The majority of transgenic mice are made with either hybrid strains of mice, such as C57Bl/6J X SJL (8) or the inbred FvB/N strain (9). Hybrid strains have the advantage of having females that respond well to the superovulatory regimen of gonadotropins and males that are sexually aggressive, mating at a high frequency with the induced female mice. However, the reproductive advantage of the hybrid males comes at the price of the lack of genetic uniformity that can be achieved by an inbred strain. The FvB strain of mice has the advantage of responding reasonably well to gonadotropins. Although inbred lines are not usually as virile and fertile as hybrids, the FvB strain produces suitable numbers of embryos for the generation of transgenic mice. This strain also offers the advantage of pronuclei that are slightly larger than other inbred strains of mice, giving the novice microinjector help with DNA injections (9). These advantages have made the FvB strain of mice the major choice of mouse strain utilized in the generation of transgenic mice. However, with the advent of knockout technology utilizing embryonic stem (ES) cells isolated from 129/Sv mice, the chimeras generated from this procedure have typically been bred to C57Bl/6J to rapidly analyze the contributions of the ES cells to the germline (10). The mice initially generated from the chimeric cross are hybrid C57Bl/6JX129/Sv mice, since the two predominant strains for gene knockout analysis are 129/Sv and C57Bl/6J. Thus, the C57Bl/6J strain has re-emerged as a popular strain for transgenics. Transgenic mice are produced as described by Hogan and colleagues (7). Briefly, onecell embryos are collected from mice receiving a superovulatory regimen of gonadotropins. The dose of gonadotropins and age of the donor female is critical. The response of female mice to the gonadotropins is maximal at prepuberty. Therefore, mice at 3 wk of age and 10–12 g of weight are optimal for the production of embryos. Also, the dose of gonadotropins may vary with the strain. Usually, 5 international units (IU) of pregnant mare serum gonadotropin (PMSG) or equine chorionic gonadotropin (eCG) is given by intraperitoneal injection, and 48 h later, the mice receive an intraperitoneal injection of human chorionic gonadotropins (hCG). The female is then placed with the male, and the
Chapter 1/Germline Genetic Engineering Techniques
5
embryos are collected the following morning. However, some inbred strains do not respond well to this regimen of gonadotropins, and usually respond to half the above dose to produce an acceptable number of embryos for microinjection. The morning following mating, the females are examined for the presence of a postcoital vaginal copulatory plug. The mice are euthanized, and the oviducts are excised. The embryos are liberated and collected by flushing or mincing the oviducts. Once the embryos are collected, they are briefly incubated in medium with hyaluronidase to remove the cumulus mass. The embryos are washed, and the embryos containing visible pronuclei are separated from the unfertilized embryos, placed in a HEPES-buffered medium (M2), and readied for microinjection (7). The embryos are microinjected with 2 pl of DNA at a concentration of 2 ng/µL (8), using the aid of an inverted microscope equipped with differential contrast optics—usually Nomarski or Hoffman objective lenses—and micromanipulators. Maximizing the production of transgenic mice is dependent upon the amount of DNA delivered to the male pronucleus, and also to the expansion of the pronucleus. It has been postulated that the hydrostatic pressure of the microinjection of DNA causes breaks in the chromatin. The DNA repair process then integrates the transgene into the chromatin. Therefore, it is important to deliver not only a specified amount of DNA, but also the appropriate volume of injection medium. The 2 pl of 2 ng/µL of DNA is the ideal compromise (8). However, there is a fine line between the injection of the maximum volume of DNA and the volume tolerated by the embryo for survival. The usual survival after microinjection is 70–80%. In our studies, higher survival rates than this is associated with a low frequency of transgene incorporation. The embryos surviving microinjection are transferred to the oviducts of synchronized, pseudopregnant ICR female mice. The recipients are allowed to gestate the embryos to birth, and to nurse the pups till weaning. Normally, 18–20 embryos are transferred to the oviducts of recipients, with only 20% of these transferred embryos surviving to birth because the survival of uninjected embryos is significantly higher, while the microinjected embryos suffer significant preimplantation loss. At weaning, the pups are identified by an ear tag, and screened for the presence of the transgene. The efficiency of the generation of transgenic mice is measured by the number of transgenic mice generated per number of embryos injected, and is generally at least 1–2% (8).
Identification of Transgenic Mice Once the mice born from the microinjection of DNA have been weaned, they are ready to be genotyped for the presence of the transgene. DNA is routinely isolated from tail biopsies and screened by either Southern blot analysis (11) or polymerase chain reaction (PCR) (12). PCR screening of transgenic mice is by far the easiest and most rapid way to identify mice. However, limited information can be obtained by PCR screening of transgenic mice. Southern blot analysis, although slower and more laborious than PCR, is extremely useful to gain some initial information regarding the genetics of the founder transgenic mice (F0). Southern blot analysis may be used to determine whether the integrated transgene is intact, as well as the number of copies of the transgene that have been integrated into the murine genome. The number of copies is important if the transgene integrates at more than one site in the murine genome, and helps to determine whether the transgene expression is proportional to the number of integrated transgenes—a rare phenomenon.
6
Chang, Reardon, and DeMayo
Transgenes usually integrate into the genome randomly, and usually in multiple, head-to-tail tandem copies (13). The power of introducing DNA into the murine genome at the one-cell stage is that the incorporation of the transgene is early, and has the potential to be incorporated into every cell in the mouse. Therefore, when the founders are bred, they transmit the transgene to one-half of their offspring. However, in about 30% of cases, the transgene integrates at a later stage, and not every cell in the F 0 has incorporated the transgene. These animals are considered mosaics, and they transmit the transgene at a significantly lower frequency (14). In some cases, the F 0 transmits the transgenes at a significantly higher frequency than 50%. Barring a phenotypic consequence of the transgene, this is usually a result of the transgene being integrated at two or more sites on separate chromosomes. It is important to monitor this phenomenon. F0 mice with multiple integrations of the transgene must be bred to isolate each integration site. Each transgene-integration site should be treated as a separate strain of transgenic mouse, because the expression properties of each integration site may be significantly different. In this case, the use of Southern blot analysis of the first generation of offspring (F1 mice) is important because it is necessary to design a strategy that can distinguish each of the transgene integration sites by either copy number or site of integration.
Transgene Expression Once breeding lines are established for each F0, expression analysis can safely be performed. The type of expression analysis conducted depends upon the specific question being addressed by the investigator. However, the generation of a specific phenotype from a transgene should not be used as the sole judgment in whether a transgene is expressed. RNA or protein analysis should be conducted to validate the expression of a transgene. Expression and phenotypic analysis should be confirmed with at least two independent lines of transgenic mice to ensure that the observed phenotype is caused by the expression of the transgene, and not the result of a change in the expression or disruption of an endogenous gene caused by the insertion of the transgene. In general, several rules should be followed regarding the expression of the transgene. First, the chromosomal environment in which the transgene is inserted usually influences its expression (1). Therefore, without the incorporation of specific sequences to ensure that the transgene can be “insulated” from surrounding elements, the expression of the transgene will vary from F0 to F0. Second, expression of the transgene is rarely proportional to the number of copies of the transgene that have been inserted into the mouse genome. Only in rare instances do promoter fragments contain elements that allow the transgene expression to be proportional to the number of transgenes integrated into the chromatin (15). Third, transgene expression is usually dependent upon the incorporation of genomic sequences in the transgene. Thus, transgenes containing cDNA sequences rather than genomic sequences are expressed at a significantly reduced frequency (6). As a rule, genomic sequences—i.e., introns—should be incorporated into the transgene to maximize expression. First priority should be given to designing transgenes that contain the sequences corresponding to the gene to be expressed. If this is not possible, minigenes can be constructed from heterologous introns to enhance expression. However, no guarantee can be given that a prescribed minigene will be effective in conferring high levels of expression of the transgene (17).
Chapter 1/Germline Genetic Engineering Techniques
7
Bitransgenic Regulatory Systems There are several disadvantages to the use of traditional transgenic technology in the generation of animal models. First, the initiation of transgene expression in mice is under the sole control of the elements regulating the developmental expression of these specific transgene promoters. Second, the level of expression of transgenes under the control of these promoters is dependent upon the relative strength of transcription of these promoters, as well as the site of integration of the transgene. Finally, the expression of the transgene is continuous and irreversible in the animal. This approach makes it difficult to differentiate the critical secondary events required for the generation of a specific phenotype. A system in which transgene expression could be regulated by the investigator would be a significant improvement over current models. Such a system could be used to investigate the changes resulting from the acute expression of the transgene. The system could also be used to examine the result of withdrawing transgene expression and identifying the events that follow. Over the last decade, three bitransgenic regulatory systems have been developed that allow for controlled transgene expression. These bitransgenic systems consist of two lines of transgenic mice generated from two transgene constructions, as shown in Fig. 2. One transgene construction, the regulator, encodes a transcription factor with transcriptional regulatory activity controlled by the administration of an exogenous compound (ligand). The regulator transgene is placed under the control of DNA promoter elements needed to express the regulator in the tissue of interest. The second transgene construction, the target or responder, contains the gene of interest that has been placed under the transcriptional control of the DNA cis-acting elements that are responsive to the regulator. When the regulator line of transgenic mice and the target line of mice are crossed and the bitransgenic mouse is administered the exogenous compound, the target gene will be expressed. The bitransgenic regulatory system should fulfill the following criteria: 1) The target gene will be silent in the absence of the regulator; 2) The regulator will not impart a phenotype in the absence of the target gene; 3) In the bitransgenic animal, the target gene will be silent in the absence of the ligand; and 4) The ligand will not impart a phenotype. The ability to generate animals in which transgene expression can be regulated is now possible because of the development of three bitransgenic regulatory systems. These systems allow transgene expression to be regulated by the administration of either an insect hormone (ecdysone); an antibiotic (tetracycline); or an antiprogestin (RU486). The most recent of the ligand-inducible bitransgenic regulatory systems is the ecdysone receptor-based regulatory system. This system exploits the insect steroid hormone receptor—the ecdysone receptor—as the regulator to control transgene expression in mice. Although this system fulfills the above criteria for a regulatory system, it is complicated by the fact that the transcriptional regulatory activity of the ecdysone receptor is dependent upon dimerization with members of the retinoic acid receptor family (18,19). Therefore, in order for the bitransgenic system to be effective, the regulator transgene must contain both the ecdysone receptor and a member of the retinoic-acid receptor family under the control of a tissue-specific promoter. Despite this limitation, this system has been demonstrated to be effective in the regulation of the expression of the Escherichia coli `-galactosidase transgene in the T-cells of transgenic mice (20). Recently, this system has been used to regulate transgene expression in the mammary gland (58).
8
Chang, Reardon, and DeMayo
Fig. 2. Bitransgenic system. The regulator transgene encodes a transcription factor and remains inactive until the administration of an exogenous compound (ligand). The target transgene is the gene of interest, and is under the transcriptional control of the DNA cis-acting elements responsive to the regulator. The two lines of mice are crossed, and with the administration of the ligand, the regulator transgene is activated and the target transgene is expressed in the mouse (shaded mouse).
Currently, the most common ligand-dependent, bitransgenic regulatory system employed is the tetracycline-based regulatory system (21). This system utilizes the bacterial tetracycline repressor gene (tet) to activate target genes that are under the control of promoter elements containing the tetracycline response element, the tet operon. Current engineering of the tet gene has generated two forms of this regulator. The first form, the tet transactivator (tTa) will activate transgenes in the absence of tetracycline. In this case, the administration of tetracycline causes the cessation of target-gene expression (22). The second tetracycline-dependent regulator, the reverse-tet transactivator (rtTa), will activate transgene expression with the administration of tetracycline (23). This system has been shown to regulate gene expression in a tissue-ubiquitous fashion (24,25), and in a tissue-specific fashion in tissues such as the heart (26), the beta cells of the pancreas (27), the brain (28), and the salivary glands (29). The third bitransgenic system used to regulate transgene expression in mice is one that utilizes a mutated human progesterone receptor that can activate gene transcription in response to antiprogestins (30). This system is based on the observation that a deletion in the carboxy terminus of the human progesterone gene, which truncates the ligand-
Chapter 1/Germline Genetic Engineering Techniques
9
binding domain of this receptor, causes the receptor to stop binding the endogenous ligand progesterone. It was observed that this mutant could bind antiprogestins and activate gene expression (31). This mutant ligand-binding domain was then used to create a chimeric receptor that consisted of the ligand-binding-domain mutant receptor, the DNA-binding domain of the yeast Gal4 transcription factor, and the activation domain of Herpes simplex virus protein 16, VP16 (VP16-AD). The chimeric receptor was called GLVP. In the presence of antiprogestins, the GLVP regulator transactivates regulatable target genes that contain the Gal4-binding site. This system has been shown to regulate gene expression in vitro using transient transfection, ex vivo after cellular transplantation (30), and in vivo in transgenic mice (32,33).
MODIFICATION OF ENDOGENOUS MURINE GENES The ability to alter genes within the genome has become a powerful tool in the investigation of the genetic regulation of development. This has been made possible by advances in homologous recombination in embryonic stem cells (34). Using this technology, gene expression can be ablated, or specific mutations as small as a single basepair change can be introduced into a desired gene. This technology has been extended to the point that entire genes can be substituted by inserting the coding region for one gene into the regulatory domain of another gene (35). The power of this technology lies in the fact that the effects of these modifications can be observed in the context of a physiological and developmentally regulated system. The ability to modify endogenous murine genes requires the construction of the appropriate targeting vector for homologous recombination, the electroporation and selection of ES cell clones with the appropriate homologous event, the generation of chimeric mice with the targeted ES cells, and the establishment of mouse lines with the desired mutation.
The Targeting Vector The targeting vector to be used in the introduction of mutations into the mouse genome by homologous recombination must be constructed from DNA that is homologous to the strain of mouse from which the ES cells have been derived. It has been shown that the frequency of homologous recombination is significantly increased by the use of syngeneic sequences (36). Since most ES cells are derived from mice of the 129/ Sv strain, most murine genes are now isolated from this strain of mice (37). Once the gene to be mutated has been identified, a targeting construct can be generated. The targeting construct most commonly generated is that of the replacement vector type (34). A schematic of a targeting vector is shown in Fig. 3. The replacement vector contains arms of the genomic sequences that flank a selectable marker. In some cases, the vector is designed to include both positive and negative selection (38). If the goal is to ablate the desired gene, the targeting construct used in the homologous recombination must be designed to generate a deletion of the entire coding region of the gene or the functional domain of the gene. The targeting vector is constructed of homologous flanking DNA sequences ligated to the positive selection marker, usually the neomycinresistance gene under the control of the phosphoglyceratekinase promoter (PGKneo) (10). In order to maximize the recombination event, the targeting construction should contain at least 3 kb of total homologous DNA, although the more sequence included, the better the recombination frequency (39). If the targeting vector incorporates a nega-
10
Chang, Reardon, and DeMayo
Fig. 3. Schematic for the construction of a targeting vector for targeted gene ablation. The gene of interest is identified and mapped (exons are illustrated as rectangles) with appropriate restriction endonuclease sites (X) noted. A targeting construct is made that consists of homologous flanking DNA sequences, a positive selection marker such as the neomycin (Neo) resistance gene, which disrupts exons in the coding sequence of the gene of interest, and a negative selection marker such as the thymidine kinase (TK) gene. A new restriction endonuclease site is introduced into the targeting construct by the NEO gene for screening by Southern blot analysis using a fragment of DNA (probe) outside the targeting construct. The homologous recombination event introduces the mutation into the mouse genome.
tive selection marker, this marker is removed upon correct homologous recombination. The negative selection marker usually consists of the thymidine kinase (TK) negative selection marker (38). Cells cultured in the presence of gangcyclovir that express the TK gene will be selected against. Therefore, the TK negative selection marker is placed at the flanking end of the targeting vector. Upon homologous recombination, the TK is removed, allowing ES cells to survive in culture in the presence of gangcyclovir. However, the use of the negative selection marker only slightly enhances the selection of ES cells with the appropriate recombination event. Also, with the correct design of targeting vectors to insert genetic elements into the murine genome, it has been shown that the use of negative selection to achieve adequate recombination is not unnecessary (40). Therefore, if the TK gene will be incorporated into the design of a construct, it is best to place this as a last step in the generation of the targeting vector. Then, it can be added only when the initial targeting frequency is unacceptably low.
Chapter 1/Germline Genetic Engineering Techniques
11
Electroporation and Selection of ES Cell Clones The success of the generation of mutant mice from ES cell manipulation results from the use of ES cells that have the potential to become part of the germline when aggregated with other embryos in the generation of chimeric mice (41). The 129/Sv strain has been exploited to generate ES cells that are highly efficient in the generation of germline chimeric mice (37). The culture requirements to maintain these ES cells in a pluripotent state depend upon the culture conditions used by the investigator to generate these ES cells. ES cells are usually derived using the procedures described by Robertson (42,43). Blastocysts are collected from the uterus of postcoitum d 3.5 pregnant 129/Sv females. The blastocysts are cultured on feeder cells that are mitotically inactivated by treatment with mytomyocin (10) or gamma irradiation. It has been shown that leukemia-inhibitory factor (LIF) can be used to maintain ES cells in a pluripotent state in culture in lieu of the feeder cells (44). However, the ES cells are usually cultured in the presence of feeders and the media supplemented with LIF to maintain the cells in the pluripotent state. The procedure for the culture of ES cells and the culture media has been previously described (41), and consists of Dulbecco’s modified Eagle’s medium (DMEM) (high-glucose formulation) supplemented with 15% (v/v) fetal calf serum (ES-cell tested, Gibco-BRL, Grand Island, NY), 2 mM glutamine, 5 × 10–5 M, 2-mercaptoethanol (2-ME), 30 µg/mL penicillin, and 50 µg/mL streptomycin (41). The serum used in the ES-cell culture must be tested from the vendor to ensure that the batch of serum used is optimal for ES-cell growth. Although ES cells are pluripotent, their ability to be maintained in pluripotency depends upon the culture conditions and the number of passages the cells have undergone. ES cells at a low passage number are very effective in developing into every cell of the mouse. However, this ability decreases with passage number (45,46). Therefore, to ensure the success of the generation of germline chimeras, low-passage cells, usually passage 10–16, should be employed. Once the targeting construct is generated, ES cells are electroporated with the linearized targeting vector. The ES cells are cultured on a monolayer of mitomycin C or gamma-irradiated feeder cells (42). The ES cells are then placed under G418 selection with or without gangcyclovir selection, depending on whether negative selection is used. Ten days after electroporation, ES cell colonies can be visualized and are picked using a dissecting microscope. ES cell clones are replicated and cryopreserved, and duplicates are screened for homologous recombination using either Southern blot or PCR analysis. Because of the frequency of PCR contamination, Southern blot analysis is the preferred method of choice for screening clones for homologous recombination. The ES-cell genomic DNA is digested with the appropriate restriction endonucleases that will allow for a distinction of the targeted event from the endogenous gene. This endonuclease restriction site is usually a site that has been added or removed from within the targeting construction. The Southern blot is probed with a fragment of DNA from the endogenous gene that is located in a region outside of the targeting vector. This approach allows the identification of targeted clones without interference of random insertions of the targeting vector. Clones showing the appropriate insertion of the targeting vector are then expanded. Further, Southern blot analysis with a variety of restriction endonucleases and probes is usually recommended to verify the fidelity of the targeting event. Once the ES cells with the appropriate insertion are verified, they can be used to generate chimeras.
12
Chang, Reardon, and DeMayo
Fig. 4. Schematic for the generation of chimeric mice from embryonic stem cells. Day 3.5 embryos (blastocysts) are collected from females (illustrated here as a black mouse) treated with a superovulatory regimen of gonadotropins before mating with a male. The embryos (illustrated here as black cells) are microinjected with 8–20 mutant ES cells (illustrated here in color) and transferred to a d 2.5 pseudopregnant female mouse (illustrated here as a white mouse) and allowed to gestate to birth. Offspring are identified by coat color: 129/SV mice have agouti (illustrated here as a purple mouse) color, C57B1/6J have black color (illustrated here as a black mouse), and chimeric mice have mottled agouti and black (illustrated here as a mixed shaded mouse). Chimeric mice are bred with C57B1/6J mice to determine ES-cell lineage and germline incorporation, since the agouti phenotype is dominant over black. Agouti mice can be screened by Southern blot analysis or PCR for further analysis of insertion of targeting vector.
Generation of Chimeric Mice The scheme for the generation of chimeric mice from ES cells is shown in Fig. 4. The procedure has been thoroughly described by Bradley (41). Briefly, chimeric mice are generated by microinjection of 8–20 ES cells into the blastocoel of embryonic d 3.5 C57Bl/6J mouse embryos, depending on the source of the ES cells. The embryos are transferred to the uteri of postcoitum d 2.5 pseudopregnant ICR mice, and the embryos are allowed to gestate. Chimeric mice are identified by coat color. 129/Sv mice have an agouti coat, and C57Bl/6J mice have a black coat. The chimeric mice have a mottled black-and-agouti coat. The appearance of an agouti coat color indicates a high degree of chimerism in the mice. Gender can be used to provide an initial assessment of the success of the ES-cell transfer. Since most ES cells are derived from male embryos, male chimeras will have a higher probability of containing germ cells derived from the ES cells.
Chapter 1/Germline Genetic Engineering Techniques
13
Male mice with a high degree of agouti coat color have a high probability of transmitting the mutation to the germline. These mice are bred to C57Bl/6J mice. Since the agouti phenotype is dominant over black, mice derived from the ES-cell lineage will be identified by the agouti coat color. These agouti mice can then be screened by PCR and/or Southern blot analysis to determine which of these have the desired mutation.
Phenotypic Analysis of Gene Mutation Once the mutation has been incorporated into the murine germline, the phenotypic consequences of the mutation can be examined. If the heterozygous mice are viable, they can be intercrossed to generate mice homozygous for the mutation. The offspring from the heterozygous crosses will be genotyped to determine whether the frequency of wildtype, heterozygous, or homozygous for the specific mutation is the expected Mendelian 1:2:1. If this frequency is achieved, it can be concluded that the mutation in the gene had no impact on murine development. Any significant deviation from this frequency will most likely be seen as a decrease in the generation of homozygous mice. In the generation of mice with a specific genetic ablation, several possible outcomes exist. First, the genetic ablation may be lethal and cause fetal, neonatal, or adult death. Second, the animals may be viable, and the gene ablation may impart a profound effect upon murine physiology. Finally, the mutation may have no obvious phenotypic effect upon murine development. If homozygous postnatal mice are not achieved, it can be concluded that the genetic ablation is lethal for either fetal or neonatal development. If this is the case, then a developmental analysis must be conducted to determine when and where the lethality occurred. If the mice produced from the gene mutation are viable, a detailed morphological, histological, and biochemical analysis must be conducted on these mice to first validate that the desired mutation has been generated and, second, to ensure that no subtle phenotype is observed.
Tissue-Specific Ablation The approaches outlined here allow genes to be ablated, permit the generation of subtle mutations in genes, and even allow replacement of one gene with another (e.g. generation of a “knockin” of one gene into the locus of another). However, although this technology is powerful, it does have limitations. The genetic alteration introduced by homologous recombination in ES cells affects all cells in which the modified gene is expressed, and these modifications are irreversible. If the gene to be ablated is expressed during embryonic development and in a variety of tissues, the analysis of the effects of gene ablation may be limited. If the ablation of a gene effects embryo viability because of disruption of one particular tissue development, then the investigation of the function of that gene may be limited to one tissue and one particular time-point. The problem encountered with ablating the expression of a gene that is expressed in a wide variety of tissues has been overcome by introducing specific DNA sequences, which are recognized by a specific recombinase, around a region of the gene to be removed. Currently, two recombinases have been used in mice, the Cre recombinase (47) and the FLP recombinase (48). The specific recombinase can be expressed in a desired tissue using a chimeric gene introduced into the murine genome by transient transgenic techniques. The expressed recombinase then binds to the introduced DNA sequences and removes the DNA flanked by these recombinase recognition sequences. This system was first used to ablate the DNA polymerase ` (pol `) gene specifically in T cells (47).
14
Chang, Reardon, and DeMayo
In this original report, the Cre recombinase gene was expressed in the T cells of transgenic mice by placing Cre under the control of the lck promoter. Homologous recombination was used to flank the pol ` gene with the recognition sites for Cre recombinase—loxP sites. The mice with the pol ` gene “floxed” were bred to the mice expressing Cre recombinase. This procedure resulted in mice with T-cell-specific ablation of the pol ` gene. The limitation of the this approach is that gene ablation under the control of the CreloxP system is dependent upon the tissue-specific expression of the promoter used to express Cre. Also, the ablation of gene expression by this system is irreversible. Therefore, if the promoter used to express the Cre gene is expressed early in development, the investigation of the effects of gene ablation may be limited to fetal development. This approach can be further modified by fusing the Cre recombinase to the ligand-binding domain of the estrogen receptor (49) or the mutated progesterone receptor (50). This has rendered the Cre recombinase active only when the specific ligand—tamoxifen or RU486, respectively—is given to the animal. Thus, a combination of these systems imparts spatiotemporal control of the ablation for the investigator.
NEW TECHNOLOGIES FOR GENETIC ALTERATION OF THE MURINE GENOME The technologies of DNA microinjection and ES cell technology have created powerful tools for all aspects of developmental biology and reproductive physiology. However, there are limitations to these systems that relate to the strains of choice for the generation of transgenic and mutant mice. Although transgenic mice can be generated in theoretically any strain of mouse, these mice can only be generated efficiently in strains that respond well to superovulatory regimens of gonadotropins. This limits these mice to a very few strains. Mutant mice can only be generated in 129/Sv strains because of the lack of germline-quality ES cells in other strains of mice. Therefore, while the majority of transgenic mice made in inbred strains are of the FvB/N strain, mutant mice are made in the 129/Sv strain and 129/Sv X C57Bl/6J hybrid strain. Since the genetic background of the mouse may affect the observed phenotype, it is important to ensure the use of common genetic backgrounds when crossing transgenic and mutant mice (51). Therefore, to combine transgenic experiments with mutant mouse experimentation requires working in a mixed genetic background, or breeding the transgenic or mutant mouse for several generations into the desired mouse strain. One solution to this problem may be found in the recent technology of sperm injection and nuclear transfer to mouse oocytes.
Sperm Injection Sperm injection or ICSI has recently been shown to be effective with murine gametes. Although established with human gametes, the development of this technology has been slow in the mouse, largely because of the difficulty in microinjecting unfertilized mouse oocytes. Although the one-cell fertilized mouse oocyte is relatively amenable for the microinjection of DNA, the permeability of the unfertilized mouse oocyte is significantly more resistant to injection. Using conventional microinjection technology, the mouse oocyte either resists penetration by the microinjection needle or lyses soon after microinjection. However, it has recently been shown that the use of a Piezo micromanipulator can increase the efficiency of microinjecting mouse oocytes. Using Piezo
Chapter 1/Germline Genetic Engineering Techniques
15
manipulation, mouse oocytes have been injected with sperm, and efficient numbers of viable mice have been born from this technology (52). The generation of mice using ICSI is not limited to freshly collected sperm, and has been successful using sperm that has been stored by freeze-drying (53). For instance, rehydration of freeze-dried sperm containing transgenes has resulted in the generation of transgenic mice (2). Although the efficiency of this technology is not significantly better than the traditional pronuclear injection protocol, this technology offers the potential for the generation of transgenic mice in strains of mice that were previously believed to be economically impossible. In most inbred strains, the difficulty in the generation of transgenic mice is not the inability of the male to produce sperm or the ability of the female to be stimulated to produce oocytes, but the ability of these strains to produce large numbers of fertilized eggs for the production of viable matings between the inbred males and the stimulated females. Therefore, transgenic mice utilizing ICSI may allow transgenes to be introduced into the 129/Sv strain and other inbred strains previously considered impossible or impractical.
Nuclear Transfer Homologous recombination in mice is limited to strains of mice in which germlinequality ES cells can be isolated. However, with the advent of nuclear-transfer technology, (i.e. cloning), the ability to generate mutations may no longer be limited to the 129/Sv strain. Cloning of mammals was first established in domestic species—sheep (54) and cattle (55). Again, the relative impermeability of the murine oocytes has made this technology virtually impossible. However, the same group that pioneered ICSI in mice has demonstrated that cloning can be accomplished with mice. Initially, cloning was first shown to be possible by the transfer of nuclei from ovarian cumulus cells (56). However, other somatic cells have since been shown to be permissive to cloning technology (57). The procedure for cloning mice has been described by Wakayama and colleagues (56). In brief, murine cloning requires the collection of oocytes by superovulation. After oocytes are cultured in media containing cytochalasin B, the oocytes are enucleated using the Piezo manipulators. Following a period of recovery, the Piezo manipulator is used to introduce the somatic-cell nucleus into the oocytes. After the nuclear transfer, the oocytes are activated, using media containing cytochalasin B and strontium chloride. This activates the egg-plasma membrane without allowing the nucleus to be expelled. The egg is then cultured in traditional culture media and transferred to synchronized recipients. The efficiency of the generation of live mice from these procedures is very low. However, as this technology improves, the use of homologous recombination in somatic cells can be exploited to increase the efficiency and versatility of the generation of mutant mice. Understanding the reproductive biology of the mouse has allowed the establishment of very powerful tools that has expanded the horizons of many scientific disciplines. The technologies for the manipulation of the murine genome are continually expanding. Incorporation of the new technologies will allow fields of research to progress at an even faster rate.
ACKNOWLEDGMENTS This research was supported in part by NICHD/NIH through cooperative agreeement (U54[HD07495-28]) as part of the Specialized Cooperative Centers Program in Reproduction Research and in part by the NCI Special Program of Research Excellence in Prostate Cancer CA-91-35.
16
Chang, Reardon, and DeMayo
REFERENCES 1. Palmiter RD, Brinster RL. Germ-line transformation of mice. Ann Rev Genet 1986;20:465–499. 2. Perry ACF, Wakayama T, Kishikawa H, Kasai T, Okabe M, Toyoda Y, Yanagimachi R. Mammalian transgenesis by intracytoplasmic sperm injection. Science 1999;284:1180–1183. 3. Rubenstein JLR, Nicholas J-F, Jacob F. Introduction of genes into preimplantation mouse embryos by use of a defective recombinant retrovirus. Proc Natl Acad Sci USA 1986;83:366–368. 4. Soriano P, Jaenisch R. Retroviruses as probes for mammalian development: allocation of cells to the somatic and germ cell lineages. Cell 1986;46:19–29. 5. Jähner D, Jaenisch R. Retrovirus-induced de novo methylation of flanking host sequences correlates with gene inactivity. Nature 1985;315:594–597. 6. Gordon JW, Scangos DJ, Plotkin DJ, Barbosa J, Ruddle FM. Genetic transformation of mouse embryos by microinjection of purified DNA. Proc Natl Acad Sci USA 1980;77:7380–7384. 7. Hogan B, Beddington R, Costantini F, Lacy E. Manipulating the Mouse Embryo: A Laboratory Manual. Cold Spring Harbor, New York, 1994:151–204. 8. Brinster RL, Palmiter RD. Factors effecting the efficiency of introducing foreign DNA into mice by microinjecting eggs. Proc Natl Acad Sci USA 1985;82:4438–4442. 9. Taketo M, Schroeder AC, Mobraaten LE, Gunning KB, Hanten G, Fox RR, et al. FVB/N: an inbred mouse strain preferable for transgenic analyses. Proc Natl Acad Sci USA 199188:2065–2069. 10. Soriano P, Montgomery C, Geske R, Bradley A. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 199164:693–702. 11. Southern PJ, Berg P. Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promoter. J Mol Appl Gen 1982;1:327–341. 12. Saiki RK. PCR Protocols. A Guide to Methods and Applications. Academic Press, San Diego, CA, 1990:13–27. 13. Lacy E, Roberts S, Evans EP, Burtenshaw MD, Costantini FD. A foreign beta-globin gene in tansgenic mice: integration at abnormal chromosomal positions and expression in inappropriate tissues. Cell 1983;34(2):343–358. 14. Wilkie TM, Brinster RL, Palmiter RD. Germline and somatic mosaicism in transgenic mice. Dev Biol 1986;118(1):9–18. 15. Grosveld F, van Assendelft GB, Greaves DR, Kollias G. Position-independent, high-level expression of the human (beta)-globin gene in transgenic mice. Cell 1987;51:975–985. 16. Brinster RL, Allen JM, Behringer RR, Gelinas RE, Palmiter RD. Introns increase the transcriptional efficiency in transgenic mice. Proc Natl Acad Sci USA 1988;85:836–840. 17. Palmiter RD, Sandgern EP, Avabock MR, Allen DD, Brinster RL. Heterologous introns can enhance expression of transgenes in mice. Proc Natl Acad Sci USA 1991;88:478–482. 18. Yao T-P, Forman BM, Jiang Z, Cherbas L, Chen J-D, McKeown M, et al. Functional ecdysone receptor is the product of EcR and Ultraspiracle genes. Nature (London) 1993;366:476–479. 19. Yao T-P, Segraves WA, Oro AE, McKeown M, Evans RM. Drosophila ultraspiracle modulates ecdysone receptor function via heterodimer formation. Cell 1992;71:63–72. 20. No D, Yao T-P, Evans RM. Ecdysone-inducible gene expression in mammalian cells and transgenic mice. Proc Natl Acad Sci USA (Genetics) 1996;93:3346–3351. 21. Shockett PE, Schatz DG. Diverse strategies for tetracycline-regulated inducible gene expression. Proc Natl Acad Sci USA 1996;93:5173–5176. 22. Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA. 1992;89:5547–5551. 23. Gossen G, Freundlieb S, Bender G, Muller G, Hillen W, Bujard H. Transcriptional activation by tetracyclines in mammalian cells. Science 1995;268:1766–1769. 24. Furth PA, St. Onge L, Boger H, Gruss P, Gossen M, Kistner A, et al. Temporal control of gene expression in transgenic mice by a tetracycline-responsive promoter. Proc Natl Acad Sci USA 1994;91:9302–9306. 25. Shockett P, Difilippantonio M, Hellman N, Schatz DG. A modified tetracycline-regulated system provides autoregulatory, inducible gene expression in cultured cells and transgenic mice. Proc Natl Acad Sci USA 1995;92:6522–6526. 26. Yu Z, Redfern CS, Fishman GI. Conditional transgene expression in the heart. Circ Res 1996;79:691–697. 27. Efrat S, Fusco-DeMane D, Lemberg H, Emran OA, Wang X. Conditional transformation of a pancreatic beta-cell line derived from transgenic mice expressing a tetracycline-regulated oncogene. Proc Natl Acad Sci USA 1995;92:3576–3580.
Chapter 1/Germline Genetic Engineering Techniques
17
28. Mayford M, Bach ME, Huang Y-Y, Wang L, Hawkins RD, Kandel ER. Control of memory formation through regulated expression of a CaMKII transgene. Science 1996;274:1678–1683. 29. Ewald D, Li M, Efrat S, Auer G, Wall RJ, Furth PA, Hennighausen L. Time-sensitive reversal of hyperplasia in transgenic mice expressing SV40 T antigen. Science 1996;273:1384–1386. 30. Wang Y, O’Malley BW, Jr, Tsai SY, O’Malley BW. A reulatory system for use in gene transfer. Proc Natl Acad Sci USA (Medical Sciences) 1994;91:8180–8184. 31. Vegeto E, Allan GF, Schrader WT, Tsai M-J, McDonnell DP, O’Malley BW. The mechanism of RU486 antagonism is dependent on the conformation of the carboxy-terminal tail of the human progesterone receptor. Cell 1992;69:703–713. 32. Wang Y, DeMayo FJ, Tsai SY, O’Malley, BW. Ligand-inducible and liver-specific target gene expression in transgenic mice. Nat Biotechnol 1997;15:239–243. 33. Pierson TM, DeMayo FJ, Matzuk MM, Tsai SY, O’Malley BW. Regulable expression of inhibin A in wild-type and inhibin a null mice. Mol Endocrinol 2000;14:1075–1085. 34. Capecchi MR. Altering the genome by homologous recombination. Science 1989;244:1288–1292. 35. Mansour SL, Thomas KR, Deng C, Capecchi MR. Introduction of a lacZ reporter gene into the mouse int-2 locus by homologous recombination. Proc Natl Acad Sci USA 1990;87:7688–7692. 36. Riele HT, Maandag ER, Berns A. Highly efficient gene targeting in embryonic stem cells through homologous recombination with isogenic DNA constructs. Proc Natl Acad Sci USA 1992;89:5128–5132. 37. Threadgill DW, Yee D, Matin A, Nadeau JH, Magnuson T. Genealogy of the 129 inbred strains: 129/ SvJ is a contaminated inbred strain. Mamm Genome 1997;8(6):390–393. 38. Gu H, Marth JD, Orban PC, Mossmann H, Rajewsky K. Deletion of a DNA polymerase beta segment in T cells using cell type-specific gene targeting. Science 1995;265:103–106. 39. Hasty P, Rivera-Perez J, Bradley A. The length of homology required for gene targeting in embryonic stem cells. Mol Cell Biol 1991;11(11):5586–5591. 40. Abuin A, Bradley A. Recycling selectable markers in mouse embryonic stem cells. Mol Cell Biol 1996;16:1851–1856. 41. Bradley A. Production and analysis of chimaeric mice. In: Robertson EJ, ed. Teratocarcinomas and Embryonic Stem Cells, A Practical Approach. IRL Press, Oxford, UK, pp. 113–151. 42. Robertson EJ. Embryo-derived stem cells. In Robertson EJ, ed. Teratocarcinomas and Embryonic Stem Cells: A Practical Approach. Oxford, New York, pp. 71–112. 43. Robertson, EJ. Derivation and maintenance of embryonic stem cell cultures. In Robertson EJ, ed. Teratocarcinomas and Embryonic Stem Cells: A Practical Approach. IRL Press, Oxford, UK, pp. 223–236. 44. Williams RL, Hilton DJ, Pease S, Willson TA, Stewart CL, GearingDP, et al. Myeloid leukemia inhibitory factor maintains the developmental potential of embryonic stem cells. Nature 1988;336:684–687. 45. Nagy A, Gocza E, Diaz EM, Prideaux VR, Ivanyi E, Markkula M, Rossant J. Embryonic stem cells alone are able to support fetal development in the mouse. Development 1990;110:815–821. 46. Nagy A, Rossant J, Nagy R, Abramow-Newerly W, Roder JC. Derivation of completely cell culturederived mice from early-passage embryonic stem cells. Proc Natl Acad Sci USA 1993;90:8424–8428. 47. Mansour SL, Thomas KR, Capecchi MR. Dispruption of the proto-oncogene int-2 in mouse embryoderived stem cells: a geneal strategy for targeting mutations to non-selectable gene. Nature 1988;366:348–352. 48. Fiering S, Epner E, Robinson K, Zhuang Y, Telling A, Hu M, et al. Targeted deletion of 5’HS2 of the murine beta-globin LCR reveals that it is not essential for proper regulation of the beta-globin locus. Genes Dev 1995;9(18):2203–2213. 49. Feil R, Wagner J, Metzger D, Chambon P. Regulation of Cre recombinase activity by mutated estrogen receptor ligand-binding domains. Biochem Biophys Res Commun 1997;237(3):752–757. 50. Kellendonk C, Trouche F, Monaghan AP, Angrand PO, Stewart F, Schutz G. Regulation of Cre recombinase activity by the synthetic steroid RU 486. Nucleic Acids Res 1996;24(8):1404–1411. 51. Banbury Conference on Genetic Background in Mice. Mutant mice and neuroscience: recommendations concerning genetic background. Neuron 1997;19:755-759. 52. Kimura Y, Yanagimachi R. Intracytoplasmic sperm injection in the mouse. Biol Reprod 1995; 52(4):709–720. 53. Wakayama T, Yanagimachi R. Development of normal mice from oocytes injected with freeze-dried spermatozoa. Nat Biotechnol 1998;16(7):639–641. 54. Wilmut I, Schnieke AE, McWhir J, Kind AJ, Campbell KH. Viable offspring derived from fetal and adult mammalian cells. Nature 1997;385(6619):810–813.
18
Chang, Reardon, and DeMayo
55. Kato Y, Tani T, Sotomaru Y, Kurokawa K, Kato J, Doguchi H, et al. Eight calves cloned from somatic cells of a single adult. Science 1998;282(5396):2095–2098. 56. Wakayama T, Perry AC, Zuccotti M, Johnson KR, Yanagimachi R. Full-term development of mice from enucleated oocytes injected with cumulus cell nuclei. Nature 1998;394(6691):369–374. 57. Wakayama T, Yanagimachi R. Cloning of male mice from adult tail-tip cells. Nat Genet 1999; 22(2):127,128. 58. Albanese C, Reutens AT, Bouzahzah B, Fu M, D’Amico M, Link T, Nicholson R, Dephino RA, Pestell RG. Sustained mammary gland-directed, ponasterone A-inducible expression in transgenic mice. FASEB J 2000;14:877–884.
Chapter 2/The Transgenic Mouse
2
19
The Transgenic Mouse in Studies of Mammalian Sexual Differentiation Deanne J. Whitworth, PHD and Richard R. Behringer, PHD CONTENTS INTRODUCTION SEX DETERMINATION: THE FATE OF THE GONAD EQUATING SRY WITH TDF SRY ALONE DOES NOT A TESTIS MAKE TRANSGENIC MARSUPIALS: A NEW FRONTIER CONCLUSION ACKNOWLEDGMENTS REFERENCES
INTRODUCTION Throughout history, the subject of sex has held an inherent fascination. The musings of Aristotle on the role of “an infinitesimally minute but essential organ” in determining whether “the animal will in one case turn to male (or) in the other to female” (Aristotle, Historia Animalium), offer an early insight into what has become one of the tenets in our understanding of sexual differentiation in mammals: that the sex of the gonad determines the sexual development of the individual. Sex determination in mammals is a remarkable process that has its origin in an indifferent gonadal primordium, common to both sexes, which has the ability to differentiate into either a testis or an ovary. In the presence of a Y chromosome, the indifferent gonad develops as a testis; in the absence of a Y chromosome, and regardless of the number of X chromosomes present, the indifferent gonad develops as an ovary. Remarkably, until fairly recently, this was about all we knew with respect to the genetic events involved in testicular differentiation. With the discovery in 1990 of SRY (sex-determining-region, Y chromosome gene), the testis-determining gene on the Y chromosome, the field seemed set for the systematic isolation of other genes functioning in the testicular differentiation pathway. Eleven years have now passed since the discovery of SRY, and the pathway from indifferent gonad to testis appears ever more complex. Our understanding of the ovarian differentiation process is even more limited. The use of transgenic mice has contributed enormously to our understanding of the mammalian sex determination and sexual differentiation pathways, and hence is the From: Contemporary Endocrinology: Transgenics in Endocrinology Edited by: M. Matzuk, C. W. Brown, and T. R. Kumar © Humana Press Inc., Totowa, NJ
19
20
Whitworth and Behringer
focus of this chapter. While there is no denying the wealth of information gleaned from mouse models, it is also our belief that much can be learned from comparative studies of other mammalian systems. This chapter concludes with a brief introduction to the efforts that are underway to generate the first transgenic marsupial.
SEX DETERMINATION: THE FATE OF THE GONAD The mammalian testis and ovary have a common origin in the indifferent gonad. In the mouse, the indifferent gonad is first discernible at 10.5 d postcoitum (dpc) as a thickening on the medial aspect of the mesonephros. At this stage, the gonad consists of four known cell types—the primordial germ cells, supporting cells, steroidogenic cells, and connective cell lineage—each capable of entering the testicular or ovarian differentiation pathway (Fig. 1). The indifferent male gonad of the mouse becomes sexually dimorphic at around 12.5 dpc when the supporting cell lineage gives rise to the Sertoli cells, which organize themselves into seminiferous cords that enclose the primordial germ cells. At the time that Sertoli cells form seminiferous cords, they begin secreting the glycoprotein Müllerian-inhibiting substance (MIS; also known as anti-Müllerian hormone, AMH). MIS is responsible for inducing the regression of the Müllerian ducts, which would otherwise persist to form the female reproductive tract. The Sertoli cells in turn appear to direct the differentiation of Leydig cells from the steroidogenic cell lineage, and peritubular myoid cells from the connective tissue (1). The production of testosterone by the Leydig cells stimulates the growth and virilization of the Wolffian ducts, which give rise to the epididymides, vasa deferentia, and seminal vesicles. At approx 13.5 dpc in the mouse testis, the germ cells become arrested in mitosis, marking their entry into the male pathway of development. Germ cells that fail to reach the gonad follow the female pathway and enter meiosis prematurely (2). In the female gonad of the mouse, the germ cells enter meiosis at approx 13.0 dpc, becoming arrested at the first prophase 2 d later. From approx 16.5 dpc, granulosa cells— derived from the supporting cell lineage—surround the oocytes to form primordial follicles. Granulosa cells do not produce MIS until after birth, thus creating a permissive environment for the differentiation of the Müllerian ducts into the oviducts, uterus, and upper one-third of the vagina. Similarly, the fetal ovary does not produce testosterone, and consequently the Wolffian ducts degenerate. Studies of XXCXY chimaeric mice provided the first clue that the differentiation of the male supporting cells into Sertoli, rather than granulosa, cells is under the cellautonomous control of a Y chromosome-encoded testis-determining factor (TDF in humans, Tdy in mouse) (1,3). In these mice, approx 95% of Sertoli cells are XY, and other testicular cell types are derived from XX and XY cells with equal probability. Thus, although the Y chromosome—and TDF/Tdy—is not essential for the differentiation of Leydig cells and peritubular myoid cells, it is required for Sertoli-cell differentiation. The first example of a mutation to Tdy was described by Lovell-Badge and Robertson in 1990. Using XY embryonic stem (ES) cells that had been infected with a retroviral vector, they generated a male chimaera whose progeny included a small proportion of XY females. The retrovirally-induced mutation segregated with the Y chromosome. Further, during meiosis it was complemented by the Sxr and Sxr' translocations—both of which are translocations of the Y chromosome, including Tdy, onto the X chromo-
Chapter 2/The Transgenic Mouse
21
Fig. 1. Gonadal differentiation in the mouse. At 10.5 dpc in the mouse, the indifferent gonad contains four known cell types that are bipotential. The first stage of testicular differentiation occurs at 12.5 dpc, when the Sertoli cells differentiate from the supporting cell lineage to form cords that enclose the spermatogonia. Shortly after, Leydig cells differentiate from the steroidogenic cells and peritubular myoid cells arise from the connective cell lineage. Sertoli cells and Leydig cells produce MIS and testosterone, respectively, which are required for the development of the male internal reproductive structures. In the female at 13.0 dpc, the germ cells enter meiosis and are termed oocytes. Granulosa cells subsequently differentiate from the supporting cells, and thecal cells develop from the steroidogenic cells.
some—thus mapping the mutation to the testis-determining region of the Y. Consequently, this study provided the first case of XY sex reversal unequivocably caused by a mutation in Tdy.
EQUATING SRY WITH TDF Major contributions to our understanding of sex determination and sexual differentiation in mammals have come from the study of mice and humans with primary sex reversal. The term “primary sex reversal” indicates XY individuals who develop as phenotypically female, despite the presence of a Y chromosome, and XX individuals who lack a Y chromosome but possess testicular tissue and consequently develop a male phenotype. Through analysis of the DNA of human patients with primary sex reversal, researchers have been able to progressively narrow down the portion of the Y chromo-
22
Whitworth and Behringer
Fig. 2. Expression profiles of genes involved in sex determination and differentiation. Relative expression profiles of genes expressed in the supporting cell lineage and believed to be involved in sex determination and differentiation. Some genes, such as Sf1 and Dax1, are also expressed in the steroidogenic cells; however, the expression profiles shown here are only representative of the supporting cell lineage and their descendents the Sertoli cells and granulosa cells.
some required to induce testicular differentiation in XX patients, which was missing in XY females (5,6). In “walking” along this 35-kb “minimal” testis-determining region, Sinclair and colleagues identified a gene they named SRY, which is now generally accepted to be TDF (6). In the mouse, Sry is absent from a strain in which XY individuals develop as females (7), and conversely, is present in a small fragment of the Y chromosome known to cause sex reversal in the XXSxrb mouse (7). Sry transcripts are detectable only within the male gonad, and during a very discrete period from 10.5–12.5 dpc, coincident with the onset of testicular differentiation at 12.5 dpc (Fig. 2) (8,9). With a few unique exceptions (10,11), SRY is conserved on the Y chromosome of all mammalian species examined (6,7,12). The SRY protein encodes an amino acid motif called the high-mobility group (HMG) box which confers its ability to bind to and bend DNA, and thus act as a transcription factor—a function in keeping with its role as a “switch” in the sex-determining pathway (7,8,13). The most compelling evidence equating SRY with TDF came in the form of Randy, a transgenic mouse. When Koopman and colleagues microinjected into XX embryos a 14-kb fragment of the Y chromosome, containing only Sry, some of the resulting XX transgenics (including Randy) developed as phenotypic males complete with male
Chapter 2/The Transgenic Mouse
23
mating behavior (14). Thus, Sry is the only gene on the Y chromosome required for testis determination or, more specifically, for Sertoli-cell differentiation. In studies of XYSry+CXYSry- chimaeras, XYSry- cells very rarely contribute to the Sertoli-cell population (reviewed in 15). Similarly, in the fetal gonads of XXSxra mice, in which the activity of the Sxra portion of the Y chromosome is influenced by the inactivation of the X chromosome, Sertoli cells display a preferentially active XSxra chromosome, while other testicular-cell types show a random inactivation of the X and XSxra chromosomes (16). Taken together these data reaffirm that Sry functions cell-autonomously within the pre-Sertoli cells to initiate Sertoli-cell differentiation.
SRY ALONE DOES NOT A TESTIS MAKE With the exception of SRY on the Y chromosome, all other genes involved in testicular differentiation are on the X chromosome or the autosomes—a fact demonstrated by the sex-reversed Sry XX transgenic mice. Intriguingly, only 30% of these mice sex reversed, and this phenomenon appears to be independent of transgene homozygosity or copy number (reviewed in 15). Over the course of breeding these mice, it became apparent that the background genotype of different strains of mice influences the propensity to sexreverse (reviewed in 15). More specifically, this indicates an incompatibility between the timing and/or level of Sry expression and that of other genes on the X chromosome, or autosomes involved in either the testicular or ovarian differentiation pathway. A similar scenario occurs in the B6.YDom mouse, in which the Y chromosome from Mus poschiavinus (YPos) is placed onto an inbred Mus musculus musculus background (C57Bl/6). XY Pos animals develop either as females with ovarian tissue or as hermaphrodites in which the gonads contain both ovarian and testicular tissue (17–19). Sex-reversal in these animals appears to be caused by a misregulation in the timing of Sry expression (20) and a functional incompatibility of SryPos with at least two autosomal alleles (19). While there is no disputing the role of SRY in initiating testicular differentiation, it is a sobering consideration that only approx 20% of XY sex-reversals in humans can be attributed to mutations or deletions of SRY or its flanking sequences. Similarly, not all cases (80%) of XX males can be explained by the presence of SRY in the genome. Sex-reversal in XY females with an intact SRY—and in the remaining 20% of XX males lacking SRY— may be explained by a loss or gain of function, respectively, of autosomal or X-linked genes acting downstream, or upstream, of SRY in the testicular-differentiation pathway. In the next section, we discuss a number of genes which are thought to play a direct, or in some cases indirect, role in testicular differentiation: some of these factors appear to function upstream of SRY, and others to function downstream. We also introduce what little is known about the genes thought to be involved in ovarian differentiation. Of central importance is the contribution that transgenic studies in mice have made in defining the roles of each of the putative sex-determining and -differentiating genes discussed.
Wt1 Heterozygous mutations of the Wilms’ tumor-suppressor gene, WT1, are associated with Wilms’ tumor, a childhood tumor of the kidney, and XY pseudohermaphroditism (reviewed in 21). The urogenital abnormalities in individuals with WT1 mutations suggests a role for WT1 in sex determination. WT1 encodes a nuclear protein with domains
24
Whitworth and Behringer
shared with transcription factors. In the mouse, Wt1 expression is initially detected in the intermediate mesoderm that will give rise to the urogenital system, and later in the mesothelium and central nervous system (CNS) (22,23). In the developing gonad, Wt1 is expressed in Sertoli cells (22). Wt1 knockout mice are embryonic-lethal, and lack kidneys and gonads (24). It appears that the initiation of genital-ridge formation occurs, but quickly fails. Thus, Wt1 appears to be essential for the initial formation of the gonads acting in males upstream of Sry. WT1 may also have functions later in male sexual differentiation by regulating genes such as Mis (25). In the Denys-Drash syndrome, point mutations in the WT1 locus that create missense, nonsense, or frameshift mutations result in more severe XY genital phenotypes in comparison to WT1 null heterozygotes (26). Recently, the Denys-Drash syndrome has been modeled in mice by the introduction of a translation-stop codon at codon 396 of Wt1 (27). However, only one heterozygous mouse carrying the T396 mutation was obtained from chimaeras. This heterozygote had small, aspermic testes. Unfortunately, this heterozygote also had sex-chromosome aneuploidy (XXY), complicating phenotype interpretations. Chimaeras generated with the T396 heterozygous ES cells also had genital abnormalities. This too was complicated by sex-chromosome chimaerism (XXCXY). The generation of mice carrying mutations that match those found in humans is a powerful approach for studying these mutations in vivo. However, it appears that these strategies may have to be modified to obtain interpretable information regarding sexual development.
M33 A more recently identified candidate for a role in gonadal development and testicular differentiation is the mouse M33 gene—a homolog of the Drosophila Polycomb gene (28). In Drosophila, Polycomb genes regulate the expression of homeotic genes that are required for segmental patterning in the embryo. Testicular differentiation in M33 mutant mice is perturbed: gonadal phenotypes range from small ovaries to “indistinct” gonads, with some animals developing as hermaphrodites with one testis and one ovary (28). To date, M33 mutant mice are the only example of recessive true hermaphroditism. Gonadal development is retarded in both XX and XY embryos at 11.5 dpc, when the expression of Sry in the male would normally reach its peak. At this stage, the gonads appear to consist of little more than a thickening of mesenchymal tissue, with an absence of coelomic epithelium. The coelomic epithelium is thought to give rise to Sertoli cells (29), and is thus likely to be the cell type in which Sry is expressed. Consequently, testicular differentiation in M33 mutants may fail because of a paucity of coelomic epithelial cells, and subsequently, few or no Sertoli cells. Thus, the principal role of M33 in the gonad appears to be in the process of gonadogenesis, with an indirect influence on testicular differentiation.
Sox9 Heterozygous mutations in SOX9 are responsible for the human skeletal-malformation syndrome, ampomelic dysplasia (CD) (30,31). Consistent with a role in testicular differentiation, approx 75% of XY patients with CD are sex-reversed (30–33). Gonadal phenotypes range from partial testicular differentiation to ovarian development with fewer than normal follicles to the most extreme of cases, where the gonads are reduced to streaks of fibrous tissue (34).
Chapter 2/The Transgenic Mouse
25
As with SRY and other members of the SOX (Sry-like HMG box) family of genes, SOX9 encodes an HMG box. In addition, SOX9 has in its carboxy terminus a transactivation domain (35). Patients with CD show a wide variety of mutations to SOX9, however in nearly all cases, the mutations result in a truncation of the transactivation domain (35). This suggests that SOX9 is required for the transactivation of downstream genes involved in skeletal and testicular development. The disparate nature of the mutations, and the observation that all patients are heterozygous for the mutation, suggest that CD and its associated sex reversal are caused by a haploinsufficiency for SOX9 rather than a dominant-negative effect. In the mouse, low levels of Sox9 expression are seen in both male and female urogenital ridges from 10.5 dpc, around the time the development of the indifferent gonad (Fig. 2) (36,37). A sexually dimorphic pattern of expression begins at 11.5 dpc, when levels in the male gonad increase, coincident with the peak in Sry expression, while in the female, expression of Sox9 is turned off. At 12.5 dpc, Sox9 transcripts in the testis are localized to the Sertoli cells. The SOX9 protein is conserved among the vertebrate groups with nonmammalian sequences thus far identified for chicken, turtle, and alligator (38–40). Expression of SOX9 in these species is similarly correlated with testicular differentiation. However, in contrast to the pattern seen in mammals, SOX9 expression in chickens and alligators occurs later in Sertoli-cell differentiation, and after the production of MIS (38,40). These data suggest that while SOX9 appears to play a role in instigating Sertoli- cell differentiation in mammals, in reptiles and birds it may function later in development—perhaps to maintain, rather than determine, Sertoli-cell fate. We are addressing the role of Sox9 in Sertoli-cell differentiation in the mouse, using both loss-of-function and gain-of-function approaches. Our loss-of-function study uses gene targeting in ES cells to generate mice with only one functional copy of Sox9. More specifically, we have deleted approx 450 bp of Sox9 including the translation start site and the majority of the HMG box, thus generating a null allele (41). Testicular development in mice heterozygous for the null allele is normal, while skeletal development is disrupted. This situation stands in contrast to the human condition, where the vast majority of XY patients with mutations of SOX9 show both sex-reversal and skeletal malformations. In a further attempt to understand the role of Sox9 in Sertoli-cell differentiation, we have generated ES cells that are homozygous for the Sox9 mutation. In chimaeras, Sox9null ES cells give rise to Sertoli cells, indicating that Sox9 is not required cell-autonomously for Sertoli-cell differentiation. We have also generated fetuses that are homozygous for the Sox9 mutation by injecting Sox9-null ES cells into blastocysts that are derived from tetraploid cells. In this instance, the embryo will be entirely ES-cell-derived, with tetraploid cells contributing only to the extraembryonic tissues. Sox9-null fetuses are grossly abnormal, and die shortly after 10.5 dpc. However, the gonad at this time appears to be normal, indicating that early expression of Sox9 is not required for the development of the indifferent gonad. More direct data implicating Sox9 in Sertoli-cell differentiation has resulted from our gain-of-function study. In these mice, a tyrosinase minigene has fortuitously inserted within 1 centimorgan of Sox9 (42). All XX mice carrying the transgene (XXtg) develop as phenotypically normal, although sterile, males. Significantly, all of these mice have a normal XX karyotype, and are devoid of known Y chromosome genes, including Sry. Gonadal development in the XXtg males follows the typical male pathway from the
26
Whitworth and Behringer
outset, with Sertoli cells and early seminiferous cords visible at 12.5 dpc. The differentiating Sertoli cells express Sox9 and MIS. By 15.5 dpc, the XXtg testis contains wellorganized seminiferous cords enclosed by peritubular myoid cells, interstitial tissue, and a tunica albuginea. In wild-type animals at 11.5 dpc, Sertoli cells have not yet differentiated; this state of morphological development corresponds with an upregulation in the male, and a downregulation in the female, of Sox9 expression. In the XXtg gonad at 11.5 dpc, Sox9 expression persists at high levels. These data indicate that the insertion of the transgene has potentially disrupted a repressor element upstream of Sox9, which would normally allow for the expression of Sox9 to be downregulated in the female. Continued expression of Sox9 in the XXtg gonad initiates testicular differentiation in the absence of Sry, implicating Sox9 as a gene involved in the early stages of Sertoli-cell differentiation, perhaps immediately downstream of Sry. If we extrapolate further, we can propose a model with Sox9 as the critical testisdifferentiating gene, and the function of Sry is to ensure that Sox9 is upregulated in the XY gonad—perhaps by repressing a negative regulator of Sox9 expression. In the XX gonad, this repression of Sox9 expression would persist, preventing testicular differentiation in the presumptive ovary. In our XXtg mice, the insertion of the transgene may have disrupted the binding site for this repressor of Sox9, thereby permitting its continued expression. The role of Sry as a repressor of a repressor of testicular differentiation was originally proposed by McElreavey and colleagues in 1993, as an alternative to the more conservative view that Sry acts as a dominant testis inducer (15). The reader will find that as we progress further into this chapter, the concept of Sry as an antagonist of an “anti-testis” factor becomes an increasingly attractive proposal.
Sf1 and Dax1: Multifunctional Regulators of Gonadal Development and Function In addition to Wt1 and M33, a strong candidate for a role in early gonadogenesis is the Ftz-F1 gene, which encodes the orphan nuclear-receptor steroidogenic factor 1 (SF1). In the fetus, SF1 has multiple roles in early gonadal, adrenal, and brain development, and throughout life is involved in the regulation of steroidogenesis in multiple tissues (see 43 and Chapter 8 for review). Mice homozygous for a null mutation in Sf1 lack adrenals, show gonadal degeneration after 11.5 dpc, have impaired gonadotrophic function, and altered structural characteristics of the ventromedial hypothalamus (44–47). Taken together, these studies demonstrate an essential role for Sf1 at multiple levels of the hypothalamic-pituitary-gonadal axis. At 9.0 dpc in the mouse, Sf1 transcripts are present in the urogenital ridge, and expression continues in the indifferent gonad of both sexes (Fig. 2) (48). A sexually dimorphic pattern of expression becomes apparent at 12.5 dpc, when Sf1 transcription increases in the developing testis and is downregulated in the prospective ovary. At 14.5 dpc, Sf1 transcripts in the testis are restricted to the Leydig cells. In the female, expression of Sf1 is reinstated predominantly in the thecal cells of the postnatal ovary. The diminished expression of Sf1 in the ovary at 12.5 dpc is coincident with the onset of testicular differentiation in the male, and suggests that SF1 may regulate the expression of testisdifferentiating genes that are disruptive to ovarian development. The expression profiles of Sf1 overlap considerably—both temporally and spatially— with that of another orphan nuclear receptor, Dax1. Mutations in DAX1 are responsible for the human disorder X-linked adrenal hypoplasia congenita (AHC), which is charac-
Chapter 2/The Transgenic Mouse
27
terized by an absence of the adrenal cortex and hypogonadotropic hypogonadism (49). In the mouse, Dax1 is first expressed in the somatic cells of the indifferent gonad of both sexes at approx 10.5 dpc (Fig. 2) (50,51). At 12.5 dpc, levels of Dax1 expression in the developing testis decrease significantly to levels that are barely detectable. In the female gonad, Dax1 continues to be expressed until approx 14.5 dpc. In the adult testis and ovary, Dax1 transcripts are restricted to the steroidogenic Leydig and thecal cells, respectively. Similar relative expression profiles for DAX1 and SF1 are conserved in the pig (52). The inverse expression profiles of Dax1/DAX1 and Sf1/SF1 during testicular differentiation, and their co-expression in the steroidogenic cells of the testis and ovary, imply that these genes interact during gonadal development and endocrine function. SF1 and DAX1 have been shown to act antagonistically in the regulation of Mis expression in the developing testis. Previous studies have demonstrated that SF1 is required for the expression of Mis in vitro and in vivo (53,54). More recently, Nachtigal and colleagues (25) have shown that DAX1 antagonizes SF1-mediated transactivation of Mis. Specifically, SF1 and the transcription factor WT1 are thought to associate and thereby synergistically promote Mis expression. DAX1, however, antagonizes this synergy, probably by interacting directly with SF1. Further, in vitro studies from several laboratories have indicated that DAX1 can inhibit the transcriptional activation by SF1 of genes involved in steroidogenesis (55–57). It is suggested that DAX1 is able to bind to DNA hairpin-loop structures (56). This DNA-binding ability is shared by SRY. Thus, a likely scenario might depict SRY and DAX1 influencing the ability of each other to either activate or repress SF1-mediated transcription of genes involved in steroidogenesis and testicular differentiation. In addition to its antagonistic effects on SF1 transcriptional activity, DAX1 has also been implicated as an ovary-determining gene, or “anti-testis” gene. DAX1 maps to a 160-kb region of the X chromosome which, when duplicated, causes XY-dosage-sensitive sex reversal (DSS) (49,58,59). In vivo confirmation that DAX1 is indeed the gene responsible for DSS was obtained by generating transgenic mice expressing a Dax1 cDNA under the regulation of a fragment of DNA taken upstream from the Dax1 start of transcription: this transgene was designated Dax:Dax (60). In one transgenic line, the levels of Dax1 expression were five times that of normal levels, with a corresponding increase in protein levels. Surprisingly, all XY transgenics from this line developed testes, although development was initially retarded. However, when transgenic females were bred to males carrying a weak Sry allele (YPos), 3 of 14 liveborns developed as hermaphrodites and eight developed as males, and at least four of these probably possessed ovotestes earlier in development. In fact, when fetal gonads were examined, 8 out of 11 XYPos transgenics had ovotestes. Similar results were obtained when the Dax1 promoter was used to express Sry (Dax:Sry transgene) in XX animals carrying Dax:Dax. Paradoxically, XY mice homozygous for the Dax1 transgene, and expressing levels of DAX1 that are approx 11 times higher than endogenous levels, still develop normal testes. Yet in humans, a double dose of DAX1 is sufficient to induce a sex-reversal. Testicular development is only disrupted in those transgenic mice that possess a weak Sry allele (YPos or Dax:Sry). The authors give a plausible account that takes into consideration two important observations. Firstly, testis development in both the YPos and Dax:Sry mice lacking the Dax:Dax transgene is delayed. This becomes significant when one also takes into account that transcription of Sry in wild-type animals appears to pass along the gonad in such a way that each cell expresses high levels of Sry for only a brief
28
Whitworth and Behringer
period. Thus, most cells will have experienced the peak in Sry expression, and become committed to the Sertoli-cell fate, before experiencing high levels of Dax1 expression. Consequently, Sry is able to outcompete Dax1 for the activation of testis-differentiating genes. Secondly, in the case of Dax:Dax transgenics with the YPos Sry allele, where levels of transcription are lower than normal, or XX Dax:Sry animals, where the onset of Sry expression appears to be delayed, Dax1 expression increases before that of Sry, allowing Dax1 to maintain its inhibition of testis-differentiating genes. Although the experiments are not optimal, these data suggest that DAX1 and SRY act antagonistically toward each other, competing to control the activation of genes in the testicular-differentiation pathway. In apparent contradiction to the above hypotheses, mice deficient for Dax1 develop normal ovaries and internal reproductive structures (61). The only abnormality in females appears to be that some follicles contain more than one oocyte. These data do not support a role for Dax1 as an ovary-determining gene. On the other hand, it is still plausible that DAX1 can act as an “anti-testis” factor by interfering with the expression of testisdifferentiating genes, such as Sox9. Very low levels of Sox9 expression are seen in both male and female urogenital ridges at 10.5 dpc, coincident with the expression of Sf1. It is possible that SF1 directs this very low level of Sox9 expression. At 10.5 dpc, Dax1 is expressed in male and female indifferent gonads, corresponding with the onset of Sry expression in the male. Critically, at 11.5 dpc, levels of Sry expression peak and Sox9 levels are substantially elevated. In the female at this time, expression of Sox9 is extinguished. If we assume that SF1 is responsible for maintaining low levels of Sox9 expression, DAX1 may heterodimerize with SF1 and counter SF1-mediated transcriptional activation of Sox9. SRY may antagonize this effect of DAX1, by competing for the same binding site or altering the comformation of the DNA in such a way that DAX1 cannot bind or dimerize with SF1. Most importantly it may directly, or indirectly, cause the substantial increase in Sox9 expression seen in the male at 11.5 dpc. This boost in Sox9 expression is essential for testicular differentiation to occur. In the loss-of-function females lacking Dax1, expression of Sox9 may continue at lower levels, but without the boost in Sox9 expression seen in the male, the gonad continues along the ovariandifferentiation pathway. The expression of Sox9 in the gonads of Dax1-deficient females is unknown. Another possibility is that another gene, or genes, is also involved in the repression of Sox9 expression in the female gonad, and that in the absence of Dax1, this other factor is sufficient to keep Sox9 levels below the threshold for testicular differentiation. A possible candidate for this role is the Sry-related gene Sox3.
Sox3: Ancestor of Sry and a Putative Ovary Determinant Of all the SOX genes, SOX3 is most closely related to SRY, sharing 82% similarity in the HMG box (62,63). Both SOX3 and SRY are encoded by one exon, and share homology outside of the HMG box—an intriguing finding, because no such homology exists between species for SRY. It has has been proposed that, in mammals, SRY evolved from SOX3 during the evolution of the X and Y chromosomes (64,65). SOX3 has been highly conserved throughout vertebrate evolution, and is X-linked in both eutherian and marsupial mammals (62–64,66). The predominant site of Sox3 expression in the mouse is in the developing central nervous system (63). However, at 11.5 dpc, Sox3 expression is observed in both male and female genital ridges (Fig. 2). Transcripts are localized to the somatic cells of the gonad
Chapter 2/The Transgenic Mouse
29
and the expression level in the female appears to be twice that of the male, reaching levels equivalent to or greater than Sry. By 12.5 dpc, transcripts are no longer detectable in either male or female gonads (A. Hacker unpublished data, cited in 63). In vitro data indicate that SOX3 and SRY bind to the same DNA target sequence; however, SOX3 binds with a much lower affinity than SRY (63). Thus, a likely scenario may be one in which SOX3 and SRY compete for the same target sequence involved in the regulation of ovarian- or testicular-differentiation genes. More specifically, Jennifer Graves (65) has proposed that SOX3 and SRY compete to regulate the expression of SOX9. In her model, SOX3 was once part of a dosage-regulated system of sex determination that involved the differential regulation of SOX9. With the evolution of SRY from SOX3, a more robust mechanism of sexual differentiation came into play. Thus, in the female, SOX3 would repress the expression of SOX9 and consequently, other testisdifferentiating genes. In the male, SRY would outcompete SOX3 for its binding site in the SOX9 promoter region, and testicular differentiation would ensue. To date, nothing is known about the presence or absence of such a binding site in the SOX9 promoter. XY human individuals deleted for SOX3 develop small, but essentially normal, testes (62); XY individuals with a duplication of SOX3, or XX individuals deleted for SOX3 have not been identified. However, loss-of-function and gain-of-function studies in mice will contribute substantially to defining the requirement of Sox3 for ovarian differentiation.
Mis MIS is one of the key hormones required in male development (see 67 and Chapter 3 for review). MIS is produced by the Sertoli cells of the fetal testis, with the highest levels observed during the period in which the Müllerian duct regresses (68,69). Expression of MIS continues after birth at reduced levels, and then declines sharply at puberty (69–72). In the mouse, Mis transcripts are first detected in the differentiating Sertoli cells at 11.5 dpc, 11/2 d before the Müllerian ducts begin to regress (Fig. 2) (69). Initially, transgenic mice were used to explore the potential roles of MIS in vivo (73). The mouse metallothionein promoter (MT) was used to direct widespread expression of human MIS (hMIS). Female MT-hMIS transgenic mice were born without a uterus or oviducts as expected. In addition, the ovaries became depleted of germ cells soon after birth, and eventually degenerated. These findings further confirmed the role of MIS in Müllerian-duct regression, and demonstrated that high levels of MIS were directly, or indirectly, toxic to female germ cells. Although most male MT-hMIS transgenic mice were overtly normal and fertile, some males from the highest expressing lines did not virilize and had undescended testes. Lyet et al. (74) determined that the high levels of hMIS caused a reduction in circulating testosterone. Presumably, those nonvirilized males from the highest expressing lines had severely reduced testosterone levels. More recently, Racine and colleagues (75) have shown that the overexpression of hMIS in male MT-hMIS transgenics blocks the differentiation of Leydig-cell precursors and decreases expression levels of the cytochrome p450 17_-hydroxylase gene, which is required for steroid synthesis. MIS appears to exert its effects on Leydig-cell differentiation and steroidogenesis directly via its receptor, which is now known to be expressed by Leydig cells in addition to Sertoli cells (75). Mis knockout mice have also been generated (76). Although Mis is specifically expressed in postnatal granulosa cells of the ovary, Mis-mutant females are normal and fertile. However, it is possible that more subtle alterations in ovarian function are present.
30
Whitworth and Behringer
Mis-mutant males developed as male pseudohermaphrodites, possessing testes and male internal organs as well as a uterus and oviducts. The majority of the Mis-mutant males proved to be infertile, not because of a germ-cell deficiency, but because of the physical abnormalities caused by the codevelopment of both male and female internal reproductive organs. In addition, a proportion of the older Mis-mutant males had Leydig-cell hyperplasia, indicating that Mis also influenced Leydig-cell proliferation. The finding that MIS receptors are expressed on Leydig cells suggests that this might be a direct interaction between Sertoli and Leydig cells (75). By generating Mis mutant males that also carried the testicular feminization (Tfm) mutation, XY animals were produced that could not respond to the two primary male hormones: testosterone and MIS. The resulting animals overtly appeared as females, with a uterus and oviducts, but no Wolffian-duct derivatives. Testes were intra-abdominal at the position where ovaries would normally be located. These studies re-emphasized the hormonal control of sexual differentiation in mammals. TGF` signaling is mediated by transmembrane receptors with serine/threonine kinase activity (77). Type I and type II receptors generate complexes upon ligand binding, and transduce their signals through Smad proteins to the nucleus. The type I receptor for MIS is unknown; however, the type II receptor for MIS has been isolated in the mouse (78), rat (79,80), rabbit (81), human (82), and tammar wallaby (D. Whitworth, unpublished data). We have generated MIS type II receptor knockout mice (83). Interestingly, these mice are a phenocopy of the MIS ligand knockout mice, suggesting that the MIS signaling pathway involves a one ligand-one type II receptor pathway. The specificity of MIS signaling was established by generating female MT-hMIS mice that were also deficient for the MIS type II receptor (84). In contrast to MT-hMIS females that lack a uterus, oviducts, and ovaries, the MT-hMIS/MIS type II receptor-mutant females were normal and fertile. In the mouse, Mis expression is detected around 11.5 dpc, specifically in preSertoli cells and later in Sertoli cells of the fetal and postnatal testes (9). The timing and cell specificity of Mis expression suggested that Sry may directly or indirectly regulate Mis transcription. However, tissue-culture and transgenic mouse experiments have indicated that steroidogenic factor 1 (SF1) is required to activate Mis transcription (53,54). In contrast, targeted mutagenesis of the SF1 binding site in the endogenous mouse Mis locus does not block Mis transcription, but rather reduces Mis transcription levels (85). This reduction is not sufficient to cause a persistence of Müllerian-duct-derived tissues. However, when a conserved SOX9 binding site is similarly mutated, no Mis transcription occurs and the mutant males develop as pseudohermaphrodites, similar to Mis mutant males. These manipulations of the endogenous promoter have revealed the distinct activities of these two transcription-factor binding sites in regulating Mis expression and have helped to piece together this important genetic pathway of male sexual differentiation.
Tfm Mice carrying the X-linked Tfm mutation have female genitalia and lack Wolffian ductderived structures, despite possessing testes and an XY karyotype (86). Tfm is a naturally occurring mutation to the androgen receptor (AR) that results in complete androgen insensitivity (reviewed in 87 and 88). In the absence of a functional AR, neither testosterone nor its more potent metabolite 5_-dihydrotestosterone can exert their effects on the Wolffian duct and the external genitalia, respectively. At the molecular level, Tfm is a single-base deletion in the N-terminal region of the AR gene. This leads to a premature termination of translation, which in turn gives rise to a truncated, unstable mRNA transcript (89–92).
Chapter 2/The Transgenic Mouse
31
The external genitalia of Tfm male mice resembles that of wild-type females, although the vagina is shorter than normal and often blind-ending (86). Testes of adults are smaller, and fail to descend beyond the internal inguinal ring into the scrotum (reviewed in 88). Spermatogenesis proceeds in the testes of Tfm mutants; however, most germ-cells fail to progress beyond the spermatocyte stage (86). Levels of the pituitary gonadotrophins luteinizing hormone (LH) and follicle-stimulating hormone (FSH) are elevated in Tfm males because of the loss of the AR-mediated negative feedback loop, which would normally regulate their production (reviewed in 88). Leydig cells appear to be normal in number, but are hypertrophied (86). In addition, the production of androgens is severely reduced, probably a result of the loss of the enzyme 17_-hydroxylase (93). By generating XX mice that are sex-reversed (XXSxr) and carrying the Tfm mutation, Ohno and colleagues were able to study the interactions during male development between cells that are wild-type for the AR, and those that are Tfm-mutated (reviewed in 87). Because of X-inactivation, sex reversed mice that are heterozygous for Tfm are mosaics of cells which are sensitive to androgens (XWT) and those that are insensitive (XTfm). The conclusion from these studies was that effects of testosterone could be mediated by local growth factors from wild-type cells to Tfm cells (reviewed in 87). While cellular differentiation was seen to occur only in wild-type cells, embryonic induction, the morphogenesis of male reproductive structures, and the postnatal maintenance of these structures were all found to be mediated effects. The Tfm mouse provides an excellent model in which to study the breadth and mechanics of androgen function.
Wnt4 WNT4 belongs to the WNT family of secreted glycoproteins, with members that function during development as signaling molecules in a diverse range of cell types (94). In the mouse,Wnt4 expression is first detected at 9.5 dpc in the mesenchyme and coelomic epithelium of the mesonephros (95). Shortly afterwards, expression of Wnt4 extends into the mesenchyme of the indifferent gonad. Transcription of Wnt4 in the gonads becomes sexually dimorphic at 11.5 dpc, when it is downregulated in the male gonad but maintained in the somatic cells of the female gonad. In the female, Wnt4 appears to be required for suppressing the differentiation of Leydig cells from the steroidogenic cell lineage. Ovaries collected from Wnt4 homozygous mutant females at 14.5 dpc express the steroidogenic enzymes 3`-HSD and P450c17, both of which are involved in the synthesis of testosterone by Leydig cells and their precursors, and are also expressed by steroidogenic cells of the adult ovary. These ovaries also express type III 17`-HSD which, unlike 3`-HSD and P450c17, is a testisspecific enzyme. The Wolffian ducts of Wnt4 mutant females persist and become coiled at their most cranial end, so that they resemble the epididymides of the male. This further suggests that the ovaries of these animals produce testosterone during fetal development. Lastly, Wnt4 also has a role in the early formation of the Müllerian duct in both sexes. At 12.5 dpc, male and female Wnt4 mutants lack an identifiable Müllerian duct and do not express the Müllerian duct markers Pax8 andWnt7a.
Wnt7a Another member of the WNT family, WNT7a, also appears to be involved in Müllerian-duct development. In the fetus, Wnt7a is expressed in the epithelium of the Müllerian duct in both males and females from 12.5 dpc to 14.5 dpc (96). In the
32
Whitworth and Behringer
male, expression of Wnt7a diminishes as the Müllerian duct regresses, while in the female expression persists into the adult where it is localized to the epithelial cells of the Müllerian-duct-derived oviducts and uterus (96,97). Development of the Müllerian duct in Wnt7a homozygous mutant females is abnormal (96). At birth, these mutant females lack coiled oviducts, and the wall of the uterus is thinner than that of wild-type littermates. Similarly, in adult females, the oviducts are still abnormal, the uterus is nearly devoid of uterine glands, and the stromal layer is thinner. Male homozygous mutants have persistent Müllerian ducts resembling those seen in the MIS and MIS type II receptor mutants. Critically, Wnt7a mutant males (and females) fail to express the MIS type II receptor in the mesenchyme surrounding the Müllerian duct. This suggests that expression of Wnt7a in the epithelial cells of the Müllerian duct is required for regulating the expression of the MIS type II receptor in the periductal mesenchyme which, in turn, induces regression of the Müllerian duct epithelium.
Dhh Hedgehogs are important signaling molecules that regulate diverse developmental processes (98). Vertebrate hedgehog genes include Sonic (Shh), Indian (Ihh), and Desert (Dhh). It is Desert hedgehog that is most relevant to mammalian sex determination and differentiation. At the moment, Dhh has only been reported in mice, however DHH has also been isolated from a marsupial mammal, the tammar wallaby (C.-A. Mao, unpublished data). In the mouse, Dhh expression is initially detected in the fetal testis at 11. 5 dpc (Fig. 2). Later, in the adult testis, Dhh is found specifically in Sertoli cells. Dhh is also detected in other tissues of the developing mouse embryo, including Schwann cells, the endothelium of the vasculature, and the endocardium (99). The highly restricted expression pattern of Dhh in the somatic cells of the male gonad suggests that Dhh may be an important regulator of the male phenotype. Dhh mutant mice have been generated by gene targeting in ES cells (100). Male Dhh mutants were found to be viable yet sterile because of a disruption to spermatogenesis. Interestingly, the expression of Patched (Ptc), which encodes the receptor for hedgehogs, is normally detected in the Leydig cells. In the Dhh mutants, Ptc was not detected. These findings suggest that DHH produced by Sertoli cells interacts with Leydig cells to support spermatogenesis. Therefore, the defects in spermatogensis may be caused by alterations in androgens that are required for male germ-cell development. This would have to be an androgen deficiency that only affects spermatogenesis because the Dhh mutant males (at least on the genetic backgrounds analyzed) were normally virilized. These results also indicate that Dhh is not involved in sex determination, but rather sex differentiation and spermatogenesis. The initiation of Dhh expression in the somatic cells of the male fetal gonad occurs soon after the initiation of Sry expression, suggesting that SRY regulates Dhh, either directly or indirectly. Therefore, it will be interesting to determine the cis- and trans-acting factors required to direct Sertoli-cell-specific transcription of Dhh.
TRANSGENIC MARSUPIALS: A NEW FRONTIER Sexual development in marsupials is fundamentally similar to that described for eutherians mammals such as the mouse and human. However, there are some significant differences in the morphology of the reproductive structures and in the timing of events. It is our goal to exploit these differences in order to gain a more detailed insight into mammalian sexual development from an alternative perspective.
Chapter 2/The Transgenic Mouse
33
In marsupials, as in eutherians, the Y chromosome is testis-determining (101,102), presumably under the direction of the marsupial homolog of SRY (12). Testicular differentiation precedes ovarian differentiation—as is the case in eutherians—and the development of the internal reproductive structures is similarly under the influence of MIS and steroids. However, in marsupials, these events occur after birth. In addition, there are some sexually dimorphic structures in the marsupial that appear to be under direct genetic—rather than secondary gonadal—hormonal control. In at least four species of marsupials, including the South American grey opossum (Monodelphis domestica), North American Virginia opossum (Didelphis virginiana), and the Australian brushtail possum (Trichosuras vulpecula) and tammar wallaby (Macropus eugenii), clearly defined scrotal and mammary anlagen are visible several days before gonadal sex differentiation (103–106). Many species of marsupials develop a pouch in the female. In these species, pouch development similarly appears to be independent of gonadal sex. Descriptions of spontaneously occurring intersexes provide further evidence for the direct genetic control of these sexual dimorphisms in marsupials. Several studies (102,107–109) together describe five intersexes from five different marsupial species with either an XXY, XXY/XX/XY, or aberrant XY karyotype. Each individual possessed functionally normal testes, as evidenced by the presence of a normal male reproductive tract, and yet lacked a scrotum, while possessing a pouch and mammary glands. Taken together, these observations provide compelling evidence that the sexually dimorphic development of the scrotum, pouch, and mammary glands is under direct genetic control, rather than hormonally mediated, as is the case in eutherians. In short, development of the scrotum occurs when only one X chromosome is present (XY, XO), while in the presence of two X chromosomes (XX, XXY) a pouch and mammary glands form (107,110,111). Using the South American grey opossum, it is possible to rigorously test this hypothesis by injecting M. domestica eggs with an M. domestica SRY transgene. XX transgenic animals would be expected to have testes, but the key issue will be whether or not they develop a scrotum. If a scrotum does form, this would suggest that scrotal development can be induced by the presence of a testis, thus refuting the current theory that scrotal development in marsupials is independent of gonadal sex. Research interest in marsupials is not only restricted to the field of sexual differentiation. Marsupials are also unique in comparison to eutherian mammals in their preimplantation development, placentation, the development of their reproductive organs, and X chromosome imprinting (reviewed in 112–114). By establishing transgenic techniques in marsupials, we will generate an exceptional resource for comparative studies of the genetic control of mammalian pre- and postimplantation development.
CONCLUSION The progression from indifferent gonad to testis or ovary is dependent upon a suite of cellular migration, differentiation, and endocrine events. The challenge in understanding how the testis and ovary come into being is in piecing together and integrating what we know at the morphological and molecular levels. From a morphological perspective, it is becoming clearer that differences between XX and XY indifferent gonads in the proliferation of coelomic epithelial cells, the migration of cells into the gonad from the mesonephros, and the cross-communication between germ cells and somatic cells, are all important factors in the development of the testis and ovary. As we learn more about
34
Whitworth and Behringer Table 1 Gene Functions and References to Studies of Transgenic Mice and Natural Mutants
Gene
Function
Sry Wt1 M33 Sox9 Mis
Sertoli cell fate Gonadogenesis/Regulation of Mis expression Gonadogenesis Sertoli-cell fate/Regulation of Mis expression Müllerian-duct regression Leydig-cell differentiation Steroidogenesis MIS signaling Androgen signaling Müllerian-duct formation Suppression of Leydig-cell differentiation in ovary Müllerian-duct regression and differentiation Spermatogenesis Gonadogenesis Sertoli-cell and Leydig-cell endocrine function Leydig-cell endocrine function Granulosa-cell fate and endocrine function
MIS Type II Receptor AR (Tfm) Wnt4 Wnt7a Dhh Sf1 Dax1
Transgenic studies (4,14) (24,27) (28) (42) (54,73–75,84,85)
(83,84) (86,89,90–92) (95) (96) (100) (44–47)
(60,61)
the discrete morphological changes that comprise the grand process of sexual differentiation, it becomes an easier prospect to isolate and place into order candidate genes and the functions of their protein products. At the molecular level, SRY is undoubtedly testis-determining, but we still don’t know whether it acts as a dominant testis-inducer or as an inhibitor of ovarian development, and so, by default, is an indirect testis-determinant. SF1 and WT1 appear to each play multiple roles in both the early stages of gonadogenesis, and later in the regulation of testicular and ovarian endocrine function (Table 1). SOX9 appears to be essential not only in determining Sertoli-cell fate, but also in regulating their production of MIS. Importantly, SOX9 expression in the embryo is not restricted to the testis and so the testisspecific expression of MIS must also require the collaboration of other factors. In addition to its long-known role in inducing the regression of the Müllerian ducts, MIS has more recently been credited with additional functions in regulating the proliferation of Leydig cells and their production of testosterone. The function of MIS in the postnatal ovary is speculative at best. Indeed, our knowledge of the molecular events required for granulosa-cell differentiation is sorely lacking. DAX1 may be important to granulosa cell fate by acting as an antagonist to SRY, while postulated roles for SOX3 remain to be supported by loss- or gain-of-function analyses in humans and mice. Thus, the picture of the molecular aspects of sexual differentiation that begins to emerge is one of an exceedingly complex meshing of factors—many with multiple functions—rather than a straightforward linear hierarchy of interactions. The difficulty in piecing together a model of molecular events to explain the morphological changes observed in the differentiating gonad is that we know relatively few of the genes which must be involved in this process. As new candidate genes are identified
Chapter 2/The Transgenic Mouse
35
and put to the test by gain- and loss-of-function studies in mice, we come closer to being able to integrate the molecular with the morphological. Comparative studies between different eutherian species and marsupials will allow us to test the generality of models extrapolated from the mouse.
ACKNOWLEDGMENTS We are grateful to Soazik Jamin and Alex Arango for their thoughtful suggestions during the preparation of this manuscript. Work from Richard R. Behringer’s laboratory discussed herein was supported by a grant from the NIH (HD30284).
REFERENCES 1. Burgoyne PS, Buehr M, Koopman P, Rossant J, McLaren A. Cell-autonomous action of the testisdetermining gene:Sertoli cells are exclusively XY in XX´XY chimaeric mouse testes. Development 1988;102:443–450. 2. Zamboni L, Upadhyay S. Germ cell differentiation in mouse adrenal glands. J Exp Zool 1983;228:173–193. 3. Palmer S, Burgoyne PS. In situ analysis of fetal, prepuberal and adult XX´XY chimaeric mouse testes:Sertoli cells are predominantly, but not exclusively, XY. Development 1991;112:265–268. 4. Lovell-Badge R, Robertson E. XY female mice resulting from a heritable mutation in the primary testis-determining gene, Tdy. Development 1990;109:635–646. 5. Page DC, Mosher R, Simpson EM, Fisher E, Mardon G, Pollack J, et al. The sex-determining region of the human Y chromosome encodes a finger protein. Cell 1987;51:1091–1094. 6. Sinclair AH, Berta P, Palmer MS, Hawkins JR, Griffiths BL, Smith MJ, et al. A gene from the human sex-determining region encodes a protein with homology to a conserved DNA-binding motif. Nature 1990;346:240–244. 7. Gubbay J, Collignon J, Koopman P, Capel B, Economou A, Münsterberg A, et al. A gene mapping to the sex determining region of the mouse Y chromosome is a member of a novel family of embryonically expressed genes. Nature 1990;346:245–250. 8. Koopman P, Münsterberg A, Capel B, Vivian N, Lovell-Badge R. Expression of a candidate sexdetermining gene during mouse testis differentiation. Nature 1990;248:450–452. 9. Hacker A, Capel B, Goodfellow P, Lovell-Badge R. Expression of Sry, the mouse sex determining gene. Development 1995;121:1603–1614. 10. Just W, Rau W, Vogel W, Akhverdian M, Fredga K, Graves JA, et al. Absence of Sry in species of the vole Ellobius. Nat Genet 1995;11:117,118. 11. Soullier S, Hanni C, Catzeflis F, Berta P, Laudet V. Male sex determination in the spiny rat Tokudaia osimensis (Rodentia: Muridae) is not Sry dependent. Mamm Genome 1998;9:590–592. 12. Foster JW, Brennan FE, Hampikian GK, Goodfellow PK, Sinclair AH, Lovell-Badge R, et al. Evolution of sex determination and the Y chromosome: SRY-related sequences in marsupials. Nature 1992;359:531–533. 13. Harley VR, Jackson DI, Hextall PJ, Hawkins JR, Berkovitz GD, Sockanathan S, et al. DNA binding activity of recombinant SRY from normal males and XY females. Science 1992;255:453–456. 14. Koopman P, Gubbay J, Vivian N, Goodfellow P, Lovell-Badge R. Male development of chromosomally female mice transgenic for Sry. Nature 1991;351:117–121. 15. Capel B. The role of Sry in cellular events underlying mammalian sex determination. Curr Top Dev Biol 1996;32:1–37. 16. Jamieson RV, Zhou SX, Wheatley SC, Koopman P, Tam PP. Seroli cell differentiation and Y-chromosome activity: a developmental study of X-linked transgene activity in sex-reversed X/XSxra mouse embryos. Dev Biol 1998;199:235–244. 17. Eicher EM, Washburn LL, Whitney JB, Morrow KE. Mus poschiavinus Y chromosome in the C57BL/6J murine genome causes sex reversal. Science 1982;217:535–537. 18. Nagamine CM, Taketo T, Koo GC. Studies on the genetics of tda-1 XY sex reversal in the mouse. Differentiation 1987;33:223–231. 19. Eicher EM, Washburn LL, Schork NJ, Lee BK, Shown EP, Xu X, et al. Sex-determining genes on mouse autosomes identified by linkage analysis of C57BL/6- YPOS sex reversal. Nat Genet 1996;14:206–209.
36
Whitworth and Behringer
20. Albrecht KH, Eicher EM. DNA sequence analysis of Sry alleles (subgenus Mus) implicates misregulation as the cause of C57BL/6J-Y(POS) sex reversal and defines the SRY functional unit. Genetics 1997;147:1267–1277. 21. Schedl A, Hastie N. Multiple roles for the Wilms’ tumour suppressor gene, WT1 in genitourinary development. Mol Cell Endocrinol 1998;140:65–69. 22. Pelletier J, Schalling M, Buckler AJ, Rogers A, Haber DA, Housman D. Expression of the Wilms’ tumor gene WT1 in the murine urogenital system. Genes Dev 1991;5:1345–1356. 23. Armstrong JF, Pritchard-Jones K, Bickmore WA, Hastie ND, Bard JB. The expression of the Wilms’ tumour gene, WT1, in the developing mammalian embryo. Mech Dev 1992;40:85–97. 24. Kreidberg JA, Sariol H, Loring JM, Maeda M, Pelletier J, Housman D, et al. WT-1 is required for early kidney development. Cell 1993;74:679–691. 25. Nachtigal MW, Hirokawa Y, Enyeart-VanHouten DL, Flanagan JN, Hammer GD, Ingraham HA. Wilms’ tumor 1 and Dax-1 modulate the orphan nuclear receptor SF-1 in sex-specific gene expression. Cell 1998;93:445–454. 26. Little M, Wells C. A clinical overview of WT1 gene mutations. Hum Mutat 1997;9:209–225. 27. Patek CE, Little MH, Fleming S, Miles C, Charlieu J-P, Clarke AR, et al. A zinc finger truncation of murine WT1 results in the characteristic urogenital abnormalities of Denys-Drash syndrome. Proc Natl Acad Sci USA 1999;96:2931–2936. 28. Katoh-Fukui Y, Tsuchiya R, Shiroishi T, Nakahara Y, Hashimoto N, Noguchi K. et al. Maleto-female sex reversal in M33 mutant mice. Nature 1998;393:688–692. 29. Karl J, Capel B. Sertoli cells of the mouse testis originate from the coelomic epithelium. Dev Biol 1998;203:323–333. 30. Foster JW, Dominguez-Steglich MA, Guioli S, Kowk G, Weller PA, Stevanovic M, et al. Campomelic dysplasia and autosomal sex reversal caused by mutations in an SRY-related gene. Nature 1994;372:525–530. 31. Wagner T, Wirth J, Meyer J, Zabel B, Held M, Zimmer J, Pasantes J, et al. Autosomal sex reversal and campomelic dysplasia are caused by mutations in and around the SRY-related gene SOX9. Cell 1994;79:1111–1120. 32. Tommerup N, Schempp W, Meinecke P, Pederson S, Bolund L, Brandt CCG, et al. Assignment of an autosomal sex reversal locus (SRA1) and campomelic dysplasia (CMPD1) to 17q24.3-q25.1. Nat Genet 1993;4:170–173. 33. Mansour S, Hall CM, Pembrey ME, Young ID. A clinical and genetic study of campomelic dysplasia. J Med Genet 1995;32:415–420. 34. Houston CS, Opitz JM, Spranger JW, Macpherson RI, Reed MH, Gilbert EF, et al. The campomelic syndrome: review, report of 17 cases, and follow-up on the currently 17-year-old boy first reported by Maroteaux et al. in 1971. Am J Med Genet 1983;15:3–28. 35. Südbeck P, Schmitz ML, Baeuerle PA, Scherer G. Sex reversal by loss of the C-terminal transactivation domain of human SOX9. Nat Genet 1996;13:230–232. 36. Kent J, Wheatley SC, Andrews JE, Sinclair AH, Koopman P. A male-specific role for Sox9 in vertebrate sex determination. Development 1996;122:2813–2822. 37. Morais da Silva S, Hacker A, Harley V, Goodfellow P, Swain A, Lovell-Badge R. Sox9 expression during gonadal development implies a conserved role for the gene in testis differentiation in mammals and birds. Nat Genet 1996;14:62–68. 38. Oreal E, Pieau C, Mattei M-G, Josso N, Picard J-Y, Carre-Eusebe D, Magre S. Early expression of AMH in chicken embryonic gonads precedes testicular SOX9 expression. Dev Dyn 1998;212:522–532. 39. Spotila LD, Spotila JR, Hall SE. Sequence and expression analysis of WT1and Sox9 in the red-eared slider turtle, Trachemys scripta. J Exp Zool 1998;281:417–427. 40. Western PS, Harry JL, Marshall Graves JA, Sinclair AH. Temperature dependent sex determination in the American alligator:AMH precedes SOX9 expression. Dev Dyn 1999;216:411–419. 41. Bi W, Deng JM, Zhang Z, Behringer RR, de Crombrugghe B. Sox9 is required for cartilage formation. Nat Genet 1999;22:85–89. 42. Bishop CE, Whitworth DJ, Qin Y, Agoulnik A, Harrison W, Agoulnik I, Harrison W, Behringer RR, et al. A transgenic insertion upstream of Sox9 is associated with dominant XX sex reversal in the mouse. Nat Genet 2000;26:490–494. 43. Parker KL, Schimmer BP. The roles of the nuclear receptor steroidogenic factor 1 in endocrine differentiation and development. Trends Endocrinol. Metab. 1996;7:203–207. 44. Ingraham HH, Lala DS, Ikeda Y, Luo X, Shen WH, Nachtigal MW, et al. The nuclear receptor steroidogenic factor 1 acts at multiple levels of the reproductive axis. Genes Dev 1994;8:2302–2312.
Chapter 2/The Transgenic Mouse
37
45. Luo X, Ikeda Y, Parker KL. A cell-specific nuclear receptor is essential for adrenal and gonadal development and sexual differentiation. Cell 1994;77:481–490. 46. Sadovsky Y, Crawford PA, Woodson KG, Polish JA, Clements MA, Tourtellotte LM, et al. Mice deficient in the orphan receptor steroidogenic factor 1 lack adrenal glands and gonads but express P450 side-chain-cleavage enzyme in the placenta and have normal embryonic serum levels of corticosteroids. Proc Natl Acad Sci USA 1995;92:10,939–10,943. 47. Shinoda K, Lei H, Yoshii H, Nomura M, Nagano M, Shiba H, et al. Developmental defects of the ventromedial hypothalamic nucleus and pituitary gonadotroph in the Ftz-F1 disrupted mice. Dev Dyn 1995;204:22–29. 48. Ikeda YW, Shen HA, Ingraham HA, Parker KL. Developmental expression of mouse steroidogenic factor 1 an essential regulator of the steroid hydroxylases. Mol Endocrinol 1994;7:852–860. 49. Muscatelli F, Strom TM, Walker AP, Zanaria E, Recan D, Meindl A, et al. Mutations in the DAX-1 gene give rise to both X-linked adrenal hypoplasia congenita and hypogonadotropic hypogonadism. Nature 1994;372:672–676. 50. Ikeda Y, Swain A, Weber TJ, Hentges KE, Zanaria E, Lalli E, et al. Steroidogenic Factor 1 and Dax-1 co-localize in multiple cell lineages: potential links in endocrine development. Mol Endocrinol 1996;10:1261–1272. 51. Swain A, Zanaria E, Hacker A, Lovell-Badge R, Camerino G. Mouse Dax-1 expression is consistent with a role in sex determination as well as in adrenal and hypothalamus function. Nat Genet 1996;12:404–409. 52. Pilon N, Behdjani R, DaneauI Lussier JG, Silversides DW. Porcine steroidogenic factor-1 gene (pSF-1) expression and analysis of embryonic pig gonads during sexual differentiation. Endocrinology 1998;139:3803–3812. 53. Shen WH, Moore CC, Ikeda Y, Parker KL, Ingraham HA. Nuclear receptor steroidogenic factor 1 regulates the Müllerian inhibiting substance gene: a link to the sex determination cascade. Cell 1994;77:651–661. 54. Giuili G, Shen WH, Ingraham HA. The nuclear receptor SF-1 mediates sexually dimorphic expression of Müllerian Inhibiting Substance, in vivo. Development 1997;124:1799–1807. 55. Ito M, Yu RN, Jameson JL. DAX-1 inhibits SF-1 mediated transactivation via a carboxy-termminal domain that is deleted in adrenal hypoplasia congenita. Mol Cell Biol 1997;17:1476–1483. 56. Zazopoulos E, Lalli E, Stocco DM, Sassone-Corsi P. DNA binding and transcriptional repression by DAX-1 blocks steroidogenesis. Nature 1997;390:311–315. 57. Crawford PA, Dorn C, Sadovsky Y, Milbrandt J. Nuclear receptor DAX-1 recruits nuclear receptor corepressor N-CoR to Steroidogenic Factor 1. Mol Cell Biol 1998;18:2949–2956. 58. Bardoni B, Zanaria E, Guioli S, Floridia G, Worley KC, Tonini G, et al. A dosage sensitive locus at chromosome Xp21 is involved in male to female sex reversal. Nat Genet 1994;7:497–501. 59. Zanaria E, Bardoni B, Dabovic B, Calvari V, Fraccaro M, Zuffardi O, et al. An unusual member of the nuclear hormone receptor superfamily responsible for X-linked adrenal hypoplasia congenita. Nature 1994;372:635–641. 60. Swain A, Narvaez V, Burgoyne P, Camerino G, Lovell-Badge R. Dax1 antagonises Sry action in mammalian sex determination. Nature 1998;391:761–767. 61. Yu RN, Ito M, Saunders TL, Camper SA, Jameson JL. Role of Ahch in gonadal development and gametogenesis. Nat Genet 1998;20:353–357. 62. Stevanovic M, Lovell-Badge R, Collignon L, Goodfellow PN. SOX3 is an X-linked gene related to SRY. Hum Mol Genet 1993;3:2013–2018. 63. Collignon J, Sockanathan S, Hacker A, Cohen-Tannoudji M, Norris D, Rastan S, et al. A comparison of the properties of Sox-3 with Sry and two related genes, Sox-1and Sox-2. Development 1996;122:509–520. 64. Foster JW, Graves JAM. An SRY-related sequence on the marsupial X chromosome—implications for the evolution of the mammalian testis determining gene. Proc Natl Acad Sci USA 1994;91:1927–1931. 65. Graves JAM. Interactions between SRY and SOX genes in mammalian sex determination. BioEssays 1998;20:264–269. 66. Uwanogho D, Rex M, Cartwright EJ, Pearl G, Healy C, Scotting PJ, Sharpe PT. Embryonic expression of the chicken Sox2, Sox3 and Sox11 genes suggests an interactive role in neuronal development. Mech Dev 1995;49:23–36.
38
Whitworth and Behringer
67. Josso N, Cate RL, Picard JY, Vigier B, di Clemente N, Wilson C, et al. Anti-Müllerian hormone: the Jost factor. Recent Prog Horm Res 1993;48:1–59. 68. Tran D, Muesy-Dessolle N, Josso N. Anti-Müllerian hormone is a functional marker of foetal Sertoli cells. Nature 1977;269:411,412. 69. Münsterberg A, Lovell-Badge R. Expression of the mouse anti-Müllerian hormone gene suggests a role in both male and female sexual differentiation. Development 1991;113:613–624. 70. Tran D, Muesy-Dessolle N, Josso N. Waning of anti-Müllerian activity: an early sign of Sertoli cell maturation in the developing pig. Biol.Reprod 1981;24:923–931. 71. Baker ML, Hutson JM. Serum levels of Müllerian inhibiting substance in boys throughout puberty and in the first two years of life. J Clin Endocrinol Metab 1993;76:245–247. 72. Rey R, Lordereau-Richard I, Carel JC, Barbet P, Cate RL, Roger M, et al. Anti-Müllerian hormone and testosterone serum levels are inversely related during normal and precocious pubertal development. J Clin Endocrinol Metab 1993;77:1220–1226. 73. Behringer RR, Cate RL, Froelick GJ, Palmiter RD, Brinster RL. Abnormal sexual development in transgenic mice chronically expressing Müllerian inhibiting substance. Nature 1990;345:167–170. 74. Lyet L, Louis F, Forest MG, Josso N, Behringer RR, Vigier B. Ontogeny of reproductive abnormalities induced by deregulation of anti-Müllerian hormone expression in transgenic mice. Biol Reprod 1995;52:444–454. 75. Racine C, Rey R, Forest MG, Louis F, Ferre A, Huhtaniemi I, et al. Receptors for anti-Müllerian hormone on Leydig cells are responsible for its effects on steroidogenesis and cell differentiation. Proc Natl Acad Sci USA 1998;95:594–599. 76. Behringer RR, Finegold MJ, Cate RL. Müllerian-inhibiting substance function during mammalian sexual development. Cell 1994;79:415–425. 77. Massague J. TGF-beta signal transduction. Annu Rev Biochem 1998;67:753–791. 78. Mishina Y, Tizard R, Deng JM, Pathak BG, Copeland NG, Jenkins NA, et al. Sequence, genomic organization, and chromosomal location of the mouse Müllerian-inhibiting substance type II receptor gene. Biochem Biophys Res Commun 1997;237:741–746. 79. Baarends WM, van Helmond MJL, Post M, van der Schoot PJCM, Hoogerbrugge JW, de Winter JP, et al. A novel member of a transmembrane serine/threonine kinase receptor family is specifically expressed in the gonads and in mesenchymal cells adjacent to the Müllerian duct. Development 1994;120:189–197. 80. Teixeira J, He WW, Shah PC, Morikawa N, Lee MM, Catlin EA, et al. Developmental expression of a candidate Müllerian inhibiting substance type II receptor. Endocrinology 1996;137:160–165. 81. di Clemente N, Wilson C, Faure E, Bouissin L, Carmillo P, Tizard R, et al. Cloning, expression, and alternative splicing of the receptor for anti- Müllerian hormone. Mol Endocrinol 1994;8:1006–1020. 82. Imbeaud S, Carre-Eusebe D, Rey R, Belville C, Josso N, Picard J-Y. Molecular genetics of the persistent Müllerian duct syndrome: a study of 19 families. Hum Mol Genet 1994;3:125–131. 83. Mishina Y, Rey R, Finegold MJ, Matzuk MM, Josso N, Cate RL, et al. Genetic analysis of the Müllerian-inhibiting substance signal transduction pathway in mammalian sexual differentiation. Genes Dev 1996;10:2577–2587. 84. Mishina Y, Whitworth DJ, Racine C, Behringer RR. High specificity of Müllerian-inhibiting substance signaling in vivo. Endocrinology 1999;140:2084–2088. 85. Arango NA, Lovell-Badge R, Behringer RR. Targeted mutagenesis of the endogenous mouse Müllerian inhibiting substance gene promoter: in vivo definition of genetic pathways of vertebrate sexual development. Cell 1999;99:409–419. 86. Lyon MF, Hawkes SG. X-linked gene for testicular feminization. Nature 1970;227:1217–1219. 87. Drews U. Direct and mediated effects of testosterone:analysis of sex reversed mosaic mice heterozygous for testicular feminization. Cytogenet Cell Genet 1998;80:68–74. 88. Couse JF, Korach KS. Exploring the role of sex steroids through studies or receptor deficient mice. J Mol Med 1998;76:497–511. 89. Charest NJ, Zhou Z-X, Lubahn DB, Olsen KL, Wilson EM, French FS. A frameshift mutation destabilizes androgen receptor messenger RNA in the Tfm mouse. Mol Endocrinol 1991;5:573–581. 90. Gaspar M-L, Meo T, Bourgarel P, Guenet J-L, Tosi M. A single base deletion in the Tfm androgen receptor gene creates a short-lived messenger RNA that directs internal translation initiation. Proc Natl Acad Sci USA 1991;88:8606–8610. 91. He WW, Kumar MV,Tindall DJ. A frame-shift mutation in the androgen receptor gene causes complete androgen insensitivity in the testicular-feminized mouse. Nucleic Acids Res 1991;19:2373–2378. 92. Wilson JD. Syndromes of androgen resistance. Biol Reprod 1992;46:168–173.
Chapter 2/The Transgenic Mouse
39
93. Murphy L, O’Shaughnessy PJ. Testicular steroidogenesis in the testicular feminized (Tfm) mouse: loss of 17_-hydroxylase activity. J Endocrinol 1991;131:443–449. 94. Cadigan KM, Nusse R. Wnt signaling: a common theme in animal development. Genes Dev 1997;11:3286–3305. 95. Vainio S, Heikkila M, Kispert A, Chin N, McMahon AP. Female development in mammals is regulated by Wnt-4 signalling. Nature 1999;397:405–409. 96. Parr BA, McMahon AP. Sexually dimorphic development of the mammalian reproductive tract requires Wnt-7a. Nature 1998;395:707–710. 97. Miller C, Sassoon DA. Wnt-7amaintains appropriate uterine patterning during the development of the mouse female reproductive tract. Development 1998;125:3201–3211. 98. Hammerschmidt M, Brook A, McMahon, AP. The world according to hedgehog. Trends Genet 1997;13:14–21. 99. Bitgood MJ, McMahon AP. Hedgehog and Bmp genes are coexpressed at many diverse sites of cellcell interaction in the mouse embryo. Dev Biol 1995;172:126–138. 100. Bitgood MJ, Shen L, McMahon AP. Sertoli cell signaling by Desert hedgehog regulates the male germline. Curr Biol 1996;6:298–304. 101. Hayman DL, Martin PG. Sex chromosome mosaicism in the marsupial genera Isoodon and Parameles. Genetics 1965;52:1201–1206. 102. Sharman GB, Robinson ES, Walton SM, Berger PJ. Sex chromosomes and reproductive anatomy of some intersexual marsupials. J Reprod Fertil 1970;21:57–68. 103. O W-S, Short RV, Renfree MB, Shaw G. Primary genetic control of somatic sexual differentiation in a mammal. Nature 1988;331:716–717. 104. Renfree MB, Robinson ES, Short RV, VandeBerg JL. Mammary glands in male marsupials: 1. Primordia in neonatal opossums Didelphis virginiansand Monodelphis domestica. Development 1990;110:385–390. 105. Robinson ES, Renfree MB, Short RV, VandeBerg JL. Mammary glands in male marsupials: 2. Development of teat primordia in Didelphis virginiansand Monodelphis domestica. Reprod Fertil Dev 1991;3:295–301. 106. Ullmann SL. Differentiation of the gonads and initiation of mammary gland and scrotum development in the brushtail possum Trichosurus vulpecula (Marsupialia). Anat Embryol 1993;187:475–484. 107. Sharman GB, Hughes RK, Cooper DW. The chromosomal basis of sex differentiation in marsupials. Aust J Zool 1990;37:451–456. 108. Cooper DW, Edwards C, James E, Sharman GB, VandeBerg JL, Graves JAM. Studies on metatherian sex chromosomes. VI. A third state of an X-linked gene: partial activity for the paternally derived Pgk-A allele in cultured fibroblasts of Macropus giganteus and M. parryi. Aust J Biol Sci 1977;30:431–443. 109. Cooper DW, Johnston PG, VandeBerg JL, Robinson ES. X-chromosome inactivation in marsupials. Aust J Zool 1990;37:411–417. 110. Renfree MB, Short RV. Sex determination in marsupials: evidence for a marsupial-eutherian dichotomy. Phil Trans R Soc Lond B 1988;322:41–53. 111. Shaw G, Renfree MB, Short RV. Primary genetic control of sexual differentiation in marsupials. Aus J Zool 1990;37:443–450. 112. Tyndale-Biscoe CH, Renfree MB. Reproductive Physiology of Marsupials. Cambridge University Press, Cambridge, UK, 1987. 113. VandeBerg JL, Robinson ES, Samollow PB, Johnston P. X-linked gene expression and X-chromosome inactivation: marsupials, mouse and man compared. In: Isozymes: Current Topics in Biological and Medical Research. Vol 15, Academic Press, San Diego, CA, 1987, pp. 225–253. 114. Renfree MB. Ontogeny, genetic control, and phylogeny of female reproduction in monotreme and therian mammals. In: Szalay FS, ed. Mammal Phylogeny: Mesozoic Differentiation, Multituberculates, Monotremes, Early Therians, and Marsupials. Springer-Verlag, Berlin, 1993, pp. 4–20. 115. McElreavey K, Vilain E, Herskowitz I, Fellous M. A regulatory cascade hypothesis for mammalian sex determination: SRY represses a negative regulator of male development. Proc Natl Acad Sci USA 1993;90:3368–3372.
Chapter 3/MIS Signaling During Sexual Development
3
41
The In Vivo Function of Müllerian-Inhibiting Substance During Mammalian Sexual Development Yuji Mishina, PHD CONTENTS INTRODUCTION MÜLLERIAN-INHIBITING SUBSTANCE IN VIVO FUNCTIONAL ANALYSIS OF MIS SIGNALING INTERACTION OF MIS SIGNALING AND OTHER SIGNALING PATHWAYS CONCLUSIONS AND PERSPECTIVES ACKNOWLEDGMENTS REFERENCES
INTRODUCTION In mammals, both XX and XY individuals develop one pair of undifferentiated gonads and two pairs of genital ducts, the Müllerian ducts and the Wolffian ducts, associated with the mesonephroi during development (Fig. 1). The undifferentiated gonads are bipotent, and will give rise to either testes or ovaries depending on the sex-chromosome genotype. The Müllerian ducts have the potential to give rise to female reproductive organs, including the uterus, oviducts, and upper portion of the vagina. The Wolffian ducts are the primordia of male reproductive organs, which are the vas deferens, epididymis, and seminal vesicles. Therefore, regardless of sex-chromosome genotype, each individual has the potential to develop male and female reproductive systems. The presence of the Y chromosome determines that an individual becomes a male because of a gene termed Sry. There must be a mechanism to select only one duct system, depending on the presence or absence of Sry. Two gonadal hormones—Müllerianinhibiting substance (MIS)—and testosterone, play essential roles during this selection process (Fig. 1) (1–3). This chapter, examines the results of in vivo approaches using transgenic and targeted mutant mice to study MIS function.
From: Contemporary Endocrinology: Transgenics in Endocrinology Edited by: M. Matzuk, C. W. Brown, and T. R. Kumar © Humana Press Inc., Totowa, NJ
41
42
Mishina
Fig. 1. Schematic representation of mammalian sexual development and its surgical alteration. The Müllerian ducts give rise to the uterus, oviducts, and upper portion of the vagina (white). The Wolffian ducts give rise to the epididymis, vas deferens, and seminal vesicles (black). MIS produced by the Sertoli cells of the fetal testes causes the regression of the Müllerian ducts and testosterone produced by Leydig cells induces the differentiation of the Wolffian duct system. The absence of both of these hormones during female fetal development permits the development of the Müllerian duct system while the Wolffian ducts passively regress. When ovaries or testes of a fetus are removed (ovx, testx), female development occurs. Unilateral testicular graft to a female fetus causes local regression of the Müllerian duct and persistence of the Wolffian duct (testis graft). Hemicastration of a male fetus causes a local persistence of the Müllerian duct (hemicastrate).
MÜLLERIAN-INHIBITING SUBSTANCE The Jost Factor: A Short History of MIS In the middle of the twentieth century, Alfred Jost performed pioneering experiments that suggested that the presence of two gonadal hormones is required for the selection of either the Müllerian or Wolffian duct system (4,5). He surgically removed the gonads of fetal rabbits during sexual differentiation. Removal of both the ovaries from female fetuses and the testes from male fetuses resulted in female development (Fig. 1). In both cases, the Müllerian ducts persisted and differentiated, while the Wolffian duct system regressed. Unilateral removal of the fetal testes resulted in regression of the Wolffian ducts and persistence of the Müllerian ducts only on the removed side. A testicular graft to a female fetus caused local regression of the Müllerian duct, as well as a local differentiation of the Wolffian ducts (3). These observations led to the following hypothesis: 1) the fetal testes secrete two types of hormones—one that stimulates the differentiation of the Wolffian ducts, and the other causing regression of the Müllerian ducts, 2) the second hormone has a limited distance of action. When a crystal of synthetic androgen is introduced into the abdominal cavity of a castrated male fetus, the development of male structures is stimulated, but the Müllerian ducts are not inhibited. This result suggests that the first hormone is androgen
Chapter 3/MIS Signaling During Sexual Development
43
Fig. 2. Summary of the mechanism of sexual dimorphic development. The expression of Sry initiates testicular differentiation to allow male steroidogenesis in Leydig cells and SF-1/AdBP4 expression in Sertoli cells. SF-1/Ad4BP activates MIS gene with WT1, SOX9 and GATA-4. DAX-1 antagonizes this process. MIS binds an MIS receptor located in the surrounding mesenchyme of the Müllerian ducts to cause regression of the Müllerian ducts. Testosterone generated by Leydig cells induces the differentiation of the Wolffian ducts toward male specific reproductive tissues. MIS also binds the MIS receptor in Leydig cells to reportedly repress biosynthesis of aromatase that converts testosterone to estradiol. WD, the Wolffian duct; MD, the Müllerian duct; MIS-R, MIS receptor.
and the second hormone is separate from the masculinizing activities of androgens. The second hormone is currently termed Müllerian-inhibiting substance (MIS) or antiMüllerian hormone (AMH) (2). The expression of Sry initiates testicular differentiation into two types of cells, Leydig cells and Sertoli cells (Fig. 2). In Sertoli cells, transcription factors that include steroidogenic factor-1 (SF-1), alternatively known as adrenal 4-binding protein (Ad4BP), initiate MIS expression (6–8). Recent studies indicate that transcription factors such as Wilms’ tumor 1 (WT1), DAX-1, SOX9, and GATA-4 are also involved in this process (9–11,93–94). Testosterone is produced in Leydig cells. MIS may be involved in this process via inhibition of biosynthesis of aromatase that converts testosterone to estradiol (12–15). MIS actively induces the regression of the Müllerian ducts, thereby preventing the development of female reproductive organs. Subsequently, testosterone induces the differentiation of the Wolffian ducts. During female development, ovaries do not express MIS, creating a permissive environment for the differentiation of the Müllerian ducts. In addition, the lack of testosterone leads to the passive regression of the Wolffian ducts. Thus, MIS and testosterone mediate a switch between the differentiation of the male and female extragonadal reproductive organs (Figs. 1 and 2).
44
Mishina
Fig. 3. Dendrogram of the TGF-` superfamily. The mature peptide sequence MIS is highly divergent from other members of the TGF-` superfamily.
MIS is a Member of the TGF-` Superfamily The MIS cDNA was cloned by two independent groups by different approaches (16,17). One approach was to sequence tryptic peptides of bovine MIS and to make degenerate oligonucleotide probes to screen a newborn bovine testis cDNA library (16). The other approach was to screen a newborn bovine testis cDNA expression library, using antisera raised against bovine MIS (17). Since then, the MIS gene has been isolated in humans, the cow, rat, and mouse (16–19). DNA sequencing of MIS revealed that MIS was a member of the transforming growth factor-` (TGF-`) gene superfamily (16) (Fig. 3). The members of this large gene family include activins, inhibins, bone morphogenetic proteins (BMPs), and growth-differentiation factors (GDFs) (20). MIS is encoded by five exons encompassing 2.8 kb. MIS is a 140-kDa dimeric glycoprotein composed of two identical 70-kDa subunits (21). Like other members of the TGF-` family, the 140-kDa MIS homodimer requires proteolytic processing to generate an N-terminal domain 110-kDa homodimer and a C-terminal domain 25-kDa homodimer (22,23). PC5—one of the kex2/subtilisin-like enzymes—
Chapter 3/MIS Signaling During Sexual Development
45
may play a critical role for MIS processing; PC5 can cleave the MIS precursor in vitro and is also expressed in developing testes, suggesting an important physiological function (24). Although only the C-terminal domain of TGF-` is required for its activity (25), both the separated N- and C-terminal domains of MIS are essential to restore its regression for biological function (26). During embryogenesis, MIS expression is detected only in the male. Expression is restricted to Sertoli cells, and the highest levels of MIS are detected during the period of Müllerian-duct regression (19,23). After birth, MIS is detected in Sertoli cells and granulosa cells in the ovary (19,27–29). MIS protein is detected most abundantly in granulosa cells that contact the oocyte and line the antrum, suggesting that an oocyte-secreted growth factor may regulate its activity in the ovary. However, the levels of MIS in the ovary after birth are 0.1% of the levels produced by the fetal testes (30). The expression pattern observed in male and female gonads suggests that, in addition to its Müllerianduct inhibitory activity, MIS may regulate gonadal function and gametogenesis, topics to be discussed later in this chapter.
Molecular Cloning of the Type II MIS Receptor In the case of TGF-` family ligands, two types of membrane bound serine/threonine kinases form heterodimers upon ligand binding to transduce a signal (type I and type II receptors, with mol wt of ~55 kd and 75–85 kd, respectively) (20). Type II receptors are cloned by their binding ability for activin (31) or TGF-` (32). Type I receptors have been cloned by sequence similarity of the kinase domain with type II receptors (33–35). Type I receptors have a characteristic serine/glycine box at the juxtamembrane region that provides phosphorylation sites for type II receptor kinases and type I receptors are believed to phosphorylate downstream proteins for their signal transduction (36). The specificity of ligand binding is primarily determined by type II receptors, although the specificity of signaling is primarily determined by type I receptors (37). Recently, a type II receptor gene for MIS was isolated from a rat Sertoli cell cDNA library as a testosterone-induced gene (38), and from a rabbit fetal ovary cDNA library using a degenerated oligonucleotide probe from the conserved kinase domain (39). Specific binding for MIS has been demonstrated by a transfection study, with a dissociation constant of 2.48–2.55 nM (39,40). By in situ hybridization, the MIS receptor gene was shown to be expressed in the mesenchymal cells adjacent to the Müllerian ducts during male and female embryogenesis (38,39,41) (Fig. 2). This is an finding was intriguing, because the receptor is not expressed in the duct epithelium itself. This suggests that MIS most likely alters the surrounding mesenchyme to elicit Müllerian-duct regression. The MIS type II receptor is also expressed in Sertoli cells and granulosa cells in fetal and adult testes and ovaries, respectively, and in the gravid uterus (38,39,42–44). Recently, the expression of the receptor has been confirmed in Leydig cells suggesting that MIS signaling may directly regulate Leydig-cell function (14,15). Like the expression pattern of the MIS ligand, expression of the MIS receptor in the gonads suggests multiple functions of MIS. In the case of other TGF-` family ligands, both type I and type II receptors are essential for their signal transduction. It is likely that MIS requires a type I receptor in addition to the type II receptor for signaling. A type I receptor termed Alk2 (alternatively known as activin type IA receptor (ActRIA), R1, Tsk7L, or SKR-1) is one candidate for the type I receptor for MIS (34,45–47), although direct evidence is needed. Alk2 is less
46
Mishina
widely expressed then other type II receptors, including those in the mesenchyme surrounding the Müllerian ducts (45). It has been reported that a point mutation in the serine/ threonine kinase domain makes the kinase activity ligand-independent (constitutive active form, ca) (48). When HEK-293 (human embryonic kidney) cells are transfected with ca-Alk2, the aromatase-promoter activity is repressed (49). This suggests that ca-Alk2 can transduce a signal similar to the MIS signal, because MIS has the ability to repress aromatase biosynthesis (12,13). Direct evidence using transgenic animals or biochemical studies is awaited.
Mechanisms of Duct Regression The question of how MIS causes regression of the Müllerian ducts is the source of great debate. Despite the long history of MIS, little is known about its molecular mechanism of regression. Two distinctive mechanisms are proposed: 1) conversion of ductal epithelial cells to mesenchymal cells, and 2) apoptosis of ductal epithelial cells. The morphology of regression has been studied in the mouse (50), the rat (51), the chick (52), and the alligator (53). These studies indicate that the processes are remarkably wellconserved. The first event of regression is loss of the basement membrane underlying the epithelial and mesenchymal cells to allow direct contact of two populations (54). Surrounding mesenchymal cells that lose the basement membrane condense to form an epithelial cuff. The epithelium subsequently shrinks by loss of cells. Phagocytic activity is observed during the duct regression in male mice, suggesting that cell death is a major mechanism of regression. However, similar activity is also observed in the developing duct in females (50). This has allowed researchers to propose a different mechanism—reentry of the ductal epithelium to the mesenchymal cell population. Ultrastructural studies have shown that there are viable epithelial cells even in highly regressing Müllerian ducts (54). Interestingly, some of the cells in the surrounding mesenchyme actively metabolize hyaluronate and glycosaminoglycans, suggesting that the origin of these cells is epithelial and they have been migrating away from the duct (55). Indeed, migration of ductal epithelial cells has been demonstrated in alligator embryos, using the fluorescent cell marker DiI (53). Ultrastructural studies also suggest that the Müllerian duct undergoes apoptosis. During regression, an increased number of lysosomes and infiltration of macrophages into the epithelium are observed in the rat and the rabbit (51,56). Recently, it was demonstrated using the TUNEL assay that the Müllerian ducts in rat embryos undergo apoptosis (41). The male genital ridge and the female genital ridge exposed to MIS show TUNEL-positive cells in ductal epithelium. It is known that caspase plays a major role in apoptosis. Interestingly, Boc-D-FMK, the caspase inhibitor, prevents MIS-induced apoptosis (41). The duct epithelium alone in organ culture, or recombined tissues consisting of the duct epithelium and the mesenchyme from the embryonic kidney, do not undergo apoptosis (41). The mesenchyme from the embryonic kidney does not express MIS type II receptor, and this finding proves that MIS acts specifically through the MIS type II receptor to alter the surrounding mesenchyme and thereby induces apoptosis indirectly. These two mechanisms are not exclusive of each other. There may be several different mechanisms occurring simultaneously, or major mechanisms for regression may differ from species to species. Interestingly, regression occurs cranially to caudally, but incompletely. Transgenic and mutated mice will provide valuable insight into the precise
Chapter 3/MIS Signaling During Sexual Development
47
molecular mechanisms of regression, and will provide the opportunity to identify downstream targets of MIS signaling.
IN VIVO FUNCTIONAL ANALYSIS OF MIS SIGNALING Transgenic Mice that Chronically Express MIS: Gain-of-Function Study of the Transgenic Mouse To investigate the in vivo functions of MIS, a gain-of-function study was initially performed in transgenic mice. The human MIS gene was expressed widely in both males and females, using the mouse metallothionein (MT) promoter (57). Transgenic lines that possessed circulating levels of human MIS in plasma, ranging on average from 40 to 4400 ng/mL, were established. Female transgenic mice lacked a uterus and oviducts, thus demonstrating the function of MIS as a Müllerian inhibitor in vivo (Table 1) (57). The Müllerian ducts in transgenic females began to regress at embryonic d 13 (E 13), the same stage as in normal males (58). In addition to lacking Müllerian duct-derived tissues, transgenic females showed abnormalities in their ovaries. Ovaries were present in newborn transgenic females, but germ cells were subsequently lost, and the somatic components of the ovary reorganized into structures reminiscent of the seminiferous tubules of the male gonad (57). Reduction of the volume of ovaries in the transgenic females was detectable at E 14. The number of germ cells in the ovaries of transgenic mice was decreased from E 16, a time when oogonia in wild-type mice cease to proliferate, and the progression of the meiotic prophase was delayed (58). It is not clear whether MIS acts directly on female germ cells. However, the results imply that an excess amount of MIS alters the function of granulosa cells, causing depletion of the germ cells (59). The subsequent degeneration of the ovaries may be a nonspecific response to the loss of germ cells (60). Most of the male MT-MIS transgenic mice were phenotypically normal and fertile. However, abnormal phenotypes were observed in a portion of the males (5/21) from the highest-expressing lines (Table 1). Externally, these transgenic males were feminized, exhibiting mammary-gland development. Internally, Wolffian-duct differentiation was arrested, and the testes were undescended (57). Serum testosterone levels of these transgenic mice were reduced, suggesting that a high level of MIS affected Leydig cell function (58). Further, more expression of steroidogenic proteins, such as P450 cholesterol side chain-cleavage enzyme and P450 hydroxylase/C17-20 lyase, are downregulated in transgenic male mice (14,15). The number of Leydig cells is also decreased (59). Because the type II receptor for MIS is expressed in Leydig-cells, it is likely that MIS signaling directly regulates Leydig cell function. Based on these observations, one of the most striking conclusions is that MIS can act in vivo as the Müllerian inhibitor. In addition, MIS can alter the function of Leydig cells to influence Wolffian-duct development. MIS may also play roles in gonadal differentiation and germ-cell development. Finally, the observation that altered levels of MIS resulted in abnormal testicular descent implies that regulated levels of MIS are required for proper descent of the testes (61).
MIS-Deficient Mice: Loss-of-Function Study From the gain-of-function study described in the previous section, we have learned what MIS can do during male and female sexual differentiation. It is also important to
48
Mishina Table 1 Summary of Gain- and Loss-of-Function Studies of MIS
MIS-overexpressing transgenic mice
MIS-deficient mice
MIS-receptor deficient mice
Male
Female
Externally female Impaired development of the Wolffian duct Undescended testes Fewer germ cells Presence of uteri Majority infertile Hyperplasia of Leydig cells Testicular atrophy Presence of uteri Majority infertile Hyperplasia of Leydig cells Testicular atrophy
No uteri No oviducts Small ovaries Normal
Normal
know the purpose of MIS during normal development. Gene targeting in mouse embryonic stem (ES) cells makes it possible to generate mice carrying mutations in specific genes. Therefore, to understand the required functions of MIS during sexual differentiation and germ-cell development, the first two exons of MIS were deleted in ES cells and MIS-deficient mice were generated (62). As summarized in Table 1, all of the female homozygous mutants possessed a uterus with oviducts and ovaries that were morphologically normal. In addition, all of the females were fertile. Therefore, although MIS is expressed in a regulated manner in the ovary of wild-type mice after birth, there is apparently no requirement for MIS expression for normal ovarian function. One possible explanation is that related molecules proteins expressed in granulosa cells may provide redundant or compensatory functions in the absence of MIS. Candidates for such related molecules include activins and inhibins. Morphological abnormalities of the reproductive tract were found only in male homozygous mutants. Testes were morphologically normal and completely descended in these males (62). The Wolffian-duct systems were fully differentiated, and a uterus also developed (Table 1). While no coiled oviducts were found in these animals, oviductal tissue was detected histologically at the distal regions of the uterine horns. Since these MIS-deficient males have testes and both Wolffian and Müllerian duct-derived tissues, they are considered to be male pseudohermaphrodites (Fig. 4). Approximately 90% of the MIS-deficient males were infertile. These males were able to plug females, but sperm were rarely detected in the uteri of the recipient females. Normal numbers of motile sperm were detected in the vas deferens and epididymis of the mutant males. These were shown to be capable of fertilizing oocytes in vitro. Thus, we concluded that although MIS is not required for male germ-cell development, the presence of the Müllerian and Wolffian duct-derived systems structurally interfered with the transfer of the sperm through the Wolffian duct-derived structures and into the reproductive tract of females.
Chapter 3/MIS Signaling During Sexual Development
49
Fig. 4. Schematic representation of male pseudohermaphroditism in XY individuals that lack MIS. Male mice that only lack MIS (“MIS –/–” or “MIS–”) differentiate both the Müllerian and Wolffian duct systems and are male in appearance. The presence of both types of reproductive organs severely hinders fertility. The physical association of the resulting oviductal tissue with the Wolffian duct derivatives blocks oviduct coiling. Male mice that carry the tfm mutation (XtfmY) are insensitive to androgens (“T–”) leading to a passive regression of the Wollfian duct in addition to the active regression of the Müllerian duct, since MIS continues to be synthesized. Male mice that lack MIS and are insensitive to androgens differentiate the Müllerian duct system, and the insensitivity to androgens prevents differentiation of the Wolffian duct system. While these mice have testes, they are female in appearance. Since the Wolffian duct system has been eliminated in these mice the oviductal tissue assumes its normal coiled morphology, despite the presence of a testis.
Histological examination of the testes of the MIS-deficient mice revealed Leydig-cell hyperplasia and a testicular tumor of Leydig-cell origin (62). However, no histological abnormalities or tumors were detected in MIS-deficient females. The development of tumors in MIS-deficient male mice was intriguing, because a targeted deletion of the related a-inhibin gene in mice leads to the development of testicular and ovarian tumors (63). Thus, like inhibin, MIS also appears to function as a gonadal tumor-suppressor, but in a sexual dimorphic manner. Together, these loss-of-function studies demonstrate that MIS is the Müllerian inhibitor, and that regression of the Müllerian duct system during fetal male development is important for male fertility. In addition, MIS is not required for male or female gametogenesis. Furthermore, the Leydig-cell hyperplasia and development of tumors suggests that MIS functions in the male gonad to influence Leydig-cell proliferation. The effect on Leydig cells is particularly interesting, because Leydig-cell numbers are decreased and function of the cells is altered in a subset of transgenic males from the highest-expressing lines (57,59).
50
Mishina
Fig. 5. Possible models to explain the contrasting results of gain-of-function and loss-of-function experiments of MIS. During normal embryogenesis, MIS interacts with the MIS receptor to regress the Müllerian ducts in male fetuses (left). In the MIS ligand mutant mice, absence of MIS may be partly rescued by interaction of other TGF-` ligands with the MIS receptor (MIS-R) (center left). However, this is not likely because the MIS receptor mutant mice are the phenocopy of the MIS ligand mutant mice (see Table 1). In the MIS overexpressing mice, excess amount of MIS may interact with other TGF-` receptors to transduce abnormal signal (center right). Alternatively, excess amount of MIS may interact specifically with the MIS receptor to transduce an abnormal signal (right). The generation of MIS overexpressor mice lacking the MIS receptor distinguishes the last two possibilities and shows that MIS interacts specifically with the MIS receptor (see text for details).
MIS Type II Receptor-Deficient Mice Both the MIS gain-of-function and loss-of-function studies demonstrate that MIS acts as a Müllerian inhibitor in vivo. However, there are some contrasting results, particularly regarding gonadogenesis and germ-cell development, as summarized in Table 1. Two explanations are possible (Fig. 5). One is that in the MT-MIS transgenic mice, an excess amount of MIS interacts with receptors for other TGF-` family members to transduce an abnormal signal. The other is that in the MIS-deficient mice, other TGF-` family members interact with the MIS receptor to rescue some of the phenotype. To distinguish between these possibilities, we generated mice mutant for the MIS type II receptor, which lacked both the MIS ligand and receptor (65). If the latter possibility is the case, MIS receptor-mutant mice would show a more severe phenotype than the MIS liganddeficient mice. The MIS type II receptor is encoded by 11 exons in a gene located on chromosome 15 in the mouse (64) and chromosome 12 in the human (75). The first six exons which encode the signal peptide, the entire extracellullar region, and part of the kinase domain were deleted in ES cells to generate the MIS type II receptor-deficient mice (65). Males and females homozygous for the MIS-receptor mutations were recovered from heterozy-
Chapter 3/MIS Signaling During Sexual Development
51
gous intercrosses at the predicted Mendelian frequencies. As summarized in Table 1, the MIS-receptor-deficient mice were a phenocopy of the MIS-ligand mutant mice. All of the female homozygous mutant mice were normal and fertile. All of the male homozygous mutant mice were male pseudohermaphrodites—i.e., they had a uterus and oviducts superimposed upon the Wolffian-duct-derived tissues (65). Like MIS-ligand mutant mice, the majority of the MIS type II receptor-deficient males were infertile, probably a result of the physical blockage of sperm transfer to females by persistence of the Müllerian-duct-derived tissues (65). In addition to the Müllerian-duct phenotype, the MIS type II-receptor-mutant mice showed hyperplasia in Leydig cells, and some of the males developed Leydig-cell tumors similar to the MIS-ligand mutant males (65). MIS ligand/MIS type II-receptor-compoundhomozygous mutant mice showed the same phenotype as either one of the single homozygous mutant male mice (65). These findings strongly demonstrate that MIS is the only ligand for the MIS type II receptor, and that the MIS type II receptor is the only receptor for MIS. These findings also indicate that the rescue of a portion of the phenotype by other TGF-` superfamily ligands through the MIS receptor system does not occur (Fig. 5).
MIS Overexpression Mice in the MIS Receptor Null Background Because the MIS type II-receptor-deficient mice phenocopy the MIS ligand-deficient mice, it is likely that the ovarian phenotype observed in female MT-MIS transgenic mice is caused by abnormal signals resulting from the excess amount of MIS. However, two possibilities remain, as shown in Fig. 5. One is that excess MIS interacts with other TGF-`-family receptors to transduce abnormal signals, and the other is that the MIS type II receptor itself transduces an abnormal signal. To address this question, we generated female mice carrying the MT-MIS transgene that were also homozygous for a targeted deletion of the MIS type II receptor (66). These females possessed normal female reproductive tracts and ovaries, and were fertile. In the absence of the receptor, despite the high serum level of MIS, these females are normal and fertile (66). These results indicate that the abnormalities in the reproductive tract and ovaries of the MT-MIS transgenic females are caused by an excess of MIS signaling through the MIS type II receptor (Fig 5). They also indicate that other TGF-` familyreceptor-signaling systems are not activated by high levels of MIS. Thus, the MIS type II receptor is the only receptor for MIS, even in the presence of pharmacologic levels of MIS. This is the only case where receptor-deficient mice are the phenocopy of the liganddeficient mice among TGF-` superfamily members that have been studied. For example, BMP2-deficient mice die at E 8.5 with defects of the heart and extraembryonic tissues (67) and BMP4-deficient mice die at E 9.5 with defects of the posterior portion of body, eye and germ cells (68–70). However, mice deficient for a type I receptor for BMP2 and BMP4 (BMP type IA receptor, Alk3) die at E 7.0 without mesoderm formation (71). Thus, the specific ligand-receptor interaction of MIS is very unique among the TGF-` superfamily.
INTERACTION OF MIS SIGNALING AND OTHER SIGNALING PATHWAYS MIS/Tfm Double-Mutant Mice One of the advantages of a genetic approach is the ability to generate compound mutant mice to uncover redundant functions and to explore genetic interactions. After
52
Mishina
formation of the testis, male sexual differentiation is controlled by two hormones, testosterone and MIS (Fig. 2) (see Chapter 2). Therefore, we generated mutant mice that lack both MIS and androgens by interbreeding mice with the classical mutation known as testicular feminization (Tfm) and MIS ligand-deficient mice. Tfm is an X-chromosome-linked mutation of the androgen receptor (72,73). Thus, XtfmY males are insensitive to androgen and become feminized, lack Wolffian-duct differentiation, and have small and incompletely descended testes in which spermatogenesis is blocked at meiotic prophase. XtfmY males do, however, produce MIS, as evidenced by the regression of the Müllerian-duct system (Fig. 4). MIS-deficient XtfmY males were generated by interbreeding the Tfm and MIS mutants (62). These animals were overtly feminized with improperly descended testes and a vaginal opening. Also, Wolffian-duct differentiation was eliminated, and a uterus was developed. Interestingly, coiled oviducts were present with an infundibulum, whereas no coiled oviducts were found in the MIS-deficient male pseudohermaphrodites (62) (Fig. 4). These results suggested that elimination of the Wolffian ducts during female development may be required for normal morphogenesis of the oviducts. As discussed in the previous section, regression of the Müllerian ducts in XY individuals by MIS is essential for transfer of sperm through the male reproductive tract, and regression of the Wolffian ducts in XX individuals lacking testosterone is essential for normal morphogenesis of oviducts. Taken together, these studies indicate that MIS and testosterone play critical roles in the generation of the functional reproductive tracts by removal of one of the two anlagen.
MIS/Inhibin Double-Mutant Mice Inhibins and activins are members of the TGF-` family and are functional antagonists (Fig. 3). Inhibins are heterodimers of inhibin a and activin `A or `B, whereas activins are homodimers or heterodimers of activin `A and `B. Both male and female mice lacking inhibin _-, fail to produce inhibins, are viable, and develop gonadal tumors of sex cord-stromal cell origin (Fig. 6) (63). These findings suggest that inhibin is a negative regulator of gonadal stromal-cell proliferation. Like MIS, inhibin expression in the gonads is most abundant in Sertoli and granulosa cells. Prior to tumor formation in the inhibin mice, germ cell development was normal, indicating that inhibin was also not required for male or female germ-cell development. Since MIS and inhibins are related hormones produced by the same gonadal-cell types, and mutant mice for each develop gonadal tumors, it seems reasonable that there may be cross-communication between MIS and inhibin signals in the gonads. Therefore, we generated double-mutant mice lacking both MIS and inhibin _ (inh_) (65,74). Both male and female MIS/inh_ double-mutant mice were generated at the expected Mendelian ratios. The most prominent phenotype observed in males exhibited a fluidfilled uterus and tumor-filled testes that had retracted from their scrotal position into the abdomen (Fig. 6). Fluid secretion into the lumen of the uterus was explained by high levels of serum estrogen produced by the tumors. Injections of these MIS/inh_ double mutant males with an estrogen antagonist eliminated the fluid-filled uterine phenotype (74). Tumors in MIS/inh_ double-mutant mice were larger, but less hemorrhagic than those in inha mutant mice (Fig. 6). Histologically, the MIS/inh_ double-mutant testicular tumors were Sertoli-/granulosa-cell tumors and Leydig-cell neoplasia (74). In addition, the tumors in double mutants developed at a significantly faster rate than the tumors
Chapter 3/MIS Signaling During Sexual Development
53
Fig. 6. Genetic interaction of MIS and inhibin _. Male sexual tracts of different genotype are shown. Testes from the MIS or MIS receptor mutant (–/–) are macroscopically normal, but hyperplasia of Leydig cells is found. The inhibin _-deficient testes are enlarged and hemorrhagic because of an invasive granulosa/Sertoli tumor. The enlarged testes from MIS/inh_ and MIS receptor/inh_ double mutant males are less hemorrhagic. The testicular tumors in the MIS/inh_ double mutant males demonstrate multifocal Leydig-cell neoplasia and multifocal granulosa/ Sertoli cell tumors. Because of the excess amount of estrogen produced by the tumor, the uterus is dilated. ep, epidydimis; sv, seminal vesicle; t, testis; u; uterus; v, vas deferens.
that arose in mice mutant for inhibin alone. Leydig-cell neoplasia was observed as early as 7 d after birth (74). These observations suggested that MIS and inhibin signaling influence each other in a synergistic manner to regulate testicular cell growth. To understand the level of cross-communication, we generated MIS-receptor/inh_ double-mutant mice. The phenotype of the double-mutant males is identical to that of the MIS ligand/inh_ double-mutant mice (65). The testicular tumors in the MIS receptor/ inh_ double-mutant males and the MIS ligand/inh_ double-mutant males are identical; this provides further evidence that MIS is the only ligand for the MIS receptor (Fig. 7). In addition, these results suggest that the synergy between the MIS and inhibin signaling pathways occurs downstream of each receptor, not between ligands and receptors (Fig. 7). Taken together, these observations suggest that MIS signaling can influence the development of Sertoli-/granulosa-cell tumors initiated by the absence of inhibins, and that inhibin signaling can influence the development of Leydig-cell neoplasia initiated by the absence of MIS signaling. We have not detected a synergistic phenotype in the double-homozygous mutant females, suggesting that the synergistic interaction of MIS and inhibin signaling is male-specific.
CONCLUSIONS AND PERSPECTIVES Human males who lack MIS develop as internal pseudohermaphrodites with uterine and oviductal tissues, a condition known as persistent Müllerian-duct syndrome (PMDS)
54
Mishina
Fig. 7. High specificity of MIS signaling. MIS acts as a Müllerian inhibitor. MIS is the only ligand for the MIS type II receptor and the type II receptor is the only receptor for MIS (left panel). In the MIS-overexpressing mice, an excess amount of MIS transduces abnormal signal through the MIS receptor to cause an abnormalities such as germ cell loss. MIS signaling and inhibin signaling cooperate together to regulate proliferation of Leydig cells and Sertoli cells in a negative manner (right panel). This interaction most likely occurs downstream of their receptors (gray arrow). The inhibin signal may play important roles in the transition from Leydig-cell hyperplasia to neoplasia.
(76). In humans, the molecular basis of the PMDS syndrome is heterogeneous (77). In “MIS-negative” cases, MIS serum levels are low, and mutations of the MIS gene have been detected (78–80). In contrast, “MIS positive” patients have normal serum levels of MIS, and a mutation of the MIS type II-receptor has been detected in the majority of these cases (40,77). Like the mouse models discussed in this chapter, patients with MIS or MIS type II receptor gene mutations share the same clinical phenotype. Thus, the mouse and human studies suggest that the MIS signaling pathway is simple and is conserved in mammals. However, little is known about the signaling pathway of MIS. As discussed earlier, Alk2 is the strongest candidate for an MIS type I receptor based on the expression pattern and ability to repress biosynthesis of aromatase (45,49). Mutant mice that lack Alk2 show embryonic lethality much earlier than the stage of Müllerian-duct regression (81,82). To overcome this problem, we will perform a conditional mutagenesis of Alk2 to generate absence of Alk2 in the surrounding mesenchyme of the Müllerian duct. Smads are fairly well characterized gene family that act as intracellular signaling proteins for TGF-` family members. Pathway-specific Smads are directly phosphorylated by type I receptors to allow translocation of these proteins along with Smad4 (a common Smad) into nuclei to alter gene expression (83). Among them, smad5 is expressed in the mesonephric shield, suggesting that it may be in the MIS signal transduction pathway (84). Since Smad5 mutant embryos die at E 9.5 (85,86), much earlier than sexual differentiation, conditional mutagenesis of smad5 will address its role in MIS signaling.
Chapter 3/MIS Signaling During Sexual Development
55
Humans with PMDS who are MIS positive and have apparently no alterations in their MIS type II receptors may have mutations in genes encoding downstream effectors of MIS signaling. Indeed, whereas MIS maps to chromosome 19 (87) and the MIS type II-receptor maps to chromosome 12 (40,75), X-chromosome-linked PMDS has been reported (88,89). The MIS ligand and MIS type II-receptor mutant mice will serve as valuable genetic resources to isolate the downstream targets of this differentiation pathway of male sexual development. Reproductive tracts are one of the targets of environmental toxicants. It is known that the clinical use of diethylstilbestrol (DES) by pregnant women causes the presistence of Müllerian-duct remnants in their sons (90). Organ culture studies indicate that the inhibitory effect of DES is mainly caused by a decrease in responsiveness of the target tissues to MIS (91). Interestingly, the expression level of MIS and MIS receptor is increased (92). Understanding of the MIS signaling mechanism should help us to solve this puzzle.
ACKNOWLEDGMENTS I thank Dr. Richard R. Behringer for providing me an opportunity to work on MIS and the MIS receptor. I also thank Drs. E. Mitch Eddy, Retha R. Newbold and Trisha M. Castranio for helpful comments of the manuscript; and Yoshiko and Kanade H. Mishina for encouragement. While in the Behringer laboratory, this work was supported, in part, by grants from the National Institutes of Health (HD30284), National Cancer Institute CA16672, and the Sid W. Richardson Foundation.
REFERENCES 1. Cate RL, Wilson CA. Müllerian-inhibiting substance. In: Gwatkin, RBL, ed. Genes in Mammalian Reproduction. Wiley-Liss, New York, 1993, pp. 185–205. 2. Josso N, Cate RL, Picard J-Y, Vigier B, di Clemente N, Wilson C, et al. Anti-Müllerian hormone: the Jost factor. Rec Prog Horm Res 1993;48:1–59. 3. Mishina Y, Behringer, RR. The in vivo function of Müllerian-inhibinting substance during mammalian sexual development. In: Wassarman, PM, ed. Advances in Developmental Biology, vol. 4. JAI Press, Greenwich, CT, 1994, pp. 1–25. 4. Jost A. Recherches sur la differenciation sexuelle de l’embryon de lapin. Arch Anat Micro Morph Exp 1947;36:271–315. 5. Jost A. Problems of fetal endocrinology: the gonadal and hypophyseal hormones. Rec Prog Horm Res 1953;8:379–418. 6. Hatano O, Takayama K, Imai T, Waterman MR, Takakusu A, Omura T, et al. Sex-dependent expression of a transcription factor, Ad4BP, resulting steroidogenic P-450 genes in the gonads during prenatal and postnatal rat development, Development 1994;120:2787–2797. 7. Shen WH, Moore CCD, Ikeda Y, Parker KL, Ingraham HA. Nuclear receptor steroidgenic factor 1 regulates the Müllerian inhibiting substance gene: a link to the sex determination cascade. Cell 1994;77:1–20. 8. Giuili G, Shen WH, Ingraham HA. The nuclear receptor SF-1 mediates sexually dimorphic expression of Müllerian Inhibiting Substance, in vivo. Development 1997;124:1799–1807. 9. Nachtigal MW, Hirokawa Y, Enyeart-VanHouten DL, Flanagan JN, Hammer GD, Ingraham, HA. (1998) Wilms’ tumor 1 and Dax-1 modulate the orphan nuclear receptor SF-1 in sex-specific gene expression. Cell 1998;93:445–454. 10. Kent J, Whitely SC, Andrew JE, Sinclair AH, Koopman P. A male-specific role for SOX9 in vertebrate sex determination. Development 1996;122:2813–2822. 11. Parker KL, Schedl A, Schimmer, BP. Gene interactions in gonadal development. Annu Rev Physiol 1999;61:417–433. 12. Vigier B, Forest MG, Eychenne B, Bézard J, Garrigou O, Robel P, et al. Anti-Müllerian hormone produces endocrine sex-reversal of fetal ovaries. Proc Natl Acad Sci USA 1989;8:3684–3688.
56
Mishina
13. di Clemente N, Ghaffari S, Pepinsky RB, Pieau C, Josso N, Cate RL, et al. A quantitative and interspecific test for biological activity of anti-Müllerian hormone: the fetal ovary aromatase assay. Development 1992;114:721–727. 14. Racine C, Rey R, Forest MG, Louis F, Ferre A, Huhtaniemi I, Josso N, di Clemente, N. Receptors for anti-müllerian hormone on Leydig cells are responsible for its effects on steroidogenesis and cell differentiation. Proc Natl Acad Sci USA 1998;95:594–599. 15. Rouiller-Fabre V, Carmona S, Merhi RA, Cate RL, Habert R, Vigier B. Effect of anti-Müllerian hormone on Sertoli and Leydig cell functions in fetal and immature rats. Endocrinology 1998; 139:1213–1220. 16. Cate RL, Mattaliano RJ, Hession C, Tizard R, Farber NM, Cheung A, et al. Isolation of the bovine and human genes for Müllerian inhibiting substance and expression of the human gene in animal cells. Cell 1986;45:685–698. 17. Picard JY, Benarous R, Guerrier D, Josso N, Kahn, A. Cloning and expression of cDNA for antiMüllerian hormone. Proc Natl Acad Sci USA 1986;83:5464–5468. 18. Haqq CM, Lee, MM, Tizard R, Wysk M, DeMarinis J, Donahoe PK, et al. Isolation of the rat gene for Müllerian inhibiting substance. Genomics 1992;12:665–669. 19. Münsterberg A, Lovell-Badge R. Expression of the mouse anti-Müllerian hormone gene suggests a role in both male and female sexual differentiation. Development 1991;113:613–624. 20. Hogan BLM. Bone morphogenetic proteins: multifunctional regulators of vertebrate development. Genes Dev 1996;10:1580–1594. 21. Budzik GP, Powell SM, Kamagata S, Donahoe PK. Müllerian inhibiting substance fractionation by dye affinity chromatography. Cell 1983;34:307–314. 22. Pepinsky RB, Sinclair LK, Chow EP, Mattaliano RJ, Manganaro TF, Donahoe PK, Cate RL. Proteolytic processing of Müllerian inhibiting substance produces a transforming growth factor-`-like fragment. J Biol Chem 1988;263:18,961–18,964. 23. Cate RL, Donahoe PK, MacLaughlin DT. Müllerian inhibiting substance. In: Sporn MB, Roberts AB, eds. Peptide Growth Factors and Their Receptors II. Springer-Verlag, Berlin, 1990, pp. 179–210. 24. Nachtigal MW, Ingraham HA. Bioactivation of Müllerian inhibiting substance during gonadal development by a kex2/subtilisin-like endoprotease. Proc Natl Acad Sci USA 1996;93:7711–7716. 25. Pircher R, Jullien P, Lawrence DA. b-transforming growth factor is stored in human blood platelets as a latent high molecular weight complex. Biochem Biophys Res Comm 1986;136:30–37. 26. Wilson CA, di Clemente N, Ehrenfels C, Pepinsky RB, Josso N, Vigier B, et al. Müllerian inhibiting substance requires its N-terminal domain for maintenance of biological activity, a novel finding within the transforming growth factor-b superfamily. Mol Endocrinol 1993;7:247–257. 27. Takahashi M, Koide SS, Donahoe PK. Müllerian inhibiting substance as oocyte meiosis inhibitor. Mol Cell Endorinol 1986;47:225–234. 28. Bézard J, Vigier B, Tran D, Mauléon P, Josso N. Immunocytochemical study of anti-Müllerian hormone in sheep ovarian follicles during fetal and post-natal development. J Reprod Fertil 1987;80:509–516. 29. Ueno S, Takahashi M, Manganaro TF, Ragin RC, Donahoe PK. Cellular localization of Müllerian inhibiting substance in the developing rat ovary. Endocrinology 1989;125:1060–1066. 30. Josso N. Anti-Müllerian hormone: new perspectives for a sexist molecule. Endocr Rev 1986;7:421–433. 31. Mathews L, Vale WW. Expression cloning of an activin receptor, a predicted transmembrane serine kinase. Cell 1991;65:973–982. 32. Lin HY, Wang X, Ng-Eaton E, Weinberg RA, Lodish HF. Expression cloning of the TGF-b type II receptor, a functional transmembrane serine/threonine kinase. Cell 1992;68:775–785. 33. Attisano L, Carcamo J, Ventura F, Weis FMB, Massagué J, Wrana JL. Identification of human activin and TGF-b type I receptors that form heterodimeric kinase complexes with type II receptors. Cell 1993;75:671–680. 34. Ebner R, Chen RH, Shum L, Zioncheck TF, Lee AR, Derynck R. Cloning of a type I TGF-b receptor and its effect on TGF-b binding to the type II receptor. Science 1993;260:1344–1348. 35. Franzen P, ten Dijke P, Ichijo H, Yamashita H, Schulz P, Heldin CH, et al. Cloning of a TGF beta type I receptor that forms a heteromeric complex with the TGF beta type II receptor. Cell 1993;75:681–692. 36. Wrana JL, Attisano L, Wieser R, Ventura F, Massagué J. Mechanism of activation of the TGF-` receptor. Nature 1994;370:341–347. 37. Cárcamo J, Weis FM, Ventura F, Wieser R, Wrana JL, Attisano L, et al. Type I receptors specify growth-inhibitory and transcriptional responses to transforming growth factor beta and activin. Mol Cell Biol 1994;14:3810–3821.
Chapter 3/MIS Signaling During Sexual Development
57
38. Baarends WM, van Helmond MJL, Post M, van der Schoot JCM, Hoogerbrugghe JW, de Winter JP, et al. A novel member of the transmembrane serine/threonine kinase receptor family is specifically expressed in the gonads and in mesenchymal cells adjacent to the Müllerian duct. Development 1994;120:189–197. 39. di Clemente N, Wilson C, Faure E, Boussin L, Carmillo P, Tizard R, et al. Cloning, expression and alternative splicing of the receptor for anti-Müllerian hormone. Mol Endocrinol 1994;8:1006–1020. 40. Imbeaud S, Faure E, Lamarre I, Mattéi MG, di Clemente N, Tizzad R, et al. Insensitivity to antiMüllerian hormone due to a mutation in the human anti-Müllerian hormone receptor. Nature Genet 1995;11:382–388. 41. Roberts LM, Hirokawa Y, Nachtigal MW, Ingraham HA. Paracrine-mediated apoptosis in reproductive tract development. Dev Biol 1999;208:110–122. 42. Baarends WM, Uilenbroek JTJ, Kramer P, Hoogerbrugghe JW, de Winter JP, Karels B, et al. AntiMüllerian hormone and anti-Müllerian hormone type II receptor messenger ribonucleic acid expression in rat ovaries during postnatal development, the estrous cycle, and gonadotropin-induced follicle growth. Endocinology 1995;136:4951–4962. 43. Baarends WM, Hoogerbrugghe JW, Post M, Visser JA, de Rooij DG, Parvinen M, et al. Anti-Müllerian hormone and anti-Müllerian hormone type II receptor messenger ribonucleic acid expression during postnatal testis development and in the adult testis of the rat. Endocinology 1995;136:5614–5622. 44. Teixeira J, He WW, Shah PC, Morikawa N, Lee MM, Catlin EA, et al. Developmental expression of a candidate Müllerian inhibiting substance type II receptor. Endocrinology 1996;137:160–165. 45. He WW, Gustafson ML, Hirobe S, Donahoe PK. Developmental expression of four novel serine/ threonine kinase receptors homologous to the activin/transforming growth factor-beta type II receptor family. Dev Dyn 1993;196:133–142. 46. Matsuzaki K, Xu J, Wang F, McKeehan WL, Krummen L, Kan M. A widely expressed transmembrane serine/threonine kinase that does not bind activin, inhibin, transforming growth factor `, or bone morphogenic factor. J Biol Chem 1993;268:12,718–12,723. 47. ten Dijke P, Ichijo H, Franzen P, Schulz P, Saras J, Toyoshima H, et al. Activin receptor-like kinases: a novel subclass of cell-surface receptors with predicted serine/threonine kinase activity. Oncogene 1993;8:2879–2887. 48. Wieser R, Wrana JL, Massague J. GS domain mutations that constitutively activate T beta R-I, the downstream signaling component in the TGF-beta receptor complex. EMBO J 1995;15:2199–2208. 49. Visser J., eds. Anti-Müllerian Hormone: Molecular Mechanism of Action. Eburon, 1998. 50. Dyche WJ. A comparative study of the differentiation and involution of the Müllerian duct and Wolffian duct in the male and female fetal mouse. J Morphol 1979;162:175–209. 51. Price JM, Donahoe PK, Ito Y, Hendren WH 3d. Programmed cell death in the Müllerian duct induced by Müllerian inhibiting substance. Am J Anat 1977;149:353–375. 52. Forsberg J, Olivecrona H. Degeneration processes during the development of the Müllerian ducts in alligator and chicken embryos. Z Anat Entwiklungsgesch 1963;124:83–96. 53. Austin HB. DiI analysis of cell migration during Mullerian duct regression. Dev Biol 1995;169:29–36. 54. Trelstad RL, Hayashi A, Hayashi K, Donahoe PK. The epithelial-mesenchymal interface of the male rate Müllerian duct: loss of basement membrane integrity and ductal regression. Dev Biol 1982;92:27–40. 55. Hayashi A, Donahoe PK, Budzik GP, Trelstad RL. Periductal and matrix glycosaminoglycans in rat Müllerian duct development and regression. Dev Biol 1982;92:16–26. 56. Djehiche B, Segalen J, Chambon Y. Ultrastructure of Müllerian and Wolffian ducts of fetal rabbit in vivo and in organ culture. Tissue Cell 1994;26:323–332. 57. Behringer RR, Cate RL, Froelick GJ, Palmiter RD, Brinster RL. Abnormal sexual development in transgenic mice chronically expressing Müllerian inhibiting substance. Nature 1990;345:167–170. 58. Lyet L, Louis F, Forest MG, Josso N, Behringer RR, Vigier B. Ontogeny of reproductive abnormalities induced by deregulation of anti-Müllerian hormone expression in transgenic mice. Biol Reprod 1995;52:444–454. 59. Josso N, Racine C, di Clemente N, Rey R, Xavier F. The role of anti-Mullerian hormone in gonadal development. Mol Cell Endocrinol 1998;145:3–7. 60. Whitworth DJ. XX germ cells: The difference between an ovary and a testis. Trends Endocrinol Metab 1998;9:2–6. 61. Hutson JM, Donahoe PK. The hormonal control of testicular descent. Endocr Rev 1986;7:270–283. 62. Behringer RR, Finegold MJ, Cate RL. Müllerian-inhibiting substance function during mammalian sexual development. Cell 1994;79:415–425.
58
Mishina
63. Matzuk MM, Finegold MJ, Su JG, Hsueh AJ, Bradley A. Alpha-inhibin is a tumour-suppressor gene with gonadal specificity in mice. Nature 1992;360:313–319. 64. Mishina Y, Tizard R, Deng JM, Pathak BG, Copeland NG, Jenkins NA, et al. Sequence, genomic organization, and chromosomal location of the mouse Mullerian-inhibiting substance type II receptor gene. Biochem Biophys Res Commun 1997;237:741–746. 65. Mishina Y, Rey R, Finegold MJ, Matzuk MM, Josso N, Cate RL, Behringer RR. Genetic analysis of the Müllerian-inhibiting substance signal transduction pathway in mammalian sexual differentiation. Genes Dev 1996;10:2577–2587. 66. Mishina Y, Whitworth DJ, Racine C, Behringer RR. High specificity of Mullerian-inhibiting substance signaling in vivo. Endocrinology 1999;140:2084-2088. 67. Zhang H, Bradley A. Mice deficient for BMP2 are nonviable and have defects in amnion/chorion and cardiac development. Development 1996;122:2977–2986. 68. Winnier G, Blessing M, Labosky PA, Hogan BLM. Bone morphogenetic protein-4 (BMP-4) is required for mesoderm formation and patterning in the mouse. Genes Dev 1995;9:2105–2116. 69. Furuta Y, Hogan BLM. BMP4 is essential for lens induction in the mouse embryo. Genes Dev 1998;12:3764–3775. 70. Lawson KA, Dunn NR, Roelen BA, Zeinstra LM, Davis AM, Wright CV, et al. Bmp4 is required for the generation of primordial germ cells in the mouse embryo. Genes Dev 1999;13: 424–436. 71. Mishina Y, Suzuki A, Ueno N, Behringer RR. Bmpr encodes a type I bone morphogenetic protein receptor that is essential for gastrulation during mouse embryogenesis. Genes Dev 1995;9:3027–3037. 72. He WW, Kumar MV, Tindall DJ. A frame-shift mutation in the androgen receptor gene causes complete testosterone insensitivity in the testicular-feminized mouse. Nucleic Acids Res 1991;19:2373–2378. 73. Charest NJ, Zhou ZX, Lubahn DB, Olsen KL, Wilson EM, French FS. A frameshift mutation destabilizes androgen receptor messenger RNA in the Tfm mouse. Mol Endocrinol 1991;5: 573–581. 74. Matzuk MM, Finegold MJ, Mishina Y, Bradley A, Behringer RR. Synergistic effects of inhibins and Müllerian-inhibiting substance on testicular tumorigenesis. Mol Endocrinol 1995;9:1337–1345. 75. Visser JA, McLuskey A, van Beers T, Weghuis DO, van Kessel AG, Grootegoed JA, Themmen AP. Structure and chromosomal localization of the human anti-mullerian hormone type II receptor gene. Biochem Biophys Res Commun 1995;215:1029–1036. 76. Guerrier D, Tran D, Vanderwinden JM, Hideux S, Van Outryve L, Legeai L, et al. The persistent Müllerian duct syndrome: a molecular approach. J Clin Endocrinol Metab 1989;68:46–52. 77. Imbeaud S, Belville C, Messika-Zeitoun L, Rey R, di Clemente N, Josso N, et al. A 27 base-pair deletion of the anti-mullerian type II receptor gene is the most common cause of the persistent mullerian duct syndrome. Hum Mol Genet 1996;5:1269–1277. 78. Knebelmann B, Boussin L, Guerrier D, Legeai L, Kahn A, Josso N, Picard JY. Anti-Müllerian hormone Bruxelles: a non-sense mutation in the last exon of the anti-Müllerian hormone gene associated with the persistent Müllerian duct syndrome in three brothers. Proc Natl Acad Sci USA 1991;88:3767–3771. 79. Carré-Eusebe, D, Imbeaud S, Harbison M, New MI, Josso N, Picard JY. Variants of the anti-Müllerian hormone gene in a compound heterozygotes with the persistent Müllerian duct syndrome and his family. Hum Genet 1992;90:389–394. 80. Imbeaud S, Carré-Eusebe D, Rey R, Belville C, Josso N, Picard JY. Molecular genetics of the persistent Müllerian duct syndrome: a study of 19 families. Hum Mol Genet 1994;3:125–131. 81. Gu Z, Reynolds EM, Song J, Lei H, Feijen A, Yu L, et al. The type I serine/threonine kinase receptor ActRIA (ALK2) is required for gastrulation of the mouse embryo. Development 1999;126:2551–2561. 82. Mishina Y, Crombie R, Bradley A, Behringer, RR. Multiple roles for Activin-Like Kinase-2 signaling during mouse embryogenesis. Dev Biol 1999;213:314–326. 83. Heldin CH, Miyazono K, ten Dijke P. TGF-beta signaling from cell membrane to nucleus through SMAD proteins. Nature 1997;390:465–471. 84. Meersseman G, Verschueren K, Nelles L, Blumenstock C, Kraft H, Wuytens G, et al. The C-terminal domain of Mad-like signal transducers is sufficient for biological activity in the Xenopus embryo and transcriptional activation. Mech Dev 1997;61:127–140. 85. Yang X, Castilla LH, Xu X, Li C, Gotay J, Weinstein M, et al. Angiogenesis defects and mesenchymal apoptosis in mice lacking SMAD5. Development 1999;126:1571–1580. 86. Chang H, Huylebroeck D, Verschueren K, Guo Q, Matzuk MM, Zwijsen A. Smad5 knockout mice die at mid-gestation due to multiple embryonic and extraembryonic defects. Development 1999;126:1631–1642. 87. Cohen-Haguenauer, O, Picard, JY, Mattei, MG, Serero, S, Nguyen VC, de Tand MF, et al. Mapping of the gene for anti-Müllerian hormone to the short arm of human chromosome 19. Cytogenet Cell Genet 1987;44:2–4.
Chapter 3/MIS Signaling During Sexual Development
59
88. Sloan WR, Walsh, PC. Familial persistent Müllerian duct syndrome. J Urol 1976;115:459–461. 89. Naguib KK, Teebi AS, Al-Awadi SA, El-Khalifa MY, Mahfouz ES. Familial uterine hernia syndrome: report of an Arab family with four affected males. Am J Hum Genet 1989;33:180,181. 90. Newbold RR. Influence of estrogenic agents on mammalian male reproductive tract development. In: Korach KS, ed. Reproductive and developmental toxicology, Marcel Dekker, New York, NY, 1998, pp. 531–551. 91. Newbold RR, Suzuki Y, McLachlan JA. Müllerian duct maintenance in heterotypic organ culture after in vivo exposure to diethylstilbestrol. Endocrinology 1984;115:1863–1868. 92. Visser JA, McLuskey A, Verhoef-Post M, Kramer P, Grootegoed JA, Themmen AP. Effect of prenatal exposure to diethylstilbestrol on Mullerian duct development in fetal male mice. Endocrinology 1998;139:4244–4251. 93. Shimamura R, Fraizer GC, Trapman J, Lau YC, Saunders GF. The Wilms’ tumor gene WT1 can regulate genes involved in sex determination and differentiation: SRY, Müllerian-inhibiting substance, and the androgen receptor. Clin Cancer Res 1997;12:2571–2580. 94. Tremblay, JJ, Viger, RS. Transcription factor GATA-4 enhances Müllerian inhibiting substance gene transcription through a direct interaction with the nuclear receptor SF-1. Mol Endcrinol 1999;13:1388–1401.
Chapter 4/Control of Ovarian Function
4
61
Control of Ovarian Function Julia A. Elvin, PHD and Martin M. Matzuk, MD, PHD CONTENTS INTRODUCTION PRENATAL OVARIAN DEVELOPMENT POSTNATAL OVARIAN FUNCTION: FOLLICULOGENESIS INITIATION OF FOLLICULOGENESIS AND PREANTRAL FOLLICLE GROWTH ANTRAL FOLLICLE DEVELOPMENT: SENSITIVITY TO EXTRA OVARIAN AND INTRA OVARIAN REGULATION OVULATION AND CORPORA LUTEA FORMATION CONCLUSION ACKNOWLEDGMENTS REFERENCES
INTRODUCTION Female fertility depends on prenatal development of the fetal gonad into an ovary and the complex interactions between the intraovarian and extraovarian factors that regulate the postnatal process of folliculogenesis. At birth, the ovary has a finite oocyte population. Folliculogenesis initiates when some oocytes within primordial follicles begin to grow in response to undiscovered intragonadal factors; other oocytes will remain quiescent until later in life, resulting in a prolonged period of fertility. Follicular development is controlled locally by paracrine factors and at a distance by endocrine hormones, such as the pituitary hormones follicle-stimulating hormone (FSH) and luteinizing hormone (LH). Intragonadal factors initiate growth of the follicle and coordinate development of the oocyte, granulosa cells, and thecal cells (1). Extragonadal factors, particularly hormones from the pituitary, synchronize granulosa cell and theca cell function later in folliculogenesis to initiate puberty and integrate the reproductive system with overall female physiology (2). To understand the regulation of ovarian function in humans, it is crucial to have physiological models that mimic events occurring during human ovarian prenatal and postnatal development. Transgenic mouse technology has created many such models to study ovarian function. Transgenic mouse technology allows for the specific and reproducible alteration of gene expression, and the subsequent observation of its effect on the From: Contemporary Endocrinology: Transgenics in Endocrinology Edited by: M. Matzuk, C. W. Brown, and T. R. Kumar © Humana Press Inc., Totowa, NJ
61
62
Elvin and Matzuk
development of a specific tissue or the entire organism (3) (see Chapter 1). The use of the transgenic approach to study gonadogenesis and the regulation of folliculogenesis in mice is expanding our understanding of ovarian development and physiology, and is helping to reveal possible causes of human infertility. This chapter summarizes several key events in female gonadogenesis and folliculogenesis in mice that have been elucidated by spontaneous or induced mutations yielding infertile or subfertile mouse models. The mouse models presented in this chapter are divided into two basic categories on the basis of whether the mutation affects prenatal ovarian formation (Tables 1–3) or postnatal ovarian function (Tables 4–9). Models with prenatal ovarian defects are subdivided into those in which the defect affects gonad formation (Table 1), germ-cell proliferation or migration (Table 2), or germ-cell survival (Table 3). Models with postnatal ovarian effects are subdivided on the basis of the stage of folliculogenesis affected by the mutation as follows: primordial follicle development and preantral follicle growth (Table 4), antrum formation and later stages of follicle growth resulting from extraovarian (Table 5) and intraovarian defects (Table 6), or ovulation and/or corpus luteum formation caused by extraovarian (Table 7) and intraovarian defects (Table 8). Models with female infertility or subfertility caused by nonfollicular defects such as fertilization, implantation, and early embryonic development (Table 9) are not described in detail in this chapter. The transgenic mouse approach has led to insights into the intricacies of gonadal development, germ-cell survival, proliferation, and migration, and control of postnatal ovarian function at all stages of folliculogenesis, ovulation, and fertilization.
PRENATAL OVARIAN DEVELOPMENT The female gonad develops during early fetal life when primordial germ cells (PGCs), derived from the inner-cell mass of the blastocyst and residing extraembryonically, migrate to the gonadal ridges of the mesonephros of the developing embryo (4). Several genes expressed in the urogenital ridge play important roles in early gonadal development (Table 1; see Chapter 2). Mice lacking the Wilms’ tumor associated gene, which encodes the transcription factor WT-1, show normal germ cell migration but the urogenital ridge fails to develop, leading to both kidney and gonadal agenesis (5). Steroidogenic factor-1 (SF-1), an orphan member of the nuclear receptor superfamily, is expressed in the hypothalamus, pituitary, all primary steroidogenic tissues, and the urogenital ridge at embryonic day (E) 9–9.5. Absence of SF-1 also leads to complete gonadal agenesis (6). Although SF-1 is known to be a key regulator of steroidogenic enzyme transcription, the defects in SF-1-deficient gonadal development do not result from the lack of steroid production, because steroid-deficient rabbit models with normal SF-1 function show normal gonad formation (7). Additionally, steroidogenic acute regulatory (StAR) protein knockout mice, which have severely impaired prenatal steroidogenesis caused by loss of cholesterol transport from the cytoplasm into mitochondria, also show normal prenatal ovarian development (8,9). Instead, SF-1 may regulate genes important to gonadal development directly, and functional SF-1 sites are present in several other genes that play a major role in reproduction, such as the oxytocin, prolactin receptor, and Müllerian-inhibiting substance (MIS) genes (10–12); (for further discussion on SF-1 and StAR, see Chapter 8). Chromosomal sex determines gonadal sex in the mouse between E 10 and E 12.5. Specifically, precursor genital-ridge somatic cells carrying the sex-determining region Y (Sry) gene on the Y chromosome direct the development of the gonad into a testis,
Chapter 4/Control of Ovarian Function
63 Table 1
Defects in Gonad Formation Transgenic/mutant mouse
Major reproductive findings
Refs
Dax1 transgenic
Male to female sex reversal in XY mice with a weak Sry allele Females lack Müllerian-duct derivatives; germ cells degenerate; feminization of high expressor males Failure of gonads to develop leading to complete agenesis; female internal and external genitalia Presence of Sry results in formation of testis in XX embryo; no spermatogenesis Failure of gonadal development; normal germ-cell migration
(15)
MT-Müllerian-inhibiting substance transgenica SF-1 (Ftz-F1) knockout
Sry transgenic WT-1 knockout
(100)
(6,123)
(13) (5)
aMT, metallothionein promoter.
Table 2 Defects in Germ-Cell Proliferation/Migration Transgenic/mutant mouse
Major reproductive findings
Atrichosis (at) mutant
Spontaneous mutation causes marked decrease (24) in primordial germ cell number Decreased germ cells from E11.5 onwards; (124) in vitro defects in folliculogenesis after primary follicle stage Transgene insertion causes drastic decrease (25) in primordial germ-cell number Ovaries lack germ cells because of defects in (19) migration and proliferation PGCs present at E 11.5 but disappear by E 13.5; (22) required for PGC proliferation Ovaries lack germ cells because of defects in (18,20) migration and proliferation Normal germ-cell migration; defects in mitotic (23) proliferation
Connexin 43 knockout
Germ-cell-deficient (gcd) transgenic Kit ligand–steel mutants (deficiency) TIAR knockout White spotting (W) mutant (c-kit deficiency) Zfx knockout
Refs
while a lack of expression of Sry allows the default pathway of ovary formation (4). XX transgenic mice carrying a 14-kb DNA fragment containing the mouse Sry gene develop testes and male secondary sex characteristics, but lack spermatozoa and thus are infertile (13). This block in spermatogenesis in the transgenic Sry-positive XX male mice confirms that other genes on the Y chromosome are important for spermatogenesis. Dax1 (Ahch), an unusual member of the nuclear hormone receptor superfamily, has also been implicated in sex determination and gonadal differentiation. Dax1 is initially expressed at the same time as Sry in both XX and XY embryos, and persists throughout ovarian development, but is downregulated during testis development. Loss of Dax1 does not affect ovarian development or female fertility, but does cause progressive
64
Elvin and Matzuk Table 3 Defects in Germ Cell Survival
Transgenic/mutant mouse
Major reproductive findings
Ataxia telangiectasia (Atm)-knockout mice Caspase-2-knockout
Male and female infertility; apoptotic germ cell death around birth Increased number of oocytes at postnatal d 4 due to deceased apoptosis; oocytes show decreased sensitivity to doxorubicin Ovaries lack germ cells because of prenatal degeneration of oocytes after proliferation Infertility in males and females; block in spermatogenesis in males; loss of germ cells beginning in utero with complete absence of oocytes by adulthood Majority of females infertile; few oocytes present at birth; increased chromosome breakage and instability Infertility; ovaries devoid of oocytes; ovarian cysts in adults Infertility; few oocytes present at birth; Leydig cells found in ovary; Müllerian duct fails to form
Dazla-knockout Dmc1-knockout
Fanconi anemia complementation group C (fac)-knockout Msh5-knockout Wnt-4-knockout
Refs (35,36) (125)
(126) (30,31)
(33,34)
(28,29) (26)
Table 4 Mouse Models of Preantral Follicle Development Transgenic/mutant mouse
Major reproductive findings
A. Defects in Primordial Follicles bax-knockout Extended reproductive lifespan; increased primordial follicles at 2 yr of age bcl-2-knockout Fertile; reduced number of primordial follicles FIG_-knockout Infertile; primordial follicles fail to form after birth; oocytes subsequently die B. Defects in Preantral Follicle Growth Growth differentiation factor-9 Infertility; defect in folliculogenesis at (Gdf9)-knockout one-layer follicle stage panda Kit Ligand – Steel mutant Infertility; reduced germ-cell number and defect in folliculogenesis at one-layer follicle stage Kit Ligand – Steelt mutant Infertility; defect in folliculogenesis at one-layer follicle stage
Refs (45) (46) (40)
(60) (51,53)
(52,127)
testicular degeneration (14). Overexpression of Dax 1 also does not affect ovary development, but causes male-to-female sex reversal in XY mice with a weak Sry allele (15). Thus, Dax1 does not function as an ovary determinant, as was initially hypothesized, but instead appears to antagonize testis development, and is responsible for the dosagesensitive sex-reversal X-chromosome syndrome in humans.
Chapter 4/Control of Ovarian Function
65 Table 5
Defects in Antral Follicle Growth:Extraovarian Defects Transgenic/mutant mouse
Major reproductive findings
Refs
Activin-receptor type IIA knockout Bovine glycoprotein hormone _-subunit promoter-DTa Common glycoprotein hormone _-subunit knockout Copper/zinc superoxide dismutase (Sod1) knockout
Infertility in females; delayed fertility in males; small gonads Infertile; hypogonadal
(90) (128)
Infertile; hypogonadal, hypothyroid
(129)
Follicle stimulating hormone `-subunit knockout Human GnRH promoter-SV40 T-antigenb Hypogonadal (hpg) mouse a (GnRH deletion) Neuronal helix-loop-helix 2 (Nhlh2) knockout Obese (ob/ob) mouse (leptin deficiency)
Subfertility in females; decreased serum (130,131) gonadotropin concentrations and embryonic death Female infertility; folliculogenesis block before (47) antral-follicle stage; males fertile, but decreased testis size Infertility caused by an arrest in GnRH neuron (66) migration; block prior to antral-follicle formation Infertility; small gonads; block prior to (48,65) antral-follicle formation Infertile, hypogonadal, and obese; females (132) fertile if reared with males Infertility; perturbation of the hypothalamic(133) pituitary axis; block prior to antral-follicle formation
a
DT, diphtheria-toxin A chain; bGnRH, gonadotropin-releasing hormone.
Table 6 Defects in Antral Follicle Formation:Intraovarian Defects Transgenic/mutant mouse
Major reproductive findings
_-inhibin knockout
Infertility in females; secondary infertility (83,84,134) in males; granulosa-/Sertoli-cell tumors; cachexia-like syndrome Female infertility secondary to granulosa-cell (77,79) defect; males fertile but decreased testis size Female infertility; folliculogenesis blocked (71) before antrum formation Hypogonadal and infertile; folliculogenesis (74,75) block before antral-follicle stage Rarely fertile; similar to Igf1 knockout (76)
Cyclin D2 knockout Follicle stimulating hormone receptor knockout Insulin-like growth factor 1 (Igf1) knockout Insulin-receptor substrate 2 knockout P450 aromatase knockout
Infertility; antral-follicle formation, but no CLs
Refs
(93)
For an ovary or testis to be truly functional later in life, primordial germ cells must migrate into the developing genital ridge. Mitotic proliferation of primordial germ cells occurs during this migration, and upon reaching the gonad, the germ cells form important
66
Elvin and Matzuk Table 7 Extra Ovarian Regulation of Ovulation and/or Corpus Luteum Formation
Transgenic/mutant mouse
Major reproductive findings
Bovine glycoprotein hormone; a _ promoter-`LHb-CTP Estrogen receptor _ knockout
Infertility, polycystic ovaries, granulosa-cell tumors Infertility; hemorrhagic ovarian cysts
Growth hormone receptor knockout Prolactin (Prl) knockout Transcription-factor NGFI-A knockout
Delayed puberty and age of first conception; prolonged pregnancy Infertility; irregular and prolonged estrus cycles Infertility; luteinizing-hormone suppression causing no corpora lutea
Refs (89,135) (95,97, 136,137) (75) (138) (103)
a
bLH`-CTP, bovine luteinizing hormone ` subunit—human chorionic gonadotropin carboxyl-terminal peptide fusion.
associations with somatic cells that will last for the duration of folliculogenesis. Unlike spermatogenesis in males, in which spermatogonia (stem cells) constantly divide and produce gametes, the ovary has a finite supply of oocytes. Therefore, the size and the rate of depletion of this pool of oocytes determine the duration of female fertility. Several mutations have been shown to disrupt either early germ-cell migration, proliferation, or both (Table 2). The tyrosine kinase receptor, c-kit, encoded by the W locus, is expressed on the surface of germ cells (16) and its ligand, stem-cell factor (SCF) (kit ligand), encoded by the Sl locus, is expressed by cells along the germ-cell migratory pathway (17). Gonads of the white-spotting (W) and Steel (Sl) mutant mice contain few, if any, germ cells (18–20), because of defects in the migration and death of germ cells. Thus, the interaction of c-kit with its ligand is required for prenatal migration, proliferation, and survival of the primordial germ cells (21) and also for postnatal folliculogenesis. Similar to c-kit, TIAR, an RNA recognition motif/ribonucleoprotein-type RNA-binding protein, is highly expressed in primordial germ cells, and is essential for regulating PGC proliferation and survival (22). TIAR belongs to a family of proteins that function in splicing, transport, translation, and stability of mRNA, and play multiple, key developmental functions in Drosophila melanogaster, such as sex determination. At E 11.5, a severely reduced number of PGCs are observed in the genital ridge of male and female mice lacking TIAR, and by E 13.5 the PGCs have completely disappeared. Postnatally, these mutant female mice essentially have streak ovaries. Because TIAR-deficient embryonic stem (ES) cells do not proliferate in vitro in the absence of leukemia-inhibitory factor, TIAR may play a role in regulating cell proliferation and survival under suboptimal conditions. Perhaps in vivo, suboptimal conditions are experienced by PGCs during migration to the gonad, providing an explanation for why proliferation and survival during this period is TIAR-dependent. The Zfx gene encodes a putative zinc-finger transcription factor located on the X-chromosome (22a). Female Zfx-deficient mice are subfertile and have a dramatically shortened reproductive lifespan, reminiscent of the human syndrome known as premature ovarian failure (23). The number of oocytes in the perinatal ovary was <25% of controls. Although germ cell migration did not appear to be disrupted, further investigation revealed <50% the normal number of primordial germ cells in the gonad at E 11.5.
Chapter 4/Control of Ovarian Function
67 Table 8
Intra Ovarian Regulation of Ovulation and/or Corpus Luteum Formation Transgenic/mutant mouse
Major reproductive findings
Refs
C/EBP` (CCAAT/enhancerbinding protein `) knockout Connexin 37 knockout
Infertility; reduced ovulation and block in (113) “mature” corpora lutea formation Infertility; defect in folliculogenesis at the (61,120) Graafian follicle stage; oocytes are meiotically incompetent Cyclin-dependent kinase Infertile; defects in hypothalamic-pituitary(139) 4 knockout gonadal axis leading to prolonged cycle length and failure to form corpora lutea Cyclooxygenase 2 (prostaglandin Largely infertile; absence of corpora lutea due (106) endoperoxide synthase-2) to apparent ovulation defect knockout Estrogen receptor _ and ` Infertile; no CLs, few healthy follicles, (99) double knockout follicular nests, degenerating oocytes, few granulosa cells and Sertoli-like cells Estrogen receptor ` knockout Subfertile; fewer litters and fewer pups/litter; (98) decreased ovulation efficiency Kip1 p27 knockout Female infertility; corpora lutea defects; males (117,118) fertile but increased testis size Progesterone receptor knockout Infertility; defects in all reproductive tissues, (116) no ovulation but corpora lutea formation Prolactin receptor Infertility; reduced ovulation and fertilization; (140) knockout preimplantation development blocked Prostaglandin F receptor Inability to undergo parturition secondary to (141) knockout failure of corpora luteum to undergo luteolysis, preventing induction of oxytocin receptor in uterus Stat5a/Stat5b double knockouts Infertility due to failure to form corpora lutea (142) Steroidogenic acute regulatory Congenital adrenal hyperplasia; males and (8,9) (StAR) protein knockout females have female external genitalia; by puberty have lipid deposits, luteinized stromal cells and no corpora lutea Transcription factor NGFI-AInfertility; luteinizing hormone deficiency, (143) LacZ knockin LH receptor suppression, causing no ovulation and no corpora lutea
Based on the mutant mouse phenotype, Zfx-deficiency has been proposed as a model for premature ovarian failure, and its location on the X chromosome suggests that it is also involved in some reproductive defects seen in Turner’s syndrome (45, XO). Similarly, a spontaneous mutation at the atrichosis (at) (24) locus and mutation of the germ-cell deficient (gcd) locus (25) by transgene insertion also causes infertility because of significantly reduced primordial germ-cell populations in the developing gonad. However, the identity and functions of the genes at the at and gcd loci are unknown. Survival of germ cells, once they reach the genital ridge, is also a key determinant of the postnatal oocyte pool size. Abnormalities in survival have been noted in several transgenic models (Table 3). At 14.5 d postcoitum (dpc), there are similar numbers of
68
Elvin and Matzuk Table 9 Nonfollicular Fertility Defects (Selected)
Transgenic/mutant mouse
Major reproductive findings
Basigin knockout
Infertility in both sexes; males show block (144,145) in spermatogenesis; females show reduced fertilization and implantation defects Decreased fertility in females only resulting (121,122) from parthogenetic activation; ovarian cysts and teratomas Subfertile because of decreased fertilization of (108–110) eggs; defects in cumulus expansion Infertile; pre- and postimplantation defects (146)
c-mos knockout
EP2 Prostaglandin E2 receptor knockout Heatshock transcription-factor 1 (Hsf1) knockout Interleukin 11 knockout Leukemia inhibitory factor (LIF) knockout Mlh1 knockout
Osteopetrotic (colony-stimulating factor-1 mutant) mice SR-BI (scavenger-receptor, class B, type I) knockout Steroid 5_-reductase type I knockout Wnt7a knockout ZP protein 1 (Zp1) knockout ZP protein 2 (Zp2) knockout ZP protein 3 (Zp3) knockout
Refs
Female infertility caused by decreased (147) implantation reaction and failed decidualization Infertility; embryo implantation does not occur (148) Male and female infertility; defective meiosis (32,74) at pachytene stage (males) and failure to complete meiosis II (females) and genome instability Male and female mice subfertile; reduced (149) testosterone (males); implantation and lactation defects (females) Female infertility caused by defects in oocyte (150,151) maturation and arrested early embryonic development Reduced litter size; parturition defects (152,153) (i.e., fetal death caused by excess estrogens) Female infertility caused by abnormalities in (27) oviduct and uterus development Thinner zona matrix; decreased fertility (41,44) caused by fertilization defect Infertile; no ZP; fragile oocytes do not survive (41) well in oviduct; no fertilization Infertile; no ZP, fragile oocytes do not survive (42,43) in oviduct, no fertilization
germ cells in the Wnt-4-deficient and control female gonad, indicating that proliferation and migration had occurred normally (26). However, at birth, the Wnt-4-deficient ovary contains only 10% the normal number of oocytes, indicating that massive oocyte death had occurred. In females, Wnt-4 deficiency also causes absence of the Müllerian duct, development of the Wolffian duct, and the presence of testosterone producing Leydig cells within the ovary. Oocyte death in these mice is not a result of increased production of ectopic androgens by the Leydig cells (since chronic administration of testosterone does not impair oocyte development), but likely reflects a direct role of Wnt-4 in maintaining the female germline. In contrast, Wnt-7a, which is expressed in the Müllerian-duct epithelium at E 12.5 to E 14.5, has no effect on ovarian development or
Chapter 4/Control of Ovarian Function
69
function, but instead only regulates Müllerian-duct differentiation in both males and females (27). Wnt-7a-deficient females have normal folliculogenesis and ovulation, but are infertile because of abnormalities in the oviduct and uterus (Müllerian-duct derivatives). By postnatal d 2 (P2), oocytes arrest in prophase of the first meiotic division, and do not complete meiosis I until ovulation. Several proteins—particularly mismatch-repair proteins—are required for meiosis. For example, mutations in the genes Msh5, Dmc1, and Mlh1 result in selective loss of germ cells, and often secondary effects on the somatic cells. Msh5 is a homolog of the Escherichia coli protein MutS, responsible for recognizing DNA replication errors and binding to the mismatched bases. Msh5 is expressed in the ovary from E 16 to P1, the time in females when germ-cell meiosis begins. Msh5deficient females are infertile, and adult ovaries are devoid of follicles and are cystic (28,29). Migration, proliferation, and embryonic survival of germ cells are unaffected up to E 18, and Msh5 knockout female embryos have normal numbers of germ cells (28). However, the germ-cell population diminishes quickly and by postnatal d 25, only 1–3 oocytes are observed per ovary. Interestingly, these oocytes are in antral follicles, indicating that they have the capability to participate in folliculogenesis if still viable. Further studies have indicated that the oocytes were blocked at the zygotene stage of oogenesis, when problems with chromosomal pairing and synapsis lead to apoptotic oocyte death. Similarly, deficiency of the germline-specific RecA homolog Dmc1 results in infertility. This defect causes meiotic prophase arrest, resulting from failure of chromosome pairing and synapsis. It also leads to oocyte loss beginning in the fetus, and eventually results in a rudimentary ovary in adulthood (30,31). This finding suggests that Dmc1 acts slightly later than Msh5, or that there is partial redundancy for Dmc1 function. In contrast to the Msh5-deficient phenotype, Mlh1-deficient mice are infertile, yet have completely normal ovary development, folliculogenesis, and ovulatory capacity (32). Mlh1 is a MutL homolog, which in E. coli interacts with MutS to activate the endonuclease MutH in mismatch repair. Superovulation of Mlh1-deficient females yields normal numbers of oocytes. However, in vitro fertilization of these oocytes has demonstrated that they were never able to complete meiosis II after fertilization, as indicated by the complete absence of a second polar body and an inability to progress beyond the one-cell embryo stage. Thus, although the Msh5, DMC1, and Mlh1 proteins function in mismatch repair, they play unique and separate functions within the mammalian ovary. Similar to Zfx and the aforementioned genes, these mismatch-repair genes should be examined closely for mutations in humans, which lead to premature ovarian failure and/or cancer. Two human diseases with impaired double-strand-break repair, Fanconi’s anemia (FA) and ataxia telangiectasia (AT), have many symptoms that include subfertility or infertility. Fanconi’s anemia is characterized by increased sensitivity to DNA crosslinking agents, and is caused by five distinct complementation groups. The mouse gene defective in complementation group C (Fac) has been cloned and disrupted in mice (33,34). 73% of female Fac –/– mice are infertile, while the remainder had a few litters of small size (1–2 pups/litter). This phenotype is similar to female FA patients, who typically have irregular menstruation with menopause occurring at approx 30 yr of age. In humans, ataxia telangiectasia is caused by mutations in the nuclear ataxia telangiectasia mutated (ATM) protein—a member of a protein family involved in cell cycle regulation, monitoring of telomere length, meiotic recombination, and DNA repair—and is associated with extreme sensitivity to ionizing radiation. ATM protein is present at high levels in the cytoplasm of oocytes in developing follicles, and infertility is a common
70
Elvin and Matzuk
feature of AT in humans. Similarly, deficiency of ATM in mice phenocopies the human syndrome, with infertility caused by a complete loss of oocytes and absence of follicles by P11 (35,36). At E 12.5, normal numbers of germ cells were observed in Atm –/– genital ridges, indicating that germ-cell migration and proliferation do not require ATM protein. However, by E 16.5, many oocytes in the ATM-deficient ovaries undergo apoptosis, leading to perinatal ovarian degeneration. Similarly, in mutant males, spermatogenesis is blocked at the zygotene stage of meiosis I, and seminiferous tubules are populated with spermatogonia and spermatocytes undergoing apoptosis. In males homozygous for a second mutation in p53 or p21, spermatogenesis can proceed to the pachytene stage, and the level of apoptosis is reduced by up to 70% (35,36). Thus, it is proposed that ATM participates in monitoring and regulating meiotic progression. The mouse models described here clearly demonstrate that prenatal ovarian development determines postnatal reproductive capacity. Factors expressed by the somatic cells along the PGC migration route and in the developing ovary, as well as the germ cells themselves, are critical for ovarian development and oocyte survival during the fetal and perinatal period (Tables 2 and 3).
POSTNATAL OVARIAN FUNCTION: FOLLICULOGENESIS The follicle is the basic functional unit of the ovary, consisting of an oocyte surrounded by granulosa and theca cells. During normal folliculogenesis, there is coordination of oocyte growth and maturation, and granulosa and theca cell proliferation and development, within each follicular unit (37). Distinct morphological and molecular changes occur in each of these components, and reflect evolving functional capabilities crucial for the continued development of the follicle and eventually, the successful completion of this developmental program. Staggered recruitment of follicles into the growing pool and consistent growth rates ensure that mature follicles are produced with every cycle. Follicular responsiveness to circulating pituitary hormones, and resultant production and secretion of steroid and peptide hormones, coordinate the release of the mature oocyte with alterations in female physiology conducive to mating, fertilization, and support of an embryo. The various mouse models discussed in the following sections are summarized in Tables 4–8.
INITIATION OF FOLLICULOGENESIS AND PREANTRAL FOLLICLE GROWTH By postnatal d 2, meiotically arrested oocytes associate with somatic cells to form primordial follicles, the first stage of folliculogenesis (4). Although the signals that trigger formation of primordial follicles and the eventual recruitment of a dormant primordial follicle into the growing pool are still unknown, the genes critical for these processes are being identified, and their functions are being analyzed (Table 4A). The subsequent period of preantral follicle growth, consisting of granulosa cell proliferation and oocyte growth, is relatively slow, and only a few mitotic figures are observed in granulosa cells at this stage (38). Initiation of follicle growth in the mouse is not restricted to sexual maturity, but in fact begins within the first wk postnatally. Since there is no evidence for a reserve pool of larger follicles, it appears that once a follicle enters the growing pool, it is normally committed to a program of growth and differentiation, culminating in either apoptotic death of the granulosa cells (atresia) or ovulation of the mature oocyte (39).
Chapter 4/Control of Ovarian Function
71
Several proteins are known to be expressed by mouse primordial follicles and follicles during the initiation period. The oocyte of the newly recruited follicle begins to secrete its unique extracellular glycoprotein matrix, called the zona pellucida (ZP). ZP formation at this early stage of folliculogenesis suggests that it may be important for oocytegranulosa cell coupling, or may play a role in continued follicle development (37). One of the genes involved in regulating the expression of all the three mouse ZP genes is Fig_ (Factor In the Germline _). Fig_ is a basic helix-loop-helix transcription factor that is first expressed in oocytes prior to primordial germ cell formation, and is also expressed in oocytes of primary and later follicles (40). Although Fig_ (with a heterodimeric partner) binds to an E-Box in the ZP-1, ZP-2, and ZP-3 genes to regulate transcription of these genes, Fig_ must also function prior to this point, because mice without Fig_ have a normal number of oocytes at birth, but subsequently fail to form primordial follicles and demonstrate dramatic apoptosis of these oocytes over the next few days (41). Thus, Fig_ not only regulates expression of the ZP genes, but may also induce the expression of an oocyte gene involved in “recruitment” of pregranulosa cells to surround the oocytes and form primordial follicles. To study the function of the ZP, all three of the ZP genes have been mutated in mice. Interestingly, mice deficient in any of the three major components of the ZP (ZP1, ZP2, or ZP3) show no defects at any stage of folliculogenesis (41–44). ZP1-knockout mice are subfertile, with litter sizes 50% of wild-type controls, whereas ZP2- and ZP3-knockout mice are absolutely infertile. The reasons for these differences in fertility are secondary to the differences in the formation of the ZP in these knockouts. ZP2-knockout and ZP3-knockout mice fail to form a ZP; this absence of a zona leads to failure of fertilization and progression to the two-cell stage. In contrast, ZP1 knockout mice have a thin ZP, and the integrity of this ZP is compromised; these structural defects have resulted in a 80% reduction in the number of two-cell embryos recovered after superovulation. Thus, ZP absence (in the case of ZP2- and ZP3-knockouts) or alteration (in the case of ZP1 knockout), decreases ovulation and fertilization in vivo, confirming an important predicted role of the ZP in female reproduction. Apoptotic cell death occurs in oocytes and granulosa cells of both primordial follicles and growing follicles. Members of the Bcl2-related protein family play either positive or negative roles in regulating apoptosis (45,46) (see Chapter 6). Bcl2 and BclxL protect against apoptosis, while Bax, which can heterodimerize with Bcl2 and BclxL, counters their protective effect and promotes cell death when overexpressed. Bax is expressed in granulosa cells and oocytes, and plays a critical role in regulating ovarian-cell death; 6-wk old Bax-deficient mice have three times more primordial follicles than controls and one-half the number of atretic primordial follicles. This difference in the rate of follicular-pool depletion results in the presence of growing, functional follicles at 640 d of age. Despite the presence of growing follicles, no corpora lutea or pregnancies have been seen in these very old mice. Ovulation could be induced by injection of exogenous gonadotropins, indicating that reproductive senescence is caused by a combination of follicular depletion and pituitary dysfunction. Thus, Bax inactivation produces a surplus of nonatretic follicles, extends the function of the ovary into advanced chronological age, and may provide additional insight into the molecular basis of oocyte depletion associated with menopause in humans. Growth of preantral follicles, corresponding to type 3b to type 5b follicles in the mouse, is gonadotropin-independent, and is regulated primarily by intraovarian and
72
Elvin and Matzuk
intrafollicular mechanisms. In the FSH` knockout mouse (47) or in the hypogonadal (hpg) mouse, in which a naturally occurring mutation in the gonadotropin-releasinghormone-gene markedly reduces the synthesis of both FSH and LH from the pituitary (48), preantral follicle growth proceeds normally, confirming the gonadotropin-independence of this stage of development. However, several mouse models have clearly demonstrated that signaling from the granulosa cells to the oocyte, as well as from the oocyte to the granulosa cells, is necessary for preantral follicle growth and does not require extragonadal input (Table 4B). For example, intrafollicular signaling of kit ligand from granulosa cells to c-kit on the oocyte is critical for preantral follicle development. All mouse oocytes express c-kit, whereas granulosa cells of one-layered growing follicles, preantral follicles, and the outer (mural) layers of preovulatory follicles express kit ligand (49,50). Two hypomorphic kit ligand alleles at the Sl locus, Slt and Slpanda, permit prenatal ovarian development (in contrast to the other alleles mentioned earlier) and initiation of follicular growth, but result in follicular arrest before the two-layer follicle stage (51–53). In Slpanda homozygous mutant ovaries, kit ligand expression is virtually absent (53), because of a large paracentric inversion located 115 kb 5' of the kit ligand coding sequences (54). In addition, blocking antibodies to the c-kit receptor administered to mice during the first 2 wk after birth inhibit ovarian follicular development beyond the one-layer primary-follicle stage (55), further supporting the essential role of kit ligand/c-kit signaling at this stage of follicular development. Growth-differentiation factor-9 (GDF-9 or Gdf9), a novel, oocyte-expressed member of the transforming growth factor ` (TGF-`) superfamily of secreted growth factors, is also necessary for early preantral follicle growth. Gdf9 is first expressed by oocytes of type 3a follicles, and its expression persists in the oocyte through ovulation (56–59). We have generated a GDF-9-deficient mouse model by deleting exon 2, which encodes the entire GDF-9 mature region (60). Heterozygotes of both sexes and males homozygous for the deletion are fertile, but homozygous mutant females are completely infertile. Although follicular recruitment and initiation of growth is grossly normal, no follicles with two or more symmetric or concentric layers of granulosa cells are evident, indicating that folliculogenesis is blocked at the type 3b (primary) follicle stage in these mice (60). This defect in follicular development is not rescued by treatment of the mice with exogenous gonadotropins. In addition, kit ligand and _ inhibin mRNA are elevated in these one-layer primary follicles (58). The increased signaling of kit ligand through its receptor, c-kit, in the oocyte, is a probable cause of the increased oocyte size in the Gdf9 knockout ovary (61), further supporting the importance of modulation of kit ligand/c-kit signaling in the postnatal ovary. This finding suggests that GDF-9 is a direct negative regulator of this signaling pathway. At the early stages of oogenesis in the Gdf9 knockout ovary, the oocytes appear to be fairly normal. However, the absence of GDF-9 signaling, and potentially the resultant increase in kit ligand signaling, eventually leads to defects in oocyte meiotic competence and abnormal germinal vesicle breakdown, and spontaneous parthenogenetic activation of the oocytes, in addition to the increased rate of growth of the oocyte. At the electronmicroscopic level, the GDF-9-deficient oocytes have several unusual features, including Golgi complexes composed of single lamellae instead of stacks and a decreased number of cortical granules. Additionally, cell-cell contacts between the oocyte and granulosa cells are unusual in that oocyte microvilli are clustered next to abnormal, large processes from surrounding somatic cells. These follicle cells subsequently invade the perivi-
Chapter 4/Control of Ovarian Function
73
telline space, and are associated with a loss of oocyte viability (60,61). The combined oocyte and granulosa cell abnormalities lead to eventual death of the oocyte, resulting in a follicular nest with granulosa cells surrounding a collapsed ZP remnant. The cells of the majority of these follicular nests are steroidogenic; these cells appear vacuolated because of the large number of lipid droplets, have an increased number of mitochondria (60), and express P450 side-chain cleavage, P450 aromatase, LH receptor, and _ inhibin mRNA (58). Thus, although these nests of cells often resemble small corpora lutea, these follicles express both luteal (i.e., p450 side-chain cleavage and LH receptor) and nonluteal (i.e., p450 aromatase and _ inhibin) markers, suggesting that the early loss of the oocyte (and possibly the absence of GDF-9) alters the differentiation program of these granulosa cells. In the periovulatory follicle, the oocyte secretes important growth factors, which stimulate the synthesis of hyaluronic acid necessary for cumulus expansion and repress the synthesis of LH receptor and urokinase plasminogen activator (uPA) (59). Because of the early block in the growth of the Gdf9 knockout ovary, and based on the continued expression of GDF-9 beyond ovulation, we have studied the biological actions of GDF-9 in the periovulatory period, using pregnant mare serum gonadotropin (PMSG)-induced mouse granulosa cells cultured with recombinant mouse and human GDF-9 protein. Recombinant mouse GDF-9 induces hyaluronan synthase 2 (Has2), cyclooxygenase 2 (Cox2), and steroidogenic acute regulator protein (StAR) mRNA synthesis, and suppresses urokinase plasminogen activator and luteinizing hormone receptor (LHR) mRNA synthesis (57). In addition, GDF-9 stimulates in vitro cumulus expansion of oocytecto–mized cumulus cell-oocyte complexes (i.e., complexes in which the oocyte has been microsurgically removed) (57). Thus, GDF-9 is essential for granulosa-cell growth and function at early stages, and is also the oocyte-secreted factor responsible for modulating the expression of a number of cumulus cell genes critical during the periovulatory period. The theca layer forms when the follicle achieves two layers of granulosa cells, and provides a source of aromatizable androgen to the adjacent granulosa cells, which is crucial for follicular estrogen production by enzymatic conversion (62). Theca cells differentiate from mesenchymal or stromal precursors adjacent to developing follicles. Theca-interstitial cell culture experiments in vitro show that rat preantral follicles with 2–5 layers of granulosa cells (but not one-layer or antral follicles) secrete a factor in the absence of gonadotropins that induces theca layer differentiation, including expression of cytochrome P450 17_-hydroxylase-C17-20 lyase (63). In GDF-9-deficient mice, a theca layer fails to form, despite the presence of increased FSH and LH (58,60). However, an identifiable theca layer is formed around the multilayer preantral follicles in the FSH-deficient ovary model (47). Taken together, these data support the presence of a paracrine, inductive signal secreted from preantral follicles with two or more layers of granulosa cells, which is necessary for theca layer development. GDF-9 is possibly an important direct or indirect regulator of these theca cell “recruitment/differentiation” factors. Primordial and small preantral follicles (type 3a and 3b) represent a minute fraction of total ovarian cells, making it difficult to isolate genes and proteins involved in the earliest stages of follicular development. In addition, these stages have generally not proven amenable to extraovarian manipulation. However, development of these mouse models, in which folliculogenesis is arrested at an early stage, have defined some key factors involved in initiation and early preantral follicle growth.
74
Elvin and Matzuk
ANTRAL FOLLICLE DEVELOPMENT: SENSITIVITY TO EXTRA OVARIAN AND INTRA OVARIAN REGULATION During follicular development in mice, follicular antrum formation represents a transition from primarily intrafollicular regulation to a combination of intraovarian and extraovarian regulation. Follicles enter a rapid period of growth, and synthesize peptide and steroid hormones that impact on the reproductive axis. Multiple positive and negative feedback loops between the hypothalamus, pituitary, and ovaries coordinate follicle maturation with sexual behavior and physiological preparation for pregnancy. The hypothalamus produces and releases gonadotropin-releasing hormone (GnRH) in a pulsatile manner directly into the pituitary blood supply via the pituitary portal vessels (64). GnRH pulse frequency is modulated by the endocrine status of the animal; estrogen increases pulse frequency and increases the sensitivity of the anterior pituitary to GnRH. In response to GnRH, the anterior pituitary releases the heterodimeric glycoprotein hormones, FSH and LH. Defects in the hypothalamic-pituitary-gonadal axis have a dramatic effect on antralfollicle development, and there are multiple mouse models that exhibit infertility or subfertility because of defects at the levels of the hypothalamus and pituitary (Table 5). Loss of pituitary stimulation by hypothalamic GnRH because of a gene deletion, as in the hypogonadal (hpg) mouse (65), or resulting from migration arrest of GnRH neurons and tumor formation, as in the GnRH-SV40 T-antigen transgenic mouse (66), prevents release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH). In the GnRH mouse models, follicles progress normally to the multilayer preantralfollicle stage, but are unable to form significant antra, similar to the FSH`-deficient mouse model (47). Additionally, the ovaries are very small, with little interstitial tissue, which may be caused by the lack of LH or a direct effect of GnRH on the ovary. Mutations in the GnRH receptor (67) also cause recessively inherited hypogonadism, primary amenorrhea, and infertility in humans. FSH, in conjunction with locally produced estradiol, functions primarily to promote follicular growth (68), causing the mitotic index of the late preantral to early antral granulosa cells to peak (37,69), and to induce the granulosa cell gene expression necessary for follicle maturation. Mutations leading to FSH deficiency, misregulation, or insensitivity disrupt antral-follicle development. In the FSH`-deficient mouse, folliculogenesis progresses normally to the multilayer preantral follicle stage, but further granulosa cell proliferation and antrum formation is blocked, and these follicles subsequently undergo atresia (47). To further study evolutionarily conserved functions of human and mouse FSH, two approaches have been taken to genetically rescue these mouse FSH` mutants (70). In the first approach, a human FSH` transgene, which is expressed exclusively in pituitary gonadotropes, was introduced into the mouse FSH`deficient line leading to the production of an interspecies hybrid FSH (i.e., mouse _:human FSH` hormone). FSH`-deficient mice carrying the human FSH` transgene resumed normal folliculogenesis, were fertile, and delivered normal sized litters. Thus, human FSH` can combine with the mouse glycoprotein hormone _ to form a functional (hybrid) heterodimer. In the second approach, two metallothionein-I promoter-driven transgenes were introduced into the mouse FSH`-deficient line, leading to the ectopic expression of both human _ and human FSH, predominantly in the liver. Ectopic production of human FSH rescued the fertility of only 30% of the females. Similarly, human
Chapter 4/Control of Ovarian Function
75
FSH can bind to mouse FSH receptors to restore fertility, but pituitary control of FSH synthesis and secretion are necessary for normal reproductive function in females. Other mutations at the level of the ovary also lead to infertility becuase of defects in antrum formation (Table 6). For example, impaired responsiveness to FSH leads to ovarian failure similar to that observed in the FSH ligand knockout. Targeted disruption of the mouse FSH receptor (FSHR) (71) also leads to female infertility and a block in folliculogenesis before antral follicle formation, similar to that observed in the mouse FSH`-deficient mouse. Based on the uterine morphology (i.e., uteri +/+ > +/– > –/–), it appears that there is also an effect of the FSHR mutation on heterozygotes, suggesting that although fertile, follicular estrogen production may be reduced because of decreased FSH binding. Additionally, homozygous FSHR deficiency leads to 15-fold elevated serum FSH levels. Significantly, these findings phenocopy humans with mutations in the FSH receptor (72), which causes recessively inherited hypergonadotropic hypogonadism, primary amenorrhea, and infertility. Recently, a woman with secondary amenorrhea and very high serum FSH concentrations was found to be a compound heterozygote for two different mutations in the FSHR (73). Ultrasonography revealed normal-sized ovaries and antral follicles up to 5 mm in diameter, but further follicular development was blocked. However, further analysis demonstrated that these FSHR mutations resulted in only partial functional impairment (i.e., a hypomorphic state), and suggested that a limited FSH effect is sufficient to promote follicular development to the small antral stage, but further development requires significant FSH stimulation (see activin-receptor-type II knockout model). Insulin-like growth factor I (Igf1) knockout mice (74,75) have an almost identical ovarian phenotype to the FSH knockout mice (for more details, see Chapter 17). Igf1 has been shown to enhance proliferation of many cell types, and Igf1 and Igf1 receptor are expressed in follicles that appear healthy, suggesting that they may be markers for follicular selection. Igf1 expression, however, is not dependent upon FSH stimulation, because Igf1 continues to be expressed in FSH-deficient follicles (75). Instead, granulosa cell Igf1 expression is initiated by intrafollicular signaling, possibly from the oocyte. The importance of Igf1 signaling in ovarian function is further supported by the reproductive defects in the insulin receptor substrate-2 (IRS-2)-deficient mouse (76). IRS proteins function as downstream signaling proteins to mediate the cellular actions of insulin and Igf1. IRS-2-deficient females rarely become pregnant, lack corpora lutea in their ovaries, and do not respond to superovulation. Both FSH and Igf1 augment the expression of FSHR, as evidenced by a 50% decrease in FSHR concentration in the Igf1-deficient ovaries or after elimination of gonadotropins by hypophysectomy. Decreased FSHR expression, leading to relative FSH insensitivity in the Igf1-deficient follicles, appears to be at least part of the mechanism for follicular arrest in the Igf1-deficient model. Although FSH has long been recognized to induce proliferation of granulosa cells, only recently has one of the molecular mechanisms of its mitogenic action been suggested. Granulosa-cell proliferation appears to be mediated by FSH and estradiol induction of cyclin D2 (77). The D-type cyclins are known to positively regulate entry into the cell cycle by binding cyclin-dependent kinases (CDK) 4 and 6 and allowing phosphorylation of the complex by CDK-activating kinase. This activated cyclin-CDK complex then phosphorylates a number of cellular substrates, eventually activating DNA synthesis and the transition from G1 to S phase (78). While cyclin D1 and D3 localize to theca
76
Elvin and Matzuk
and interstitial cells, cyclin D2 is expressed specifically in granulosa cells within the ovary (77). Studies of rat granulosa cells cultured in vitro showed that forskolin induced cyclin D2 comparably to FSH, indicating that FSH signal transduction through the cAMP/protein kinase A pathway activated cyclin D2 expression (79). Conversely, cyclin D2 expression is dramatically reduced in nonproliferating granulosa cells. For example, cyclin D2 expression in preovulatory follicle is downregulated by human chronic gonadortropin (hCG) treatment and subsequent luteinization, but continues in smaller growing follicles that do not express receptors (77). Increased expression and gene amplification of cyclin D2 has been detected in a variety of human granulosa cell tumors (79), emphasizing its potential clinical importance in regulating granulosa cell proliferation. Cyclin D2-deficient mice provide definitive evidence that cyclin D2 is functionally significant for granulosa cell proliferation (79). While the number of oocytes and follicles in cyclin D2-deficient ovaries was normal, there was an obvious reduction in the number of granulosa cells surrounding each oocyte. Mutant ovaries showed minimal response to FSH administration in contrast to the rapid FSH-induced proliferation of the granulosa cell layer in wild-type ovaries. This was particularly apparent in cyclin D2-deficient antral follicles that rarely had more than four layers of granulosa cells, compared with controls containing up to ten layers. The gonadotropin signal transduction cascade was shown to be intact, as cyclin D2-deficient follicles produce estradiol in response to FSH, and expressed the periovulatory and luteal cell markers, cyclooxygenase 2, cytochrome P450, cholesterol side-chain cleavage, and progesterone receptor in response to LH (80). However, cyclin D2-deficient mice fail to ovulate in response to LH, and instead, corpora lutea are formed with oocytes trapped inside. The cause of the ovulation defect is still unclear, but this phenotype emphasizes the importance of the coordination of growth and differentiation for successful completion of folliculogenesis. FSH stimulates expression of the _ and ` subunits of inhibin in the pituitary and ovary, leading to the production of the peptide hormones activin and inhibin, which can function in autocrine and paracrine signaling or as endocrine factors (81). Activins and inhibins are dimeric members of the TGF-` superfamily, in which the ratio of _ subunits to ` subunits produced by the cell determines whether the hormonal output is FSH-stimulating (activin) or FSH-suppressing (inhibin) (82). The _-inhibin and the activin-receptor type IIA-deficient (ActRIIA) mice emphasize the importance of gonadproduced peptide hormone feedback and the intrapituitary effects of these peptides on FSH regulation. The _-inhibin knockout mice have increased serum FSH, confirming the known role of inhibin to decrease pituitary FSH release. Furthermore, few fertilizable oocytes could be recovered from the oviducts of PMSG/hCG-primed immature inhibin-deficient females (83). This finding indicates that inhibin plays an important intra ovarian function in folliculogenesis. Consistent with this intra ovarian function, inhibin also has a novel antiproliferative and tumor-suppressive role in the gonads. 100% of male and female inhibin-deficient mice develop early onset, rapidly growing granulosa/Sertoli cell tumors, which cause death secondary to a cancer cachexia-like syndrome mediated by activins secreted from the tumors (84,85). The predisposition of inhibin-deficient mice to develop gonadal tumors identifies inhibin as a secreted tumor suppressor. The involvement of gonadotropins in promoting gonadal tumorigenesis has been the subject of considerable debate. Elevated postmenopausal levels of serum FSH have been
Chapter 4/Control of Ovarian Function
77
associated with some forms of human ovarian epithelial cancer in elderly (86), but no direct in vivo causal relationship between FSH and ovarian cancer development has been demonstrated until recently. To investigate the role of FSH as a component of the cascade of events leading to development of gonadal tumors in inhibin-deficient mice, double-homozygous mutant mice deficient in inhibin and FSH were created (87). In contrast to mice lacking inhibin alone, in which 95% develop highly hemorrhagic ovarian tumors, cachexia, and death by 17 wk of age, 70% of double-mutant females live beyond 17 wk. Although 100% of the female double-mutants still develop ovarian tumors (in contrast to the double-mutant males where 70% are still alive at 1 yr), the ovarian tumors are slow-growing and less hemorrhagic. Additionally, reduced or delayed tumor-associated cachexia-like symptoms in the double-mutants were associated with low levels of serum estradiol (decreased 87% compared to inhibin single-mutant) and activin A (<0.078 vs 157.5 ng/mL). In contrast to inhibin/FSH double mutants, mice deficient in inhibin and GnRH, leading to suppressed FSH and LH, survive more than 1 yr, do not develop cancer cachexia-like symptoms, show only premalignant lesions in the ovary (88). Consistent with an important role of LH in ovarian tumorigenesis, transgenic mice overexpressing either a bovine LH_ subunit or a bovine LH` analog in the pituitary also develop granulosa cell tumors of the ovary (89). Thus, these results clearly demonstrate that gonadotropins are significant determinants of ovarian tumor phenotype and progression. In contrast to the inhibin-deficient mice, mice lacking one of the activin receptors, activin receptor type IIA (ActRIIA), have dramatically suppressed serum and pituitary levels of FSH. These results indicate that ActRIIA is the major pituitary receptor through which activins affect FSH synthesis and secretion (90). ActRIIA-deficient ovaries display a block in folliculogenesis at a slightly later developmental stage than that seen in FSH-deficient mice (i.e., the small antral follicle stage). This suggests that the block in folliculogenesis is a result only to the decreased FSH concentrations (that is, the phenotype is similar to an FSH hypomorphic allele) and not to the lack of paracrine signaling through ActRIIA in the ovary. These findings are similar to the findings in human female, with low-level activity of the FSHR in the granulosa cells (73). Consistent with the primary role of ActRIIA in the pituitary, ActRIIA-deficient ovaries transplanted into ovariectomized immunocompatible wild-type hosts (females with normal pituitaries and therefore normal serum FSH levels) resumed normal folliculogenesis, including formation of ovulatory follicles and corpora lutea in the host mice (M. M. Matzuk, unpublished data). Thus, lack of signaling through ActRIIA in the pituitary suppresses serum FSH levels, resulting in impaired folliculogenesis in the ActRIIA-deficient mice. To understand further the roles of activins (and other members of the TGF-` superfamily members) in the ovary, we have generated mice that overexpress follistatin, an activin-binding protein, using the metallothionein promoter (91). Female mice from two of the transgenic lines with the highest expression of the follistatin transgene often had blocks in folliculogenesis at the preantral and antral follicle stage, resulting in infertility in the most severely affected mice. Overexpression of follistatin may block follicular development by binding and inactivating activin and possibly other TGF-` family members, since both TGF-` and activin are capable of stimulating follicle growth in vitro (92), and GDF-9 is required for early stages of follicular growth. In the rat, intrafollicular estrogen signaling enhances the granulosa cell response to FSH, augmenting granulosa cell proliferation and expression of numerous FSH-regulated genes, including inhibin _ and ` subunits, LH receptor, and cytochrome P450
78
Elvin and Matzuk
aromatase (2). Cytochrome P450 aromatase catalyzes the conversion of theca-produced androgens to estrogens demonstrating the importance of coordinated development of follicular components. The interplay between FSH and aromatase and estrogen signaling sets up a positive-feedback loop for FSH within the follicle, which is important for later stages of follicle development. Three different mouse models demonstrate the importance and complexity of estrogen action within the ovary. In the aromatase knockout mouse (ArKO), conversion of androgens to estrogen is blocked (93,94). ArKO female mice have increased FSH and LH and ~10-fold elevated levels of testosterone compared to controls, leading to development of male body habitus and excessive internal fat deposition. Although ovaries develop in ArKO mice and folliculogenesis proceeds with granulosa cell proliferation and evidence of limited antrum formation, corpora lutea are absent, and the mice are infertile. By 21–23 wk of age, hemorrhagic cystic follicles develop similar to the ER_ knockout model, and by 1 yr, there is a dramatic reduction in the number of secondary and antral follicles. Thus, estrogen synthesis is required for formation of large antral follicles and ovulation. Estrogens exert their effects through interaction with estrogen receptors located in the nuclei of target cells. Two different estrogen receptors, ER_ and ER`, have been cloned and are expressed in ovarian cells. ER_ has a broad expression pattern, whereas ER` is expressed at high levels only in the ovary, prostate, epididymis, lung, and hypothalamus. Within the ovary, ER_ protein is expressed in theca and interstitial cells (95), while ER` is specifically expressed in granulosa cells of small, growing, and preovulatory follicles (95,96). Knockout mice for either ER_ or ER` have been created, and these mice have dramatically different phenotypes from each other and from the ArKO mouse. The ER_-knockout mouse (_ERKO) develops large preovulatory follicles, but fails to subsequently ovulate and form corpora lutea. Some arrested follicles undergo atresia, while others develop into large, hemorrhagic cysts (97). This ovarian phenotype is caused by failure of steroid feedback at the level of the hypothalamus and brain, leading to overstimulation of the LH receptor on theca and granulosa cells by the high LH levels in the serum (95). ER` is still detected in _ERKO ovaries, and cannot completely compensate for loss of ER_, indicating that ER` and ER_ have distinct functions. On the other hand, female ER`-knockout mice are subfertile, demonstrating reduced litter number and pups per litter because of reduced ovulation efficiency (98). Pharmacologic superovulation resulted in only 20% of the oocytes produced in controls. These differences in phenotypes in the `ERKO and ArKO mice vs the _ERKO mice may be ascribed to ER_-mediated estrogen regulation of gonadotropin synthesis and secretion in the hypothalamus and/or pituitary. Double-mutant mice lacking both ER_ and ER` (termed _`ERKO mice) have also been described (99). Prepubertal _`ERKO mice exhibit prominent ovarian growth and development of follicles to the antral follicle stage. These findings are reminiscent of hypergonadotropic precocious puberty, and are probably the result of elevated gonadotropins in these prepubertal females. Adult _`ERKO female mice are completely infertile, follicles never develop to the preovulatory stage, and no corpora lutea are seen. One surprise in these mice is the presence of “Sertoli” tubule-like structures that are the result of oocyte loss and the dedifferentiation of the granulosa cells into “Sertoli” cells. Consistent with this phenotype, Müllerian-inhibiting substance (MIS) mRNA is increased, and Sox9, a marker for Sertoli cells, is also increased. Similar findings have been seen in female mice overexpressing MIS (100) after oocyte loss, and also in _-inhibin knock-
Chapter 4/Control of Ovarian Function
79
out female mice that develop mixed granulosa/Sertoli cell tumors (83,84,88). These findings suggest an important role for estrogens, inhibins, and possibly oocyte-secreted factors in the maintenance of the normal granulosa cells phenotype.
OVULATION AND CORPORA LUTEA FORMATION The preovulatory follicle responds to the LH surge by releasing the oocyte and undergoing a series of functional and morphological changes in a process known as luteinization. The mural granulosa cells of the preovulatory follicle express LH receptors at high levels enabling them to sense the LH surge. LH, like FSH, stimulates adenylyl cyclase to produce cAMP and activate PKA, and may also increase inositol triphosphate and activate protein kinase C (101). Activation of this additional second messenger system may explain why the follicular response to the LH surge is so radically different from its response to FSH. P450 aromatase expression is abolished, cell division is halted, and genes responsible for breakdown of the follicular wall and basement membrane begin to be expressed (102). Disruption of pituitary LH synthesis, LH-receptor (LH-R) binding, or its downstream signaling are likely to block ovulation, luteinization, or both. Multiple mouse models have defects in ovulation and/or corpus luteum formation because of extra-ovarian (Table 7) or intra-ovarian (Table 8) defects. Regulation of the LH` subunit in the pituitary occurs during transcription, polyadenylation, and glycosylation of the protein. The LH` promoter contains binding sites for SF-1, ER_, CREB, and the zinc-finger transcription factor, NGFI-A (103). Whereas either SF-1 or NGFI-A can activate LH expression at a relatively low level, together they have been shown to synergistically activate high-level LH` expression. Female mice carrying a targeted disruption of NGFI-A are infertile due to a block in ovulation (103). In this model, serum LH concentration demonstrated a sexually dimorphic response to NGFI-A disruption: LH was decreased in males and undetectable in females. Administration of exogenous LH to the NGFI-A-deficient females resulted in normal ovulation and corpus luteum formation, indicating that the critical defect causing ovarian failure was LH deficiency. In contrast, a second model in which a lacZ marker gene was inserted into the NGFI-A exon 1 to disrupt gene function showed a deficiency of LH synthesis in both males and females (104). LacZ staining was observed in corpora lutea, granulosa cells of the mature antral follicles, and oocytes of mice heterozygous for the NGFI-A-LacZ knockin. Interestingly, the anovulatory phenotype in the homozygous NGFI-A-LacZ knockin females could not be rescued by pharmacological replacement of LH, potentially because of the significantly reduced levels of LHR in the granulosa cells of preovulatory follicles. These latter findings suggest that NGFI-A regulates expression of LH receptors in granulosa cells, as well as synthesis of LH in the anterior pituitary. It is unclear why these two different mutations, which are presumably both null mutations, result in somewhat different phenotypes. Ovulation is frequently compared to an inflammatory response. Follicular hyperemia and edema occur within a few hours of the gonadotropin surge, and are probably mediated by vasoactive agents such as histamine, kinins, and prostaglandins (102). In response to the gonadotropin surge and inflammatory mediators, serine proteases and metalloproteinases, such as plasminogen activator and collagenases, also increase in ovulatory follicles, suggesting a biochemical mechanism for follicular rupture. Indomethacin, a potent nonsteroidal anti-inflammatory agent, can block ovulation potentially through
80
Elvin and Matzuk
inhibition of prostaglandin synthesis. Cyclooxygenase 2 (Ptgs2 herein called COX-2) is one of two genes that catalyzes the formation of prostaglandins from arachadonic acid, and has been shown to be rapidly, but transiently, induced in granulosa cells of the preovulatory follicle after the LH surge (2). Normally, COX-2 mRNA concentrations peak 4 h after administration of hCG, and return to almost undetectable concentrations by 6–8 h after treatment (105). In response to hCG administration, the granulosa cells closest to the oocyte, the cumulus cells, express the highest level of COX-2 mRNA (58). Recently, we have shown that the oocyte-derived growth factor, GDF-9, induces COX-2 gene expression, and also induces cumulus expansion and expression of hyaluronan synthase 2 mRNA (57). Thus, both extraovarian stimulation by gonadotropins and intrafollicular signaling operate to control periovulatory gene expression. The critical role of COX-2-mediated prostaglandin synthesis in ovulation and postovulatory events is supported by the phenotype of COX-2-deficient mice and the effects of pharmacologic inhibition of COX-2 function in vivo and in vitro. In COX-2deficient ovaries, folliculogenesis progresses normally to the preovulatory stage (106), but the number of oocytes ovulated in a normal cycle or in response to exogenous gonadotropins was reduced to 20–40% of controls. Additionally, only 1% of ovulated oocytes from COX-2-deficient mice were successfully fertilized (107). A similar, although less dramatic, fertilization defect is also seen for knockouts of the EP2 prostaglandin E2 receptor (108,109). The defects in fertilization in these EP2-receptor knockout mice appears to be secondary to defective cumulus expansion (110). Thus, similar to GDF-9 (57), prostaglandin E2—acting through the EP2 receptor—stimulates cumulus expansion in vivo. This suggests that at least a portion of the fertility defects in the COX-2 knockout is secondary to a decrease in prostaglandin E2 signaling through this receptor. Consistent with the COX-2 knockout phenotype and the EP2 knockout phenotype, COX-2 protein is detected in the cumulus granulosa cells that are attached to the ovulated oocyte and pharmacologic inhibition of COX-2 in wild-type cumulus-oocyte complexes reduces their rate of fertilization (111) and implantation (107). Thus, local production of prostaglandins by cumulus cells establishes an ideal microenvironment around the oocyte essential for efficient ovulation, fertilization, and implantation. The COX-2 promoter has a binding site for the LH surge-induced transcription factor, CCAAT/enhancer-binding protein ` (C/EBP`), suggesting that C/EBP` is one factor that may control COX-2 transcription (112). Furthermore, C/EBP` is highly expressed in granulosa cells of late antral follicles by 7 h after hCG injection, suggesting its importance in late follicular development. C/EBP`-deficient mice demonstrate a significant decrease in ovulation efficiency and an absolute block in “mature” corpus luteum formation (113). In C/EBP`-deficient ovaries, COX-2 is still induced by the LH surge, eliminating the possibility that the phenotypic similarities between the C/EBP` knockout and COX-2 knockout are caused simply by an absence of COX-2. However, both COX-2 and cytochrome P450 aromatase mRNA persisted at least 7 h after the LH surge suggesting that C/EBP` instead mediates the transcriptional attenuation of COX-2 and aromatase. Wild-type, immunocompatible females retaining one wild-type ovary and one transplanted C/EBP`-deficient ovary mated to wild-type males produce heterozygous pups, although at a much lower frequency than wild-type pups, confirming that successful ovulation and fertilization of mutant oocytes can occur. Corpora lutea are never seen in the C/EBP`-deficient ovaries even after confirmed ovulations have occurred, suggesting that the pregnancy is supported entirely by corpora lutea of the wild-type contralat-
Chapter 4/Control of Ovarian Function
81
eral ovary. The absolute requirement for C/EBP` in luteal maturation may reflect a role in transcriptional attenuation of preovulatory genes or activation of other unknown genes. It will be of interest to determine whether the phenotype of the C/EBP` knockout mice is secondary to persistent expression of key preovulatory genes, and also to understand the role of the oocyte in the regulation of genes involved in ovulation. Coincident with inactivation of estrogen biosynthesis through P450 aromatase loss, the LH surge activates progesterone biosynthesis by stimulating cytochrome P450 cholesterol side-chain cleavage mRNA expression in granulosa cells. Progesterone is known to play an essential role in preparing the uterus for implantation of the embryo and has physiological functions in the mammary gland, brain, and ovary. These effects are mediated through binding to the progesterone receptor (PR), a member of the nuclearreceptor superfamily of transcription factors. PR mRNA has been shown to be induced by ovulatory concentrations of LH in granulosa cells in culture and in vivo (114,115). The generation of the PR-knockout (PRKO) mouse has confirmed that progesterone plays an essential physiological role in ovulation (116) (see Chapter 9). PRKO females are infertile, although the ovaries exhibit normal folliculogenesis through the preovulatory stage and demonstrate corpora lutea. However, these mice fail to ovulate, even with pharmacological treatment with PMSG and hCG. Histological examination of the ovaries reveals many unruptured follicles containing oocytes surrounded by cumulus cells that have undergone expansion. Progesterone is required for postfertilization events, and these studies demonstrate that PR directly regulates the synthesis of one or more enzymes involved in proteolysis, leading to follicular rupture. Luteinization is the terminally differentiated state of granulosa cells, and is accompanied by cell cycle arrest. p27KIP1 is a cell cycle regulatory protein that controls cell cycle progression by binding to and inactivating cyclin-CDK complexes in response to extracellular, anti-mitogenic signals. p27 KIP1 is widely expressed in nonproliferating cells, including the cells of the corpus luteum, but is not detectable in nonluteinized granulosa cells. In addition, p27KIP1 has been shown to be induced in granulosa cells by LH (77). p27KIP1 knockout mice are infertile, supporting a role for p27KIP1 in regulating follicular function (117,118). p27KIP1 deficient females have prolonged estrous cycles, infrequent ovulation, and decreased copulation. Histologic examination of the ovaries reveals intact follicular development, but a marked absence of corpora lutea. However, exogenous administration of PMSG and hCG stimulates ovulation (117,118) and the subsequent formation of corpora lutea capable of increasing serum progesterone (117). Further characterization of the reproductive abnormalities associated with p27KIP1 deficiency demonstrates that embryos fail to implant at E 4.5, but can be rescued by administering E2 and P4 to p27 KIP1-deficient mothers (119). Additionally, unilateral, transplantation of a p27 KIP1-deficient ovary into a wild-type host results in offspring derived from oocytes of both the p27KIP1-deficient and the remaining wild-type ovary. In contrast, bilateral transplantation of a p27KIP1-deficient ovaries into a wild-type host disrupts the estrous cycle and compromiss fertility. Conversely, transplantation of a wildtype ovary into a p27KIP1-deficient host does not restore estrous cyclicity (119). Taken together, these results suggest that perturbed ovarian steroid production, possibly caused by the failure of the luteal cell to withdraw from the cell cycle, in combination with extra ovarian—likely pituitary—defects cause infertility in the p27KIP1 -deficient mice.
82
Elvin and Matzuk
During follicular growth, the oocyte grows and matures, first acquiring competence to undergo germinal vesicle (oocyte nucleus) breakdown (GVBD) and then competence to complete meiosis I. Granulosa cell-oocyte gap junctions, composed of channels of connexins, permit diffusion of ions, metabolites and, potentially, other signaling molecules. Connexin 37 forms the oocyte-granulosa cell gap junctions, and connexin 37-deficient ovaries demonstrate a lack of junctional communication between the oocyte and granulosa cells, but not among granulosa cells. Oocyte growth is reduced in these mutant ovaries compared with controls, and >90% of the oocytes are incompetent to resume meiosis (120). In addition, there are defects in the later stages of follicular development, and a failure to ovulate in these connexin 37 knockout mice. These studies demonstrate that gap junction-mediated communication is important for the later stages of both oocyte and follicle development. The LH surge stimulates the mature oocyte to undergo GVBD and progress through meiosis I. The ovulated oocyte enters meiosis II, where it arrests in metaphase of meiosis II until fertilization with subsequent release of the second polar body. pp39mos, the protein product of c-mos, plays an important role in this process, as c-mos-deficient oocytes fail to maintain meiotic arrest after maturation (121,122). c-mos deficiency leads to decreased fertility resulting from parthenogenic activation of ovulated oocytes, which renders them incapable of fertilization. The small numbers of offspring that do arise from c-mos-deficient mothers are presumed to be derived from fertilization of eggs shortly after maturation and before parthenogenic activation occurs.
CONCLUSION Transgenic mouse models have been generated to study each stage of ovarian development and function. The transgenic mouse approach is providing in vivo evidence at all stages of folliculogenesis to support previous in vitro studies of intra-ovarian and extra-ovarian regulators, as well as defining novel mediators of ovarian function. A number of female mice with abnormalities other than follicular defects have also been generated to study processes such as the role of the zona pellucida in ovarian physiology, the functions of specific proteins in uterine development, and so forth (Table 9). Mouse models to study prenatal ovarian development and the earliest stages of folliculogenesis are particularly important, as these periods of development have been less accessible to other methods of investigation. One challenge in interpreting the phenotype of any model is to determine the direct effects of a mutation vs secondary effects caused by compensatory mechanisms. This is particularly difficult because of the multiple, interacting positive and negative feedback loops within the hypothalamic-pituitary-gonadal axis. Intercrosses to generate mice with multiple mutations have helped in some cases to clarify primary vs indirect effects of mutations. One drawback to conventional knockout mouse technology is that only the first essential function of the gene product can be examined in ovarian development or folliculogenesis, while expression may occur at multiple stages. For example, although knockout of GDF-9 results in a block in folliculogenesis at the primary follicle stage (60), we have used recombinant GDF-9 to demonstrate that GDF-9 regulates multiple key periovulatory events required for normal female reproduction (57). Generation of stage-specific, tissue-specific, and inducible knockout models may be useful in further elucidating of functions of already known and soon-tobe-discovered genes which play key roles in ovarian regulation.
Chapter 4/Control of Ovarian Function
83
ACKNOWLEDGMENTS The authors thank Ms. Shirley Baker for her expert assistance in manuscript formatting. Studies in our laboratory on ovarian development and ovarian cancer have been supported by Genetics Institute and National Institutes of Health grants HD33438, CA60651, HD32067, and the Specialized Cooperative Centers Program in Reproduction Research (HD07495). Dr. Julia A. Elvin is a student in the Medical Scientist Training Program supported by NIH Training Grants GM07330 and GM08307 and Baylor Research Advocates for Student Scientists (BRASS).
REFERENCES 1. Adashi EY. Intraovarian peptides. Stimulators and inhibitors of follicular growth and differentiation. Endocrinol Metab Clin N Am 1992;21:1–17. 2. Richards JS. Hormonal control of gene expression in the ovary. Endocr Rev 1994;15:725–751. 3. Capecchi MR. Targeted gene replacement. Sci Am 21994;70:52–59. 4. Byskov AG, Hoyer PE. Embryology of mammalian gonads. In: Knobil E, Neill J, eds., The Physiology of Reproduction, Raven Press, New York, NY, 1994, pp. 487–540. 5. Kreidberg JA, Sariola H, Loring JM, Maeda M, Pelletier J, Housman D, Jaenisch R. WT-1 is required for early kidney development. Cell 1993;74:679–691. 6. Luo X, Ikeda Y, Parker KL. A cell-specific nuclear receptor is essential for adrenal and gonadal development and sexual differentiation. Cell 1994;77:481–490. 7. Pang S, Yang X, Wang M, Tissot R, Nino M, Manaligod J, et al. Inherited congenital adrenal hyperplasia in the rabbit: absent cholesterol side-chain cleavage enzyme cytochrome P450 gene expression. Endocrinology 1992;131:181–186. 8. Caron KM, Soo S-C, Wetsel WC, Stocco DM, Clark BJ, Parker KL. Targeted disruption of the mouse gene encoding steroidogenic acute regulatory protein provides insights into congenital lipoid adrenal hyperplasia. Proc Natl Acad Sci USA 1997;94:11,540–11,545. 9. Caron KM, Soo SC, Parker KL. Targeted disruption of StAR provides novel insights into congenital adrenal hyperplasia. Endocr Res 1998;24:827–834. 10. Wehrenberg U, Goedecke Sv, Ivell R, Walther N. The orphan receptor SF-1 binds to the COUP-like element in the promoter of the actively transcribed oxytocin gene. J Neuroendocrinol 1994;6:1–4. 11. Giuili G, Shen WH, Ingraham HA. The nuclear receptor SF-1 mediates sexually dimorphic expression of Mullerian Inhibiting Substance, in vivo. Development 1997;124:1799–1807. 12. Hu Z, Zhuang L, Guan X, Meng J, Dufau ML. Steroidogenic factor-1 is an essential transcriptional activator for gonad-specific expression of promoter I of the rat prolactin receptor gene. J Biol Chem 1997;272:14,263–14,271. 13 Koopman P, Gubbay J, Vivian N, Goodfellow P, Lovell-Badge R. Male development of chromosomally female mice transgenic for Sry. Nature 1991;351:117–121. 14. Yu RN, Ito M, Saunders TL, Camper SA, Jameson JL. Role of Ahch in gonadal development and gametogenesis. 15. Swain A, Narvaez V, Burgoyne P, Camerino G, Lovell-Badge R. Dax1 antagonizes Sry action in mammalian sex determination. Nature 1998;391:761–767. 16. Manova K, Bachvarova RF. Expression of c-kit encoded at the W locus of mice in developing embryonic germ cells and presumptive melanoblasts. Dev Biol 1991;146:312–324. 17. Matsui Y, Zsebo KM, Hogan BLM. Embryonic expression of a haematopoietic growth factor encoded by the Sl locus and the ligand for c-kit. Nature 1990;347:667–669. 18. Coulombre JL, Russell ES. Analysis of the pleiotropism at the W-locus in the mouse: the effects of W and WV substitution upon postnatal development of germ cells. J Exp Zool 1954;126:277–296. 19. Bennett D. Developmental analysis of a mutation with pleiotropic effects in the mouse. J Morphol 1956;98:199–233. 20. Mintz B, Russell ES. Gene-induced embryological modifications of primordial germ cells in the mouse. J Exp Zool 1957;134:207–237. 21. Besmer P, Manova K, Duttlinger R, Huang EJ, Packer A, Gyssler C, et al. The kit-ligand (steelfactor) and its receptor c-kit/W: pleiotropic roles in gametogenesis and melanogenesis. Development (Suppl) 1993:125–137.
84
Elvin and Matzuk
22. Beck ARP, Miller IJ, Anderson P, Streuli M. RNA-binding protein TIAR is essential for primordial germ cell development. Proc Natl Acad Sci USA 1998;95:2331–2336. 22a. Schneider-Gaddicke A, Beer-Romano P, Rown LG, Nussbaum R, Pge DC. ZFX has a gene structure similar to ZFY, the putative human sex determinant, and escapes X inactivation. Cell 1989;57:1247–1258. 23. Luoh S-W, Bain PA, Polakiewicz RD, Goodheart ML, Gardner H, Jaenisch R, et al. Zfx mutation results in small animal size and reduced germ cell number in male and female mice. Development 1997;124:2275–2284. 24. Handel MA, Eppig JJ. Sertoli cell differentiation in the testes of mice genetically deficient in germ cells. Biol Reprod 1979;20:1031–1038. 25. Pellas TC, Ramachandran B, Duncan M, Pan SS, Marone M, Chada K. Germ-cell deficient (gcd), an insertional mutation manifested as infertility in transgenic mice. Dev Biol 1991;88:8787–8791. 26. Vainio S, Heikkila M, Kispert A, Chin N, McMahon AP. Female development in mammals is regulated by Wnt-4 signalling. Nature 1999;397:405–409. 27. Parr BA, McMahon AP. Sexually dimorphic development of the mammalian reproductive tract requires Wnt-7a. Nature 1998;395:707–710. 28. Edelmann W, Cohen PE, Kneitz B, Winand N, Lia M, Heyer J, et al. Mammalian MutS homologue 5 is required for chromosome pairing in meiosis. Nat Genet 1999;21:123–127. 29. deVries SS, Baart EB, Dekker M, Siezen A, Rooij DGd, Boer Pd, et al. Mouse MutS-like protein Msh5 is required for proper chromosome synapsis in male and female meiosis. Genes Dev 1999;13:523–531. 30. Pittman DL, Cobb J, Schimenti KJ, Wilson LA, Cooper DM, Brignull E, et al. Meiotic prophase arrest with failure of chromosome synapsis in mice deficient for Dmc1, a germline-specific RecA homolog. Mol Cell 1998;1: 697–705. 31. Yoshida K, Kondoh G, Matsuda Y, Habu T, Nishimune Y, Morita T. The mouse RecA-like gene Dmc1 is required for homologous chromosome synapsis during meiosis. Mol Cell 1998;1:707–718. 32. Edelmann W, Cohen PE, Kane M, Lau K, Morrow B, Bennett S, et al. Meitoic pachytene arrest in MLH1-deficient mice. Cell 1996;85:1125–1134. 33. Chen M, Tomkins DJ, Auerbach W, McKerlie C, Youssoufian H, Liu L, et al. Inactivation of Fac in mice produces inducible chromosomal instability and reduced fertility reminiscent of Fanconi anaemia. Nat Genet 1996;12:448–451. 34. Whitney MA, Royle G, Low MJ, Kelly MA, Axthelm MK, Reifsteck C, et al. Germ cell defects and hematopoietic hypersensitivity to g-interferon in mice with a targeted disruption of the fanconi anemia C gene. Blood 1996;88:49–58. 35. Barlow C, Hirotsune S, Paylor R, Liyanage M, Eckhaus M, Collins F, et al. Atm-deficient mice: a paradigm of ataxia telangiectasia. Cell 1996;86:159–171. 36. Barlow C, Liyanage M, Moens PB, Tarsounas M, Nagashima K, Brown K, et al. Atm deficiency results in severe meiotic disruption as early as leptonema of prophase I. Development 1998;125:4007–4017. 37. Hirshfield AN. Development of follicles in the mammalian ovary. Intl Rev Cytol 1991;124:43–101. 38. Hirshfield AN. Granulosa cell proliferation in very small follicles of cycling rats studied by longterm continuous tritiated-thymidine infusion. Biol Reprod 1989;41:309–316. 39. Peters H, Byskov AG, Himelstein-Braw R, Faber M. Follicular growth: the basic event in the mouse and human ovary. J Reprod Fertility 1975;45:559–566. 40. Liang L-F, Soyal S, Dean J. FIG_, a germ cell specific transcription factor involved in the coordinate expression of the zona pellucida genes. Development 1997;124:4939–4947. 41. Rankin T, Soyal S, Dean j. The mouse zona pellucida: folliculogenesis, fertility, and pre-implantation development. Mol Cell Endocrinol 2000;163:21–25. 42. Liu C, Litscher ES, Mortillo S, Sakai Y, Kinloch RA, Stewart, CL, et al. Targeted disruption of the mZP3 gene results in production of eggs lacking a zona pellucida and infertility in male mice. Proc Natl Acad Sci USA 1996;93:5431–5436. 43. Rankin T, Familari M, Lee E, Ginsberg A, Dwyer N, Blanchette-Mackie J, et al. Mice homozygous for an insertional mutation in the Zp3 gene lack a zona pellucida and are infertile. Development 1996;122:2903–2910. 44. Rankin T, Talbot P, Lee E, Dean J. Abnormal zonae pellucidae in mice lacking ZP1 result in early embryonic loss. Development 1999;126:3847–3855. 45. Perez GI, Robles R, Knudson CM, Flaws JA, Korsmeyer SJ, Tilly JL. Prolongation of ovarian lifespan into advanced chronological age by Bax-deficiency. Nat Genet 1999;21:200–203.
Chapter 4/Control of Ovarian Function
85
46. Ratts VS, Flaws JA, Kolp R, Sorenson CM, Tilly JL. Ablation of bcl-2 gene expression decreases the numbers of oocytes and primordial follicles established in the post-natal female mouse gonad. Endocrinology 1995;136:3665–3668. 47. Kumar TR, Wang Y, Lu N, Matzuk MM. Follicle stimulating hormone is required for ovarian follicle maturation but not male fertility. Nat Genet 1997;15:201–204. 48. Cattanach BM, Iddon CA, Charlton HM, Chiappa SA, Fink G. Gonadotrphin-releasing hormone deficiency in a mutant mouse with hypogonadism. Nature 1977;269:338–340. 49. Motro B, Bernstein A. Dynamic changes in ovarian c-kit and steel expression during the estrous reproductive cycle. Dev Dyn 1993;197:69–79. 50. Manova K, Huang EJ, Angeles M, DeLeon V, Sanchez S, Pronovost SM, et al. The expression of the c-kit ligand in gonads of mice supports a role for the c-kit receptor in oocyte growth and in proliferation of spermatogonia. Dev Biol 1993;157:85–99. 51. Beechey CV, Loutit JF, Searle AG. Panda, a new steel allele. Mouse News Lett 1986;74:92. 52 Kuroda H, Terada N, Nakayama H, Matsumoto K, Kitamura Y. Infertility due to growth arrest of ovarian follicles in the Sl/Slt mice. Dev Biol 1988;126:71–79. 53. Huang EJ, Manova K, Packer AI, Sanchez S, Bachvarova RF, Besmer P. The murine steel panda mutation affects kit ligand expression and growth of early ovarian follicles. Dev Biol 1993;157:100–109. 54. Bedell MA, Brannan CI, Evans EP, Copeland NG, Jenkins NA. DNA rearrangements located over 100 kb 5' of the Steel (Sl)-coding region in Steel-panda and Steel-contrasted mice deregulate Sl expression and cause female sterility by disrupting ovarian follicle development. Genes Dev 1995;9:455–470. 55. Yoshida H, Takakura N, Kataoka H, Kunisada T, Okamura H, Nishikawa S-I. Stepwise requirement of c-kit tyrosine kinase in mouse ovarian follicle development. Dev Biol 1997;184:122–137. 56. McGrath SA, Esquela AF, Lee S-J. Oocyte-specific expression of growth/differentiation factor-9. Mol Endocrinol 1995;9:131–136. 57. Elvin JA, Clark AT, Wang P, Wolfman NM, Matzuk MM. Paracrine actions of growth differentiation factor-9 in the mammalian ovary. Mol Endocrinol 1999;13:1035–1048. 58. Elvin JA, Yan C, Wang P, Nishimori K, Matzuk MM. Molecular characterization of the follicle defects in the growth differentiation factor-9-deficient ovary. Mol Endocrinol 1999;13:1018–1034. 59. Elvin JA, Yan C. Matzuk MM. Oocyte-expressed TGF-` superfamily members in female fertility. Mol Cell Endocrinol 2000;159:1–5. 60. Dong J, Albertini DF, Nishimori K, Kumar TR, Lu N, Matzuk MM. Growth differentiation factor9 is required during early ovarian folliculogenesis. Nature 1996;383:531–535. 61. Carabatsos MJ, Elvin JA, Matzuk MM, Albertini DF. Characterization of oocyte and follicle development in growth differentiation factor-9-deficient mice. Dev Biol 1998;203:373–384. 62. Magoffin DA. Regulation of differentiated functions in ovarian theca cells. Sem Reprod Endocrinol 1991;9:321–331. 63. Magarelli PC, Zachow RJ, Magoffin DA. Developmental and hormonal regulation of rat theca-cell differentiation factor secretion in ovarian follicles. Biol Reprod 1996;55:416–420. 64. Everett JW. Pituitary and Hypothalamus: perspectives and overview. In: Knobil E, Neill J, eds., The Physiology of Reproduction, Raven Press, New York, NY, 1994, pp. 1509–1526. 65. Mason AJ, Hayflick JS, Zoeller RT, III, Young WS, Phillips HS, Nikolics K, et al. A deletion truncating the gonadotropin-releasing hormone gene is responsible for hypogonadism in the hpg mouse. Science 1986;234:1366–1371. 66. Radovick S, Wray S, Lee E, Nicols DK, Nakayama Y, Weintraub BD, et al. Migratory arrest of gonadotropin-releasing hormone neurons in transgenic mice. Proc Natl Acad Sci USA 1991;88:3402–3406. 67. Layman LC, Cohen DP, Jin M, Xie J, Li Z, Reindollar RH, et al. Mutations in gonadotropin-releasing hormone receptor gene cause hypogonadotropic hypogonadism. Nat Genet 1998;18:14,15. 68. Rao MC, Midgley AR, Richards JS. Hormonal regulation of ovarian cellular proliferation. Cell 1978;14:71–78. 69. Pedersen,T. Follicle Growth in the Mouse Ovary. In: Bigger JD, Schuetz AW, eds., Oogenesis, University Park Press, Baltimore, MD, 1972, pp. 361–376. 70. Kumar TR, Low MJ, Matzuk MM. Genetic rescue of follicle-stimulating hormone `-deficient mice. Endocrinology 1998;139:3289–3295. 71. Dierich A, Sairam MR, Monaco L, Fimia GM, Gansmuller A, LeMeur M, et al. Impairing folliclestimulating hormone (FSH) signaling in vivo: Targeted disruption of the FSH receptor leads to aberrant gametogenesis and hormonal imbalance. Proc Natl Acad Sci USA 1998;95:13,612–13,617.
86
Elvin and Matzuk
72. Aittomaki K, Lucena JLD, Pakarinen P, Sistonen P, Tapanainen J, Gromoll J, et al. Mutation in the follicle stimulating hormone receptor gene causes hereditary hypergonadotropic ovarian failure. Cell 1995;82:959–968. 73. Beau I, Touraine P, Meduri G, Gougeon A, Desroches A, Matuchansky C, et al. A novel phenotype related to partial loss of function mutations of the follicle stimulating hormone receptor. J Clin Invest 1998;102:1352–1359. 74. Baker J, Hardy MP, Zhou J, Bondy C, Lupu F, Bellvé AR, et al. Effects of an Igf1 gene null mutation on mouse reproduction. Mol Endocrinol 1996;10:903–918. 75. Zhou J, Kumar TR, Matzuk MM, Bondy C. Insulin-like growth factor I regulates gonadotropin responsiveness in the murine ovary. Mol Endocrinol 1997;11:1924–1933. 76. Burks DJ, deMora JF, Schubert M, Winters DJ, et al. IRS-2 pathways integrate female reproduction and energy homeostasis. Nature 2000;407:377–382. 77. Robker RL, Richards JS. Hormone-induced proliferation and differentiation of granulosa cells: a coordinated balance of the cell cycle regulators cyclin D2 and p27KIP1. Mol Endocrinol 1998;12:924–940. 78. Elledge SJ. Cell cycle checkpoints: preventing an identity crisis. Science 1996;274:1664–1672. 79. Sicinski P, Donaher JL, Gene Y, Parker SB, Gardner H, Park MY, et al. Cyclin D2 is an FSH-responsive gene involved in gonadal cell proliferation and oncogenesis. Nature 1996;384:470–474. 80. Robker RL, Richards JS. Hormonal control of the cell cycle in ovarian cells: proliferation versus differentiation. Biol Reprod 1998;59:476–482. 81. Vale W, Bilezikjian LM, Rivier C. Reproductive and other roles of inhibins and activins. In: Knobil E, Neill J, eds., The Physiology of Reproduction, Raven Press, New York, NY, 1994, pp. 1861–1878. 82. Meunier H, Cajander SB, Roberts VJ, Rivier C, Sawchenko PE, Hsueh AJW, et al. Rapid changes in the expression of inhibin a-, bA-, and bB-subunits in ovarian cell types during the rat estrous cycle. Mol Endocrinol 1998;2:1352–1363. 83. Matzuk MM, Kumar TR, Shou W, Coerver KA, Lau AL, Behringer RR, et al. Transgenic models to study the roles of inhibins and activins in reproduction, oncogenesis, and development. Recent Prog Hormone Res 1996;51:123–157. 84. Matzuk MM, Finegold MJ, Su J-GJ, Hsueh AJW, Bradley A. a-Inhibin is a tumor-suppressor gene with gonadal specificity in mice. Nature 1992;360:313–319. 85. Coerver KA. Activin function in Cachexia-like syndrome and gonadal tumor development in inhibindeficient mice. In: Molecular and Human Genetics, Puglisher, Houston, TX, 1996, p. 161. 86. Gershenson DM. Ovarian germ cell and stromal tumors, In: Greer BE and Berek JS, eds., Gynecologic Oncology: Treatment Rationale and Technique. Elevier Publishing, New York, NY, 1991; pp. 167–184. 87. Kumar TR, Palapattu G, Wang P, Woodruff TK, Boime I, Byrne MC., et al. Transgenic models to study gonadotropin function: the role of follicle-stimulating hormone in gonadal growth and tumorigenesis. Mol Endocrinol 1999;13:851–865. 88. Kumar TR, Wang Y, Matzuk MM. Gonadotropins are essential modifier factors for gonadal tumor development in inhibin-deficient mice. Endocrinology 1996;137:4210–4216. 89. Risma KA, Clay CM, Nett TM, Wagner T, Yun J, Nilson JH. Targeted overexpression of luteinizing hormone in transgenic mice leads to infertility, polycystic ovaries, and ovarian tumors. Proc Natl Acad Sci USA 1995;92:1322–1326. 90. Matzuk MM, Kumar TR, Bradley A. Different phenotypes for mice deficient in either activins or activin receptor type II. Nature 1995;374:356–360. 91. Guo Q, Kumar TR, Woodruff T, Hadsell LA, DeMayo FJ, Matzuk MM. Overexpression of mouse follistatin causes reproductive defects in transgenic mice. Mol Endocrinol 1998;12:96–106. 92. Liu X, Andoh K, Abe Y, Kobayashi J, Yamada K, Mizunuma H, Ibuki Y. A comparative study on transforming growth factor-beta and activin A for preantral follicles from adult, immature, and diethylstilbestrol-primed immature mice. Endocrinology 1999;140:2480–2485. 93. Fisher CR, Graves KH, Parlow AF, Simpson ER. Characterization of mice deficient in aromatase (ArKO) because of targeted disruption of the cyp19 gene. Proc Natl Acad Sci USA 1998;95:6965–6970. 94. Britt KL, Drummond AE, Cox VA, Dyson M, Wreford NG, Jones MEE, et al. An age-related ovarian phenotype in mice with targeted disruption of the Cyp19 (aromatase) gene. Endocrinology 2000;141:2514–2623. 95. Schomberg DW, Couse JF, Mukherjee A, Lubahn DB, Sar M, Mayo KE, Korach KS. Targeted disruption of the estrogen receptor-a gene in female mice: characterization of ovarian responses and phenotype in the adult. Endocrinology 1999;140:2733–2744.
Chapter 4/Control of Ovarian Function
87
96. Byers M, Kuiper GG, Gustafsson JA, Park-Sarge OK. Estrogen receptor-beta mRNA expression in rat ovary: down-regulation by gonadotropins. Molecular Endocrinology 1997;11:172–182. 97. Lubahn DB, Moyer JS, Golding TS, Couse JF, Korach KS, Smithies O. Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene. Proc Natl Acad Sci USA 1993;90:11,162–11,166. 98. Krege JH, Hodgin JB, Couse JF, Enmark E, Warner M, Mahler JF, et al. Generation and reproductive phenotypes of mice lacking estrogen receptor b. Proc Natl Acad Sci USA 1998;95:15,677–15,682. 99. Couse JF, Hewitt SC, Bunch DO, Sar M, Walker VR, Davis BJ, et al. Postnatal sex reversal of the ovaries in mice lacking estrogen receptors a and b. Science 1999;286:2328–2331. 100. Behringer RR, Cate RL, Froelick GJ, Palmiter RD, Brinster RL. Abnormal sexual development in transgenic mice chronically expressing Müllerian-inhibiting substance. Nature 1990;345:167–170. 101. Richards JS, Fitzpatrick SL, Clemens JW, Morris JK, Alliston T, Sirois J. Ovarian cell differentiation: A cascade of multiple hormones, cellular signals, and regulated genes. Recent Prog Hormone Res 1995;50:223–254. 102. Espey LL, Lipner H. Ovulation. In: Knobil E, Neill J, eds., The Physiology of Reproduction, Raven Press, New York, NY, 1994, pp. 725–780. 103. Lee SL, Sadovsky Y, Swirnoff AH, Polish JA, Goda P, Gavrilina G, et al. Luteinizing hormone deficiency and female infertility in mice lacking the transcription factor NGFI-A (Egr-1). Science 1996;273:1219–1221. 104. Topilko P, Schneider-Maunory S, Levi G, Trembleau A, Gourdji D, et al. Multiple pituitary and ovarian defects in Krox-24 (NGFI-A, EGR-1)-targeted mice. Mol Endocrinol 1997;12:107–122. 105. Sirois J, Simmons DL, Richards JS. Hormonal regulation of messenger ribonucleic acid encoding a novel isoform of prostaglandin endoperoxide H synthase in rat preovulatory follicles. J Biol Chem 1992;267:11,586–11,592. 106. Dinchuk JE, Car BD, Focht RJ, Johnston JJ, Jaffee BD, Covington MB, et al. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature 1995;378:406–409. 107. Lim H, Paria BC, Das SK, Dinchuk JE, Langenbach R, Trzaskos JM, Dey SK. Multiple female reproductive failures in cyclooxygenase 2-deficient mice. Cell 1997;91:197–208. 108. Kennedy CRJ, Zhang Y, Brandon S, Guan Y, Coffee K, Funk CD, et al. Salt-sensitive hypertension and reduced fertility in mice lacking the prostaglandin EP2 receptor. Nat Med 1999;5:217–220. 109. Tilley SL, Audoly LP, Hicks EH, Kim H-S, Flannery PJ, Coffman TM., et al. Reproductive failure and reduced blood pressure in mice lacking the EP2 prostaglandin E2 receptor. J Clin Invest 1999;103:1539–1545. 110. Hizaki H, Segi E, Sugimoto Y, Hirose M, Saji T, Ushikubi F, et al. Abortive expansion of the cumulus and impaired fertility in mice lacking the prostaglandin E receptor subtype EP(2). Proc Natl Acad Sci USA 1999;96:10,501–10,506. 111. Viggiano JM, Herrero MB, Cebral E, Boquet MG, Gimeno MFd. Prostaglandin synthesis by cumulus-oocyte complexes: effects on in vitro fertilization in mice. Prostaglandins, Leukotrienes and Essential Fatty Acids 1995;53:261–265. 112. Sirois J, Richards JS. Transcriptional regulation of the rat prostaglandin endoperoxide synthase 2 gene in granulosa cells: evidence for the role of a cis-acting C/EBPb promoter element. J Biol Chem 1993;268:21,931–21,938. 113. Sterneck E, Tessarollo L, Johnson PF. An essential role for C/EBPb in female reproduction. Genes Dev 1997;11:2153–2162. 114. Natraj U, Richards JS. Hormonal regulation, localization, and functional activity of the progesterone receptor in granulosa cells of rat preovulatory follicles. Endocrinology 1993;133:761–769. 115. Park-Sarge OK, Mayo KE. Regulation of the progesterone receptor gene by gonadotropins and cyclic adenosine 3',5'-monophosphate in rat granulosa cells. Endocrinology 1994;134:709–718. 116. Lydon JP, DeMayo FJ, Funk CR, Mani SK, Hughes AR, Montgomery CA, et al. Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. Genes Dev 1995;9:2266–2278. 117. Fero ML, Rivkin M, Tasch M, Porter P, Carow CE, Firpo E, et al. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27Kip1-deficient mice. Cell 1996;85:733–744. 118. Kiyokawa H, Kineman RD, Manova-Todorova KO, Soares VC, Hoffman ES, Ono M, et al. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27Kip1. Cell 1996;85:721–732. 119. Tong W, Kiyokawa H, Soos TJ, Park MS, Soares VC, Manova K, et al. The absence of p27Kip1, an inhibitor of G1 cyclin-dependent kinases, uncouples differentiation and growth arrest during the granulosa -> luteal transition. Cell Growth Differ 1998;9:787–794.
88
Elvin and Matzuk
120. Simon AM, Goodenough DA, Li E, Paul DL. Female infertility in mice lacking connexin 37. Nature 1997;385:525–529. 121. Colledge WH, Carlton MB, Udy GB,Evans MJ. Disruption of c-mos causes parthenogenetic development of unfertilized mouse eggs. Nature 1994;370:65–68. 122. Hashimoto N, Watanabe N, Furuta Y, Tamemoto H, Sagata N, Yokoyama M, Oet al. Parthenogenetic activation of oocytes in c-mos-deficient mice. Nature 1994;370:68–71. 123. Ikeda Y, Luo X, Abbud R, Nilson JH, Parker KL. The nuclear receptor steroidogenic factor-1 is essential for the formation of the ventromedial hypothalamic nucleus. Mol Endocrinol 1995;9:478–486. 124. Juneja SC, Barr KJ, Enders GC, Kidder GM. Defects in the germ line and gonads of mice lacking connexin43. Biol Reprod 1999;60:1263–1270. 125. Bergeron L, Perez GI, Macdonald G, Shi L, Sun Y, Jurisicova A, et al. Defects in regulation of apoptosis in caspase-2-deficient mice. Genes Dev 1998;12:1304–1314. 126. Ruggiu M, Speed R, Taggart M, McKay SJ, Kilanowski F, Saunders P, et al. The mouse Dazla gene encodes a cytoplasmic protein essential for gametogenesis. Nature 1997;389:73–76. 127. Kohrogi T, Yokoyama M, Taguchi T, Kitamura Y, Tutikawa K. Effect of the Slt mutant allele on the production of tissue mast cells in mice. J Hered 1983;74:375–377. 128. Kendall SK, Saunders TL, Jin L, Lloyd RV, Glode LM, Nett TM, et al. Targeted ablation of pituitary gonadotropes in transgenic mice. Mol Endocrinol 1991;5:2025–2036. 129. Kendall SK, Samuelson LC, Saunders TL, Wood RI, Camper SA. Targeted disruption of the pituitary glycoprotein hormone a-subunit produces hypogonadal and hypothyroid mice. Genes Dev 1995;9:2007–2019. 130. Matzuk MM, Dionne L, Guo Q. Kumar TR, Lebovitz RM. Ovarian function in superoxide dismutase 1 and 2 knockout mice. Endocrinology 1998;139:4008–4011. 131. Ho Y-S, Gargano M, Cao J, Bronson RT, Heimler I, Hutz RJ. Reduced fertility in female mice lacking copper-zinc superoxide dismutase. J Biol Chem 1998;273:7765–7769. 132. Good DJ, Porter FD, Mahon KA, Parlow AF, Westphal H, et al. Hypogonadism and obesity in mice with a targeted deletion of the Nhlh2 gene. Nat Genet 1997;15:397–401. 133. Chehab FF, Lim ME, Lu R. Correction of the sterility defect in homozygous obese female mice by treatment with the human recombinant leptin. Nature Genetics 1996;12:318–320. 134. Matzuk MM, Finegold MJ, Mather JP, Krummen L, Lu H, Bradley A. Development of cancer cachexia-like syndrome and adrenal tumors in inhibin-deficient mice. Proc Natl Acad Sci USA 1994;91:8817–8821. 135. Risma KA, Hirshfield AN, Nilson JH. Elevated luteinizing hormone in prepubertal transgenic mice causes hyperandrogenemia, precocious puberty, and substantial ovarian pathology. Endocrinology 1997;138:3540–3547. 136. Korach KS. Insights from the study of animals lacking functional estrogen receptor. Science 1994;266:1524–1527. 137. Couse JF, Curtis SW, Washburn TF, Lindzey J, Golding TS, et al. Analysis of transcription and estrogen insensitivity in the female mouse after targeted disruption of the estrogen receptor gene. Mol Endocrinol 1995;9:1441–1454. 138. Horseman ND, Zhao W, Montecino-Rodriguez E, Tanaka M, Nakashima K, Engle SJ, et al. Defective mammopoiesis, but normal hematopoiesis, in mice with a targeted disruption of the prolactin gene. EMBO J 1997;16:6926–6935. 139. Rane SG, Dubus P, Mettus RV, Galbreath EJ, Boden G, Reddy EP, et al. Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in b-islet cell hyperplasia. Nat Genet 1999;22:44–52. 140. Ormandy CJ, Camus A, Barra J, Damotte D, Lucas B, Buteau H, et al. Null mutation of the prolactin receptor gene produces multiple reproductive defects in the mouse. Genes and Development 1997;11:167–178. 141. Sugimoto Y, Yamasaki A, Segi E, Tsuboi K, Aze Y, Nishimura T, et al. Failure of parturition in mice lacking the prostaglandin F receptor. Science 1997;277:681–683. 142. Teglund S, McKay C, Schuetz E, Deursen JMV, Stravopodis D, Wang D, et al Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell 1998;93:841–850. 143. Topilko P, Schneider-Maunoury S, Levi G, Trembleau A, Gourdji D, Driancourt MA, et al. Multiple pituitary and ovarian defects in Krox-24 (NGFI-A, Egr-1)-targeted mice. Mol Endocrinol 1998;12:107–122.
Chapter 4/Control of Ovarian Function
89
144. Kuno N, Kadomatsu K, Fan Q-W, Hagihara MN, Senda T, Mizutani S, et al. Female sterility in mice lacking the basigin gene, which encodes a transmembrane glycoprotein belonging to the immunoglobulin superfamily. Fed Eur Biochem Sci 1998;425:191–194. 145. Igakura T, Kadomatsu K, Kaname T, Muramatsu H, Fan QW, Miyauchi T, et al. A null mutation in basigin, an immunoglobulin superfamily member, indicates its important roles in peri-implantation development and spermatogenesis. Dev Biol 1998;194:152–165. 146. Xiao X, Zuo X, Davis AA, McMillan DR, Curry BB, Richardson JA, Benjamin IJ. HSF1 is required for extra-embryonic development, postnatal growth and protection during inflammatory responses in mice. EMBO J 1999;18:5943–5952. 147. Robb L, Li R, Hartley L, Nandurkar HH, Koentgen F, Begley CG. Infertility in female mice lacking the receptor for interleukin II is due to a defective uterine response to implantation. Nat Med 1998;4:303–308. 148. Stewart CL, Kaspar P, Brunet LJ, Bhatt H, Gadi I, Kontgen F, Abbondanzo SJ. Blastocyst implantation depends on maternal expression of leukemia inhibitory-function. Nature 1992;359:6–79. 149. Cohen PE, Zhu L, Pollard JW. Absence of colony stimulating factor-1 in osteopetrotic (csfmop/ csfmop) mice disrupts estrous cycles and ovulation. Biol Reprod 1997;56:110–118. 150. Rigotti A, Trigatti BL, Penman M, Rayburn H, Herz J, Krieger M. A targeted mutation in the murine gene encoding the high density lipoprotein (HDL) receptor scavenger receptor class B type I reveals its key role in HDL metabolism. Proc Natl Acad Sci USA 1997;94:12,610–12,615. 151. Trigatti B, Rayburn H, Vinals M, Braun A, Miettinen H, Penman M, et al. Influence of the high density lipoprotein receptor SR-BI on reproductive and cardiovascular pathophysiology. Proc Natl Acad Sci USA 1999;96:9322–9327. 152. Mahendroo MS, Cala KM, Russell DW. 5a-reduced androgens play a key role in murine parturition. Molecular Endocrinology 1996;10:380–392. 153. Mahendroo MS, Cala KM, Landrum CP, Russell DW. Fetal death in mice lacking 5_-reductase type I caused by estrogen excess. Molecular Endocrinology 1997;11:1–11.
Chapter 5/Mouse Models to Study Male Reproduction
5
91
Mouse Models to Study the Pituitary-Testis Interplay Leading to Regulated Gene Expression Emiliana Borrelli, PHD, T. Rajendra Kumar, PHD, and Paolo Sassone-Corsi, PHD CONTENTS INTRODUCTION PITUITARY HORMONES TRANSFORMING GROWTH FACTOR-` FAMILY NUCLEAR RECEPTORS PROLIFERATION AND APOPTOSIS TRANSCRIPTION FACTOR CREM CHAPERONE HSP70-2 CONCLUSIONS ACKNOWLEDGMENTS REFERENCES
INTRODUCTION The past decade has seen the astounding development of transgenic animal technology, which has become the most powerful tool for the study of gene function and dysfunction in vivo. All fields of biology, including endocrinology, oncogenesis, neuroscience, and embryogenesis, have greatly advanced because of the ease in generating genetically modified animals in an increasing number of research laboratories worldwide. The capacity to explore the function of one specific gene in the living animal has particularly enriched our view of complex physiological systems, such as the neuroendocrine axis. In various cases, mutant mice have been developed to verify the presumptive function of previously studied molecules. In others, the generated mutation has revealed unexpected actions of the targeted gene. This chapter focuses on some mutations affecting the male reproductive axis, as these reveal the high complexity of the system and the interplay between the regulation of gene expression and pituitary signaling. The aim of this chapter is not to provide an exhaustive list of all mice presenting defects in male gametogenesis, but to present a selected number of representative examples. From: Contemporary Endocrinology: Transgenics in Endocrinology Edited by: M. Matzuk, C. W. Brown, and T. R. Kumar © Humana Press Inc., Totowa, NJ
91
92
Borrelli et al.
A large number of transgenic mice present alterations in the differentiation of germ cells. In many cases, the phenotype observed is the result of random insertion of the transgene in the genome, with the consequent inactivation of one or more genes affecting gametogenesis function. Since 10% of all transgenic insertion mutations are associated with male infertility (1), this suggests that a significant proportion of cases of human male infertility may have a genetic origin, and that a large number of genes must be implicated in the process of germ-cell differentiation. The advent of targeted mutagenesis techniques has allowed a precise analysis of the physiological role of gene dysfunction. The use of homologous recombination is now a popular approach. For example, from 1989 to 1995, over 327 genes have been “knocked-out” and the number is growing exponentially every year (2). Tables 1 and 2 summarize some of the knockout mouse models with reproductive defects either only in males or in both males and females. Gametogenesis is a complex and highly regulated process, during which stem cells undergo multiple steps of differentiation (see Chapter 7). This program is under tight control from multiple hormones, many of which originate from the hypothalamo-pituitary axis (3). In the male, spermatogenesis occurs in the seminiferous epithelium as a finely tuned, cyclic process that can be divided into three phases: spermatogonial multiplication, meiosis, and spermiogenesis (4,5). Histological, physiological, and biochemical studies have provided a wealth of information on the mechanisms controlling spermatogenesis, but many components of this differentiation cascade still remain obscure. Several lines of evidence indicate that highly specialized transcriptional mechanisms ensure stringent stage-specific gene expression in the germ cells. Specific checkpoints correspond to the activation of transcription factors; these regulate gene promoters with a restricted pattern of activity, in a germ-cell-specific fashion (6). There is also evidence that general transcription factors may be differentially regulated in germ cells. For example, TBP (TATA-binding protein) accumulates in early haploid germ cells at much higher levels than in any other somatic-cell type. It has been calculated that adult spleen and liver cells contain 0.7 and 2.3 molecules of TBP mRNA per haploid genome-equivalent, respectively, while adult testis contain 80–200 molecules of TBP transcript per haploid genome-equivalent (7). In addition to TBP, TFIIB and RNA polymerase II were also found to be overexpressed in testis. These remarkable features are consistent with the potent transcriptional activity that occurs in a coordinated manner during the differentiation of germ cells.
PITUITARY HORMONES Spermatogenesis is under the hormonal control of the hypothalamo-pituitary axis (3). Gonadotropin-releasing hormone (GnRH) is released from the hypothalamus into the hypothalamo-pituitary vein, and stimulates the release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the gonadotroph cells of the anterior pituitary. FSH and LH bind to receptors located respectively on the somatic Sertoli and Leydig cells of the testis. Pituitary gonadotropins (FSH and LH) and thyroid-stimulating hormone thyrotropin (TSH) are heterodimers composed of a common _-subunit (_-GSU) and a unique `-subunit. Disruption of the gene for the _-subunit has resulted in mice that did not produce FSH, LH, or TSH. The homozygous mutant mice are hypogonadal, and suffer from severe hypothyroidism resulting in dwarfism (8). The _-subunit-deficient male mice are infer-
Chapter 5/Mouse Models to Study Male Reproduction
93
Table 1 Knockout Models with Reproductive Defects Only in Males Knockout mouse model
Major reproductive findings
Acrosin
Delayed fertility, normal binding and (85) penetration of ZP by sperm Infertile; progressive degeneration of the (86) testicular germinal epithelium Reduced fertility caused by decreased ability (87) of sperm to fertilize ova Only 5% of the mutants survive to adulthood; (88) males infertile; spermatogonial degeneration Reduced fertility; spermatozoa fertilization defects (89) Infertile; spermatogenesis block at premeiotic stage (61) Infertile; spermatogenesis block during late (90) spermatogenesis; eventual loss of all germ cells and Sertoli cells Progressive infertility; germ-cell degeneration, (91) spermiogenesis defects, and epididymis degeneration Infertile; germ-cell proliferation/depletion defects (92) Infertile; meiotic failure (93) Infertility due to impairment of sperm (94) binding to ZP Infertile; oligospermia and globozoospermia (95) Infertile; defect in volume regulatory (96) mechanism in mature sperm, sperm flagellar angulation Infertile; block at first stage of spermiogenesis (75,76) Reduced fertility, failure of corpora cavernosa (97) to relax on activation of the NO/cGMP signaling Infertile; block of spermatogenesis before (65) first meiotic division, increased germ-cell apoptosis Infertile; failure of sperm to bind to the ZP (98) Infertile; defects in germ cell development (99) Infertile; defects in sperm-egg adhesion, fusion and ZP binding (100) Normal fertility, macroorchidism due to increased (101) embryonic Sertoli-cell proliferation Infertile; depletion of stem-cell reserves (102) Infertile; vacuolated epithelial cells in tubules, (103) oligospermia Defects in formation of the seminal vesicles, (104) ventral and dorsal prostate, and bulbourethral gland Infertile; possible defect in histone poly (105) ubiquitination and degradation during spermatogenesis
Ahch (Dax1) Angiotensin-converting enzyme Apaf-1 Apolipoprotein B heterozygotes Bax Bclw
Bone morphogenetic protein 8A
Bone morphogenetic protein 8B BRCA-1, p53 double mutant Calmegin Casein kinase II alpha' c-ros tyrosine kinase receptor
CREM Cyclic GMP-dependent kinase 1
Cyclin A1
Cyritestin Desert hedgehog Fertilin b Fragile X mental retardation 1 (FMR1) GDNF Hormone-sensitive lipase Hoxd-13
HR6B Ubiquitin-conjugating enzyme
Refs
(continued)
94
Borrelli et al. Table 1 (continued)
Knockout mouse model
Major reproductive findings
Refs
Hsp70
Infertile; block at meiotic prophase and increased spermatocyte apoptosis Granulosa-/Sertoli-cell tumors; Leydig-cell neoplasia; large fluid-filled uteri; complete infertility Marked testicular atrophy, increased germ-cell apoptosis, although fertile Infertile; hormonal imbalance, abnormalities in sperm head and flagellum Uteri in males causes obstruction and secondary infertility in majority of mice Partial fertility; presence of Müllerian duct causing physical blockage Infertile; reduced spermatids, defects in epididymal transport of sperm Infertile; absence of intramembranous tight junctions between Sertoli cells Reduced fertility; hypogenitalism Reduced fertility, oligospermia, defects in contraction of the vas deferens Infertile; impaired fertilizing ability of spermatozoa Infertile; decreased proliferation and enhanced apoptosis of spermatogonial cells Infertile; meiosis defects leading to abnormal spermatozoa Infertile; defects in spermiogenesis Male infertility secondary to germ-cell mutation defects and tubular degeneration Male sterility secondary to squamous metaplasia of the seminal vesicles and prostate Male infertility secondary to seminiferous tubule degeneration Infertile; defects in synapsis, apoptosis during meiotic prophase Infertility caused by defects in male reproductive behavior Subfertile despite normal testicular morphology and sperm number Infertile; defects in pairing in premeiotic spermatocytes Reduced fertility; abnormal pattern of chromatin condensation and a severe reduction in sperm motility Infertile; progressive death of differentiating germ cells, absence of mature sperm Infertile; defects in proliferation and differentiation of primordial germ cells, absence of sperm in the testes
(82)
Inhibin/MIS double mutants
INK4d JunD Müllerian-inhibiting substance Müllerian-inhibiting substance receptor Na(+)-K(+)-2Cl(-) cotransporter Osp-11 (Claudin-11) Ovo P2X1 receptor PC4 Pi3'-kinase (cKit receptorinduced) PMS2 DNA mismatch repair enzyme Protein phosphatase 1ca Retinoic acid receptor ` Retinoic acid receptor a Retinoid receptor _ SCP3 Sp4 Sperm-1 TLS Tnp1 Tyro-3 family receptors Vasa
(32)
(106) (107) (18) (108) (109) (110) (111) (112) (113) (114) (115) (116) (46) (117) (44) (118) (119) (120) (121) (122) (123) (124)
Chapter 5/Mouse Models to Study Male Reproduction
95
Table 2 Knockout Models with Reproductive Defects in Both Sexes Knockout mouse model
Major reproductive findings
Refs
_-inhibin
Infertility in females; secondary infertility (27,30) in males; granulosa-/Sertoli-cell tumors; cachexia-like
syndrome Activin receptor type II
Infertility in females; delayed fertility in males; (125) small gonads A-myb Male infertility; pachytene stage arrest of germ (126) cells; nursing defects in females due to underdevelopment of mammary glands Ataxia telangiectasia (Atm) Male and female infertility; complete absence (127,128) of germ cells `1,4-Galactosyltransferase Male and female infertility caused by abnormal (129) glycoprotein hormone glycosylation Centromere protein B Males hypogonadal, decreased sperm number (130,131) strain-dependent uterine defects in females, disrupted luminal and glandular epithelium in the uterus, reduced fertility Cyclin D2 Female infertility secondary to a block in (64) folliculogenesis; males fertile but with decreased testis size Cyp 19 Progressive infertility, spermiogenic defects, (132,133) Leydig-cell hyperplasia in males, females infertile, increased follicular atresia prior to ovulation, defects in mammary gland development Dazla Male and female infertility; loss of germ cells (134) and complete absence of gamete production Dmc1 Arrest of spermatogenesis at zygotene stage (135,136) in males; no oocytes in the adult ovary Emx2 Accelerated degeneration of Wolffian-duct (137) and mesonephric tubules without the formation of the Müllerian duct ER` No defect in male fertility, prostate hyperplasia (50) in old males; decreased fertility in females Estrogen receptor _ (ER_) Uterine/ovarian defects in females; small (47,49,51) testes, reduced number of spermatozoa in males Estrogen receptor _/` double Male phenotypes similar to ER_ mice, (51) knockout sex-reversal at the gonad level in females Follicle-stimulating hormone Female infertility; folliculogenesis block (9) ` subunit prior to antral follicle stage; males fertile but with decreased testis size Glycoprotein hormone _-subunit Infertile; hypogonadal and hypothyroid (8) Hoxa 11 Partial homeotic transformation of vas (138) deferens to epididymis; failure of testicular descent; absence of uterine stromal, decidual, and glandular cells in females (continued)
96
Borrelli et al. Table 2 (continued)
Knockout mouse model
Major reproductive findings
Hoxa10
Variable infertility in males and females (139) caused by cryptorchidism and preimplantation embryonic loss, respectively Hypogonadal and infertile; pre-antral block (140) in folliculogenesis in females Male and female infertility; Defective meiosis (141) at pachytene stage (males) and failure to complete meiosis II (females) Male and female infertility; defects in zygotene (142) stage in both sexes, characterized by impaired and aberrant chromosome synapsis, apoptotic cell death Males infertile; females fertile only in (143) presence of males; hypothalamic defect Female infertility; corpus luteum defects; (144–146) males fertile and increased testis size Female infertility caused by multiple (147) abnormalities including irregular estrous cycles and implantation defects; males infertile or subfertile of unknown origin Male and female infertility; impaired (148) spermatogenesis with vacuolar degeneration of seminiferous tubules in males; postimplantation defects in females Progressive infertility in males and females; (149) increased apoptosis in testicular germ cells, and reduced testis size; decreased number of oocytes and uterine abnormalities Infertility; complete absence of primordial (150) germ cells by E 13.5 leading to absence of spermatogonia and oogonia Reduced germ-cell number in both sexes (151) resulting from defective proliferation
Insulin-like growth factor (IGF-1) MLH1 DNA mismatch repair enzyme Msh5
Neuronal helix-loop-helix 2 (Nhlh2) Kip1 p27 CDK inhibitory protein Prolactin receptor
Rho GDIalpha
Telomerase
TIAR
Zfx
Refs
tile and exhibit prepubertal external genitalia. The testes are severely reduced in size, but the epididymis and vas deferens are present. The presence of normal prepubertal genitalia support the hypothesis that the differentiation of these structures from the Wolffian duct is testosterone-dependent. LH stimulates testosterone secretion from Leydig cells, and serum-testosterone concentrations are severely reduced in _-GSU–/– mice. However, these low concentrations of testosterone are still sufficient to induce sexual differentiation. Histological examination of _-GSU–/– testis showed that the seminiferous tubules are reduced in diameter, and that spermatogenesis is blocked at the first meiotic division. Therefore, these results indicate that gonadotropins are necessary for postnatal testicular differentiation, but that testis development proceeded normally during the fetal period. This view has been validated by other mouse models.
Chapter 5/Mouse Models to Study Male Reproduction
97
Mice carrying a targeted mutation in the FSH` subunit gene have been generated (9). Mutant females are infertile because of a block in folliculogenesis prior to antral-follicle formation. Importantly, and in contrast to the classical view of the FSH requirement for spermatogenesis and Sertoli-cell growth, FSH`-deficient males are fertile, despite their small testes. The critical role played by FSH signaling is illustrated by the effect of FSHR mutations in humans (10–12). An inactivating mutation (Ala189Val) found in females with pure ovarian dysgenesis leads to a disease characterized by normal karyotype, high gonadotropins, and streaky gonads associated with primary amenorrhea. More recently, additional mutations have been described (Asp224Val and Leu601Val) that are associated to a similar pathological condition (13). These mutations lie either in the extracellular domain (Ala189Val and Asp224Val) or in the third extracellular loop (Leu601Val) of the FSH-R, and are believed to modify protein folding. Importantly, males with the Ala189Val mutation display various degrees of spermatogenic failure, without azoospermia or absolute infertility (14). Thus, the same inactivating mutation differentially influences reproduction in males or females. A more recent approach, aimed at altering FSH signaling at the target tissue, has been to mutate the gene encoding the FSH receptor (15). Similar to the FSH` mutant mice, FSH-R-deficient males display small testes, partial spermatogenic failure, and reduced fertility. Thus, it appears that FSH signaling is not essential for initiating spermatogenesis, but is required to sustain adequate viability and motility of the sperm. The phenotype of mutant females is much more severe. These display thin uteri and small ovaries, and are sterile as a result of a block in folliculogenesis prior to antral-follicle formation. Drastic changes have been found in pituitary hormone levels, especially FSH, which is increased 15- to 20-fold in females and about threefold in males. This dramatic increase in FSH levels verifies the classical view of FSH signaling retroinhibition, underscoring the apparent simplicity of the system in which no alternative retroinhibitory routes seem to be activated by the lack of FSH signaling (15). Additional hormonal changes include a significant decrease in the levels of testosterone in the males. This result indicates that low testoterone levels are sufficient to sustain sex accessories, and indicates a link between FSH signaling and testosterone production. This link could involve an intracellular communication pathway that would be compromised, despite normal LH levels, in the FSH-R mutants. At the level of the pituitary gland, there is a moderate but significant enlargement in the anterior lobe, accompanied by a drastic increase of FSH-positive cells. These animals have been considered as possible models for the study of the physiological link between gonads and pituitary, and hypergonadotropic ovarian dysgenesis and infertility. A mouse model to study aberrant LH signaling has not yet been developed. However, mice with a targeted mutation in the LH-receptor gene would constitute an invaluable tool to explore the link between pituitary-hormonal signaling and sexual differentiation. In this respect, it is important to note that homozygous missense mutations in the LH-R gene in humans are tightly associated with male pseudohermaphroditism (16).
TRANSFORMING GROWTH FACTOR-` FAMILY Müllerian-Inhibiting Substance During mammalian embryogenesis, the Müllerian ducts have the potential to differentiate into the oviducts, uterus, and upper vagina of the female reproductive tract, while
98
Borrelli et al.
the Wolffian ducts differentiate into the vas deferens, epididymis, and seminal vesicles in the male. During male development, the Sertoli cells of the testis produce Müllerianinhibiting substance (MIS), a protein that actively represses the differentiation of the Müllerian ducts and prevents the development of female reproductive organs (17). Subsequently, testosterone produced by the Leydig cells induces the differentiation of the Wolffian ducts into male external genitalia. The MIS protein is a member of the transforming growth factor-` (TGF`) gene superfamily which also includes the activin and inhibin genes. The MIS gene has been mutated in the mouse by homologous recombination. The testis of MIS–/– males descend normally, their size is normal, and the Wolffian duct system differentiates properly (18). Histological analysis of the testis shows no obvious anomalies, and there is no apparent difference in the spermatogenesis from wild-type and MIS+/– males. However, these males also develop Müllerian-duct-derived tissues such as a uterus, oviducts, and a vagina. About 85% of the males are infertile. Although MIS is not necessary for normal germ-cell development, the infertility of MIS–/– males probably results from a diversion of the sperm from its normal pathway. Finally, MIS appears to play an antitumor role in the testis, because about 25% of MIS-deficient males develop Leydig-cell hyperplasia and neoplasia.
Activin and Inhibin Activins and inhibins are members of the TGF` gene superfamily. Inhibins were initially isolated from mammalian follicular fluid on the basis of their ability to inhibit the release of FSH from anterior pituitary cells (19). Side fractions that activated FSH release led to the isolation of activins. Activins and inhibins are protein dimers composed of a unique _-subunit and common but homologous `A or `B subunits. In adult animals, the highest levels of activin and inhibin transcripts are found in the Sertoli cells of the testis and the granulosa cells of the ovaries (20–22). Interestingly, recent evidence points to the regulation of inhibin _ gene expression by some isoforms of CREM (23). In the testis, activin stimulates spermatogonial proliferation and androgen biosynthesis by Leydig cells, whereas inhibin has the opposite activity. Activin interacts with type I and type II cell-surface receptors, which have serine/threonine kinase activity. Two type II activin receptors—activin-receptor type IIA (ActRIIA) and activin-receptor type IIB (ActRIIB)—have been identified (24). The ActRIIA isoform has been detected in specific populations of male germ cells, suggesting that this hormone can act as a gonadal paracrine and/or autocrine regulator (20,25,26). A previous study indicates that _-inhibin functions as a tumor suppressor with gonadal specificity. Male mice with a targeted mutation of the _-inhibin gene initially appeared healthy, and had normal external genitalia. However, male mutants were sterile, and analysis of the testis showed the presence of mixed or incompletely differentiated gonadal stromal tumors (27). Spermatogenesis was initially active in the first 5–7 wk of life, but regression was evident with the enlargement of the tumor masses. Serum FSH concentrations were elevated two- to threefold in the homozygous mutants as compared to wild-type littermates, which confirmed the inhibitory role of inhibin on FSH release. A regulatory mechanism between activin and inhibin has been described by showing that _-inhibin–/– mice have a 200-fold overexpression of the activin `A subunit and a threefold reduction of ActRIIA mRNA transcript in the testis (28). These results suggest that inhibin is not necessary for the normal differentiation of embryonic gonads and sper-
Chapter 5/Mouse Models to Study Male Reproduction
99
matogenesis, but plays an important autocrine and/or paracrine function as a tumor suppressor in the gonads. Activin-`A-deficient mice develop to term, but die within 24 h. These mice present multiple cranio-facial deformities, such as a lack of whiskers and lower incisors (29). Mice with a mutation in the ActRcIIA gene have also been generated (24), and were expected to possibly mimic the phenotype of the activin-`A–/– mice. Although some ActRcIIA–/– mice suffered from cranio-facial anomalies, most of them developed into adults. The ActRcIIA-deficient mice suffered from a complete suppression in FSH synthesis, and their reproductive ability was altered. Male ActRcIIA–/– mice reached puberty later than wild-type animals, but their stages of spermatogenesis were seemingly normal. Seminiferous-tubule diameter and volume were reduced, which could result from an overall decrease in the number of Sertoli cells. Since activin stimulates FSH synthesis in the pituitary, the small testis of the ActRcIIA–/– animals may result from the decreased levels of FSH, although though LH levels were normal. Mice with a double mutation of either the _-inhibin and activin `B genes or of the _-inhibin and ActRcIIA genes also develop testicular tumors (30). Disruption of the common activin/inhibin `B subunit gene produces mice deficient in activin B, activin AB, and inhibin B (31). Homozygous mutants present defects in eyelid development, and `B–/– females manifest a profoundly impaired reproductive ability. However, the reproductive organs from `B–/– males appeared normal, and these mice bred normally.
MIS and Inhibin The gonadal tumors of inhibin-deficient mice are first detected around 4 wk of age. It could be hypothesised that MIS, which is synthesized in the same gonadal cells as inhibin, may act as a tumor suppressor at this early stage. It has been demonstrated that inhibin/MIS double-mutant male mice develop testicular tumors at an even earlier age. These tumors are different from those observed in either _-inhibin–/– or MIS–/– mice (32). They grow more rapidly, are less hemorrhagic, and produce less estradiol as compared to the tumors of inhibin-deficient male mice. These results suggest that inhibin and MIS synergize to function as gonadal-tumor suppressors.
NUCLEAR RECEPTORS Retinol Receptors Vitamin A, or retinol, is absolutely essential for spermatogenesis. Rats fed a vitamin A-deficient diet become sterile and show a drastic reduction in testis weight (33,34). In animals on a vitamin A-deficient diet, only Sertoli cells and spermatogonia are apparent, while meiotic and postmeiotic germ cells degenerate. There are two known classes of retinol receptors, retinoic-acid receptors (RAR_, `, and a) that bind 13-cis-retinoic acid, and all-trans-retinoic acid (35,36), and the retinoic X receptors (RXR_, ` and a), which have a high affinity for 9-cis-retinoic acid (37). All retinoid receptors are member of the nuclear-receptor superfamily. The RAR_, RXR_, and RXR` isoforms are widely expressed in the embryo and adult tissues (38–41), while the expression of the RARa gene is restricted to the skin. These receptors can homodimerize and heterodimerize with a wide variety of nuclear receptors, and are believed to be responsible for a wide variety of signaling pathways (42).
100
Borrelli et al.
The RAR_ gene encodes two isoforms. The major isoform, RAR_1, is expressed ubiquitously, while the RA-inducible isoform RAR_2 has a more restricted expression pattern (43). Knocking out the RAR_2 gene has no apparent deleterious effect since RAR_2-deficient mice are healthy and fertile. However, high postnatal lethality is observed in mice homozygous for a mutation of the entire RAR_ gene (44). Although most RAR_–/– mutants survive at birth, the survival rate at 24 h of age is 40%, and only 12% of homozygous animals are alive after 1–2 mo. Mice surviving over 2 mo of age appear normal, but none of the males are able to sire any litters. Histological analysis of the testis has showed severe degeneration of the germinal epithelium, although some of the tubules appear normal. Vacuolization of the Sertoli cells is evident, and cytoplasmic expansion of these cells often partially fills the lumen. The epidymal duct appears normal, but contains very few spermatozoa. The degeneration observed in RXR_–/– testis is almost identical to that observed in animals kept on a vitamin A-deficient diet. This observation suggests that retinoic acid, and not retinol, is required for the maintenance of spermatogenesis. This hypothesis is supported by the observation that high doses of retinoic acid can restore the germ-cell degeneration induced by the vitamin A-deficient diet (45). The RXR` gene is expressed mostly in Sertoli cells. Targeted mutation of the RXR` gene (46) reveals that approx 50% of RXR`–/– mutants die in utero or shortly after birth, for unknown reasons. Homozygote females are fertile, but RXR`-deficient males are sterile. Histological analysis of the epididymis of males RXR`–/– mice shows low levels of spermatozoa, most of which (95%) remains immotile. A majority of spermatozoa from RXR`-deficient mice exhibit a coiling of the tail, and 30% have an acrosome that is indented or partially detached from the nuclear envelope. It has been suggested that the high frequency of such defects in mutant spermatozoa results from an impaired attachment of the acrosomal membrane to the nucleus. The diameter of the seminiferous tubules is normal, and the proportion and length of stages of the cycle is apparently normal. However, some of the late spermatids fail to align at the luminar side of the tubules. Moreover, remnants of spermatid heads are located inside the cytoplasm of the Sertoli cells. In young animals, lipid droplets are apparent in the cytoplasm of Sertoli cells—droplets which become more and more apparent as the animal gets older. In 6-moold RXR`–/– animals, the lipid droplets are larger than the Sertoli-cell nuclei, and the tubule have a reduced diameter with variable degrees of cell loss. By the age of 12 mo over one-half of the tubules are replaced by tubular ghosts consisting of a thickened and convoluted basement membrane filled with lipids. These results demonstrate that disruption of RXR` gene results in alterations of Sertoli-cell function and underscore the crucial role played by retinols in the germ-cells differentiation process.
Estrogen Receptors Two types of estrogen receptors exist, ER_ and ER`. These receptors have significant homology, and both belong to the steroid-receptor superfamily (47,48). These receptors bind 17`-estradiol, the female-sex steroid that plays a critical role in female sexual development. Targeting of the ER_ has been achieved, while a full description of the anatomical and physiological features of mice mutated for ER` is ongoing (49,50). Surprisingly, inactivation of ER_ gene affects male fertility. The mutant males exhibit impaired sexual behavior, including decreased intromission and ejaculation. ER_–/– males have low fertility with reduced testis size, and a 90% reduction in sperm number. In contrast to the severe reproductive phenotypes of ER_-deficient male mice, ER`-deficient
Chapter 5/Mouse Models to Study Male Reproduction
101
male mice are fertile and have no testicular defects. Older males demonstrate epithelial hyperplasia in the prostate and the bladder (50). Double-mutant male mice that are deficient in both ER_ and ER` are infertile (51) and essentially demonstrate the ER_-deficient phenotypes, i.e., infertility and reduction in sperm number and motility.
PROLIFERATION AND APOPTOSIS The p53 Protein In contrast to the great body of information on the regulation of the mitotic-cell cycle, much less is known about the molecular mechanisms involved in the regulation of meiosis. Yet, the stringent control in the differentiation and proliferation timing of the germ cells indicates the presence of critical checkpoints. An analysis of cyclin-dependent kinases (cDKs) has revealed that their expression occurs at specific steps of the meiotic-cell cycle, and suggests a role in the differentiation program (52). Normally, a proportion of germ cells undergo apoptosis in the seminiferous epithelium. This number increases dramatically in some pathological conditions, including idiopathic infertility caused by spermatogenic arrest in human males. Interestingly, somatic-cell-cycle regulation by the Cdk family of genes is modulated by the pleiotropic action of the tumor suppressor p53 (53). The activity of the p53 protein has been associated with both apoptosis and cell differentiation (53–55). The pattern of expression of the p53 gene has been studied in mice by developing transgenic animals in which the bacterial gene encoding chloramphenicol acetyltransferase (CAT) is under the control of the p53-gene promoter (56). This study showed that the testis is the organ with the highest levels of p53-gene expression in the adult. In the testis, p53-gene expression is mostly restricted to primary spermatocytes at the pachytene phase of meiosis, just before they develop into haploid spermatids. A giant cell testicular degeneration syndrome is occasionally seen in transgenic mice carrying a p53-promoter-CAT fusion, which results in decreased p53 levels in the testes (57). These mice seem to recapitulate a degenerative syndrome, probably resulting from the inability of the tetraploid primary spermatocytes to complete meiotic division. The severity of this syndrome is variable from one strain to another, and can be correlated to the reduction in p53 levels. The role of p53 in the regulation of the cell cycle and in the apoptotic pathway is further emphasized by the finding of the robust overexpression of wild-type p53 protein in most testicular tumors (58). The mouse p53 gene is knocked out in ES cells and susbsequently p53-deficient mice are generated (59). Mutant animals initially appear healthy and fertile. However, most p53-deficient animals die by 3–6 mo of age from multiple neoplasms. Spermatogenesis appears normal, although giant cells can be found in some tubules. Testicular section of p53-deficient mice of the 129 background exhibit a high incidence of seminomas and undifferentiated teratocarcinomas. In fact, this strain of mice seems to have a profound effect on the testicular phenotype, because p53–/– mice of pure 129 strain are sterile, whereas p53-deficient mice of other strains and mixed background are fertile (57).
The Bax Protein A direct connection with the germ-cell apoptotic pathway is provided by the finding that p53 acts as a transcriptional activator of the Bax gene (60). Bax is a dimerization partner of Bcl-2, a protein with the potential to interfere with programmed cell death in
102
Borrelli et al.
response to a number of apoptotic stimuli. Importantly, Bax has an opposing function to Bcl-2—its ablility to accelerate apoptosis. The deletion of the Bax gene by homologous recombination results in a complete block of the spermatogenesis (see Chapter 6). Baxdeficient male mice are infertile, with atrophied testes and empty epididymis and vas deferens. Histological analysis of the seminiferous tubules shows spermatogenic arrest, accumulation of premeiotic spermatocytes, abnormal mitotic or meiotic figures, and multinucleated giant cells. Round spermatids are rare, and elongated spermatids are completely absent. Electron microscopy analysis has also revealed a disordered maturation scheme. Premeiotic cells have an atypical distribution of decondensed chromatin, and an irregular size and shape not typical of spermatogonia or preleptotene spermatocytes. Flow cytometry of testicular cells shows an elevated number of 2N cells, which reflects the abnormal premeiotic-cell expansion noted in the testicular section. A small proportion of 1N cells representing the round spermatids is present, but the more condensed 1N population represented by elongating spermatids and spermatozoa is completely absent. Multinucleated and pyknotic cells are also present in the testes of Bax-deficient mice, suggesting increased apoptosis in this tissue. Thus, in Bax-null mice, the premeiotic germ cells appear atypical, and instead of differentiating, enter a pathway of programmed cell death (61). Deletion of the genes encoding the Bax partners Bcl-2 and Bcl-x reveals massive cell death in the lymphoid-cell lineage, but does not cause germ-cell aberrations (62,63). Interestingly, Bax-null mice also show lymphoid hyperplasia (61). Thus, the same molecule may act positively or negatively in the apoptotic pathway of different cell lineages.
Cyclin D2 The D-type cyclins D1, D2, and D3 are critical controllers of the G1 phase of the mammalian cell cycle. The three cyclins are expressed in overlapping, apparently redundant fashion in various proliferating tissues. Homologous recombination at the cyclin D2-gene locus has been achieved in mouse ES cells (64). Male mice carrying a cyclin-D2 mutated gene are fertile but display hypoplastic testes, suggesting a role for this cyclin in the regulation of testis growth. Interestingly, the expression of the cyclin D2 gene, and not of the D1 or D3 genes, was found to be FSH-inducible via the cAMPdependent pathway. This finding indicates that the regulation of the various cyclin genes is under the control of various intracellular signaling pathways. The hypoplasia observed in testes correlates with the observation that some human testicular tumors display a high cyclin-D2 expression.
Cyclin A1 There are two mammalian members of cyclin A family—cyclin A1 and cyclin A2. Cyclin A2 exhibits a more widespread expression, and cyclin A2-deficient mice die embryonically. In contrast, cyclin A1 is expressed extensively in the male germ-cell lineage in mice (65). Cyclin A1-deficient male mice are infertile because of a block in spermatogenesis before the first meiotic division. This is accompanied by increased germ-cell apoptosis defects in desynapsis, and a 80% reduction in cdc2 kinase activation at the end of the meiotic prophase (65). The residual cyclin B1/cdc2 activity in the complete absence of cyclin A1 has been found to be insufficient for the progression of meiotic divisions. Thus, cyclin A1 represents a novel male meiotic lineage-specific class of cyclins.
Chapter 5/Mouse Models to Study Male Reproduction
103
TRANSCRIPTION FACTOR CREM A Molecular Master-Switch Cyclic AMP-dependent signaling is known to play an important role in spermatogenesis (2). The receptors for LH and FSH are coupled to Gs proteins, and activate the adenylyl cyclase, further leading to an activation of the cAMP-dependent protein kinase A (PKA). Many genes that are expressed during spermatogenesis possess cAMP-responsive elements (CRE) in their promoter (66). These sequences are targets for CRE-binding proteins, such as CREB or CREM, that can be phosphorylated and activated by the PKA as well as other signaling pathways (67). CRE-binding proteins are relatively ubiquitous and uninducible (68). However, in adult male germ cells, the activator CREM is expressed at levels that are hundreds of times higher than those in other tissues (69). The CREM activator has been shown to function as a regulator of gene expression in haploid cells. CREM levels are regulated during germ-cell differentiation and by the FSH-signaling pathway (70). CREM proteins are expressed in haploid spermatids, where they activate multiple genes, such as transition proteins, angiotensinconverting enzyme (ACE), calspermin, and cholesterogenic lanosterol 14_-demethylase (CYP51) (66,71–74). A summary of cAMP signaling in the testis and expression patterns of key regulators of this pathway is schematically represented in Fig. 1. The crucial role of CREM during spermatogenesis has been confirmed by its targeted mutation in the mouse (75,76). In male CREM+/– mice, there is a 50% reduction in the number and motility of spermatazoa. There is also a twofold increase in the number of spermatozoa with an aberrant structure. In CREM–/– animals, the females are fertile, but the males are sterile and produce no spermatozoa. Histological analysis of seminiferous tubules reveals a complete arrest of spermatogenesis at the first stage of spermiogenesis (Fig. 2). A 10-fold increase in apoptotic germ cells is also observed, and in many cases, these apoptotic bodies acquire the shape of multinucleated giant cells (75). Finally, serum concentrations of LH, FSH, and testosterone are not reduced in CREM-deficient males, indicating that the phenotype observed in these animals does not result from hormonal alterations.
ACT, A Testis-Specific Coactivator Crucial steps in transcriptional activation by factors of the CREB/CREM class are phosphorylation at a specific serine regulatory site and the subsequent recruitment of the coactivator, CBP (CREB-binding protein) (65,66). Thus, the phosphorylation event is considered to be the key event, leading to transcriptional activation in response to induction of a specific signaling route. Surprisingly, CREM is found to be unphosphorylated in male germ cells. Thus, activation by CREM must occur independently of phosphorylation, and therefore of binding of CBP. A yeast two-hybrid screen of a testis-derived cDNA library, using the CREM activation domain as bait, has revealed the presence of a novel protein, activator of CREM in testis (ACT) (77). The distinctive feature of ACT is the presence of four complete LIM motifs and another half motif at the N-terminus. LIM domains comprise a conserved cysteine- and histidine-rich structure that forms two adjacent zinc fingers. This structural motif was first identified in the protein products of three genes, Lin-11, Isl-1, and Mec-3. The LIM domain functions as a protein-protein interaction domain. LIM domains can be present with other functional protein motifs, such as homeobox and kinase domains, but ACT belongs to the class of the LIM-only proteins (LMO), and contains no other structural motif.
104
Borrelli et al.
Fig. 1. Schematic representation of a section of a seminiferous tubule where the CREM expression patteren is indicated. CREM expression is regulated at multiple levels during spermatogenesis. Premeiotic germ cells spermatogonia (SG) express a low level of CREM repressor isoforms. During meiotic prophase, the pituitary follicle-stimulating hormone (FSH) is responsible for the stabilization of CREM activator transcripts in spermatocytes (SC); CREM protein, on the other hand, is detected only after meiosis in haploid spermatids (ST). Note the strict relationships between the Sertoli and germ cells (arrows). In the haploid spermatids, CREM proteins activate a number of cellular genes expressed specifically during spermtid maturation.
Several lines of evidence point to the coordinated expression of CREM and ACT. ACT is abundantly and exclusively expressed in testis; ACT colocalizes with CREM in spermatids; and ACT and CREM exhibit the same expression pattern during testis development. CREM and ACT efficiently associate; the biological significance of this is that ACT has an intrinsic transactivation capacity and can convert CREM into a powerful transcriptional activator (77) (Fig. 3). Most importantly, co-activation through ACT can occur also in yeast, which lacks CBP and TAF130 homologs. Thus, ACT can bypass the need for CREM or CREB phosphorylation. Indeed, ACT converts an inactive CREM mutant (with the serine phosphoacceptor site mutated into alanine) into a transcriptionally active molecule, both in yeast and in mammalian cells. Thus, in male germ cells, ACT provides a novel, tissue-specific phosphorylation-independent route for transactivation by members of the CREB family (77). A general model of CREM interacting with the general transcriptional machinery is depicted in Fig. 4.
Chapter 5/Mouse Models to Study Male Reproduction
105
Fig. 2. CREM deficiency causes spermiogenesis arrest and make germ-cell apoptosis. Testes from a 8-wk-old homozygous mutant (–/–) and a wild-type (+/+) mouse littermate. Histological analysis of testis sections. The tubules from the CREM-deficient mice show impared spermatogenesis and some multinucleated apoptotic cells.
CHAPERONE HSP70-2 Members of the 70-kDa heat shock protein (HSP70) family are chaperones that assist in the folding, transport, and assembly of protein in the cytoplasm, mitochondria, and endoplasmic reticulum (78) HSP70-2 is a testis-specific gene that is expressed at high levels in pachytene spermatocytes during the meiotic phase of spermatogenesis (79,80). The developmentally regulated expression of HSP70-2 during spermatogenesis implies
106
Borrelli et al.
Fig. 3. ACT is exclusively in testis. Co-expression of ACT and CREM druring testis development. RNA was extracted from testes of mice at different ages and analyzed by RNase protection assay, using ACT- and CREM-specific riboprobes. C indicates a b-actin protected frgament used as an intenal control. DBD I and DBD II refer to the two alternative DNA-binding domains of CREM.
that it performs a specialized function during meiosis. This protein has been identified as a component of the synaptonemal complex in prophase nuclei of spermatogenic cells (81). HSP70-2 mutant males produce no spermatozoa and are infertile (82). Spermatogonia and pachytene spermatocytes, mainly with aberrant structures, are present in HSP70-2–/– testis, but postmeiotic spermatids are completely absent. Pachytene spermatocytes with condensed nuclei are observed, and there is a major increase in the level of apoptotic cells in HSP70-2 mutant testis. Although typical-appearing synaptonemal complexes are observed in pachytene cells from HSP70-2–/– testis, synaptonemal complex development beyond the middle to late pachytene stages is not observed (82). These observations suggest that HSP70-2 is not necessary for synaptonemal complex assembly, but is required during synapsis, which allows progression to the subsequent meiotic divisions.
CONCLUSIONS The use of genetically modified mice has brought a wealth of information on the genetic control of gametogenesis, yet additional questions have arisen. Much more will be revealed by the homologous recombination approach in reproductive biology as many other animal models will be generated. Importantly, not all gene inactivations believed to influence the germ-cell differentiation program have led to the anticipated sterile phenotype. For example, the normal fertility of the acrosin-mutant mice suggests that this endoprotease is not essential for sperm penetration of the oocyte zona pellucida (ZP) or fertilization (83). Important considerations include the finding that analysis of testicular function is often complicated by deleterious or lethal consequences of a specific gene inactivation. On the other hand, it is evident that many crucial elements are involved in the regulation of gametogenesis, some of which have not been considered.
Chapter 5/Mouse Models to Study Male Reproduction
107
Fig. 4. CREM-mediated transcription is promoted by interaction with different co-activators. (Top) A schematic representation of the classical view by which, through interaction with CBP, activators as CREB and CREM elicit their function. A key event in this scenario is phosphorylation at Ser117 P, since it is required for binding to CBP and subsequent transcriptional activation. Interaction with TAF130 is constitutive, and occurs via the Q2 domain of CREB/CREM. (Bottom) Representation of how ACT may elicit its co-activator function via interaction with CREM. In yeast, CREB and CREM are inactive because of the lack of CBP and TAF130. ACT elicits its function and interacts with CREM, also in the absence of Ser117 phosphorylation. Thus, ACT provides an alternative activation pathway that appears to work in a signalingindependent manner. A hypothetical bridging factor, linking ACT to the basal transcription machinery, is represented.
Special attention should be given to the pathway of programmed cell death of germ cells. Very little is known, as little research has been done on the meiosis cycle as compared to the mitotic cell cycle. The increased proportion of apoptotic bodies in many mutated animals with testicular alterations indicates that apoptosis must play an important, but poorly defined, role in the spermatogenic cascade. Further studies will focus on the precise role played by well-known mitotic apoptosis-related proteins, and possibly on the discovery of novel, meiosis-specific, cell-death molecules. One interesting approach has been the screen of lines of mutant mice created using a retroviral gene-trap system for male infertility (84). This approach has led to the finding that Bclw-deficient mice have testicular degeneration (84). Analysis of some of the mutant mice suggests previously unrecognized relationships. Of particular interest is the very close testicular phenotype observed in the CREM, HSP70-2, and BAX-deficient mice, suggesting that an interplay of these genes may place them on the same, or related, signaling cascades. Future work will take advantage of multiple mutations, and of conditional homologous recombination, to remarkably improve our understanding of gametogenesis.
108
Borrelli et al.
ACKNOWLEDGMENTS We would like to thank all the members of our laboratories for discussions. Research in the laboratories of Emiliana Borrellu and Paola Sassone-Corsi is supported by grants from CNRS, INSERM, CHUR, FRM, La Ligue and the Association pour la Recherche sur le Cancer. T. Rajendra Kumar acknowledges financial support from The Moran Foundation, Texas.
REFERENCES 1. Al Shawi R, Burke J, Bishop JO, Mullins JJ, Sharpe RM, Lathe R, et al. Transgenesis and infertility. In: Hiller SG, ed., Gonadal Development and Function . Raven Press, New York, NY, 1992; pp. 195–206. 2. Brandon EP, Idzerma RL, McKnight GS. Targeting the mouse genome: a compendium of knockouts. Curr Biol 1995;5:625–634. 3. Veldhuis JD. The hypothalamic-pituitary-gonadal axis. In: Yen SSC, Jaffe RB, eds., Reproductive Endocrinology. Saunders, Philadelphia, PA, 1991; pp. 409–459. 4. Skinner MK. Cell-cell interactions in the testis. Endocrine Rev 1991;12:45–77. 5. Parvinen M. Regulation of the seminiferous epithelium. Endocrine Rev 1992;13:404–417. 6. Sassone-Corsi P. Transcriptional checkpoints determining the fate of male germ cells. Cell 1997;88:163–166. 7. Schmidt EE, Schibler U. High accumulation of components of the RNA polymearse II transcription machinery in rodent spermatids. Development 1995;121:2373–2383. 8. Kendall SK, Samuelson LC, Saunders TL, Wood RI, Camper SA. Targeted disruption of the pituitary glycoprotein hormone a-subunit produces hypogonadal and hypothyroid mice. Genes Dev 1995;9:2007–2019. 9. Kumar TR, Wang Y, Lu N, Matzuk M. Follicle stimulating hormone is required for ovarian follicle maturation but not male fertility. Nature Genet 1997;15:201–204. 10. Aittomäki K, Herva R, Stenman U, Juntunen K, Ylöstalo P, Hovata O, et al. Clinical features of primary ovary failure caused by a point mutation in the follicle stimulating hormone receptor gene. J Clin Endocr Metab 1996;81:3722–3726. 11. Aittomäki K, Dieguez Lucena JL, Pakarinen P, Sistonen P,Tapanainen J, Lehväslaiho H, et al. Mutation in the follicle-stimulating hormone receptor gene causes hereditary hypergonadotropic ovarian failure. Cell 1995;82:959–968. 12. Gromoll J, Simoni M, Nieschlag E. An activating mutation of the follicle-stimulating hormone receptor autonomously sustains spermatogenesis in a hypophysectomized man. J Clin Endocr Metab 1996;81:1367–1370. 13. Touraine P, Beau I, Gougeon A, Meduri G, Desroches A, Pichard C, et al. New natural inactivating mutations of the follicle-stimulating hormone receptor: correlations between receptorfunction and phenotype. Mol Endocrinol 1999;13:1844–1854. 14. Tapanainen JS, Aittomaki K, Min J, Vaskivuo T, Huhtaniemi IL. Men homozygous for an inactivating mutation of the follicle-stimulating hormone (FSH) receptor gene prosent variable suppression of spermatogenesis and fertility. Nature Gen 1997;15:205,206. 15. Dierich A, Sairam MR, Monaco L, Fimia GM, Gansmuller A, LeMeur M, et al. Impairing folliclestimulating hormone signaling in vivo: targeted disruption of the FSH receptor leads to aberrant gametogenesis and hormonal imbalance. Proc Natl Acad Sci USA 1998;95:13,612–13,617. 16. Kremer H, Kraaij R, Toledo S, Post M, Fridman J, Hayashida C, et al. Male pseudoheramphroditism due to a homozygous missense mutation of the luteinizing hormone receptor gene. Nature Genet 1995;9:160–164. 17. Cate RL, Donahoe PK, MacLaughlin J. Müllerian-inhibiting substance. In: Sporn MB, Roberts AB, eds., Peptide Growth Factors andTheir Receptors, Vol. 2. Springer-Verlag, Berlin, Germany, 1990; pp. 179–210. 18. Behringer RR, Finegold MJ, Cate RL. Müllerian-inhibiting substance funstion during mammalian sexual development. Cell 1994;79:415–425. 19. Vale W, Hsueh A, Rivier C, Yu J. The inhibin/activin family of hormones and growth factors. In: Sporn MB, Roberts AB, eds., Peptide Growth Factors and their Receptors: Handbook of Experimental Pharmacology. Springer-Verlag, Berlin, Germany, 1990; pp. 211–248.
Chapter 5/Mouse Models to Study Male Reproduction
109
20. Mather JP, Woodruff TK, Krummen LA. Paracrine regulation of reproductive function by inhibin and activin. Proc Soc Exp Biol Med 1992;201:1–15. 21. Moore A, Krummen LA, Mather JP. Inhibins, activins, their binding proteins and receptors: interactions underlying paracrine activity in the testis. Mol Cell Endocrinol 1994;100:81–86. 22. Jaffe RB, Spencer SJ, Rabinovici J. Activins and inhibins: gonadal peptides during prenatal development and adult life. Ann NY Acad Sci 1993;687:1–9. 23. Mukherjee A, Urban J, Sassone-Corsi P, Mayo KE. Gonadotropins regulate inducible cyclic adenosine 3',5'-monophosphate early repressor in the rat ovary: implications for inhibin _ subunit gene expression. Mol Endocrinol 1998;12:785–800. 24. Matzuk MM. Functional analysis of mammalian members of the transforming growth factor-b. Trends Endocrinol Metab 1995;6:120–127. 25. de Jong F, Grootenhuis AJ, Klaij IA, Van Beurden W. Inhibin and related proteins: localization, regulation and effects. Adv Exp Med Biol 1990;274:271–293. 26. Findlay JK. An update on the roles of inhibin, activin and follistatin as regulators of folliculogenesis. Biol Reprod 1993;48:15–23. 27. Matzuk MM, Finegold MJ, Su JJ, Hsueh AJW, Bradley A. _-inhibin is a tumor suppressor gene with gonadal specificity in mice. Nature 1992;360:313–319 . 28. Trudeau VL, Matzuk MM, Haché RJG, Renaud V. Overexpression of activin-`A subunit mRNA is associated with decreased activin type II receptor mRNA levels in the testes of _-inhibin deficient mice. Biochem Biophys Res Comm 1994;203:105–112. 29. Matzuk MM, Kumar TR, Vassali A, Bickenbach JR., Roop DR, Jaenisch R, et al. Functional analysis of activins during mammalian development. Nature 1995;374:354–356. 30. Coerver KA, Woodruff TK, Finegold MJ, Mather J, Bradley A, Matzuk MM. Activin signaling through activin receptor type II causes the cachexia-like symptoms in inhibin-deficient mice. Mol. Endocrinol. 1996;10:534–543. 31. Vassali A, Matzuk MM, Gardner HAR, Lee KF, Jaenisch R. Activin/inhibin `B subunit gene disruption leads to defects in eyelid development and female reproduction. Genes Dev 1994;8:414–427. 32. Matzuk MM, Finegold MJ, Mishina Y, Bradley A, Behringer RR. Synergistic effects of inhibins and Müllerian-inhibiting substance on testicular tumorigenesis. Mol Endocrinol 1995;9:1337–1345. 33. Huang HFS, Hembree WC. Spermatogenic response to vitamin A in vitamin A deficient rats. Biol Reprod 1979;21:891–904. 34. Morales CR, Griswold MD. Retinol-induced stage synchronization in seminiferous tubules of the rat. Endocrinology 1987;121:432–434. 35. Giguère V, Ong ES, Segui P, Evans RM. Identification of a receptor for the morphogen retinoic acid. Nature 1987;330:624–629. 36. Petkovich M, Brand NJ, Krust A, Chambon P. A human retinoic acid receptor which belongs to the family of nuclear receptors. Nature 1987;330:444–450. 37. Heyman RA, Mangelsdorf DJ, Dyck JA, Stein RB, Eichele G, Evans RM., et al. 9-cis retinoic acid is a high affinity ligand for the retinoid X receptor. Cell 1992;68:397–406. 38. Dollé P, Fraulob V, Kastner P, Chambon P. Developmental expression of murine retinois X receptor (RXR) genes. Mech Dev 1994;45:91–104. 39. Mangelsdorf DJ, Borgmeyer U, Heyman R, Zhou JY, Ong E, Oro A, et al. Characterization of three RXR genes that mediate the action of 9-cis retinoic acid. Genes Dev 1992;6:329–344. 40. Leroy P, Krust A, Zelent A, Mendelson C, Garnier JM, Kastner P, et al. Multiple isoforms of the mouse retinoic acid receptor alpha are generated by alternative splicing and differential induction by retinoic acid. EMBO J 1991;10:59–69. 41. Ruperte E, Dollé P, Chambon P, Morriss-Kay G. Retinoic acid receptors and cellular retinoid binding proteins. II. Their differential pattern of transcription during early morphogenesis in mouse embryos. Development 1991;111:45–60. 42. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, et al. The nuclear receptor superfamily: the second decade. Cell 1995;83:835–839. 43. Leroy P, Nakshatri H, Chambon P. Mouse retinoic acid receptor alpha 2 isoform is transcribed from a promoter that contains a retinoic acid response element. Proc Natl Acad Sci USA 1991;88:10,138–10,142. 44. Lufkin T, Lohnes D, Mark M, Dierich A, Gorry P, Gaub M-P, et al. High postnatal lethality and testis degeneration in retinoic acid receptor a mutant mice. Proc Natl Acad Sci USA 1993;90:7225–7229. 45. Van Pelt AM, De Rooij DG. Retinoic acid is able to reinitiate spermatogenesis in vitamin A-deficient rats and high replicate doses support the full development of spermatogenic cells. Endocrinology 1991;128:697–704.
110
Borrelli et al.
46. Kastner P, Mark M, Leid M, Gansmuller A, Chin W, Grondona JM, et al. Abnormal spermatogenesis in RXR beta mutant mice. Genes Dev 1996;10:80–92. 47. Korach KS. Insights from the study of animals lacking functional estrogen receptor. Science 1994;266:1524–1527. 48. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 1996;93:5925–5930. 49. Lubahn DB, Moyer JS, Golding TS, Couse JF, Korach KS, Smithies O. Alteration of reproductive funstion but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene. Proc Natl Acad Sci USA 1993;90:11,162–11,166. 50. Ogawa S, Chan J, Chester AE, Gustafsson JA, Korach KS, Pfaff DW. Survival of reproductive behaviors in estrogen receptor beta gene-deficient (betaERKO) male and female mice. Proc Natl Acad Sci USA 1996;96:12,887–12,892. 51. Couse JF, Hewitt SC, Bunch DO, Sar M, Walker VR, Davis BJ, et al. Postnatal sex reversal of the ovaries in mice lacking estrogen receptors alpha and beta. Science 1999;286:2328–2331. 52. Rhee K, Wolgemuth DJ. Cdk family genes are expressed not only in dividing bu also in terminally differentiated mouse germ cells, suggesting their possible function during both cell division and differentiation. Dev Dyn 1995;204:406–420. 53. Donehower LA, Bradley A. The tumor suppressor p53. Biochim Biophys Acta 1993;1155:181–205. 54. Levine A. The tumor supressor genes. Annu Rev Biochem 1993;62:623-651. 55. Ko LJ, Prives C. p53: puzzle and paradigm. Genes Dev 1996;10:1054–1072. 56. Almon ET, Goldfinger N, Kapon A, Schwartz D, Levine AJ, Rotter V. Testicular tissue-specific expression of the p53 suppressor gene. Dev Biol 1993;156:107–116. 57. Rotter V, Schwartz D, Almon E, Goldfinger N, Kapon A, Meshorer,A, et al. Mice with reduced levels of p53 protein exibit the testicular giant-cell degenerative syndrome. Proc Natl Acad Sci USA 1993;90:9075–9079. 58. Chresta CM, Hickman JA Oddball p53 in testicular tumors. Nature Med 1996;2:744–745. 59. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA, Butel JS, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature 1992;356:215–221. 60. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human Bax gene. Cell 1995;80:293–299. 61. Knudson CM, Tung KSK, Tourtellotte WG, Brown GAJ, Korsmeyer SJ. Bax-deficient mice with lymphoid hyperplasia and male germ cell death. Science 1995;270:96–99. 62. Motoyama N, Wang F, Roth KA, Sawa H, Nakayama K, Nakayama K, et al. Massive cell death of immature hematopoietic cells and neurons in Bcl-x-deficient mice. Science 1995;267:1506–1510. 63. Nakayama K, Nakayama K, Negishi I, Kuida K, Shinkai Y, Louie MC, et al. Disappearance of the lymphoid system in Bcl-2 homozygous mutant chimeric mice. Science 1993;261:1584–1588. 64. Sicinsky P, Donaher J, Geng Y, Parker S, Gardner H, Park MY, et al. Cyclin D2 is an FSH-responsive gene involved in gonadal cell proliferation and oncogenesis. Nature 1996;384:470–474. 65. Liu D, Matzuk MM, Sung WK, Guo Q, Wang P, Wolgemuth DJ. Cyclin A1 is required for meiosis in the male mouse. Nat Genet 1998;20:377–380. 66. Delmas V, van der Hoorn F, Mellström B, Jégou B, Sassone-Corsi P. Induction of CREM activator proteins in spermatids: downstream targets and implications for haploid germ cell differentiation. Mol Endocrinol 1993;7:1502–1514. 67. De Cesare D, Fimia GM, Sassone-Corsi P. Signaling routes to CREM and CREB: plasticity in transcriptional activation. Trends Biochem 1999;24:281–285. 68. Sassone-Corsi P. Transcription factors responsive to cAMP. Annu Rev Cell Dev Biol 1995;11:355–377. 69. Foulkes NS, Mellström B, Benusiglio E, Sassone-Corsi P. Developmental switch of CREM function during spermatogenesis: from antagonist to transcriptional activator. Nature 1992;355:80–84. 70. Foulkes NS, Schlotter F, Pévet P, Sassone-Corsi P. Pituitary hormone FSH directs the CREM functional switch during spermatogenesis. Nature 1993;362:264–267. 71. Kistler MK, Sassone-Corsi P, Kistler SW. Identification of a functional cAMP-response element in the 5'-flanking region of the gene for transition protein 1 (TP1), a basic chromosomal protein of mammalian spermatids. Biol Reprod 1994;51:1322–1329. 72. Sun Z, Sassone-Corsi P, Means A. Calspermin gene transcription is regulated by two cyclic AMP response elements contained in an alternative promoter in the calmodulin kinase IV gene. Mol Cell Biol 1995;15:561–571.
Chapter 5/Mouse Models to Study Male Reproduction
111
73. Zhou Y, Sun Z, Means AR, Sassone-Corsi P, Bernstein KE. CREMt is a positive regulator of testis ACE transcription. Proc Natl Acad Sci USA 1996;93:12,262–12,266. 74. Rozman D, Fink M, Fimia GM, Sassone-Corsi P, Waterman MR. Cyclic Adenosine 3', 5'-monophosphate (cAMP)/cAMP-responsive element modulator (CREM)-dependent regulation of cholesterogenic lanosterol 14a-demethylmase (CYP51) in spermatids. Mol Endocrinol 1999;13:1951–1999. 75. Nantel F, Monaco L, Foulkes NS, Masquilier D, LeMeur M, Henriksén K, et al. Spermiogenesis deficiency and germ cell apoptosis in CREM-mutant mice. Nature 1996;380:159–162. 76. Blendy J, Kastner K, Weinbauer G, Nieschlag F, Schutz G. Severe impairement of spermatogenesis in mice lacking the CREM gene. Nature 1996;380:163–165. 77. Fimia GM, De Cesare D, Sassone-Corsi P. CBP-independent activation of CREM and CREB by the LIM-only protein ACT. Nature 1999;398:165–169. 78. Georgopoulos C, Welch WJ. Role of major heat shock proteins as molecular chaperones. Annu Rev Cell Biol 1993;9:601–634. 79. Allen RL, O’Brien DA, Eddy EM. A novel hsp 70-like protein (P70) is present in mouse spermatogenic cells. Mol Cell Biol 1988;8:828–832. 80. Zakeri ZF, Wolgemuth DJ, Hunt CR. Identification and sequence analysis of a new member of the mouse HSP70 gene family and characterization of its unique cellular and developmental pattern of expression in the male germ line. Mol Cell Biol 1988;8:2925–2932. 81. Allen JW, Dix DJ, Collins BW, Merrick BA, He C, Selkirk JK, et al. HSP70-2 is part of the synaptonemal complex in mouse and hamster spermatocytes. Chromosoma 1996;104:414–421. 82. Dix DJ, Allen JW, Collins BW, Mori C, Nakamura N, Poorman-Allen P, et al. Targeted gene disruption of Hsp 70-2 results in failed meiosis, germ cell apoptosis, and male infertility. Proc Natl Acad Sci USA 1996;93:3264–3268. 83. Baba T, Azuma S, Kashiwabara S, Toyoda Y. Sperm from mice carrying a targeted mutation of the acrosin gene can penetrate the oocyte zona pellucida and effect fertilization. J Biol Chem 1994;269:31,845–31,849. 84. Ross AJ, Waymire KG, Moss JE, Parlow AF, Skinner MK, Russell LD., et al. Testicular degeneration in Bclw-deficient mice. Nature Genet 1998;18:251–261. 85. Adham IM, Nayernia K, Engel W. Spermatozoa lacking acrosin protein show delayed fertilization. Mol Reprod Dev 1997;46:370–376. 86. Yu RN, Ito M, Saunders TL, Camper SA, Jameson J. Role of Ahch in gonadal development and gametogenesis. Nat Genet 1998;20:353–357. 87. Krege JH, John SW, Langenbach LL, Hodgin JB, Hagaman JR, et al. Male-female differences in fertility and blood pressure in ACE-deficient mice. Nature 1995;375:146–148. 88. Honarpour N, Du C, Richardson JA, Hammer RE, Wang X, Herz J. Adult Apaf-1-deficient mice exhibit male infertility. Dev Biol 2000;218:248–258. 89. Huang L-S, Voyiaziakis E, Chen HL, Rubin EM, Gordon JW. A novel functional role for apolipoprotein B in male infertility in heterozygous apolipoprotein B knockout mice. Proc Natl Acad Sci USA 1996;93:10,903–10,907. 90. Ross AJ, Waymire KG, Moss JE, Parlow AF, Skinner MK, Russell LD, et al. Testicular degeneration in Bclw-deficient mice. Nat Genet 1998;8:251–256. 91. Zhao G-Q, Liaw L, Hogan BLM. Bone morphogenetic protein 8A plays a role in the maintenance of spermatogenesis and the integrity of the epididymis. Development 1998;125:1103–1112. 92. Zhao G-Q, Deng K, Labosky PA, Liaw L, Hogan BLM. The gene encoding bone morphogeneetic protein 8B is required for the initiation and maintenance of spermatogenesis in the mouse. Genes Dev 1996;10:1657–1669. 93. Cressman VL, Backlund DC, Avrutskaya AV, Leadon SA, Godfrey V, Koller BH. Growth retardation, DNA repair defects, and lack of spermatogenesis in BRCA1-deficient mice. Mol Cell Biol 1999;19:7061–7075. 94. Ikawa M, Wada I, Kominami K, Watanabe D, Toshimori K, Nishimune Y, et al. The putative chaperone calmegin is required for sperm fertility. Nature 1997;387:607–611. 95. Xu X, Toselli PA, Russell LD, Seldin DC. Globozoospermia in mice lacking the casein kinase II alpha’ catalytic subunit. Nat Genet 1999;23:118–121. 96. Yeung CH, Sonnenberg-Riethmacher E, Cooper TG. Infertile spermatozoa of c-ros tyrosine kinase receptor knockout mice show flagellar angulation and maturational defects in cell volume regulatory mechanisms. Biol Reprod 1999;61:1062–1069. 97. Hedlund P, Aszodi A, Pfeifer A, Aim P, Hofmann F, Ahmad M, et al. Erectile dysfunction in cyclic GMP-dependent kinase I-deficient mice. Proc Natl Acad Sci USA 2000;97:2349–2354.
112
Borrelli et al.
98. Shamsadin R, Adham IM, Nayernia K, Heinlein UA, Oberwinkler H, Engel W. Male mice deficient for germ-cell cyritestin are infertile. Biol Reprod 1991;61:1445–1451. 99. Bitgood MJ, Shen L, McMahon AP. Sertoli cell signaling by Desert hedgehog regulates the male germline. Curr Biol 1996;6:298–304. 100. Cho C, Bunch DO, Faure JE, Goulding EH, Eddy EM, Primakoff P, et al. Fertilization defects in sperm from mice lacking fertilin beta. Science 1998;281:1857–1859. 101. Bakker CE, Verheij CE, Willemsen R, van der Helm R, Oerlemans F, Vermeij M, et al. Fmr1 knockout mice: a model to study fragile X mental retardation. Cell 1994;78:23–33. 102. Meng X, Lindahl M, Hyvonen ME, Parvinen M, Rooij DGd, Hess MW, et al. Regulation of cell fate decision of undifferentiated spermatogonia by GDNF. Science 2000;287:1489–1493. 103. Osuga J, Ishibashi S, Oka T, Yagyu H, Tozawa R, Fujimoto A, et al. Targeted disruption of hormonesensitive lipase results in male sterility and adipocyte hypertrophy, but not in obestiy. Proc Natl Acad Sci USA 2000;97:787–792. 104. Podlasek CA, Duboule D, Bushman W. Male accessory sex organ morphogenesis is altered by loss of function in Hoxd-13. Dev Dyn 1998;208:454–465. 105. Roest HP, van Klaveren J, de Wit J, van Gurp CG, Koken MHM, et al. Inactivation of HR6B ubiquitin-conjugating DNA repair enzyme in mice causes male sterility associated with chromatin modification. Cell 1996;86:799–810. 106. Zindy F, Deursen Jv, Grosveld G, Sherr CJ, Roussel MF. INK4d-deficient mice are fertile despite testicular atrophy. Mol Cell Biol 2000;20:372–378. 107. Thepot D, Weitzman JB, Barra J, Segretain D, Stinnakre MG, Babinet C, et al. Targeted disruption of the murine junD gene results in multiple defects in male reproductive function. Development 2000;127:143–153. 108. Mishina Y, Rey R, Finegold MJ, Matzuk MM, Josso N, Cate RL, et al. Genetic analysis of the Müllerian-inhibiting substance signal transduction pathway in mammalian sexual differentiation. Genes Dev 1996;10:1–11. 109. Pace AJ, Lee E, Athirakui K, Coffman TM, O’Brien DA, Koller BH. Failure of spermatogenesis in mouse lines deficient in the Na(+)-K(+)-2Cl(-) cotransporter. J Clin Invest 2000;105:441–450. 110. Gow A, Southwood CM, Li JS, Pariali M, Riordan GP, Brodie SE, et al. CNS myelin and sertoli cell tight junction strands are absent in Osp/claudin-11 null mice. Cell 1999;99:649–659. 111. Dai X, Schonbaum C, Degenstein L, Bai W, Mahowald A, Fuchs E. The ovo gene required for cuticle formation and oogenesis in flies is involved in hair formation and spermatogenesis in mice. Genes Dev 1998;12:3452–3463. 112. Mulryan K, Gitterman DP, Lewis CJ, Vial C, Leckie BJ, Cobb AL, et al. Reduced vas deferens contraction and male infertility in mice lacking P2X1 receptors. Nature 2000;403:86–89. 113. Mbikay M, Tadros H, Ishida N, Lerner CP, Lamirande ED, Chen A, et al. Impaired fertility in mice deficient for the testicular germ cell protease PC4. Proc Natl Acad Sci USA 1997;94:6842–6846. 114. Blume-Jensen P, Jiang G, Hyman R, Lee KF, O’Gorman S, et al. Kit/stem cell factor receptorinduced activation of phosphatidylinositol 3'-kinase is essential for male fertility. Nat Genet 2000;24:157–162. 115. Baker SM, Bronner CE, Zhang L, Plug AW, Robatzek M, Warren G, et al. Male mice defective in the DNA mismatch repair gene PMS2 exhibit abnormal chromosome synapsis in meiosis. Cell 1995;82:309–319. 116. Varmuza S, Jurisicova A, Okano K, Hudson J, Boekelheide K, Shipp EB. Spermiogenesis is impaired in mice bearing a targeted mutation in the protein phosphatase 1c gamma gene. Dev Biol 1999;205:98–110. 117. Lohnes D, Kastner P, Dierich A, Mark M, LeMeur M, Chambon P. Function of retinoic acid receptor g in the mouse. Cell 1993;73:643–658. 118. Yuan L, Liu JG, Zhao J, Brundell E, Daneholt B, Hoog C. The murine SCP3 gene is required for synaptonemal complex assembly, chromosome synapsis, and male fertility. Mol Cell 2000;5:73–83. 119. Supp DM, Witte DP, Branford WW, Smith EP, Potter SS. Sp4, a member of the Sp1-family of zinc finger transcription factors, is required for normal murine growth, viability, and male fertility. Dev Biol 1996;176:284–299. 120. Pearse II, RV, Drolet DW, Kalla KA, Hooshmand F, Bermingham Jr. JR, et al. Reduced fertility in mice deficient for the POU protein sperm-1. Proc Natl Acad Sci USA 1997;94:7555–7560. 121. Kuroda M, Sok J, Webb L, Baechtold H, Urano F, Yin Y, et al. Male sterility and enhanced radiation sensitivity in TSL (-/-) mice. EMBO J 2000;19:453–462.
Chapter 5/Mouse Models to Study Male Reproduction
113
122. Yu YE, Zhang Y, Unni E, Shirley CR, Deng JM, Russell LD, et al. Abnormal spermatogenesis and reduced fertility in transition nuclear protein 1-deficient mice. Proc Natl Acad Sci USA 2000;97:4683–4688. 123. Lu Q, Gore M, Zhang Q, Camenisch T, Boast S, Casagranda F, et al. Tyro-3 family receptors are essential regulators of mammalian spermatogenesis. Nature 1999;398:723–728. 124. Tanaka SS, Toyooka Y, Akasu R, Katoh-Fukui Y, Nakahara Y, Suzuki R, et al. The mouse homolog of Drosophila Vasa is required for the development of male germ cells. Genes Dev 2000;14:841–853. 125. Matzuk MM, Kumar TR. Bradley A. Different phenotypes for mice deficient in either activins or activin receptor type II. Nature 1995;374:356–360. 126. Toscani A, Mettus RV, Coupland R, Simpkins H, Litvin J, Orth J, et al. Arrest of spermatogenesis and defective breast development in mice lacking A-myb. Nature 1997;386:713–717. 127. Barlow C, Hirotsune S, Paylor R, Liyanage M, Eckhaus M, Collins F, et al. Atm-deficient mice: a paradigm of ataxia telangiectasia. Cell 1996;86:159–171. 128. Xu Y, Ashley T, Brainerd EE, Bronson RT, Meyn MS, Baltimore D. Targeted disruption of ATM leads to growth retardation, chromosomal fragmentation during meiosis, immune defects, and thymic lymphoma. Genes Dev 1996;10:2411–2422. 129. Lu Q, Shur BD. Sperm from beta 1,4-galactosyltransferase-null mice are refractory to ZP3-induced acrosome reactions and penetrate the zona pellucida poorly. Development 1997;124:4121–4131. 130. Hudson DF, Fowler KJ, Earle E, Saffery R, Kalitsis P, Trowell H, Wreford NG, et al. Centromere protein B null mice are mitotically and meiotically normal but have lower body and testis weights. J Cell Biol 1998;141:309–319. 131. Fowler KJ, Hudson DF, Salamonsen LA, Edmondson SR, Earle E, Sibson MC, et al. Uterine dysfunction and genetic modifiers in centromere protein B-deficient mice. Genome Res 2000;10:30–41. 132. Fisher CR, Graves KH, Parlow AF, Simpson ER. Characterization of mice deficient in aromatase (ArKO) because of targeted disruption of the cyp19 gene. Proc Natl Acad Sci USA 1998;95:6965–6970. 133. Robertson KM, O’Donnell L, Jones ME, Meachem SJ, Boon WC, Fisher CR, et al. Impairment of spermatogenesis in mice lacking a functional aromatase (cyp 19) gene. Proc Natl Acad Sci USA 1999;96:7986–7991. 134. Rugglu M, Speed R, Taggart M, McKay SJ, Kilanowski F, Saunders P, et al. The mouse Dazla gene encodes a cytoplasmic protein essential for gametogenesis. Nature 1997;389:73–77. 135. Yoshida K, Kondoh G, Matsuda Y, Habu T, Nishimune Y, Morita T. The mouse RecA-like gene Dmc1 is required for homologous chromosome synapsis during meiosis. Mol Cell 1998;1:707–718. 136. Pittman DL, Cobb J, Schimenti KJ, Wilson LA, Cooper DM, Brignull E, et al. Meiotic prophase arrest with failure of chromosome synapsis in mice deficient for Dmc1, a germline-specific RecA homolog. Mol Cell 1998;1:697–705. 137. Miyamoto N, Yoshida M, Kuratani S, Matsuo I, Aizawa S. Defects of urogenital development in mice lacking Emx2. Development 1997;124:1653–1664. 138. Hsieh-Li HM, Witte DP, Weinstein M, Branford W, Li H, Small K, et al. Hoxa 11 structure, extensive antisense transcription, and function in male and female fertility. Development 1995;121:1373–1385. 139. Satokata I, Benson G, Maas R. Sexually dimorphic sterility phenotypes in Hoxa10-deficient mice. Nature 1995;374:460–463. 140. Baker J, Hardy MP, Zhou J, Bondy C, Lupu F, Bellvé AR, et al. Effects of an Igf1 gene null mutation on mouse reproduction. Mol Endocrinol 1996;10:903–918. 141. Edelmann W, Cohen PE, Kane M, Lau K, Morrow B, Bennett S, et al. Meiotic pachytene arrest in MLH1-deficient mice. Cell 1996;85:1125–1134. 142. deVries SS, Baart EB, Dekker M, Siezen A, Rooij DGd, Boer Pd, et al. Mouse MutS-like protein Msh5 is required for proper chromosome synapsis in male and female meiosis. Genes Dev 1999;13:523–531. 143. Good D, Porter E, Mahon K, Parlow A, Westphal H, Kirsch I. Hypogonadism and obesity in mice with a targeted deletion of the Nhlh2 gene. Nat Genet 1997;15:397–401. 144. Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, Shishido N, et al. Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 1996;85:707–720. 145. Fero ML, Rivkin M, Tasch M, Porter P, Carow CE, Firpo E, et al. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27Kip1-deficient mice. Cell 1996;85:733–744.
114
Borrelli et al.
146. Kiyokawa H, Kineman RD, Manova-Todorova KO, Soares VC, Hoffman ES, Ono M, et al. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27Kip1. Cell 1996;85:721–732. 147. Ormandy CJ, Camus A, Barra J, Damotte D, Lucas B, Buteau H, et al. Null mutation of the prolactin receptor gene produces multiple reproductive defects in the mouse. Genes Dev 1997;11:167–178. 148. Togawa A, Miyoshi J, Ishizaki K, Tanaka M, Takakura A, Nishioka H, et al. Progressive impairment of kidneys and reproductive organs in mice lacking Rho GDIalpha. Oncogene 1999;18:5373–5380. 149. Lee H-W, Blasco MA, Gottlieb GJ, Horner II JW, Greider CW, DePinho RA. Essential role of mouse telomerase in highly proliferative organs. Nature 1998;392:569–577. 150. Beck ARP, Miller IJ, Anderson P, Streuli M. RNA-binding protein TIAR is essential for primordial germ cell development. Proc Natl Acad Sci USA 1998;95:2331–2336. 151. Luoh S-W, Bain P, Polakiewicz R, Goodheart M, Gardner H, Jaenisch R, et al. Zfx mutation results in small animal size and reduced sperm cell number in male and female mice. Development 1997;124:2275–2284.
Chapter 6/The Bcl2 Gene Family
6
115
Functional Analysis of the Bcl2 Gene Family in Transgenic Mice Andrea J. Ross, PHD and Grant R. MacGregor, DPHIL CONTENTS APOPTOSIS: AN OVERVIEW APOPTOSIS: PIVOTAL MOLECULAR EVENTS REGULATION OF APOPTOSIS BY THE Bcl2 GENE FAMILY FUNCTIONAL ANALYSIS OF Bcl2 GENE FAMILY IN TRANSGENIC MICE APOPTOSIS AND Bcl2 FAMILY FUNCTION IN REPRODUCTIVE TISSUES SUMMARY AND FUTURE PERSPECTIVES ACKNOWLEDGMENTS REFERENCES
APOPTOSIS: AN OVERVIEW Historical Perspective Over 150 years have elapsed since the realization that cell death is a normal feature of animal development. This fundamental concept was introduced in 1842 by Carl Vogt, following his observation of dying notochordal and cartilaginous cells in the metamorphosing tadpole (1). Since this time, there have been numerous other descriptions of naturally occurring cell deaths during the development and homeostasis of a variety of metazoan species. Initially, the term “programmed cell death” (PCD) was used to describe the phenomenon of carefully controlled deletion of specific cells at predetermined times during development (2). Walter Flemming gave the first clear description of the morphology of PCD in 1885 while studying regression of follicles in the rabbit ovary (1). Using the red dye safranin, Flemming noted condensation of the chromatin along the nuclear envelope and fragmentation of the nucleus in granulosa cells, a process he termed “chromatolysis.” Nearly a century later, Kerr, Wyllie, and Currie used electron microscopy to revisit the morphology of dying cells in a number of different tissues. They renamed the process “apoptosis” (from the Greek term used to describe leaves falling from trees, apo = off, ptosis = falling) (3). Although the term “programmed cell death” was originally used in reference to developmentally regulated cell death, with “apoptosis” used to describe the From: Contemporary Endocrinology: Transgenics in Endocrinology Edited by: M. Matzuk, C. W. Brown, and T. R. Kumar © Humana Press Inc., Totowa, NJ
115
116
Ross and MacGregor
morphological changes associated with cell death, the two terms are now routinely used interchangeably.
Hallmarks Electron microscopy of dying cells has provided a detailed picture of the cellular features of apoptosis. As described by Flemming, early hallmarks of PCD include shrinkage of the cytoplasm and compaction of nuclear chromatin. This is followed by crowding of the organelles and formation of vacuoles derived from the endoplasmic reticulum, giving the cytoplasm a “bubbling” appearance. Finally, the cell is broken down into a number of membrane-bound apoptotic bodies that are phagocytosed by neighboring cells. These morphological features can be contrasted with the cellular events associated with necrosis, which usually include swelling of the mitochondria, ER, and nucleus, with eventual rupturing of the plasma membrane. This cellular lysis often stimulates an inflammatory response that is precluded when cells are removed in an apoptotic manner. Although it is convenient to categorize all cell death into one of these two classes, the validity of such classification has recently been debated, particularly with reference to neuronal (4) and germ-cell death (5).
Functions Programmed cell death is required for a number of fundamental processes in metazoan development and homeostasis. PCD is associated with sculpting of body structures such as the digits on the human hand or the proamniotic cavity of the early postimplantation mouse embryo (6,7). PCD also mediates removal of functionally unnecessary structures, such as the tadpole’s tail during amphibian metamorphosis (8) or the Müllerian ductal system, the anlagen of the oviduct and uterus, during male mammalian development (9). PCD regulates cell number, for example, in both the neuronal and hematopoietic lineages of vertebrates where excessive cell populations must be culled to appropriate numbers (10,11). Finally, PCD fulfills an important function in surveillance systems, where potentially dangerous cells (such as auto-reactive lymphocytes, cells that have incurred excessive DNA damage, or cells that are virally infected or preneoplastic) are removed (12). Improper regulation of cell death is often associated with disease. Decreased apoptosis can result in cancer or auto-immune disorders, while increased or inappropriate apoptosis is a feature of pathologies including AIDS, Alzheimer’s disease, and Parkinson’s disease (13). It is possible that the inappropriate PCD associated with such diseases may eventually be prevented. However, an understanding of the molecular basis underlying PCD is required before such molecular therapeutics can be developed.
APOPTOSIS: PIVOTAL MOLECULAR EVENTS The study of apoptosis is moving at a remarkable pace. A MEDLINE search with “apoptosis” as a search term identifies over 6500 published articles for 1998 alone. Indeed, by the time this chapter is in print, it is likely that significant new breakthroughs will have been made in this field. Because of the great volume of information about the regulation of apoptosis, the following discussion will be restricted to more fundamental aspects of the process. Where appropriate, the reader will be directed to more extensive review articles.
Chapter 6/The Bcl2 Gene Family
117
Regulation of PCD by Extracellular Signals How does a cell know when to die? Considerable evidence suggests that many independent cell types require continuous stimuli from the environment to suppress activation of PCD. Such cell-survival stimuli can be in several forms, which include soluble factors, cell-surface molecules, and/or components of the extracellular matrix (ECM) (14–16). The role of survival factors in suppression of PCD has been demonstrated convincingly by in vitro cell-culture work. Many cells in culture require sera or specific growth factors for survival. For example, the cytokine interleukin-2 promotes survival of resting T cells, while interleukin-3 is required for myeloid cell survival. Similarly, platelet-derived growth factor and insulin-like growth factor (IGF-1) enhance survival of fibroblasts in culture, while nerve-growth factor and other neurotrophins can promote survival of specific classes of neurons (14,17). Similar conclusions have been drawn from whole-animal studies. The adrenal cortex requires pituitary-derived adrenocorticotropic hormone for normal development. Removal of this survival factor in rats results in high levels of apoptosis within the adrenal cortex (18). Many cells undergo apoptotic death during the course of normal kidney development in the rat. However, injection of young rats with epidermal growth factor (EGF) prevents this cell death, establishing an antiapoptotic role for EGF in this tissue (19). Analysis of mice with spontaneous and induced genetic mutations has also been informative. The c-kit proto-oncogene encodes a transmembrane tyrosine-kinase receptor that is the product of the Dominant White-Spotting (W) locus. Mast-cell growth factor (MGF) is a ligand for this receptor that is encoded by the Steel (Sl) locus. Mice with mutations in either of this receptor-ligand pair display defects in three migratory cell lineages. Survival of hematopoietic stem cells (HSC), neural crest-derived melanocytes, and primordial germ cells are all affected, resulting in macrocytic anemia, reduced pigmentation, and sterility(20). Conversely, a number of extracellular signals can promote cell death. The steroid hormone ecdysone triggers apoptosis in tissues of metamorphosing insects (21). In male mammals, Müllerian-inhibiting substance (MIS), a member of the transforming growth factor-` (TGF-`) family, stimulates apoptosis and regression of the Müllerian duct during embryogenesis (9,22). Finally, Fas ligand can directly activate PCD through the Fas/TNF receptor pathway. These are but a few of the many factors known to instruct a cell to survive or die. One area of currently intensive research concerns the signal transduction machinery that links the extracellular signal to the intracellular apoptotic control system. Because of its complexity, this aspect of PCD is not discussed here, but is covered in refs. 23–25.
The Genetics of Apoptosis: Insights from C. elegans Genetic analysis of the nematode, Caenorhabditis elegans (C. elegans), has provided significant insight into the molecular basis for PCD. It appears that the fundamental molecular events that control apoptosis have been conserved throughout metazoan evolution. Knowledge of the precise cellular program of its development and sophisticated genetics make C. elegans an ideal system for studying the regulation of PCD. During normal development of a hermaphrodite, exactly 1090 somatic cells are formed, of which 131 cells always undergo PCD (26,27). Genetic studies have identified over a dozen genes required for this process of cellular elimination (28). Three genes required for normal developmental cell deaths to occur are ced-3, ced-4 (ced = cell-death abnor-
118
Ross and MacGregor
mal) and egl-1 (egl = egg-laying defective) (29,30). Loss-of-function alleles of any of these individual genes results in survival of cells that would otherwise normally undergo PCD. In contrast, ced-9 is required for negative regulation of apoptosis, and protects cells that are not predestined to die. While gain-of-function alleles of ced-9 prevent most cell deaths, loss-of-function mutations in ced-9 result in embryonic lethality associated with excessive cell death. Excessive cell death can be suppressed by secondary mutations in ced-4 and ced-3, demonstrating that ced-9 acts upstream of both these genes (31). Further analysis has shown that ced-4 positively regulates ced-3 (32), and that egl-1 is a positive regulator of apoptosis, acting upstream of ced-9 (30). A simplified diagram of the genetic pathway of apoptosis in C. elegans in shown in Fig. 1.
Caspases: Intracellular Executioners As part of the apoptotic program, a variety of cellular proteins are cleaved prior to removal of the cell. These include regulatory, structural, and housekeeping proteins such as poly(ADP)-ribose polymerase, nuclear lamins, actin, fodrin, MEK kinase 1, PI-3 kinase (Akt), Raf-1, focal-adhesion kinase, and DNA fragmentation factor (DFF) (33). This proteolytic cleavage is performed by a family of gene products called caspases. The term caspase is derived from the specificity of these enzymes, which contain a cysteine residue at their active site and cleave following aspartate residues within the substrates. Cloning of the ced-3 gene, which is required for cell death in C. elegans, provided the first insight that caspases are involved in effecting PCD. It was discovered that ced-3 encodes a ortholog of the previously cloned mammalian protease, interleukin-1`-converting enzyme (ICE, now known as caspase-1) (34). Although CED-3 is the only known caspase involved in apoptosis in C. elegans, at least 14 members to date have been identified in mammals (caspase-1 through 14) (33). Caspases have a wide range of substrates, not all of which are directly associated with the cell-death process. For example, some are involved in activation of proinflammatory cytokines. Caspase inhibitors block apoptosis in diverse cell types, and mice deficient for specific caspases show defects in development associated with reduced PCD, confirming the role of caspases in apoptosis both in vitro and in vivo (35–38). Because of their potent activity, caspases must be tightly regulated. Reliance upon transcription alone as a means of regulating caspase production would be capricious and impractical, especially in light of the rapidity with which some cells undergo PCD following receipt of a death-signal. Indeed, caspase activity is primarily regulated at the posttranslational level. Caspases are present in cells as inactive zymogens that are cleaved to form the active configuration, which consists of two heterodimers (39). Some unprocessed zymogens have low levels of proteolytic activity, suggesting one model for the initial activation of the caspases—the “induced-proximity” model (40). Procaspases associate with adaptor molecules, leading to aggregation of the zymogens and their autoprocessing caused by close proximity. Procaspases can also be activated by other caspases. This proteolytic cascade is well-suited to ensuring the rapid and efficient activation of the cell-death process. What then regulates activation of these executioners?
Death Receptors: The Fast-Track to Cell Death Perhaps the most direct pathway for induction of caspase activation is through mammalian “death receptors.” The two best characterized death receptors are Fas (also known as APO-1 or CD95), and TNFR1(p55), which are members of the tumor necrosis factor
Chapter 6/The Bcl2 Gene Family
119
Fig. 1. Summary of the genetic pathway regulating apoptosis in C. elegans. The slashed line between Ced-3 and RIP indicates that other gene products are required for destruction and engulfment of the dying cells.
(TNF) receptor family. Other death receptors of this family include death receptor-3 (DR-3, also known as APO-3, TRAMP, or LARD), DR-4 (TRAIL-R1, APO-2), DR-5 (TRAIL-R2, KILLER, TRICK2), the p75 nerve-growth-factor receptor, and avian CAR1 (41,42). These transmembrane proteins have a number of extracellular cysteine-rich domains and share a cytoplasmic sequence called the “death-domain,” which is used for recruitment of proteins involved in regulating the apoptotic pathway (43). The ligands for these receptors (including FasL/CD95L, TNF, APO2L, and APO3L) are type II transmembrane proteins found on the cell surface as homotrimeric molecules, although they can also be cleaved by metalloproteases and released as soluble molecules (44). Upon ligand (FasL) binding, the monomeric Fas receptor homotrimerizes, resulting in an intracellular clustering of the death domains. FADD (Fas-associating protein with death-domain) is a cytoplasmic adaptor molecule, which also contains a death domain that can bind to these clustered Fas-receptor death domains (45). FADD in turn contains another domain (called a caspase recruitment domain or CARD) that allows it to interact with the inactive form of caspase-8 (also called FLICE). CARD domains are found in some—but not all—caspases (46). When procaspase-8 interacts with FADD, it is activated by low intrinsic self-cleavage and or cross-cleavage because of the proximity of other procaspase-8 molecules. The resulting mature active caspase subsequently activates downstream caspases, which are required to effect apoptosis. Analyses of mice mutant for either Fas receptor or FasL suggest that the pathway is required for the deletion of activated mature T cells at the end of an immune response and the killing of cells (such as viral-infected or cancer cells) by cytotoxic T cells and natural killer cells (41,47). TNFR1 can also activate caspase-8 in a similar pathway involving different adaptor molecules, but, to complicate matters, TNFR1 can bind alternative death-domain-containing adaptor proteins that can activate other signal transduction pathways, some of which promote cell survival (41,42). Less is known about the biological functions of the other death receptors, most of which have only recently been cloned.
REGULATION OF APOPTOSIS BY THE BCL2 GENE FAMILY Identification of Bcl2, a Mammalian Ortholog of ced-9 Members of the Bcl2 gene family also control cell survival through regulation of procaspase activation. The prototypical family member Bcl2 (B cell lymphoma gene 2) was cloned because of its involvement in t(14;18) chromosomal translocations that result in human B-cell follicular lymphoma. In such cases, the translocation breakpoint juxtaposes the Bcl2 gene with the immunoglobulin heavy-chain transcriptional enhancer (48,49). Overexpression of Bcl2 results in a novel form of cancer in which the production of excessive cells is caused by an increase in cell longevity rather than increased rate of
120
Ross and MacGregor
proliferation. This mechanism was demonstrated in experiments where overexpression of BCL2 in IL-3 dependent pre-B cells prolonged survival upon cytokine withdrawal (50,51). At the time of its cloning, the peptide sequence of BCL2 provided no significant insight into the mechanism by which the protein regulates cell survival. Consequently, it was of great interest when the ced-9 gene, which is required to prevent excessive cell death during C. elegans development, was shown to encode the ortholog of BCL2. Indeed, BCL2 can partially compensate for loss of function of ced-9 in C. elegans, (52), illustrating the conservation of cell death pathways over a thousand million years of metazoan evolution.
Bcl2 is the Founding Member of a Multi-Gene Family in Mammals In vertebrates, a number of proteins have been discovered that share one or more domains of homology with Bcl2. These domains have been termed BH1, BH2, BH3, and BH4 (BH = Bcl2 homology domain). As with Bcl2, some of these proteins display antiapoptotic activity following expression in cells. However, many other related proteins actually kill cells; consequently, the Bcl2 family has been divided into two functional classes. The current death-protecting members of the family are Bcl2, BclxL (53), Bclw (54), A1 (55), and Mcl-1(56). The death-promoting members include Bax (57), Bak (58), Bad (59), Bclxs (53), Bik (60), Bid (61), Bim (62), Bok (63), Blk (64), Hrk (65), Diva (66), Bfl-1 (67), Nix (68), Nip3 (69), and EGL-1 of C. elegans (30). Figure 2 lists the currently known family members, and summarizes some of their structural features. All of the death-promoting family members contain a BH3 domain, and many of these members show little conservation to the rest of the gene family outside of this domain, suggesting the importance of this domain for killing activity. Several viral homologs of the anti-apoptotic members of the family also exist, including E1B 19K from adenovirus (70), Bhrf1 from Epstein-Barr virus (71), and Lmw5-hl from the African swine fever virus (72). Expression of these viral proteins is believed to prevent host cells from undergoing apoptosis following infection with the virus.
Mechanism of Bcl2 Gene Function Several of the pro- and anti-apoptotic members of the Bcl2 family can dimerize with each other, and in many cases these interactions may be required for their respective functions. Bcl2 and Bax can both homodimerize and heterodimerize through interaction of specific BH domains. Mutations in the BH1 or BH2 domain of Bcl2 abrogate both its capacity to dimerize with Bax and prevent Bax-induced death (73). Mutations in the BH3 domain of Bax block its ability to homo- and heterodimerize, and most of these mutations inhibit its pro-apoptotic activity (74). Based on these findings, a “rheostat” model was proposed for Bcl2 family function, in which relative levels of Bcl2 and Bax control cell survival, and if the intracellular level of Bax:Bax homodimers exceeds that of Bax:Bcl2 heterodimers, the cell will become committed to death (75). Analysis of additional members of the Bcl2 family suggests that while the rheostat model is useful, in certain cases it may be too simplistic. For example, not all proapoptotic Bcl2 family members appear to function in the same manner as Bax. Many of the BH3-only proteins do not homodimerize, and can only interact with anti-apoptotic proteins (76). It is possible that these BH3-only proteins promote death only by blocking the activity of Bcl2 or other death-protecting family members, whereas Bax may have additional functional roles in initiation of apoptosis.
Chapter 6/The Bcl2 Gene Family
121
Fig. 2. The Bcl2 family of apoptosis regulators. Proteins are classified according to apoptotic activity, BH homology domains are denoted. “PHO” = hydrophobic C-terminal tail. Many members contain mRNA destabilization sequences or PEST sequences, which can effect rapid degradation of proteins, suggesting a mechanism for tightly controlling steady-state levels of family members in the cell. mRNA destabilization sequences are defined as minimal (circle containing an “m”): AUUUA, or full (solid circle): UUAUUUA(U/A)(U/A). The minimal sequence may not be adequate to mediate degradation in all circumstances (209,210). PEST elements were defined using PESTfind (www.at.embnet.org/embnet/tools/bio/PESTfind/). A question mark indicates that sequence information was unavailable at the time of writing. A small circle is used if homology is minimal.
Regulation of Caspase Activation by CED-9/Bcl2 Family Genetic studies in C. elegans provided the first evidence that Bcl2 is involved in regulation of caspases. Control of the apoptotic pathway in C. elegans has been ordered genetically, with ced-4 acting upstream of ced-3, while ced-9 negatively regulates the activity of ced-4 (Fig. 1). Biochemical studies have demonstrated physical interactions between several of these gene products. CED-4 has been shown to interact with both CED-9 and with pro-CED-3 (the inactive form of the caspase) (77), while EGL-1 can also directly associate with CED-9 (30). Based on these findings, a model was proposed in which CED-4 facilitates processing of pro-CED-3 into an active caspase, subsequently effecting apoptotic death, and this activity is blocked by CED-9. This is supported by the finding that overexpression of CED-4 can kill cells, and that this effect is blocked by caspase inhibitors (77). The mechanism by which CED-9 prevents activation of pro-CED-3 by CED-4 is believed to involve physical association of CED-9 with CED-4. However, it is currently unclear whether CED-9 prevents CED-4 from interacting
122
Ross and MacGregor
with CED-3 directly, or perhaps holds CED-4 in a conformation in which it is unable to activate processing of CED-3. EGL-1, a BH3-only pro-apoptotic member of the Bcl2 family, appears to activate the apoptotic pathway by interacting with CED-9 to mediate release of CED-4, allowing it to initiate the caspase cascade (30). As might be anticipated, the cognate process in the mammalian system appears to be more complex. APAF-1 (Apoptosis Activating Factor-1) is a mammalian protein containing regions of homology to CED-4. APAF-1 was identified as one of three biochemically purifiable cytosolic molecules (APAF 1-3) required to activate caspase-3 in the presence of dATP in vitro (78,79). APAF-2 was identified as cytochrome c, while APAF-3 was discovered to be caspase-9 (80). Both APAF-1 and CED-4 contain a CARD domain and a nucleotide-binding oligomerization (NOD) domain. The C-terminus of APAF-1 contains a series of WD-40 domains, which are not found in CED-4. APAF-1 and procaspase-9 interact through their respective CARD domains, similar to the interaction between CED-3 and CED-4 (80). It has been demonstrated that APAF-1 can bind cytochrome c, and in the presence of dATP forms an oligomeric complex (81). These APAF-1/cytochrome c complexes can then bind and process procaspase-9, initiating the caspase cascade. The WD-40 repeats at the C-terminus of APAF-1 can interact with the N-terminal CED-4 homologous region of the protein, and expression of the WD-40 repeats alone can inhibit the self-association of APAF-1 and procaspase activation (82). Therefore, the WD-40 repeats may function to negatively regulate procaspase-9 activation by blocking the ability of APAF-1 to oligomerize, potentially through its interaction with the CED-4 homologous region of APAF-1. Binding of cytochrome c and dATP hydrolysis by APAF-1 may disrupt this interaction and allow APAF-1 to undergo a conformational change and self-associate. Truncated APAF-1, lacking the WD-40 repeats, can also recruit and process procaspase-9, yet cannot release the active caspase-9 from the complex (81). Thus, the WD-40 domains also appear to play a specific role in regulating release of processed, active caspases. There is conflicting evidence regarding the role of the Bcl2 family in regulation of APAF-1 activity. BclxL can interact with APAF-1 or CED-4 in vitro (83,84), as shown by coimmunoprecipitation experiments with transfected cells, and these interactions are blocked if BclxL is complexed with the pro-apoptotic members Bax, Bak, or Bik (77). In vitro interactions between Boo and APAF-1 have also been reported (85). Thus, it has been postulated that BclxL (and Boo) may prevent cell death by inhibiting the capacity of APAF-1 to activate caspase-9, which is conceptually similar to the model for regulation of CED-4 by CED-9 in C. elegans. By extension, pro-apoptotic family members could then kill cells by disrupting the interactions between BclxL and APAF-1, leaving APAF-1 free to activate caspase-9. However, independent studies failed to show any interaction between both overexpressed and endogenous APAF-1 and a number of the anti-apoptotic Bcl2 family members (Bcl2, Bclw, Mcl-1, A1, Boo, and BclxL), under conditions in which APAF-1 would interact with procaspase-9 (86). Thus, in contrast to the nematode system, it is currently unclear whether the mammalian antiapoptotic Bcl2 family members actually have a role in regulating caspase activation through direct interactions with APAF-1. It is possible that inclusion of the WD-40 domains in the Cterminus of mammalian APAF-1 eliminates the requirement for negative regulation of Apaf-1 by anti-apoptotic Bcl2 family members. Other mechanisms by which the Bcl2 family may regulate caspase activation are discussed here.
Chapter 6/The Bcl2 Gene Family
123
The Mitochondrion as a Cellular Pandora’s Box APAF-1 requires cytochrome c as a cofactor for activation of caspase-9. In living cells, cytochrome c is usually found in the mitochondrial intermembrane space, where it functions in the electron transport chain. However, during apoptosis, cytochrome c is released from mitochondria into the cytosol (87–89). Apoptosis-inducing factor (AIF), a flavoprotein, also resides in the mitochondrial intermembrane space in living cells. AIF can induce nuclear morphological changes associated with apoptosis in vitro, and during apoptosis it also exits the mitochondrion and translocates to the nucleus (90). Release of these and perhaps other apoptogenic molecules from the mitochondrion is an important step in regulation of apoptosis, and the Bcl2 family is involved in this regulation. Addition of recombinant Bax to isolated mitochondria stimulates release of cytochrome c (91). Overexpression of Bcl2 or BclxL can block release of cytochrome c from mitochondria in cells treated with a variety of apoptotic stimuli (87,88,92). The subcellular localization of several Bcl2 family proteins suggests that they may play a direct role in the release of cytochrome c. Several of the family members (Fig. 2) have hydrophobic carboxy-terminal tails which can anchor the proteins in organelle membranes (93). Bcl2 has been localized to the mitochondria, nucleus, and endoplasmic reticulum (94,95), and BclxL has been localized to the mitochondrial outer membrane (96). Removal of the hydrophobic tail of Bcl2 changes its localization to the cytosol, and reduces its ability to block apoptosis, demonstrating that its localization is important for its function (97). Although the death-promoting member Bax has a hydrophobic tail, it is localized in the cytoplasm until an apoptotic stimuli is received, when it translocates to the mitochondrial outer membrane (98). This sub-cellular redistribution of Bax and the subsequent release of cytochrome c is associated with a conformational change in the molecule, although the mechanism which triggers this change is not yet known (99). In contrast, Bcl2 is localized to mitochondria both prior to and during apoptosis (98). The manner in which Bax promotes release of cytochrome c and AIF from the mitochondrial intermembrane space is unclear, and may involve multiple mechanisms. One model explaining the mechanism for release of these molecules involves the pore-forming ability of several members of the Bcl2 family. Analysis of the three-dimentional structure of BclxL revealed similarity to the pore-forming domains of the bacterial toxins, known as diptheria toxin and colicin (100), and showed that Bcl2, BclxL, and Bax can all form ion channels in synthetic membranes (101–103). Diptheria toxin can form pores large enough for proteins to move through lysosomal membranes, which led to the postulate that pores formed by Bcl2 family proteins might permit efflux of cytochrome c and other proteins (104). However, no direct evidence exists that any of the Bcl2 family proteins could form a pore large enough to permit passage of cytochrome c. In several cell types, apoptotic stimuli cause a dissipation of the mitochondrial innermembrane potential (6^m), which occurs prior to the changes seen in the nucleus and plasma membrane (105). Loss of 6^m results in uncoupling of electron transport and ATP production. The loss of 6^m results from opening of the mitochondrial permeability transition (PT) pore, a large conductance channel in the mitochondrial membrane (106). The PT pore is a multi-protein complex, and its components include the adenine nucleotide translocator (ANT), an inner-membrane protein, and voltage-dependent anion channel (VDAC), an outer-membrane protein (107). Overexpression of Bax can induce mitochondrial 6^m loss, which can be blocked by inhibitors of the PT pore, and addition of recombinant Bax or Bak to isolated mitochondria induces loss of 6^m (108,109). Bax,
124
Ross and MacGregor
Bak, and Bcl2 can physically interact with ANT in vitro, and both Bax and Bak coimmunoprecipitate with VDAC (108,110). Bcl2 or Bclx can both block changes in mitochondrial membrane permeability induced by a number of stimuli, including overexpression of Bax (111). These combined results indicate that the Bcl2 family can regulate activity of the PT pore, and that loss of 6^m is a critical event in Bax-induced apoptosis. These findings have provided another model to explain the mechanism of cytochrome c release from mitochondria. Upon loss of 6^m, there is an influx of water into the matrix of the mitochondrion, which leads to swelling and rupture of the smaller outer membrane. This rupture allows proteins in the intermembrane space (cytochrome c, AIF) to escape into the cytosol. By initiating or blocking loss of mitochondrial 6^m, the Bcl2 family proteins could regulate release of cytochrome c. Indeed, it has been reported that this loss of integrity of the outer membrane occurs in some apoptotic cells and results in release of cytochrome c (111). Moreover, in support of this model, the mitochondrial permeability transition is required for TNF_-induced apoptosis in rat hepatocytes, and occurs prior to release of cytochrome c (112). However, there are also conflicting reports that movement of cytochrome c from the mitochondria precedes the dissipation of 6^m during apoptosis, and that the mitochondria remain intact (87,88,113). A recent finding may explain how Bax could stimulate release of cytochrome c without simultaneously causing a loss of 6^m. Either Bax or Bak, in combination with VDAC, can form a channel in liposome membranes, which allows passage of fluorescein labled cytochrome c (114). In contrast, Bax and Bak alone cannot allow passage of cytochrome c. In certain situations, Bax or Bak may translocate to the mitochondria and interact with VDAC in the outer membrane to form a channel capable of releasing apoptogenic proteins from the intermembrane space. In other instances, Bax or Bak may interact with both ANT and VDAC (and potentially, other components of the PT pore) to cause a loss of mitochondrial 6^m, which subsequently leads to rupture of the mitochondrial outer membrane, release of cytochrome c, and apoptosis. In either case, interactions of Bcl2 family proteins with components of the PT pore would be important for execution or prevention of apoptosis. The ability of proapoptotic Bcl2 family members to induce release of cytochrome c, thereby activating a caspase cascade, and to disrupt mitochondrial function, may more thoroughly ensure a cell’s commitment to death. In summary, Bcl2 family members may initiate or prevent cell death by 1) regulating the activity of the other Bcl2 family members via dimerization, 2) controlling the release of cytochrome c and other proteins from the mitochondrial intermembrane space, and 3) affecting mitochondrial function by maintaining or disrupting the innermembrane potential. For more comprehensive information regarding mechanisms of apoptosis regulation by the Bcl2 family (see refs. 72,115–117) Figure 3 shows a simplified model summarizing the mechanisms by which the Bcl2 family regulates apoptosis.
Upstream Regulation of Bcl2 Family Member Activity Which upstream factors regulate the activity of the Bcl2 family? In many cases, it is not yet known how extracellular signals are linked to Bcl2 family proteins. However, progress has been made regarding the mechanisms by which Bid and Bad, two deathpromoting Bcl2 family members, are regulated. Both of these are BH3-only proteins, lack hydrophobic tails, and are found in the cytosol. Bad can activate apoptosis by interacting with BclxL or Bcl2 to inhibit their deathprotecting function (59). In an interleukin-3 (IL-3)-dependent cell line in the presence
Chapter 6/The Bcl2 Gene Family
125
Fig. 3. Simplified model for regulation of apoptosis by the Bcl2 family. Many potential regulatory mechanisms are shown, not all of which may operate in the same cell type. Bax undergoes a conformational change, then translocates to mitochondria during apoptosis. Insertion of Bax into the mitochondrial membrane then promotes release of cytochrome c. Bid is activated by cleavage in the Fas/caspase-8 pathway, and also promotes apoptosis via stimulation of cytochrome c release. Bcl2, or other death-protecting members can block release of cytochrome c from mitochondria. Bad, when phosphorylated, is held inactive by 14-3-3 family proteins. When dephosphorylated, Bad interacts with Bcl2 or BclxL via their BH4 domains to block their deathprotecting activity. APAF-1, in the presence of cytochrome c and dATP (or ATP), can activate caspase-9 by facilitating cleavage of the procaspase. This may involve formation of a large multimeric complex of APAF-1 and caspase-9 molecules. For the sake of simplicity, APAF-1 is shown as a dimer in the figure. See text for more detailed explanation and references.
of cytokine, Bad is phosphorylated on two serine residues, 112 and 136. When phosphorylated, Bad is sequestered by 14-3-3, cytosolic proteins which prevent Bad from interacting with Bcl2 or BclxL. In the absence of survival factor, Bad is free to interact with these proteins, resulting in initiation of the apoptotic cascade (17,118). Two kinases have been identified as potential regulators of Bad function. PKB/Akt can phosphorylate
126
Ross and MacGregor
serine 136 in vitro and when overexpressed in cells (17,119–121). PKA can phosphorylate BAD on serine 112, and inhibitors of PKA can block the phosphorylation triggered by IL-3 (122). These findings suggest that there may be multiple signalling pathways that regulate the phosphorylation status of Bad and thus affect cell survival. Bid is another pro-apoptotic, BH3-only family member, and its function is regulated by the Fas/TNFR1 signaling pathways. Bid exists in the cytosol as an inactive precursor protein. Caspase-8 activated by the FasL or TNFa pathway cleaves the N-terminus of Bid. After cleavage, the C-terminal portion of Bid (p15 Bid) translocates to the mitochondrion, where it stimulates the release of cytochrome c, thereby activating caspase9 (123,124). The release of cytochrome c induced by p15 Bid can be blocked by Bcl2 or BclxL (125). The cross-communication between the Fas pathway and the Bcl2 family may serve to amplify or reinforce the caspase cascade in specific cell types.
FUNCTIONAL ANALYSIS OF BCL2 GENE FAMILY IN TRANSGENIC MICE With the exception of studies in C. elegans, many of the findings discussed here result from experiments performed in mammalian-cell-culture systems. This has generated information regarding the molecular events that take place during apoptosis. However, it provides little insight about essential functions for each Bcl2 family member in vertebrates in vivo. Transgenic mouse models are ideally suited to providing such information and both gain-of-function and loss-of-function approaches have been used with success to gain insight into the in vivo function of different Bcl2 family members.
Gain-of-Function Bcl2 Transgenics A gain-of-function approach was first used to study the function of Bcl2 in B and T lymphocytes in vivo. Overexpression of Bcl2 extends the survival of this cell population, increasing the number of mature B cells, and eventually results in malignancy (126–128). Expression of Bcl2 in immature cortical thymocytes also rendered the cells less sensitive to a number of insults, including PMA, ionomycin, glucocorticoids, or a-irradiation (129). These experiments demonstrate the powerful utility of the transgenic system to model the effects of overexpression of Bcl2 in human follicular lymphoma. Bcl2 has also been expressed at high levels in a variety of tissues to determine the effect of perturbing apoptosis during normal development. Expression of Bcl2 in neurons results in hypertrophy of the central nervouse system (CNS) associated with a reduction in cell death during early neural development (130). In a similar manner, targeted expression of Bcl2 to the lens of the eye disrupted normal fiber-cell differentiation, causing cataracts, vacuolization, disorganization, and inhibited fiber-cell enucleation (131). Formation of the mouse vaginal opening at puberty requires apoptosis, and expression of Bcl2 in the suprabasal epithelial cells and subepithelial cells of the vaginal mucosa blocks vaginal formation entirely (132). Such studies demonstrate the importance of PCD during normal development, and show that Bcl2 can function in these tissues to block apoptosis, at least when expressed at supraphysiological levels. Ectopic expression of Bcl2 family members can also correct developmental defects associated with increased levels of apoptosis. Osteopetrotic op/op mice have an inactivating mutation in the macrophage colony-stimulating factor (M-CSF) gene. These mice have impaired development of monocytes and reduction in the macrophage and osteoclast populations. Overexpression of Bcl2 in monocytes in op/op mice ameliorated loss
Chapter 6/The Bcl2 Gene Family
127
of macrophages and mediated an almost complete reversal of the osteopetrosis (133). This suggests that the M-CSF gene product is involved in survival of monocytes, potentially through a Bcl2 -dependent pathway. Mice with mutations in the IL-7 receptor are lymphopenic, and have severely reduced numbers of developing T cells and B cells. Overexpression of Bcl2 rescues T-cell development and function in the IL-7R deficient mice. This is a significant finding, as severe combined immunodeficiency, an X-linked disorder in humans, may arise from defects in the IL-7 pathway (134,135). These studies illustrate the potential for development of novel therapeutic regimens to treat disease resulting from an imbalance in apoptosis.
Loss-of-Function Bcl2 Family Transgenics BCL2 Several groups have independently used a loss-of-function approach to identify the normal physiological roles of Bcl2. Bcl2 is expressed in a wide range of tissues during mouse embryogenesis, and later in a more restricted subset of adult tissues, primarily epithelial and lymphoid stem-cell populations and neurons (136). Despite this widespread embryonic expression, mice with targeted mutations in Bcl2 complete embryonic development, yet display a number of interesting postnatal phenotypes (136,137). Bcl2 null-mutant mice display severe kidney defects. At birth, the kidneys are considerably smaller than those of wild-type littermates, and these eventually become grossly enlarged and cystic (136,137). These defects result from problems during kidney development. Analysis of kidneys in Bcl2 homozygous mutant embryos using TUNEL staining during early stages of nephrogenesis revealed high levels of apoptosis of mesenchymal cells and a significant decrease in the number of nephrons. Prior to birth, the kidneys show irregular branching and convolution of the ureteric buds (138). At birth, the kidneys are reduced in size and usually become cystic within the first 2 wk after birth (136,139). Most Bcl2 mutants on a congenic C57BL/6 genetic background die before 3 wk of age as a result of the kidney defect. Bcl2 is expressed in immature cells of both B and T lineages. At birth, hematopoietic lineages are normal in the Bcl2 mutants, but a decrease in the size of both the thymus and spleen is seen as the mice age. TUNEL staining was used to demonstrate that this is associated with apoptotic death of thymocytes and B- and T-cell populations in the spleen. Thymocytes isolated from Bcl2 mutants were also more sensitive to both dexamethasone and a-irradiation than thymocytes from control animals (136,137). This finding indicates that Bcl2 is important for survival of hematopoietic lineages in wild-type animals, supporting the results seen in the gain-of-function models. The hair of Bcl2 mutants that survive past the first few weeks turns gray. The timing of this change corresponds to the second cycle of hair-follicle growth, which produces an entire new set of hair starting at around 4 wk of age. Analysis of the hair follicles in these mice shows a reduction in both melanocytes and melanin granules indicating that Bcl2 is important for survival of melanocytes. Significantly, epidermal melanocytes express high levels of Bcl2 (136,137,140). Bcl2 mutant mice also display phenotypes in both the intestine and nervous system. Bcl2 is expressed in epithelial cells of the gut, and Bcl2 mutants have abnormal villi and increased levels of apoptotic cell death in the intestinal epithelium (137). Many neurons of the peripheral nervous system express Bcl2, and careful analysis of mutants reveals a reduction in number of both sensory and sympathetic neurons after the first postnatal week (141).
128
Ross and MacGregor
These studies demonstrate multiple essential roles for Bcl2 during mouse development and homeostasis. Bcl2 is expressed widely during embryogenesis, yet Bcl2-deficient mice show relatively few developmental defects. This may be caused by redundancy between Bcl2 and its other anti-apoptotic relatives, such as, Bclx, Bclw, and A1, many of which are also expressed during embryogenesis (142,143). BCLX Bclx is a death-protecting member of the Bcl2 family that is most closely related to Bcl2. Two different alternatively spliced transcripts of Bclx—termed BclxS and BclxL— have been detected in humans (53). In contrast to BclxL, BclxS—which lacks the BH1 and BH2 domains—has killing activity in vitro. However, BclxS is expressed at extremely low levels in murine tissues, making it difficult to evaluate the role of the truncated form in regulation of apoptosis in vivo (96). Mice homozygous mutant for Bclx die at approx embryonic d 13.5 (E 13.5) (144). By E 11.5, homozygous mutant Bclx embryos display extensive cell death in the differentiating neurons of the brain and spinal cord, and by E 12.5, there is massive apoptosis of neurons in the brain. Bclx-null embryos manifest a threefold increase in apoptotic death in hematopoietic cells of the liver as compared to control animals, and this is believed to be the primary cause of lethality at E 13.5 (144). Bclx is normally expressed in both differentiating neurons and the hematopoietic system during embryogenesis and other death-protecting members of the Bcl2 family appear unable to compensate for loss of Bclx in these tissues. Death of mice null for Bclx early in embryogenesis precludes the analysis of roles of Bclx in other tissues later in embryonic or postnatal development. To circumvent this problem, chimeric mice were generated by injection of Bclx-null ES cells into wild-type host blastocysts. Adult chimeric mice that did not express Bclx in lymph nodes or spleen had reduced numbers of T and B cells, although the population distributions for both cell types was normal (144). Collectively, these results demonstrate that Bclx is required for neural and hematopoietic development during mouse embryogenesis and hematopoietic cell survival in adult tissues. BAX In contrast to Bcl2 and Bclx, Bax is a pro-apoptotic member of the gene family. Consequently, it may be predicted that genetic ablation of Bax would result in excessive cell survival. Indeed, Bax-null mutant mice display two major phenotypes that are both associated with cellular hyperplasia (145). Bax mutant mice have an excess of cells in lymphoid tissues. Mutants have a 60% increase in numbers of thymocytes compared to wild-type controls, although the ratio of the various thymocyte populations is unaffected. Similarly, the spleen in Bax mutants is enlarged, and displays an 80% increase in numbers of B cells compared to control animals. Bax mutant males are also sterile, and fail to produce mature sperm. Spermatogenesis is largely arrested at premeiotic stages with a major increase in the numbers of type B spermatogonia. Paradoxically, there is increased apoptosis in the male germ-cell population with only rare examples of germ cells in advanced stages of development. Possible mechanisms underlying the development of this phenotype are discussed later in this chapter. BCLW Bclw, another death-protecting member of the family, is also required for spermatogenesis. On a hybrid genetic background, mice mutant for Bclw are viable but male
Chapter 6/The Bcl2 Gene Family
129
sterile (146,147). The testes of Bclw mutant mice display widespread apoptosis of all stages of germ cells and a complete block in elongate haploid germ-cell development. By 6 mo of age, loss of testicular germ cells is complete. Surprisingly, Sertoli cells are also lost from the seminiferous epithelium with completion of loss at 6–8 mo of age. Subsequently, there is a dramatic reduction of the number of Leydig cells, which occurs via apoptosis and engulfment by macrophages (L. Russell et al., Biology of Reproduction 2001; in press). These findings suggest that Bclw is important for survival of both germ-cell and somatic cells in the testis. Females also display reduced fertility, although this effect is subject to a genetic background effect. Bclw is expressed in oocytes (148) (A. Ross and G. MacGregor, unpublished observation), and appears to be required for survival of primordial follicles (A. Ross, J. Tilly and G. MacGregor, unpublished observations). Finally, most Bclwdeficient mice on a C57BL/6 genetic background can be identified because of a reduction in their body size and a facial dysmorphology. The developmental basis for these defects is currently under investigation, but is presumably associated with an increase in PCD within specific tissues. Bclw is widely expressed in both embryonic and adult tissues (54) (A. Ross and G. MacGregor, unpublished observations), yet, as with Bcl2 deficient mice, Bclw mutant mice display only a limited number of overt developmental defects. BID Bid is a death-promoting, BH3-only member of the Bcl2 family, which is activated upon cleavage by caspase-8 in the FasR/TNFR1 pathway (123). Mice deficient for Bid are born at normal Mendelian frequencies, with no overt developmental defects (149). This demonstrates that Bid is not required for normal embryonic development and survival. However, when wild-type and Bid-deficient mice were injected with anti-Fas antibody (which activates the Fas pathway), wild-type mice died rapidly from liver failure associated with massive hepatocellular apoptosis, while most of the Bid-deficient mice survived, showing little or no hepatic apoptosis. In the livers of wild-type mice injected with the antibody, downstream caspases were activated, and cytochrome c was released into the cytosol, but in the Bid –/– mice, cytochrome c was not released from the mitochondria and downstream caspases were not activated (149). This confirms that Bid can mediate cytochrome c release in the FasR/TNFR1 pathway in vivo.
Double Mutants To determine which Bcl2 family members interact in vivo, mice were generated that have mutations in multiple Bcl2 family genes. Mice lacking both Bax and Bclx were generated to determine whether loss of the death-promoting member Bax could rescue the lethality of Bclx-null mutants associated with excessive hematopoietic and neuronal cell loss (150). Although Bax/Bclx double-null mutants also died during embryogenesis, a large decrease was observed in the amount of neural apoptotic death in the double mutants compared to the Bclx null embryos. This indicates that Bax and Bclx regulate survival of neurons in the development of the CNS. The lethality of the Bax/Bclx mutants is most likely caused by a failure to correct the excessive apoptosis in hematopoietic cells of the liver. A different death-promoting member of the Bcl2 family may effect the death pathway in the hematopoietic cells of this tissue (150). Mice null-mutant for both Bax and Bcl2 have also been generated (151). Removal of Bax rescues the apoptosis and thymic hypoplasia in the Bcl2-deficient mice, indicating that Bax and Bcl2 both regulate cell death and survival in the thymus. In contrast, the
130
Ross and MacGregor
kidney defect of the bcl2 mutants and the testicular phenotype of bax mutants are not altered in the bcl2/bax mutants. It is possible that additional Bcl2 family members expressed in these tissues may prevent rescue of the respective mutant phenotypes.
APOPTOSIS AND BCL2 FAMILY FUNCTION IN REPRODUCTIVE TISSUES Functional analyses of the Bcl2 family using transgenic mice have demonstrated multiple roles for the family in regulation of apoptosis in both male and female germ cells, as well as a number of hormonally sensitive reproductive tissues. The following is an overview of known functions for Bcl2 family members in several of these organs.
Testis Apoptosis is a normal feature of gametogenesis in both males and females. In males, there are two peak periods of germ-cell apoptosis, one during embryogenesis and the other postnatal. PRENATAL The primordial germ cells (PGCs) can first be identified in the mouse at E 7.5 d post coitum as a population of around 50 alkaline phosphatase expressing cells, which are located close to the allantoic bud (152–154). Between E 8.5 and E 10.5, these cells migrate from the hindgut and into the genital ridges. The PGCs undergo several mitotic divisions during migration, until by E 13.5 there are approx 25,000 PGCs within each gonad (153). PGCs in the developing ovary differentiate into oogonia, initiate meiosis to become oocytes, and by birth are arrested at prophase of the first meiotic division. Following onset of testicular differentiation the prospermatogonia continue to divide until E 14, at which point they undergo mitotic arrest (154–156). Just prior to this arrest, at around E 13, large numbers of apoptotic prospermatogonia are observed, using both TUNEL and electron microscopy as criteria for identification of dying cells. By E 14, the number of apoptotic cells has dramatically decreased, and there is very little germ-cell death during the rest of the prenatal period (157). What controls survival of germ cells during embryogenesis? Several endocrine factors have been implicated in the regulation of PGC survival. C-kit, a tyrosine-kinase receptor encoded by the W locus, and a ligand, (Kit-ligand [KL]), that is encoded by the Sl locus are essential for migration, proliferation and survival of PGCs. This role has been demonstrated both in vivo and in vitro with mutations in either locus result in dramatic germ-cell deficiencies. KL can also promote the survival of PGCs in culture (158). Other factors that may be critical for the survival of PGCs include interleukin-4, basic fibroblast growth factor, oncostatin M (OSM), leukemia-inhibitory factor (LIF) and gp130, a receptor that heterodimerizes with both OSM and LIF (159). Little is known regarding the potential role of the Bcl2 family in PGC survival. Expression of Bcl2 or Bclx can extend the survival of PGCs in culture (160). However, it is currently unknown whether these members of the Bcl2 family are normally expressed in PGCs. Bcl2-null males are fertile, indicating that there is no requirement for Bcl2 during male germline development. However, since Bclx-null mutant embryos die around the time of gonadal differentiation, the status of the germline in these mutants could not be addressed. Thus, it remains possible that Bclx may have an essential role in survival of the germline during embryonic or postnatal development (160a).
Chapter 6/The Bcl2 Gene Family
131
POSTNATAL The second peak in apoptotic death of male germ cells occurs postnatal. Shortly after birth, mitosis resumes and the first wave of spermatogenesis begins. During the first week, prospermatogonia differentiate into type A spermatogonia, the stem-cell population of the testis. This is followed by a period of spermatogonial proliferation until postnatal d 10, at which time germ cells initiate meiosis (161). Many apoptotic spermatogonia and spermatocytes are seen in the testis in the second and third weeks after birth (157,162). The incidence of cell death declines following the third week, when haploid cells are first found in the testis. While apoptosis is observed in male germ cells throughout adult life, the incidence of this never approaches that seen in prepubertal animals. Considerably more is known about functions of the Bcl2 family in the postnatal and adult testis than the prenatal testis. Several Bcl2 family members are expressed in the testis, including Bclx (163), Bclw (54,147), Mcl-1 (164), Bax (162), Bak (165), Bok (166), Diva/Boo (66), Bid (A. Ross and G. MacGregor, unpublished), Blk (64), and Bod/ Bim (167). This makes it possible that Bcl2 family members could play many important roles in regulating cell death in the testis. Indeed, as mentioned earlier loss of function transgenic mouse studies mice have demonstrated a requirement for at least two Bcl2 family members in spermatogenesis. Bax is expressed in spermatogonia of prepubertal and adult testes (161). Analysis of prepubertal animals suggests that Bax expression in testis is maximal during the second and third weeks after birth with significantly lower levels of expression observed in the adult testis. The peak of Bax expression coincides with maximal apoptotic germ-cell deaths that occurs in the testis of wild-type animals 2–3 wk after birth. Bax-deficient mice have defective spermatogenesis that is associated with an accumulation of type B spermatogonia (145). Testis histology of Bax-null mice shows that at postnatal d 9 (P9), ratios of germ cells to Sertoli cells are normal, yet by P12, there are 4–5 times as many germ cells in the knockout than in wild-type (L. D. Russell and C. M. Knudson, unpublished observations). This accumulation of spermatogonia in the Bax mutants coincides temporally with the peak of male germ-cell apoptosis in wild-type animals. Moreover, immunohistochemistry and TUNEL analyses indicate that many of the dying spermatogonia in testis of a 2.5-wk-old wild-type animal expressed Bax at high levels (161). Collectively, these findings indicate that Bax is required for the wave of apoptotic death seen in the prepubertal testis. Interestingly, an almost identical phenotype is seen in gain-of-function transgenic mice that overexpress either Bcl2 or Bclx in germ cells in the testis (161,168). In each of the latter cases, transgenic males were sterile and the seminiferous epithelium displayed a variety of defects. Some tubules had reduced numbers of spermatocytes and spermatids and increased numbers of spermatogonia. Other tubules contained either giant multinucleated cells or, in certain cases, virtually no germ cells. These phenotypes are also found in many tubules of older Bax mutant males. This suggests that the wave of Bax-induced apoptosis can be perturbed by ectopic and/or overexpression of either Bclx or Bcl2. What is the function of this dramatic wave of apoptosis during prepubertal testicular development? The Sertoli cell is the somatic cell of the seminiferous epithelium that provides the immediate somatic environment in which male germ-cell development occurs (169). Sertoli cells contact neighboring Sertoli cells to establish the basal and adluminal compartments, and these interactions are important for proper function of the
132
Ross and MacGregor
Sertoli cell (170). Sertoli cells also form a complex network of contacts with different developmental stages of germ cells. A careful balance must be maintained between the Sertoli cells and germ cells, and this wave of apoptosis may keep germ-cell numbers at an appropriate level so as not to perturb this balance. By disrupting normal germcell:Sertoli-cell ratios, the accumulation of germ cells in testes of Bax-null mice may preclude Sertoli cells from being able to support spermatogenesis, resulting in the arrest in spermatogenesis seen in these animals, and the resulting increase in apoptotic death of germ cells. Alternatively, it is possible that Bax-deficient germ cells arrest in development in a cell-autonomous manner under some form of fail-safe mechanism. Finally, as Bax is expressed in mouse Sertoli cells (A. Ross and G. MacGregor, unpublished observation), it is possible that there is a fundamental developmental defect in Baxdeficient Sertoli cells. Discrimination between an intrinsic or extrinsic developmental defect in Bax-deficient germ cells, and Sertoli cells could be addressed by testicular germ-cell transplantation techniques (171). From an endocrine perspective, there is evidence that this crucial period of apoptotic death is under hormonal control. Wild-type male mice administered testosterone from 1–3 wk of age, during the normal wave of spermatogonial apoptosis, display abnormalities of the seminiferous epithelium similar to those of the Bcl2 and Bclx gain-of-function and Bax-null transgenic mice. This suggests that testosterone can also block the early wave of apoptosis (161). Conversely, androgen withdrawal in adult mice is associated with the reverse effect. Mice treated with ethane dimethanesulfonate (EDS), a Leydigcell toxicant, showed a 24-fold increase in apoptotic germ-cell deaths (172). Testicular levels of Bax also increased after this treatment; thus, it is possible that Bax expression could be regulated by androgens. In prepubertal mice, a relatively high level of apoptotic death is required to regulate the spermatogonial population, as evidenced by the phenotype of the Bax mutants. At this point, gonadotropin levels are considerably lower than in adults, and LH-stimulated testosterone secretion is also reduced. Lower androgen levels may facilitate increased expression of Bax, and as a result, allow the higher levels of apoptosis that are required for proper initiation of spermatogenesis. Bclw mutant mice also show defects in spermatogenesis and are sterile, although the testicular phenotype is significantly different from that seen in the Bax mutants. Germ-cell development in prenatal and prepubertal testis of Bclw mutants appears to proceed normally through postnatal d 16 (P16). However, by P19, a sevenfold increase in degenerating spermatocytes is seen in Bclw mutants (147). At P24, there is a significant increase in incidence of TUNEL-positive spermatocytes, and a 10-fold reduction in the number of spermatids. Subsequently, spermatids are arrested in development at step 13, and the first wave of spermatogenesis is never completed. By 2–3 mo of age, the majority of germ cells in the testis are apoptotic, and by 5–6 mo, the tubules are essentially devoid of germ cells. In contrast to the testis in Bax-null animals, the Leydig-cell and Sertoli-cell populations are also affected in Bclw mutants. By 6 wk of age, the Sertoli population is reduced by approx 84% compared to wild-type, and by 7–8 mo the Sertoli cells are essentially absent from the tubules (146,147). The Leydig-cell compartment displays hyperplasia prior to completion of loss of Sertoli cells, with an increase of as much as 50% in cell numbers compared to wild-type controls. However, the majority of Leydig cells are lost by apoptosis and phagocytosis following completion of loss of Sertoli cells, with only a relatively small number of mesenchymal cells and some phagocytes remaining in the interstitial space by 8 mo of age. At this time, the peritubular myoid cells and endothelial
Chapter 6/The Bcl2 Gene Family
133
cells of the tubule basement are the primary cell types remaining within the testis (146,147). The primary cause of germ-cell loss in Bclw mutants does not appear to be caused by endocrine effects, as gonadotropin levels were initially equivalent in Bclw mutants and controls and, as expected, FSH levels were elevated during the period of protracted germ-cell loss (147). Additionally, weights of seminal vesicles, a testosterone-sensitive tissue, were similar in young mutants and controls, suggesting that testosterone levels were not significantly affected (146,147). Bclw is expressed in both Sertoli cells and in premeiotic and meiotic male germ cells, but not in elongate germ cells as first described (146) (Russell et al., Biology of Reproduction 2001; in press). Thus it is likely that the arrest in elongate germ-cell development in Bclw mutants is not cause by cell-intrinsic effects. It is currently unknown whether Bclw is required in an autonomous manner for diploid male germ-cell survival, or whether germ-cell loss in Bclw mutant males is entirely an indirect consequence of Bclwdeficient Sertoli-cell dysfunction. This could be ascertained by transplantation of Bclwdeficient male germ cells into a wild-type syngenic recipient testis. Similarly, while Sertoli cells are notoriously difficult to ablate, it is possible that the excessive loss of germ cells is indirectly responsible for Sertoli-cell attrition in Bclw-null males. To test this, mice deficient for both c-kit and Bclw were generated. C-kit deficient mice lack germ cells from birth, resulting from germ-cell-intrinsic defects. Sertoli cells are not affected, as they do not normally express c-kit. In testis lacking germ cells, Bclwnull Sertoli cells showed reduced survival compared to Sertoli cells from Bclw wildtype, c-kit deficient mice (Ross and MacGregor, submitted). This confirms that loss of Bclw-deficient Sertoli cells occurs independently of germ cells, and suggests that Bclw is required cell-intrinsically for Sertoli-cell survival. Finally, Bclw is not expressed in Leydig cells (146,147). Thus, it is likely that the depletion of Leydig cells in aged Bclw mutants is a secondary effect related to loss of Sertoli cells, which would indicate a function for Sertoli cells in support of adult Leydigcell survival. Bax, Bak, and Bid are all expressed in mouse Sertoli cells (Ross and MacGregor, submitted), and one or more of these proapoptotic molecules may be responsible for killing the Sertoli cells in the Bclw mutants. To determine whether Bax mediates the loss of Sertoli cells in the Bclw-deficient mice, Bclw/Bax mutant animals were generated. While spermatogenesis is still defective in the Bclw/Bax mutants, as it is in the Bax mutants alone, the loss of Sertoli cells seen in Bclw single mutants is suppressed (Ross and MacGregor, submitted). This demonstrates that Bclw and Bax both regulate survival of this specific cell type.
Prostate Apoptosis occurs in a hormone-sensitive manner in the prostate. Either androgen withdrawal or castration results in increased apoptotic death in the prostate glandular epithelium (173). Little is currently known about the roles of the Bcl2 family in the regulation of prostate apoptosis. While Bcl2 is not detected in normal prostate epithelial cells in humans, Bcl2 expression is detectable, and increases as prostate cancers become androgen-independent, raising the possibility that Bcl2 may have a role in neoplastic growth in this tissue (174). In support of this hypothesis, mice that overexpress a Bcl2
134
Ross and MacGregor
transgene in prostate epithelial cells have morphologically abnormal prostates, with an accumulation of cells in stromal and epithelial compartments (175). Understanding Bcl2 family function in the prostate may ultimately have useful value for treatment of prostatic cancer.
Ovary As with male germ-cell development, a significant loss of female germ cells is associated with normal ovarian development (see Morita and Tilly, 1999) (176). Following the onset of ovarian differentiation, the oogonial population undergoes a short period of mitotic activity during which modest loss of germ cells is observed (177). After exiting mitosis, oogonia progress through meiosis until they arrest at the diplotene stage of the first meiotic prophase. Many of the oocytes are subsequently surrounded by a single layer of somatic granulosa cells to form primordial follicles, and naked oocytes invariably degenerate in a process called attrition (178). This is a short period of relatively high levels of germ-cell death that effectively regulates the follicular endowment of the ovary and is completed by d 4 postnatal. The other major period of regulated cell death in the ovary occurs during follicular development. In both prepubertal and adult life, subsets of the primordial follicle endowment are recruited to develop. However, from these recruited follicles, only a small number will complete development and be ovulated. The remainder degenerate in a process called atresia, which can occur at each stage of follicular development (179). Atresia results from the hormonally regulated death of granulosa cells, which are apoptotic in nature (180,181). Several endocrine factors have been identified that can regulate follicle atresia. Reduction of serum gonadotropins by hypophysectomy results in follicular atresia, which supports the role of these hormones in follicle survival in vivo (182). In vitro models have also been useful in identifying factors that promote follicle survival. Both follicle-stimulating hormone (FSH) and luteinizing hormone (LH) can suppress apoptosis of isolated follicles (183,184). Several growth factors produced by the follicular cells can enhance survival of isolated granulosa cells as well as survival of antral follicles including EGF, basic fibroblast growth factor (bFGF), and IGF-1 (185,186). Estrogens and progesterones have also been implicated in follicular cell survival both in vivo and in vitro (187,188). The basis for hormonal regulation of follicle survival is likely to be complex. As with the testis, many members of the Bcl2 family are expressed in the ovary, including Bcl2 (189,190), Bclx (190), Bax (190), Bad (191), Bak (165), Bclw (191), Bok (166), Bod (167), and Mcl1 (164). Transgenic mouse models have revealed essential roles of three of these family members, Bax, Bclw, and Bcl2, in ovarian function in vivo. To determine whether Bcl2 could protect follicular cells from PCD, mice that overexpress Bcl2 in granulosa cells were generated. These transgenic animals show reduced apoptosis of ovarian cells, larger litter size, and formation of teratomas in advanced age (193). Conversely, analysis of ovaries from Bcl2-null mutants also supported a role for Bcl2 in survival of female germ cells during normal development. On a hybrid genetic background, Bcl2 mutant female mice are fertile, and all stages of follicular development are represented. However, the total number of primordial follicles at birth was significantly reduced in the mutants compared with wild-type or heterozygous controls (181). Moreover, a significant proportion of the primordial follicles did not contain an oocyte. These findings indicate that Bcl2 is important for
Chapter 6/The Bcl2 Gene Family
135
survival of a proportion of female germ cells. It is not yet clear when the reduction in oocyte and primordial follicle number initially occurs. Bcl2 may be important for survival of oogonia during prenatal development, or it could protect oocytes during the postnatal period of extensive cell death when primordial follicles form. Bax also functions in control of ovarian cell death. Ovaries from adult Bax mutant mice contain approximately three times the number of primordial follicles as control littermates. Moreover, ovaries of 20–22-mo-old Bax-null females that would normally have exhausted their follicle endowment have hundreds of follicles at all stages of development (194). In contrast, Bax mutants had the same number of follicles as control animals 4 d after birth. Thus, Bax is not required for oocyte attrition during embryogenesis, but instead appears to be essential for follicular atresia postnatal. Bax probably functions by initiating death of follicular granulosa cells, in which it is expressed (191). Thus, while Bcl2 function is important for early oocyte survival and establishing the primordial follicle endowment, the most important function of Bax in the ovary appears to involve rendering follicles susceptible to hormonally induced PCD. Of clinical relevance, Bax-deficient mice were also used to study the requirement for Bax in mediating PCD of oocytes in response to the chemotherapeutic drug doxorubicin (Adriamycin). Unfertilized oocytes exposed to doxorubicin undergo apoptosis. However, oocytes from Bax-null female mice are completely resistant to this treatment (195). This experimental finding could have important implications for the development of novel therapies with which to combat female infertility that results from cancer treatment. Ovaries from 4-d-old Bclw-mutant females on a B6-enriched genetic background display a 40% reduction in oocyte endowment (MacGregor and J. Tilly, unpublished observations). Bclw is expressed in oocytes, suggesting that it is required cell-intrinsically for oocyte survival. To determine whether Bax mediates the reduced oocyte endowment in Bclw mutants, Bclw/Bax-deficient mice were analyzed. Removal of Bax restored the oocyte endowment at p4 to wild-type levels. Thus, as with the testis, both Bclw and Bax have important roles in regulation of female germ-cell survival.
Mammary Gland Apoptosis occurs during both development of the mammary gland and its involution following withdrawal of a suckling response (weaning). During mammary-gland development, a proliferative structure called the terminal endbud is responsible for penetrating the fat pad and forming lumena and ducts from the solid tissue mass. Consistent with this developmental process, high levels of apoptosis occur in the terminal endbud, and Bclx, Bax, and Bcl2 are all expressed in this structure. To determine whether regulated expression of Bcl2 in the mammary gland was important for its development, mice were generated that expressed Bcl2 ectopically in this organ under control of the whey acidic protein (WAP) promoter. In these mice, apoptosis was reduced during mammary-gland development, and the endbud was highly disorganized. This indicates that this process requires regulation of PCD, and that this can be influenced by the Bcl2 pathway (196). PCD also occurs during mammary-gland involution, when lactational epithelial cells are removed. This hormone-sensitive process is triggered by a decrease in levels of prolactin and glucocorticoid hormone following removal of a suckling response at weaning. Many members of the Bcl2 family are expressed in mammary gland during lactation and involution, including Bcl2, Bclx, Bclw, Bax, Bak, and Bad (197). Interest-
136
Ross and MacGregor
ingly, both Bcl2 and Bclw are downregulated prior to involution. While Bclw and Bcl2 may function in mammary gland involution, Bclw is not essential for this developmental process, as Bclw-null mutant females do not appear to have an overt defect in mammarygland development (A. Ross and G. MacGregor, unpublished results). It is possible that functional redundancy between Bclw and Bcl2 could mask the effects of loss of Bclw function in this tissue. WAP-Bcl2 mice were also used to examine apoptosis during involution (198). Overexpression of Bcl2 blocked apoptosis of the lactational cells following weaning. However, the alveolar collapse that is part of involution still occurred. This indicates that alveolar collapse, which is triggered by activity of matrix metalloproteases, occurs independently of apoptosis. In summary, apoptosis during mammary gland involution may involve Bcl2 family function. However, the precise role that each member plays and to what extent there is functional overlap with other family members is currently unclear. Bax can also function as a suppressor of mammary-gland tumor formation. In an experimental mouse model of mammary tumorigenesis, expression of Bax was increased during early stages of mammary cancer development, then down regulated following transformation (199). This is consistent with findings in human breast carcinomas where expression of Bax is also downregulated (200). In mice mutant for one allele of Bax, there was a significantly increased rate in mammary cancer development and tumor growth (199). These findings indicate a dose-dependent role for Bax in mediating PCD within preneoplastic mammary-gland tumors. Interestingly, the rate of tumor incidence in Bax-null mice was actually decreased compared with the heterozygous Bax mutants. However, Bax-null females displayed a ductal hypoplasia, which may be responsible for their reduced sensitivity to tumor formation. The ductal hypoplasia in Bax mutants is also of interest as it supports a role for Bax in normal development of mouse mammary glands.
Uterus The uterine endometrium undergoes many cycles of steroid hormone-induced cell proliferation, differentiation, and death during its normal function. Estrogen depletion results in apoptotic death of murine endometrial epithelium, and estrogen, progesterone, and androgen all can suppress this epithelial cell death (201–203). The manner in which these hormones regulate uterine apoptosis, and to what extent the Bcl2 family may control this process is not yet clear. Initial studies suggest a potential role for the Bcl2 family in uterine-cell deaths. Bcl2 is expressed in human endometrium during all stages of the menstrual cycle, with its strongest expression during the proliferative phase of the cycle (204,205). In a rat endometrial-cell line, apoptosis was induced by withdrawal of progesterone, or addition of antiprogestins. When these cells were treated with progesterone, levels of BclxL in the cell increased and levels of BclxS decreased, suggesting a possible mechanism for the protective effects of the hormone (206). During uterine decidualization induced by progestin and estradiol treatment in rats, levels of Bax increased, and levels of Bcl2 decreased in stromal cells (207). These studies suggest that Bcl2 family proteins could function in apoptosis during cycling of the uterine endothelium and regression of decidual zones during pregnancy, and that the levels of the family members may be under hormonal control. The death of Bcl2- or Bclx-deficient females prior to reproductive age currently precludes analysis of essential roles for Bcl2 or Bclx in uterine function in the mouse.
Chapter 6/The Bcl2 Gene Family
137
SUMMARY AND FUTURE PERSPECTIVES Studies using transgenic mice have demonstrated a number of essential roles for Bcl2 family members in the regulation of apoptosis, both during embryonic development and adult tissue homeostasis. Of interest, several members of the family are involved in hormonally regulated cell deaths occurring in reproductive tissues. Both spermatogenesis and oogenesis require apoptosis of a proportion of germ cells for normal gametogenesis. Bax, a pro-apoptotic protein, and Bclw, a death-protecting protein, are both required for normal levels of apoptosis during spermatogenesis. Bclw, Bax, Bcl2, and possibly BclxL, all function in regulation of oocyte and follicular apoptosis. Many more Bcl2 family members are expressed in the ovary and testis, and it is important to determine whether these genes also play crucial roles in gametogenesis. Loss-of-function mutations have only been generated for a handful of Bcl2 family members. A greater understanding of the roles of the Bcl2 family in different tissues will be gained as other knockout mice are produced. Generation of mice with mutations in multiple independent Bcl2-family genes can be used to establish which family members act in the same pathway in specific tissues, and which members have redundant functions. Mice deficient for Bclx die embryonically, and other Bcl2 relatives may have essential functions during development. Consequently, it is important to generate new conditional knockouts, such as those generated using the Cre/lox P system (208), that are both temporally and spatially restricted, which can be used to reveal functions of these gene products in adult tissues. Future studies of the Bcl2 gene family in mice should provide a wealth of additional insight into the mechanisms controlling apoptosis, and the physiological roles of cell death. These findings will in turn assist efforts to devise novel therapies to treat human diseases that arise from an imbalance in programmed cell death.
ACKNOWLEDGMENTS Andrea J. Ross was supported by NIH training grant number 5 T32 GM08367. Research in Grant R. MacGregor’s laboratory is supported by NIH grant number HD-36437.
REFERENCES 1. Clarke PGH, Clarke S. Historic apoptosis. Nature 1995;378:230. 2. Lockshin RA, Williams CM. Programmed cell death II: Endocrine potentiation of the breakdown of the intersegmental muscles of silkmoths. J Insect Physiol 1964;10:643. 3. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972;26:239–257. 4. Clarke PG, Posada A, Primi MP, Castagne V. Neuronal death in the central nervous system during development. Biomed Pharmacother 1998;52:356–362. 5. Russell LD. Cell loss during spermatogenesis: apoptosis or necrosis? In: Hamamah S, Mieusset R, Olivennes O, Frydman R, eds. Male Sterility and Motility Disorders: Etiological Factors and Treatment. Springer, New York, NY, 1999, pp. 203–214. 6. Saunders JW. Death in embryonic systems. Science 1966;154:604–612. 7. Coucouvanis E, Martin GR. Signals for death and survival: a two-step mechanism for cavitation in the vertebrate embryo. Cell 1995;83:279–287. 8. Kerr JF, Harmon B, Searle J. An electron-microscope study of cell deletion in the anuran tadpole tail during spontaneous metamorphosis with special reference to apoptosis of striated muscle fibers. J Cell Sci 1974;14:571–585. 9. Roberts LM, Hirokawa Y, Nachtigal MW, Ingraham HA. Paracrine-mediated apoptosis in reproductive tract development. Dev Biol 1999;208:110–122. 10. Ellis RE, Yuan JY, Horvitz HR. Mechanisms and functions of cell death. Ann Rev Cell Bio 1991;7:663–698.
138
Ross and MacGregor
11. Vaux DL, Korsmeyer SJ. Cell death in development. Cell 1999;96:245–254. 12. Stellar H. Mechanisms and genes of cellular suicide. Science 1995;267:1445–1449. 13. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995;267: 1456–1462. 14. Raff MC. Social controls on cell survival and cell death. Nature 1992;356:397–399. 15. Collins MK, Lopez Rivas A. The control of apoptosis in mammalian cells. TIBS 1993;18:307–309. 16. Bates RC, Buret A, van Helden DF, Horton MA, Burnes GF. Apoptosis induced by inhibition of cellular contact. J Cell Biol 1994;125:403–415. 17. Gajewski TF, Thompson CB. Apoptosis meets signal transduction: elimination of a BAD influence. Cell 1996;87:589–592. 18. Wyllie AH, Kerr JF, Macaskill IA, Currie AR. Adrenocortical cell deletion: the role of ACTH. J Pathol 1973;111:85–94. 19. Coles HSR, Burne JF, Raff MC. Large-scale normal cell death in the developing rat kidney and its reduction by epidermal growth factor. Development 1993;18:777–784. 20. Fleischman RA. From white spots to stem cells: the role of the Kit receptor in mammalian development. Trends Genet 1993;9:285–290. 21. Jiang C, Baehrecke EH, Thummel CS. Steroid regulated programmed cell death during Drosophila metamorphosis. Development 1997;124:4673–4683. 22. Catlin EA, MacLaughlin DT, Donahoe PK. Mullerian inhibiting substance: new perspectives and future directions. Microsc Res Tech 1993;25:121–133. 23. Anderson P. Kinase cascades regulating entry into apoptosis. Micr Mol Biol Rev 1997;61:33–46. 24. Dragovich T, Rudin CM, Thompson CB. Signal transduction pathways that regulate cell survival and cell death. Oncogene 1998;17:3207–3213. 25. Jarpe MB, Widmann C, Knall C, Schlesinger TK, Gibson S, Yujiri T, et al. Anti-apoptotic versus pro-apoptotic signal transduction: checkpoints and stop signs along the road to death. Oncogene 1998;17:1475–1482. 26. Sulston JE, Horvitz HR. Post-embryonic cell lineages of the nematode, Caenorhabditis elegans. Dev Biol 1977;56:110–156. 27. Sulston JE, Schierenberg E, White JG, Thomson JN. The embryonic cell lineage of the nematode Caenorhabditis elegans. Dev Biol 1983;100:64–119. 28. Hengartner MO. Programmed cell death in invertebrates. Curr Opin Genet Dev 1996;6:34–38. 29. Ellis HM, Horvitz HR. Genetic control of programmed cell death in the nematode C. elegans. Cell 1986;44:817–829. 30. Conradt B, Horvitz HR. The C. elegans protein EGL-1 is required for programmed cell death and interacts with the Bcl-2-like protein CED-9. Cell 1998;93:519–529. 31. Hengartner MO, Ellis RE, Horvitz HR. Caenorhabditis elegans gene ced-9 protects cells from programmed cell death. Nature 1992;356:494–499. 32. Metzstein MM, Stanfield GM, Horvitz HR. Genetics of programmed cell death in C. elegans: past, present and future. Trends Genet 1998;14:410–416. 33. Nunez G, Benedict MA, Hu Y, Inohara N. Caspases: the proteases of the apoptotic pathway. Oncogene 1998;17:3237–3245. 34. Yuan J, Shaham S, Ledoux S, Ellis HM, Horvitz HR. The C. elegans cell death gene ced3 encodes a protein similar to mammalian interleukin-1 beta-converting enzyme. Cell 1993;75:641–652. 35. Nicholson DW, Thornberry NA. Caspases: killer proteases. TIBS 1997;22:299–306. 36. Varfolomeev EE, Schuchmann M, Luria V, Chiannilkulchai N, Beckmann JS, Mett IL, et al. Targeted disruption of the mouse Caspase 8 gene ablates cell death induction by the TNF receptors, Fas/Apo1, and DR3 and is lethal prenatally. Immunity 1998;9:267–276. 37. Kuida K, Zheng TS, Na S, Kuan C, Yang D, Karasuyama H, et al. Decreased apoptosis in the brain and premature lethality in CPP32-deficient mice. Nature 1996;384:368–372. 38. Bergeron L, Perez GI, Macdonald G, Shi L, Sun Y, Jurisicova A, et al. Defects in regulation of apoptosis in caspase-2-deficient mice. Gen Dev 1998;12:1304–1314. 39. Wilson KP, Black JA, Thomson JA, Kim EE, Griffith JP, Navia MA, et al. Structure and mechanism of interleukin-1 beta converting enzyme. Nature 1994;370:270–275. 40. Salvesen GS, Dixit VM. Caspase activation: the induced-proximity model. Proc Natl Acad Sci USA 1999;96:10,964–10,967. 41. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998;281:1305–1308.
Chapter 6/The Bcl2 Gene Family
139
42. Baker SJ, Reddy EP. Modulation of life and death by the TNF receptor superfamily. Oncogene 1998;17:3261–3270. 43. Nagata S. Apoptosis by death factor. Cell 1997;88:355–365. 44. Gearing AJ, Beckett P, Christodoulou M, Churchill M, Clements J, Davidson AH, et al. Processing of tumour necrosis factor-alpha precursor by metalloproteinases. Nature 1994;370:555–557. 45. Boldin MP, Varfolomeev EE, Pancer Z, Mett IL, Camonis JH, Wallach D. A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain. J Biol Chem 1995;270:7795–7798. 46. Hofmann K, Bucher P, Tschopp J. The CARD domain: a new apoptotic signalling motif. TIBS 1997;22:155,156. 47. Nagata S. Mutations in the Fas antigen gene in lpr mice. Semin Immunol 1994;6:3–8. 48. Bakhshi A, Jensen JP, Goldman P, Wright JJ, McBride OW, Epstein AL, et al. Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell 1985;41:899–906. 49. Tsujimoto Y, Gorham J, Cossman J, Jaffe E, Croce CM. The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. Science 1985;229:1390. 50. Nunez G, London L, Hockenbery D, Alexander M, McKearn JP, Korsmeyer SJ. Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. J Immunol 1990;144:3602–3610. 51. Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1988;335:440–442. 52. Hengartner MO, Horvitz HR. C. elegans cell survival gene ced-9 encodes a functional homolog of the mammalian proto-oncogene bcl-2. Cell 1994;76:665–676. 53. Boise LH, Gonzalez-Garcia M, Postema CE, Ding L, Lindsten T, Turka LA, et al. bcl-x, a bcl-2related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993;74:597–608. 54. Gibson L, Holmgreen SP, Huang DC, Bernard O, Copeland NG, Jenkins NA, et al. bcl-w, a novel member of the bcl-2 family, promotes cell survival. Oncogene 1996;13:665–675. 55. Lin EY, Orlofsky A, Berger MS, Prystowsky MB. Characterization of A1, a novel hemopoieticspecific early-response gene with sequence similarity to bcl-2. J Immunol 1993;151:1979–1988. 56. Kozopas KM, Yang T, Buchan HL, Zhou P, Craig RW. MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. Proc Natl Acad Sci USA 1993;90: 3516–3520. 57. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993;74:609–619. 58. Chittenden T, Harrington EA, O’Connor R, Flemington C, Lutz RJ, Evan GI, et al. Induction of apoptosis by the Bcl-2 homologue Bak. Nature 1995;374:733–736. 59. Kelekar A, Chang BS, Harlan JE, Fesik SW, Thompson CB. Bad is a BH3 domain-containing protein that forms an inactivating dimer with Bcl-XL. Mol Cell Biol 1997;17:7040–7046. 60. Boyd JM, Gallo GJ, Elangovan B, Houghton AB, Malstrom S, Avery BJ, et al. Bik, a novel deathinducing protein shares a distinct sequence motif with Bcl-2 family proteins and interacts with viral and cellular survival-promoting proteins. Oncogene 1995;11:1921–1928. 61. Wang K, Yin XM, Chao DT, Milliman CL, Korsmeyer SJ. BID: a novel BH3 domain-only death agonist. Genes Dev 1996;10:2859–2869. 62. O’Connor L, Strasser A, O’Reilly LA, Hausmann G, Adams JM, Cory S, et al. Bim: a novel member of the Bcl-2 family that promotes apoptosis. EMBO J 1998;17:384–395. 63. Inohara N, Ekhterae D, Garcia I, Carrio R, Merino J, Merry A, et al. Mtd, a novel Bcl-2 family member activates apoptosis in the absence of heterodimerization with Bcl-2 and Bcl-XL. J Biol Chem 1998;273:8705–8710. 64. Hegde R, Srinivasula SM, Ahmad M, Fernandes-Alnemri T, Alnemri ES. Blk, a BH3-containing mouse protein that interacts with Bcl-2 and Bcl-xL, is a potent death agonist. J Biol Chem 1998;273:7783–7786. 65. Inohara N, Ding L, Chen S, Nunez G. harakiri, a novel regulator of cell death, encodes a protein that activates apoptosis and interacts selectively with survival-promoting proteins Bcl-2 and Bcl-X(L). EMBO J 1997;16:1686–1694. 66. Inohara N, Gourley TS, Carrio R, Muniz M, Merino J, Garcia I, et al. Diva, a Bcl-2 homologue that binds directly to Apaf-1 and induces BH3-independent cell death. J Biol Chem 1998; 273:32,479–32,486. 67. D’Sa-Eipper C, Subramanian T, Chinnadurai G. bfl-1, a bcl-2 homologue, suppresses p53-induced apoptosis and exhibits potent cooperative transforming activity. Cancer Res 1996;56:3879–3882.
140
Ross and MacGregor
68. Chen G, Cizeau J, Vande Velde C, Park JH, Bozek G, Bolton J, et al. Nix and Nip3 form a subfamily of pro-apoptotic mitochondrial proteins. J Biol Chem 1999;274:7–10. 69. Chen G, Ray R, Dubik D, Shi L, Cizeau J, Bleackley RC, et al. The E1B 19K/Bcl-2-binding protein Nip3 is a dimeric mitochondrial protein that activates apoptosis. J Exp Med 1997;186:1975–1983. 70. Subramanian T, Boyd JM, Chinnadurai G. Functional substitution identifies a cell survival promoting domain common to adenovirus E1B 19 kDa and Bcl-2 proteins. Oncogene 1995;11:2403–2409. 71. Subramanian T, Tarodi B, Chinnadurai G. Functional similarity between adenovirus E1B 19-kDa protein and proteins encoded by Bcl-2 proto-oncogene and Epstein-Barr virus BHRF1 gene. Curr Top Microbiol Immunol 1995;199:153–161. 72. Minn AJ, Swain RE, Ma A, Thompson CB. Recent progress on the regulation of apoptosis by Bcl-2 family members. Adv Immunol 1998;70:245–279. 73. Yin XM, Oltvai ZN, Korsmeyer SJ. BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature 1994;369:321–323. 74. Wang K, Gross A, Waksman G, Korsmeyer SJ. Mutagenesis of the BH3 domain of BAX identifies residues critical for dimerization and killing. Mol Cell Biol 1998;18:6083–6089. 75. Korsmeyer SJ, Shutter JR, Veis DJ, Merry DE, Oltvai ZN. Bcl-2/Bax: a rheostat that regulates an anti-oxidant pathway and cell death. Semin Cancer Biol 1993;4:327–332. 76. Kelekar A, Thompson CB. Bcl-2-family proteins: the role of the BH3 domain in apoptosis. Trends Cell Biol 1998;8:324–330. 77. Chinnaiyan AM, O’Rourke K, Lane BR, Dixit VM. Interaction of CED-4 with CED-3 and CED9: a molecular framework for cell death. Science 1997;275:1122–1126. 78. Liu X, Kim CN, Yang J, Jemmerson R, Wang X. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell 1996;86:147–157. 79. Zou H, Henzel WJ, Liu X, Lutschg A, Wang X. Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell 1997;90:405–413. 80. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997;91:479–489. 81. Saleh A, Srinivasula SM, Acharya S, Fishel R, Alnemri ES. Cytochrome c and dATP-mediated oligermization of Apaf-1 is a prerequisite for procaspase-9 activation. J Biol Chem 1999;274: 17,941–17,945. 82. Hu Y, Ding L, Spencer DM, Nunez G. WD-40 repeat region regulates Apaf-1 self-association and procaspase-9 activation. J Biol Chem 1998;273:33,489–33,494. 83. Hu Y, Benedict MA, Wu D, Inohara N, Nunez G. Bcl-XL interacts with Apaf-1 and inhibits Apaf1-dependent caspase-9 activation. Proc Natl Acad Sci USA 1998;95:4386–4391. 84. Pan G, O’Rourke K, Dixit VM. Caspase-9, Bcl-XL, and Apaf-1 form a ternary complex. J Biol Chem 1998;273:5841–5845. 85. Song Q, Kuang Y, Dixit VM, Vincenz C. Boo, a novel negative regulator of cell death, interacts with APAF-1. EMBO J 1999;18:167–178. 86. Moriishi K, Huang DCS, Cory S, Adams JM. Bcl-2 family members do not inhibit apoptosis by binding the caspase activator Apaf-1. Proc Natl Acad Sci USA 1999;96:9683–9688. 87. Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 1997;275:1132–1136. 88. Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, et al. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 1997;275:1129–1132. 89. Reed JC. Cytochrome c: can’t live with it—can’t live without it. Cell 1997;91:559–562. 90. Susin SA, Lorenzo HK, Zamzami N, Marzo I, Snow BE, Brothers GM, et al. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 1999;397:441–446. 91. Jurgensmeier JM, Xie Z, Deveraux Q, Ellerby L, Bredesen D, Reed JC. Bax directly induces release of cytochrome c from isolated mitochondria. Proc Natl Acad Sci USA 1998;95:4997–5002. 92. Kharbanda S, Pandey P, Schofield L, Israels S, Roncinske R, Yoshida K, et al. Role for Bcl-xL as an inhibitor of cytosolic cytochrome C accumulation in DNA damage-induced apoptosis. Proc Natl Acad Sci USA 1997;94:6939–6942.
Chapter 6/The Bcl2 Gene Family
141
93. Lithgow T, van Driel R, Bertram JF, Strasser A. The protein product of the oncogene bcl2 is a component of the nuclear envelope, the endoplasmic reticulum, and the outer mitochondrial membrane. Cell Growth Differ 1994;5:411–417. 94. Nguyen M, Millar DG, Yong VW, Korsmeyer SJ, Shore GC. Targeting of Bcl-2 to the mitochondrial outer membrane by a COOH-terminal signal anchor sequence. J Biol Chem 1993;268:25,265–25,268. 95. Krajewski S, Tanaka S, Takayama S, Schibler MJ, Fenton W, Reed JC. Investigation of the subcellular distribution of the bcl-2 oncoprotein: residence in the nuclear envelope, endoplasmic reticulum and outer mitochondrial membranes. Cancer Res 1993;53:4701–4714. 96. Gonzalez-Garcia M, Perez-Ballestero R, Ding L, Duan L, Boise LH, Thompson CB, et al. bcl-XL is the major bcl-x mRNA form expressed during murine development and its product localizes to mitochondria. Development 1994;120:3033–3042. 97. Hockenberry DM, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990;348:334–336. 98. Wolter KG, Hsu YT, Smith CL, Nechushtan A, Xi XG, Youle RJ. Movement of Bax from the cytosol to mitochondria during apoptosis. J Cell Biol 1997;139:1281–1292. 99. Nechushtan A, Smith CL, Hsu Y, Youle RJ. Conformation of the Bax C-terminus regulates subcellular location and cell death. EMBO J 1999;18:2330–2341. 100. Muchmore SW, Sattler M, Liang H, Meadows RP, Harlan JE, Yoon HS, et al. X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death. Nature 1996;381:335–341. 101. Antonsson B, Conti F, Ciavatta A, Montessuit S, Lewis S, Martinou I, et al. Inhibition of Bax channel-forming activity by Bcl-2. Science 1997;277:370–372. 102. Minn AJ, Velez P, Schendel SL, Liang H, Muchmore SW, Fesik SW, et al. Bcl-x(L) forms an ion channel in synthetic lipid membranes. Nature 1997;385:353–357. 103. Schlesinger PH, Gross A, Yin XM, Yamamoto K, Saito M, Waksman G, et al. Comparison of the ion channel characteristics of proapoptotic BAX and antiapoptotic BCL-2. Proc Natl Acad Sci USA 1997;94:11,357–11,362. 104. Reed JC. Bcl-2 family proteins. Oncogene 1998;17:3225–3236. 105. Petit PX, Susin S, Zamzami N, Mignotte B, Kroemer G. Mitochondria and programmed cell death: back to the future. FEBS Lett 1996;396:7–13. 106. Xiang J, Chao DT, Korsmeyer SJ. BAX-induced cell death may not require interleukin 1 betaconverting enzyme-like proteases. Proc Natl Acad Sci USA 1996;93:14,559–14,563. 107. Zoratti M, Szabo I. The mitochondrial permeability transition. Biochim Biophys Acta 1995;1241: 139–176. 108. Narita M, Shimizu S, Ito T, Chittenden T, Lutz RJ, Matsude H, et al. Bax interacts with the permeability transition pore to induce permeability transition and cytochrome c release in isolated mitochondria. Proc Natl Acad Sci USA 1998;95:14,681–14,686. 109. Pastorino JG, Chen S, Tafani M, Snyder JW, Farber JL. The overexpression of Bax produces cell death upon induction of the mitochondrial permeability transition. J Biol Chem 1998;273:7770–7775. 110. Marzo I, Brenner C, Zamzami N, Jurgensmeier JM, Susin SA, Vieira HL, Prevost MC, Xie Z, Matsuyama S, Reed JC, Kroemer G. Bax and adenine nucleotide translocator cooperate in the mitochondrial control of apoptosis. Science 1998;281:2027–2031. 111. Vander Heiden MG, Chandel NS, Williamson EK, Schumacker PT, Thompson CB. Bcl-xL regulates the membrane potential and volume homeostasis of mitochondria. Cell 1997;91:627–637. 112. Bradham CA, Qian T, Streetz K, Trautwein C, Brenner D, Lemasters JL. The mitochondrial permeability transition is required for Tumor Necrosis Factor alpha-mediated apoptosis and cytochrome c release. Molec Cell Biol 1998;18:6353–6364. 113. Bossy-Wetzel E, Newmeyer DD, Green DR. Mitochondrial cytochrome c release in apoptosis occurs upstream of DEVD-specific caspase activation and independently of mitochondrial transmembrane depolarization. EMBO J 1998;17:37–49. 114. Shimizu S, Narita M, Tsujimoto Y. Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC. Nature 1999;399:483–487. 115. Newton K, Strasser A. The Bcl-2 family and cell death regulation. Curr Opin Genet Dev 1998;8:68–75. 116. Lincz LF. Deciphering the apoptotic pathway: all roads lead to death. Immunol Cell Biol 1998;76:1–19. 117. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 1998;281: 1322–1325.
142
Ross and MacGregor
118. Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 1996;87:619–628. 119. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997;91:231–241. 120. del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 1997;278:687–699. 121. Franke TF, Cantley LC. Apoptosis. A Bad kinase makes good. Nature 1997;390:116,117. 122. Harada H, Becknell BMW, Mann M, Huang LJ, Taylor SS, Scott JD, et al. Phosphorylation and inactivation of BAD by mitochondria-anchored protein kinase A. Mol Cell 1999;3:413–422. 123. Li H, Zhu H, Xu CJ, Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998;94:491–501. 124. Luo X, Budihardjo I, Zou H, Slaughter C, Wang X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 1998;94:481–490. 125. Gross A, Yin X, Wang K, Wei MC, Jockel J, Milliman C, et al. Caspase cleaved Bid targets mitochondria and is required for cytochrome c release, while Bcl-xL prevents this release but not Tumor Necrosis Factor-R1/Fas death. J Biol Chem 1999;274:1156–1163. 126. Strasser A, Whittingham S, Vaux DL, Bath ML, Adams JM, Cory S, et al. Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease. Proc Natl Acad Sci USA 1991;88:8661–8665. 127. McDonnell TJ, Korsmeyer SJ. Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14; 18). Nature 1991;349:254–256. 128. McDonnell TJ, Deane N, Platt FM, Nunez G, Jaeger U, McKearn JP, Korsmeyer SJ. Bcl2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 1989;57:79–88. 129. Strasser A, Harris AW, Cory S. bcl-2 transgene inhibits T cell death and perturbs thymic selfcensorship. Cell 1991;67:889–899. 130. Martinou JC, Dubois-Dauphin M, Staple JK, Rodriguez I, Frankowski H, Missotten M, Albertini P, Talabot D, Catsicas S, Pietra C, et al. Overexpression of BCL-2 in transgenic mice protects neurons from naturally occurring cell death and experimental ischemia. Neuron 1994;13:1017–1030. 131. Fromm L, Overbeek PA. Inhibition of cell death by lens-specific overexpression of Bcl-2 in transgenic mice. Dev Genet 1997;20:276–287. 132. Rodriguez I, Araki K, Khatib K, Martinou JC, Vassalli P. Mouse vaginal opening is an apoptosisdependent process which can be prevented by the overexpression of Bcl2. Dev Biol 1997;184: 115–121. 133. Lagasse E, Weissman IL. Enforced expression of Bcl-2 in monocytes rescues macrophages and partially reverses osteopetrosis in op/op mice. Cell 1997;89:1021–1031. 134. Akashi K, Kondo M, von Freeden-Jeffry U, Murray R, Weissman IL. Bcl-2 rescues T lymphopoiesis in interleukin-7 receptor-deficient mice. Cell 1997;89:1033–1041. 135. Maraskovsky E, O’Reilly LA, Teepe M, Corcoran LM, Peschon JJ, Strasser A. Bcl-2 can rescue T lymphocyte development in interleukin-7 receptor-deficient mice but not in mutant rag-1-/mice. Cell 1997;89:1011–1019. 136. Veis DJ, Sorenson CM, Shutter JR, Korsmeyer SJ. Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair. Cell 1993;75:229–240. 137. Kamada S, Shimono A, Shinto Y, Tsujimura T, Takahashi T, Noda T, et al. Bcl-2 deficiency in mice leads to pleiotropic abnormalities: accelerated lymphoid cell death in thymus and spleen, polycystic kidney, hair hypopigmentation, and distorted small intestine. Cancer Res 1995;55:354–359. 138. Nagata M, Nakauchi H, Nakayama K, Loh D, Watanabe T. Apoptosis during an early stage of nephrogenesis induces renal hypoplasia in Bcl-2-deficient mice. Am J Path 1996;148:1601–1611. 139. Sorenson CM, Padanilam BJ, Hammerman MR. Abnormal postpartum renal development and cystogenesis in the Bcl-2 (-/-) mouse. Am J Phys 1996;271:F184–F193. 140. Yamamura K, Kamada S, Ito S, Nakagawa K, Ichihashi M, Tsujimoto Y. Accelerated disappearance of melanocytes in Bcl-2-deficient mice. Cancer Res 1996;56:3546–3550. 141. Michaelidis TM, Sendtner M, Cooper JD, Airaksinen MS, Holtmann B, Meyer M, et al. Inactivation of Bcl-2 results in progressive degeneration of motoneurons, sympathetic and sensory neurons during early postnatal development. Neuron 1996;17:75–89.
Chapter 6/The Bcl2 Gene Family
143
142. Gonzalez-Garcia M, Garcia I, Ding L, O’Shea S, Boise LH, Thompson CB, et al. Bcl-x is expressed in embryonic and postnatal neural tissues and functions to prevent neuronal cell death. Proc Natl Acad Sci USA 1995;92:4304–4308. 143. Carrio R, Lopez-Hoyos M, Jimeno J, Benedict MA, Merino R, Benito A, et al. A1 demonstrates restricted tissue distribution during embryonic development and functions to protect against cell death. Am J Path 1996;149:2133–2142. 144. Motoyama N, Wang F, Roth KA, Sawa H, Nakayama K, Negishi I, et al. Massive cell death of immature hematopoietic cells and neurons in Bcl-x-deficient mice. Science 1995;267:1506–1510. 145. Knudson CM, Tung KS, Tourtellotte WG, Brown GA, Korsmeyer SJ. Bax-deficient mice with lymphoid hyperplasia and male germ cell death. Science 1995;270:96–99. 146. Print CG, Loveland KL, Gibson L, Meehan T, Stylianou A, Wreford N, et al. Apoptosis regulator bcl-w is essential for spermatogenesis but appears otherwise redundant. Proc Natl Acad Sci USA 1998;95:12,424–12,431. 147. Ross AJ, Waymire KG, Moss JE, Parlow AF, Skinner MK, Russell LD, et al. Testicular degeneration in Bclw-deficient mice. Nature Genet 1998;18:251–256. 148. Jurisicova A, Lathan KE, Casper RF, Varmuza SL. Expression and regulation of genes associated with cell death during murine preimplantation embryo development. Mol Reprod Dev 1998;51:243–253. 149. Yin X, Wang K, Gross A, Zhao Y, Zinkel S, Klocke B, Roth KA, Korsmeyer SJ. Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis. Nature 1999;400:886–891. 150. Shindler KS, Latham CB, Roth KA. Bax deficiency prevents the increased cell death of immature neurons in bcl-x-deficient mice. J Neurosci 1997;17:3112–3119. 151. Knudson CM, Korsmeyer SJ. Bcl-2 and Bax function independently to regulate cell death. Nat Genet 1997;16:358–363. 152. Ginsburg M, Snow MHL, McLaren A. Primordial germ cells in the mouse embryo during gastrulation. Development 1990;110:521–528. 153. MacGregor GR, Zambrowicz BP, Soriano P. Tissue non-specific alkaline phosphatase is expressed in both embryonic and extra-embryonic lineages during mouse embryogenesis but is not required for migration of primordial germ cells. Development 1995;121:1487–1496. 154. Lawson K, Hage W. Clonal analysis of the origin of primordial germ cells in the mouse, in germline development. In: Ciba Foundation Symposium, Wiley Press, Chichester, 1994, pp. 68–91. 155. Tam PP, Snow MH. The in vitro culture of primitive-streak-stage mouse embryos. J Embryol Exp Morphol 1980;59:131–143. 156. Hogan B, Beddington R, Costantini F, Lacy E. Manipulating the Mouse Embryo, A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1994, pp. 497. 157. Wang RA, Nakane PK, Koji T. Autonomous cell death of mouse male germ cells during fetal and postnatal period. Biol Reprod 1998;58:1250–1256. 158. Pesce M, Farrace MG, Piacentini M, Dolci S, De Felici M. Stem cell factor and leukemia inhibitory factor promote primordial germ cell survival by suppressing programmed cell death (apoptosis). Development 1993;118:1089–1094. 159. Matsui Y. Regulation of germ cell death in mammalian gonads. Apmis 1998;106:142–147; discussion 1487,1488. 160. Watanabe M, Shirayoshi Y, Koshimizu U, Hashimoto S, Yonehara S, Eguchi Y, et al. Gene transfection of mouse primordial germ cells in vitro and analysis of their survival and growth control. Exp Cell Res 1997;230:76–83. 160a. Rucker EB, Dierisseau P, Wagner K-U, Garret L, Wynshaw-Boris A, Flaws J, et al. Analysis of mice with a hypomorphic mutant allele of Bclx indicates that Bclx and Bax function to regulate survival of gonocytes following their arrival in the developing gonad. Mol Endo 2000;14:1038–1046. 161. Rugh R. The Mouse, Its Reproduction and Development, Oxford University Press, Oxford, UK, 1968, pp. 430. 162. Rodriguez I, Ody C, Araki K, Garcia I, Vassalli P. An early and massive wave of germinal cell apoptosis is required for the development of functional spermatogenesis. EMBO J 1997;16:2262–2270. 163. Krajewski S, Krajewska M, Shabaik A, Wang HG, Irie S, Fong L, et al. Immunohistochemical analysis of in vivo patterns of Bcl-X expression. Cancer Res 1994;54:5501–5507. 164. Krajewski S, Bodrug S, Krajewska M, Shabaik A, Gascoyne R, Berean K, et al. Immunohistochemical analysis of Mcl-1 protein in human tissues. Differential regulation of Mcl-1 and Bcl-2 protein
144
165. 166.
167.
168.
169. 170. 171. 172.
173. 174. 175. 176. 177. 178. 179. 180.
181.
182. 183. 184. 185. 186. 187. 188.
Ross and MacGregor production suggests a unique role for Mcl-1 in control of programmed cell death in vivo. Am J Path 1995;146:1309–1319. Kiefer MC, Brauer MJ, Powers VC, Wu JJ, Umansky SR, Tomei LD, et al. Modulation of apoptosis by the widely distributed Bcl-2 homologue Bak. Nature 1995;374:736–739. Hsu SY, Kaipia A, McGee E, Lomeli M, Hsueh AJ. Bok is a pro-apoptotic Bcl-2 protein with restricted expression in reproductive tissues and heterodimerizes with selective anti-apoptotic Bcl2 family members. Proc Natl Acad Sci USA 1997;94:12,401–12,406. Hsu SY, Lin P, Hsueh AJ. BOD (Bcl-2-related ovarian death gene) is an ovarian BH3 domaincontaining proapoptotic Bcl-2 protein capable of dimerization with diverse antiapoptotic Bcl-2 members. Mol Endocrinol 1998;12:1432–1440. Furuchi T, Masuko K, Nishimune Y, Obinata M, Matsui Y. Inhibition of testicular germ cell apoptosis and differentiation in mice misexpressing Bcl-2 in spermatogonia. Development 1996;122:1703–1709. Russell LD, Griswold MD. The Sertoli Cell, Cache River Press, Clearwater FL, 1993, pp. 801. Knobil E. The Physiology of Reproduction, Raven Press, 1994. . Ogawa T, Arechaga JM, Avarbock MR, Brinster RL. Transplantation of testis germinal cells into mouse seminiferous tubules. Int J Dev Biol 1997;41:111–122. Woolveridge I, de Boer-Brouwer M, Taylor MF, Teerds KJ, Wu FCW, Morris ID. Apoptosis in the rat spermatogenic epithelium following androgen withdrawal: changes in apoptosis-related genes. Biol Reprod 1999;60:461–470. Sinowatz F, Amselgruber W, Plendl J, Kolle S, Neumuller C, Boos G. Effects of hormones on the prostate in adult and aging men and animals. Microsc Res Tech 1995;30:282–292. Kiess W, Gallaher B. Hormonal control of programmed cell death/apoptosis. Eur J Endocrinol 1998;138:482–491. Zhang X, Chen MW, Ng A, Ng PY, Lee C, Rubin M, et al. Abnormal prostate development in C3(1)bcl-2 transgenic mice. Prostate 1997;32:16–26. Morita Y, Tilly JL. Oocyte apoptosis: like sand through an hourglass. Dev Biol 1999;213:1–17. Beaumont HM, Mandl AM. A quantitative and cytological study of oogonia and oocytes in the foetal and neonatal rat. Proc R Soc Lond B Biol Sci 1961;155:557–579. Ohno S, Smith JB. Role of fetal follicular cells in meiosis of mammalian oocytes. Cytogenetics 1964;3:324–333. Martimbeau S, Tilly JL. Physiological cell death in endocrine-dependent tissues: an ovarian perspective. Clin Endocrinol 1997;46:241–254. Hughes FM, Gorospe WC. Biochemical identification of apoptosis (programmed cell death) in granulosa cells: evidence for a potential mechanism underlying follicular atresia. Endocrinology 1991;129:2415–2422. Ratts VS, Flaws JA, Kolp R, Sorenson CM, Tilly JL. Ablation of bcl-2 gene expression decreases the numbers of oocytes and primordial follicles established in the post-natal female mouse gonad. Endocrinology 1995;136:3665–3668. Braw RH, Bar-Ami S, Tsafriri A. Effect of hypophysectomy on atresia of rat preovulatory follicles. Biol Reprod 1981;25:989–996. Chun SY, Billig H, Tilly JL, Furuta I, Tsafriri A, Hsueh AJ. Gonadotropin suppression of apoptosis in cultured preovulatory follicles: mediatory role of endogenous insulin-like growth factor I. Endocrinology 1994;135:1845–1853. Chun SY, Eisenhauer KM, Minami S, Billig H, Perlas E, Hsueh AJ. Hormonal regulation of apoptosis in early antral follicles: follicle-stimulating hormone as a major survival factor. Endocrinology 1996;137:1447–1456. Davoren JB, Kasson BG, Li CH, Hsueh AJ. Specific insulin-like growth factor (IGF) I- and II-binding sites on rat granulosa cells: relation to IGF action. Endocrinology 1986;119:2155–2162. Tilly JL, Billig H, Kowalski KI, Hsueh AJ. Epidermal growth factor and basic fibroblast growth factor suppress the spontaneous onset of apoptosis in cultured rat ovarian granulosa cells and follicles by a tyrosine kinase-dependent mechanism. Mol Endocrinol 1992;6:1942–1950. Peluso JJ, Pappalardo A. Progesterone and cell-cell adhesion interact to regulate rat granulosa cell apoptosis. Biochem Cell Biol 1994;72:547–551. Billig H, Furuta I, Hsueh AJ. Estrogens inhibit and androgens enhance ovarian granulosa cell apoptosis. Endocrinology 1993;133:2204–2212.
Chapter 6/The Bcl2 Gene Family
145
189. Rodger FE, Fraser HM, Duncan WC, Illingworth PJ. Immunolocalization of bcl-2 in the human corpus luteum. Hum Reprod 1995;10:1566–1570. 190. Kugu K, Ratts VS, Piquette GN, Tilly KI, Tao X, Martimbeau S, et al. Analysis of apoptosis and expression of bcl-2 gene family members in the human and baboon ovary. Cell Death Differ 1998;5:67–76. 191. Kaipia A, Hsu SY, Hsueh AJ. Expression and function of a proapoptotic Bcl-2 family member Bcl-XL/Bcl-2-associated death promoter (BAD) in rat ovary. Endocrinology 1997;138:5497–5504. 192. Jurisicova A, Rogers I, Fasciani A, Casper RF, Varmuza S. Effect of maternal age and conditions of fertilization on programmed cell death during murine preimplantation embryo development. Mol Hum Reprod 1998;4:139–145. 193. Hsu SY, Lai RJ, Finegold M, Hsueh AJ. Targeted overexpression of Bcl-2 in ovaries of transgenic mice leads to decreased follicle apoptosis, enhanced folliculogenesis, and increased germ cell tumorigenesis. Endocrinology 1996;137:4837–4843. 194. Perez GI, Robles R, Knudson CM, Flaws JA, Korsmeyer SJ, Tilly JL. Prolongation of ovarian lifespan into advanced chronological age by Bax-deficiency. Nature Genet 1999;21:200–203. 195. Perez GI, Knudson CM, Leykin L, Korsmeyer SJ, Tilly JL. Apoptosis-associated signaling pathways are required for chemotherapy-mediated female germ cell destruction. Nat Med 1997;3:1228–1232. 196. Humphreys RC, Krajewska M, Krnacik S, Jaeger R, Weiher H, Krajewski S, et al. Apoptosis in the terminal endbud of the murine mammary gland: a mechanism of ductal morphogenesis. Development 1996;122:4013–4022. 197. Metcalfe AD, Gilmore A, Klinowska T, Oliver J, Valentijn AJ, Brown R, et al. Developmental regulation of the Bcl-2 family protein expression in the involuting mammary gland. J Cell Sci 1999;112:1771–1783. 198. Jager R, Herzer U, Schenkel J, Weiher H. Overexpression of Bcl-2 inhibits alveolar cell apoptosis during involution and accelerates c-myc-induced tumorigenesis of the mammary gland in transgenic mice. Oncogene 1997;15:1787–1795. 199. Shibata M, Liu M, Knudson MC, Shibata E, Yoshidome K, Bandey T, et al. Haploid loss of bax leads to accelerated mammary tumor development in C3(1)/SV40-TAg transgenic mice: reduction in protective apoptotic response at the preneoplastic stage. EMBO J 1999;18:2692–2701. 200. Krajewski S, Blomqvist C, Franssila K, Krajewska M, Wasenius VM, Niskanen E, Nordling S, Reed JC. Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res 1995;55:4471–4478. 201. Jo T, Terada N, Saji F, Tanizawa O. Inhibitory effects of estrogen, progesterone, androgen and glucocorticoid on death of neonatal mouse uterine epithelial cells induced to proliferate by estrogen. J Steroid Biochem Mol Biol 1993;46:25–32. 202. Terada N, Yamamoto R, Takada T, Miyake T, Terakawa N, Wakimoto H, et al. Inhibitory effect of progesterone on cell death of mouse uterine epithelium. J Steroid Biochem 1989;33:1091–1096. 203. Terada N, Yamamoto R, Takada T, Taniguchi H, Terakawa N, Li W, et al. Inhibitory effect of androgen on cell death of mouse uterine epithelium. J Steroid Biochem 1990;36:305–310. 204. Koh EA, Illingworth PJ, Duncan WC, Critchley HO. Immunolocalization of bcl-2 protein in human endometrium in the menstrual cycle and simulated early pregnancy. Hum Reprod 1995;10:1557– 1562. 205. Gompel A, Sabourin JC, Martin A, Yaneva H, Audouin J, Decroix Y, et al. Bcl-2 expression in normal endometrium during the menstrual cycle. Am J Path 1994;144:1195–1202. 206. Pecci A, Scholz A, Pelster D, Beato M. Progestins prevent apoptosis in a rat endometrial cell line and increase the ratio of bcl-XL to bcl-XS. J Biol Chem 1997;272:11,791–11,798. 207. Akcali KC, Khan SA, Moulton BC. Effect of decidualization on the expression of bax and bcl-2 in the rat uterine endometrium. Endocrinology 1996;137:3123–3131. 208. Vasioukhin V, Degenstein L, Wise B, Fuchs E. The magical touch: Genome targeting in epidermal stem cells induced by tamoxifen application to mouse skin. Proc Natl Acad Sci USA 1999;96:8551–8556. 209. Zubiaga AM, Belasco JG, Greenberg ME. The nonamer UUAUUUAUU is the key AU-rich sequence motif that mediates mRNA degradation. Molec Cell Biol 1995;15:2219–2230. 210. Lagnado CA, Brown CY, Goodall GJ. AUUUA is not sufficient to promote poly(A) shortening and degradation of an mRNA: the functional sequence within AU-rich elements may be UUAUUUA(U/A)(U/A). Mol Cell Biol 1994;14:7984–7995.
Chapter 7/Role of the C-Kit Ligand Axis
7
147
The Role of the C-Kit/Kit Ligand Axis in Mammalian Gametogenesis Peter J. Donovan, PHD and Maria P. de Miguel, PHD CONTENTS INTRODUCTION: THE DEVELOPMENT OF THE GERMLINE MUTATIONS AFFECTING FERTILITY AND GAMETOGENESIS MOLECULAR CHARACTERIZATION OF THE STEEL/DOMINANT WHITE SPOTTING KIT LIGAND IN GERMLINE DEVELOPMENT ROLE OF KIT LIGAND IN MALE GAMETOGENESIS ROLE OF KIT LIGAND IN FEMALE GAMETOGENESIS COULD GONADAL TUMORS BE A CONSEQUENCE OF C-KIT/KL DYSREGULATION? FUTURE PROSPECTS ACKNOWLEDGMENTS REFERENCES
INTRODUCTION: THE DEVELOPMENT OF THE GERMLINE The survival of the germline is vital to the survival of all animal species. Failure of germ cells to survive or to differentiate properly in the animal can result in reduced fertility, or in some cases, complete sterility (1). In addition, defects in germline development can predispose individuals to development of cancer. For example, loss of germ cells from the ovary can be associated with premature ovarian failure, but can also dispose affected individuals to the development of ovarian cancer (2). Similarly in the male, loss of germ cells from the developing testis can be associated with the development of testicular teratocarcinoma (3). Testicular cancer is the most common malignancy in young men with a peak incidence from 18–35 yr of age (4,5). This contrasts with the incidence of ovarian tumors, which show a higher incidence after 50 yr of age, as is the case with most other solid tumors (6). Thus, even in otherwise healthy individuals, survival of the germline is an important feature of adult homeostasis. From: Contemporary Endocrinology: Transgenics in Endocrinology Edited by: M. Matzuk, C. W. Brown, and T. R. Kumar © Humana Press Inc., Totowa, NJ
147
148
Donovan and de Miguel
Over time, the molecular mechanisms regulating germline development, differentiation, and maintenance are being elucidated. There are several reasons for this. First, the advances in our knowledge of animal genomes have allowed a number of sterile mouse mutations to be molecularly cloned. Second, genomic DNA and cDNA sequencing projects have identified many new growth factors that would have been difficult to identify by other means. Some of these growth factors have been found to be active on germline cells. Third, the revolution in mouse genetics, brought about by the ability to carry out targeted mutations in embryonic stem (ES) cells, has both deliberately and inadvertently generated a wealth of information about germline development in mammals. Understanding how survival, growth, and differentiation of germ cells is regulated will likely lead to the development of improvements in the diagnosis and treatment of human diseases including infertility and cancer. This chapter focuses on the c-kit receptor tyrosine kinase and its ligand (kit ligand or KL) and their interrelated role in the development, differentiation, and homeostasis of the mammalian germline. Early in development, the germ cells are set aside from the somatic-cell lineages. The molecular mechanisms regulating this process and the reasons for it are poorly understood (7). In most species studied to date, the germ cells arise some distance from their eventual home, the gonad. In order to reach the gonad, they must undergo a period of migration (8). During the period of migration to the gonad and for a few days afterwards, the germ cells will proliferate to establish the population of cells that will give rise to the gametes. In the fully-formed mouse embryonic gonad, approx 35,000 germ cells arise from a population of about 100 cells that began migration several days earlier (see ref. 1, for review). The differentiation of germ cells in the gonad depends on their sex and on the sex of the embryo. Male germ cells, now called gonocytes, enter a mitotic arrest. They resume mitosis after birth to form the testicular stem cell, the spermatogonium. The timing of when male germ cells resume mitosis depends on the species. In mice, spermatogonia resume meiosis on the day of birth, and in rats and hamsters they do so a few days after birth, while in humans, proliferation begins around three years after birth. In the prepubertal period, spermatogonia give rise to daughter cells that enter meiosis. At later points, these haploid cells undergo spermiogenesis, and at puberty they give rise to mature sperm (9–11). Although there are differences in the timing of events between different species, many of the fundamental events of spermatogenesis are highly conserved in mammals. In contrast to the situation in the male, female germ cells enter meiosis in the embryo and then immediately arrest in meiotic prophase. After birth, germ cells (now called oocytes) in the mouse will resume meiosis in waves, complete meiosis I, and then arrest at metaphase of the second meiotic division (MII). At puberty, females begin to release ovulated oocytes that will complete the second meiotic division after fertilization, and these oocytes are continually released up until menopause (see ref. 1 for review). During the period between entering meiosis and birth, many female germ cells are lost in a process called atresia (see refs. 12 and 13 for reviews). Most likely, this represents a form of programmed cell death. The reasons for this atresia and the molecular mechanisms regulating the process are poorly understood. It may represent a mechanism of quality control in which unhealthy germ cells are deleted. Alternatively, it could represent the end point of a counting mechanism in which germ-cell numbers are regulated. In males, programmed cell death is also an important part of the spermatogenic process and is regulated by p53-dependent and p53-independent mechanisms (see ref. 14 for
Chapter 7/Role of the C-Kit Ligand Axis
149
review). Interestingly, blocking programmed-cell death in the testis results in aberrant spermatogenesis, and eventually infertility (15). Most likely, increased numbers of differentiating spermatogonia inhibit the proliferation of undifferentiated spermatogonia resulting in sterility (16). Regardless of the reasons for, and mechanisms of, apoptosis, these data suggest that programmed cell death is a requisite part of mammalian gametogenesis (see refs. 14 and 17 for reviews).
MUTATIONS AFFECTING FERTILITY AND GAMETOGENESIS The molecular mechanisms regulating mammalian gametogenesis are gradually being determined. In part, this results from the wealth of information being obtained from studies of gametogenesis in model organisms including flies, worms, and yeast. Although there are clear differences between these organisms and mammals, some of the developmental mechanisms regulating germline development and meiosis are evolutionarily conserved. Furthermore, the cloning of mouse mutations that affect fertility has allowed some of the genes involved in mammalian gametogenesis and meiosis to be determined. A recent survey of the mouse mutants held at the Jackson Laboratories revealed that approx 78 mutants affecting some aspect of gametogenesis exist. In addition, a large number of knockout mice have defects in gametogenesis, thereby identifying genes involved in germline development. Two of the best-characterized sterile mouse mutants are those of the Dominant White Spotting (W) and Steel (Sl) loci.
MOLECULAR CHARACTERIZATION OF THE STEEL/DOMINANT WHITE SPOTTING Mutations at the Dominant White Spotting (W) and Steel (Sl) loci are among the oldest mutations of the mouse fancy. They are characterized in part by the semidominant effect on coat color. Many, if not all, of the W and Sl mutants have a prominent head spot as well as a generalized lightening of the coat, particularly on the belly. The number of mutations identified at these loci is large, and constitutes two of the largest allelic series of mouse mutants thus far studied. Thus, a significant amount of information has been accumulated on the structure-function relationships of the proteins encoded at the W and Sl loci. W encodes the c-kit transmembrane receptor tyrosine kinase (18,19) related to the colony-stimulating factor-1 (CSF-1) family of growth-factor receptors and Sl encodes its ligand, variously termed mast-cell growth factor (MGF), stem-cell factor (SCF), kitligand (KL), and steel factor (SF) (20–23). For the purposes of this chapter, this factor will be known as kit-ligand or KL. KL is a transmembrane growth factor that exists in two major forms (KL-1 and KL-2), that are derived by alternate splicing (20,24). KL-1 has a proteolytic cleavage site in the ectodomain (encoded in exon 6), which can be cleaved to produce a soluble factor (25). KL-2 lacks the major proteolytic cleavage site encoded in exon 6. However, KL-2 is in fact proteolytically cleaved at another site (believed to be encoded in exon 7), but in a much less efficient manner (25,26). Therefore, KL-2 is believed to remain largely as a membrane-bound or cell-associated factor. The cleavage of these two forms is believed to occur by distinct mechanisms, perhaps involving different metalloproteinases (25,26) The different KL mRNA species are expressed in distinct patterns in the adult animal, and presumably during embryonic development. Although both membrane-bound and soluble forms of KL have biological
150
Donovan and de Miguel
activity, there are discrete differences in the ability of cells to respond to the membranebound vs soluble forms. Clearly, it is possible to regulate (temporally and spatially) both the expression of different forms of KL and the enzyme responsible for their proteolytic cleavage. By these mechanisms, it should be possible to exquisitely regulate KL biological activity during development and in the adult animal. Binding of KL to the c-kit receptor causes receptor autophosphorylation, and the activation of a signaling transduction cascade required for the development of several cell lineages in the embryo and adult animal (see refs. 27 and 28 for reviews). Consistent with this model of KL-c-kit interaction, mutations at the W and Sl loci have many overlapping features in addition to the effect on coat color described here. Many mutations at the W and Sl loci cause lethality when homozygous because of the role of c-kit and KL in embryonic hematopoiesis and erythropoiesis. The severe anaplastic anemia seen in these mutants is first detected at around Embryonic (E) d 15, at which time hematopoiesis is occuring in the fetal liver. Another major feature of these mutants is their drastic effect on the development of the germline. A large number of W and Sl mutants, if viable, are completely sterile, demonstrating an important role for this signaling pathway in germ-cell development (see ref. 29 for review). The remainder of this review will expand on the roles of the c-kit receptor and its ligand, KL, in germ-cell development, growth, and homeostasis. A large body of evidence has accumulated showing that the c-kit receptor is expressed within the cells affected by the W mutation, while the KL is expressed in surrounding cells (see refs. 30–32). Thus, the c-kit receptor is expressed in melanoblasts, in hemopoietic stem cells (HSC), and in germ cells. KL is expressed by epidermal cells, bonemarrow stromal cells, and, depending on the sex of the animal, Sertoli cells, or granulosa cells. These data are entirely consistent with earlier data from grafting and transplantation studies, which showed that the W mutation acted within the affected lineages, while the Sl mutation was extrinsic to them. The c-kit receptor is also expressed in other cell types, but the description of these cell types and the effect of W and Sl mutations on these cells is beyond the scope of this chapter. As described here, a large number of mutations have been identified at the W and Sl loci, and have variable effects on development. The nature of the Sl mutations fall into four general classes, including lethal mutations that die around E 15.5. These mutations involve deletion of the entire coding region of KL. Lethality is most likely caused by the severe effect on fetal hematopoiesis. Since the fetal liver is a hematopoietic organ, mutants lacking KL are defective in fetal hematopoiesis that is detectable by the pale color of the fetal liver in the mutants. The original Sl-null mutation is representative of this class of mutation. Second, lethal mutations which die prior to E 15.5, usually around the time of implantation. This class of mutation involves deletion of the KL gene as well as other genes required for peri-implantation development. Such mutants include the Sl18H and Sl 12H mutations. Third, there are viable mutations in which a defective form of KL is produced. This class of mutation includes the Sldickie (Sld) and Sl17H mutations. Fourth, there are viable mutations in which the coding region of KL is intact, but in which the regulatory domains of the KL genomic locus are altered. This class of mutation includes the Slpanda (Slpan) and Slcontrasted (Sl con) mutations. The large number and variety of mutations at this locus have greatly contributed to the wealth of knowledge about the role of this factor in germline development and growth.
Chapter 7/Role of the C-Kit Ligand Axis
151
KIT LIGAND IN GERMLINE DEVELOPMENT The infertility seen in many W and Sl mutants signifies the important role played by this signaling pathway in germline development. A growing body of evidence suggests that c-kit receptor and its ligand function at different times during the development of the germline. Moreover, the function of this signaling pathway appears to vary depending on the cell type and stage of development in which the receptor or ligand is expressed. The first stage at which these mutants affect germ-cell development is around E 9.5 in the mouse embryo, a time in which the primordial germ cells (PGC) are migrating towards the embryonic gonad. In both W and Sl mutants, PGC numbers are first altered at this time of development (33–36). This suggests that prior to this time, PGC development is independent of the c-kit/KL-signaling pathway. In the fully colonized gonad of a normal embryo, there are estimated to be approx 35,000 germ cells. In W or Sl mutants, this number can be reduced by over 90%. In this situation, the numbers of germ cells that survive until birth is very small, and usually incompatible with fertility. What is the function of KL during the period of gonad colonization? In principle, KL can regulate germ-cell survival, proliferation, migration, or differentiation, or perhaps a combination of these functions. Data from in vitro studies strongly suggests that activation of the c-kit receptor is required for PGC survival (37–39). PGCs isolated from embryos will adhere to a variety of feeder layers, but will only survive on feeder layers of cells that express KL. Moreover, long-term survival of PGCs seems to depend on the expression of full-length, membrane-bound KL by feeder cells (37). Confirmation of this idea comes from analysis of PGC numbers in Sld mice carrying a genomic deletion of sequences encoding the cytoplasmic tail and transmembrane region of KL. Because of this genomic deletion, Sld mice only express a soluble form of KL (40,41). Since Sld animals are sterile, this suggests that membrane-bound KL is required for PGC survival in vivo also (36). But analysis of PGC migration in Sl/Sld mice demonstrates that many PGCs do not reach the embryonic gonad (36). These data suggest that KL may also be involved in regulating PGC migration in the developing embryo. Consistent with this idea, defective PGC migration has been observed in We/We mutant mice (35). The requirement of PGC survival for membrane-bound forms of KL provides an excellent mechanism for regulating PGC migration and survival in the developing embryo. PGC migration can be controlled spatially and temporally by regulating the expression of KL by embryonic somatic cells. If the PGCs diverge away from the pathway expressing KL, they are expected to die through programmed cell death. During the period between colonization of the gonad and birth, the c-kit/KL signal does not appear to play a significant role, since there appears to be no effect on germcell numbers in mutants during this period. For example, in Sl17H/Sl17H embryos, the numbers of PGCs are severely reduced (42). But some of the germ cells survive until birth, suggesting that the germ cells that reach the embryonic gonad do not die in the intervening period (42). One interesting question is whether female germ-cell atresia in the embryo is affected in W or Sl mutants, since germ-cell number is already severely reduced in these animals. Atresia may represent a simple mechanism for reducing germcell numbers prior to birth, or it could represent a mechanism for deleting germ cells that are inferior. Careful examination of germ-cell number in W or Sl mutant mice during this period may provide an important insight into this question. In summary, KL seems to be required for PGC survival in the mouse embryo from E 9.5 to E 13.5. During this period, it likely acts in concert with other factors to stimulate
152
Donovan and de Miguel
PGC proliferation. It may also play a role in directing migrating germ cells toward the gonad anlagen. This provides a mechanism for ensuring that only the PGCs that are in the correct position will survive and proliferate. The c-kit signal induced by KL binding also appears to have multiple functions later in germline development.
ROLE OF KIT LIGAND IN MALE GAMETOGENESIS Once PGCs have reached the genital ridge in the male embryo, they become surrounded by somatic cells of the embryonic gonad anlagen. These somatic cells, which will eventually be called Sertoli cells, differentiate to form the seminiferous cords. The PGCs also differentiate to form the gonocyte that is morphologically distinct from the PGCs. In mice and rats, the gonocytes will proliferate for a few days, but then arrest at G0/G1 phase of the cell-division cycle (11). In the postnatal period in the testis, the gonocytes will resume mitosis to form the testicular stem cell or spermatogonium. In rats, the timing of resumption of mitosis is strain-dependent. The gonocytes begin proliferating, and simultaneously migrate toward the basement membrane on which Sertoli cells are already established. In vitro studies suggest that expression of c-kit by gonocytes is required for the migration of gonocytes towards the basement membrane (43). Ultimately, the gonocytes come to lie between Sertoli cells. Therefore, the growth and proliferation of germ cells in the testis is strictly controlled by the surrounding Sertoli cells. The division of the gonocyte likely gives rise to two cells, the true stem cell of the testis (the first undifferentiated A Spermatogonium) and the first differentiated type A spermatogonium (44). The onset of division by gonocytes is considered to be the beginning of spermatogenesis. The undifferentiated type A spermatogonium actively proliferates to give rise to daughters, A2-A4, and then type B spermatogonia, which will eventually enter into meiosis (forming spermatocytes) and ultimately undergo spermiogenesis. Once the first spermatocytes have formed, the Sertoli cells form tight junctions (45). The presence of the tight junctions between the Sertoli cells effectively divides the germ-cell population into two compartments. Some of the germ cells lie in the basal layer below the tight junctions, and the others lie above the tight junctions in the adluminal compartment. Potentially, this allows the Sertoli cell to control the germ-cell populations in different ways. KL could play an important role in this form of regulation because it is a membrane-bound factor, and its cleavage can be regulated temporally and spatially. A number of important studies point to a key role for the c-kit/KL signaling pathway in the regulation of spermatogenesis. Analysis of c-kit and KL expression in the testis has given valuable insights into the function of these proteins in spermatogenesis. In the adult testes, the highest levels of c-kit expression are observed in interstitial Leydig cells (46). However, c-kit is also expressed in some spermatogenic cells at the basal layer of the seminiferous cords. Immunocytochemical staining with anti-c-kit antibodies demonstrates that differentiating type A spermatogonia, intermediate type B spermatogonia, and early spermatocytes all express c-kit on the cell surface (46). In some studies, c-kit was not detected on later-stage spermatocytes, spermatids, or the surrounding Sertoli cells. These data are entirely consistent with the idea that the c-kit/KL signaling pathway regulates germ-cell survival and/or proliferation in the adult gonad, but is not a regulator of meiosis. However, other studies suggest that c-kit is expressed in meiotic germ cells and could play a role in regulation of meiosis.
Chapter 7/Role of the C-Kit Ligand Axis
153
Mutations at both the W and Sl loci affect postnatal germ-cell development and adult spermatogenesis. This effect is observed in W and Sl mutants that are viable, and therefore carry mutations (but not complete deletions) in the c-kit and KL genes. For example, Sl17H mice that produce an abnormal form of KL have only a few germ cells that survive until birth (42). However, these few germ cells undergo the first round of spermatogenesis, but the differentiating germ cells are eventually lost, and the mice become sterile. At 8 wk of age, testes from Sl17H/Sl17H mice contained Sertoli cells and a few spermatogonia (42). These data suggest that the survival and division of gonocytes in the early postnatal testis is independent of the c-kit signaling pathway. Further, they suggest that the survival of the adult spermatogonial stem cell may also be independent of this pathway. Finally, these data suggest that the growth and survival of differentiated type A spermatogonia is a c-kit-dependent process. Consistent with this data, experiments have been performed in which an anti-c-kit monoclonal antibody (ACK2) was injected into adult mice. This antibody blocks signaling via the c-kit receptor. The result of this experiment was that spermatogenesis was arrested, and the testis was depleted of differentiated germ cells (46). However, undifferentiated type A spermatogonia are unaffected by such treatment, suggesting that the growth and/or survival of these cells is independent of the c-kit/KL axis (46). Kit binding to its ligand leads to activation of a variety of signaling molecues, including JAK2, Src, Shc, Grb2, PLCa, Ras, PI3K, and AKT (for review, see 46a). In two recent studies, the PI3K binding site on the C-Kit receptor was mutated in mice by gene replacement, and PGC survival was shown to be unaffected (46b,46c). However, these studies also demonstrated that activation of the PI3K signaling pathway downstream of c-Kit is of special importance in make spermatogonial stem cells (46b). A large body of evidence suggests that KL is required for the survival of germ cells, and that along with other factors, KL can stimulate proliferation. Studies analyzing other cell systems have identified some of the genes that regulate cell survival and its counterpart, cell death (apoptosis). One of the major regulators of cell death in mammals is the p53 tumor-suppressor gene (see refs. 47–49 for reviews). In normal cells, p53 levels are low, but the protein is rapidly increased in response to DNA damage or other cellular stress. The p53 signaling pathway induces cell death in damaged cells. Loss of function of the p53 gene in mice leads to tumor formation in a variety of tissues in young adult animals (50,51). This is brought about, in part, by the survival of cells that would otherwise be targeted for apoptosis by the wild-type p53 protein. Spermatogenesis in mammals is normally associated with large numbers of spermatogenic cells undergoing apoptosis. In fact, inhibition of apoptosis in the testis by forced expression of the antiapoptotic bcl-2 protein disrupts normal spermatogenesis (15). Previous studies have shown that programmed cell death in the testis is regulated by both p53-dependent and p53-independent mechanisms. Most likely, binding of KL to the c-kit receptor in germ cells activates pathways that promote cell survival. Conversely, failure to activate the c-kit receptor is likely to activate pathways that induce programmed cell death or apoptosis. These pathways probably include the p53-mediated pathway. Interestingly, when sterile W mutant mice (Wv -bearing a defective c-kit receptor) were intercrossed with mice lacking p53, these mice became fertile (52). Thus, by disrupting p53-mediated apoptosis, cells that lack a functional c-kit signaling pathway (and would otherwise die) are now viable. This data suggests that in the male germline, a major function of the c-kit signaling pathway is to mediate germ cell survival (52). In p53–/–; Wv/Wv double-homozy-
154
Donovan and de Miguel
gous-mutant testes, apoptosis is still apparent, demonstrating that a p53-independent cell death is intact. However, the fact that these double-mutant mice are now fertile demonstrates the important roles of activation of the c-kit receptor by its ligand in controlling p53 activity to regulate life and death in the testis. Germ-cell survival in the testis requires the membrane-bound form of KL rather than the soluble version. This is nicely demonstrated by the observed sterility in Sld mice that can only produce a soluble form of KL (36). The requirement for a membrane-bound factor for germ-cell survival ensures that germ cells can only proliferate when they are in association with Sertoli cells. Thus, germ-cell growth can be strictly controlled within the testis. While the Sld mutation provides evidence of the role of the membrane-bound form of KL in germ cell survival, the Sl17H mutation provides evidence for the specific role of the cytoplasmic tail of KL in this process. In principle, the cytoplasmic tail of KL may have a number of functions, including cytoplasmic signaling, membrane-anchorage, ectodomain cleavage, and ligand dimerization (26,42,53). However, recent studies suggest that the cytoplasm tail has a unique function. In Sl17H mice, a point mutation at a splice-acceptor site results in an alternative reading frame of the KL protein, and leads to the production of a KL polypeptide in which the cytoplasmic tail is altered (42). The protein sequence of this mutant KL is normal from the N-terminus through the first amino acid of the cytoplasmic juxtamembrane region, but then diverges. This mutation has a drastic effect on spermatogenesis, leading to loss of germ-cell loss and male infertility, and this demonstrates an important function for the KL cytoplasmic spermatogenesis (42). Recent studies on the Sl17H gene product suggests that the cytoplasmic tail of KL plays an important role in localization of KL within the cell (54). The Sl17H mutation alters the membrane presentation of KL within the cell and affects the localization of KL on the basolateral surface of polarized epithelial cells (54). Polarized epithelial cells transfected with the Sl17H form of KL or mutants that lack the cytoplasmic tail express or secrete KL from their apical surface. Thus, the loss of germ cells from the testes of Sl17H mice is likely caused by the inability of KL to be properly localized to the basolateral surface of Sertoli cells (54). Although many studies have suggested a role for KL in germ cell survival or proliferation, a number of studies suggest that it may also play a role in regulating male meiosis. For example, at stages VII–VIII of the mouse seminiferous epithelium, the membraneanchored KL extends from the basal to the adluminal compartment of the Sertoli cells. Moreover, the c-kit protein is localized in germ cells that are undergoing meiosis up to pachytene stage (55). In an in vitro culture system in which germ cells can transit through meiosis, an anti-c-kit antibody blocked the appearance of haploid cells and of haploidphase gene expression. These data suggest that the c-kit/KL interaction may play a role in meiotic progression. c-Kit mRNA has also been found in round spermatids (56) and in the acrosomal region of sperm (57). Interestingly, in haploid germ cells, a c-kit mRNA splice variant gives rise to an intracellular protein that only possesses the C-terminal portion of the kinase domain, (termed truncated c-kit or tr-kit) (58). Introduction of tr-kit into metaphase II-arrested mouse oocytes causes complete oocyte activation. The oocytes underwent cortical granule exocytosis, completion of metaphase II, formation of a parthenogenetic pronucleus, and progression through the cleavage stages (59). In addition, sperm undergoing the acrosome reaction demonstrate association of c-kit with the acrososme plasma membrane (60), and blocking c-kit signaling in mature sperm with
Chapter 7/Role of the C-Kit Ligand Axis
155
an anti-c-kit monoclonal antibody (mAb) prevents the acrosomal reaction (61). These data support the idea that tr-kit may be the putative sperm factor required for triggering activation of mouse eggs at fertilization. Again, it is clear that the c-kit/KL axis plays multiple roles in regulating the survival, proliferation, and differentiation of germ cells in the neonatal, prepubertal, and adult testis. Although the action of the c-kit/KL signal in some cells types is well-characterized, the role played by this signaling pathway during meiosis and in sperm function is less well understood. Understanding the role of the C-Kit signal transduction pathway in these processes represents the challenges of the next decade of research.
ROLE OF KIT LIGAND IN FEMALE GAMETOGENESIS In female embryos, once PGCs have entered the fetal ovary, they complete mitotic divisions and enter meiosis. They eventually arrest meiosis at Prophase I, and each germ cell will become invested by a layer of flattened somatic cells that are the precursors of the follicle or granulosa cells. Therefore, in the ovary, just as in the testis, germ-cell survival, growth, and differentiation is controlled by the complex interaction between the germ cells and the surrounding somatic cells (62,63) (see Chapter 4). The structure described here, which contains a germ cell surrounded by follicle cells, is called a primordial follicle. Within a few days of birth, the ovary is filled with oocytes within these primordial follicles. But as the oocyte grows in size, the follicle cells differentiate into cuboidal cells. The appearance of these changes represents the hallmark of the next stage of follicle development, the primary follicle. About 2 wk after birth, secondary follicles containing at least two layers of follicle cells first appear in the mouse ovary. The appearance of a fluid-filled cavity (antrum) within the follicle marks the change to the tertiary- or antral-follicle stage. The follicle not only provides an environment in which the germ cell can be nursed and nourished by surrounding somatic cells but also one in which the progress of the meiotic cell cycle can be regulated. During follicle development, the oocyte grows in size so that the 12–10-µm-diameter cell present in the primordial follicle becomes an 80-µm-diameter cell in a large antral follicle. During this period, the oocytes also acquire the ability to resume meiosis following meiotic arrest (termed meiotic competence acquisition), to be fertilized, and to complete preimplantation development. Thus, the ovarian follicle is a structure in which many complex interactions take place (see ref. 63 and Chapter 4, for review). The granulosa cells receive and respond to signals around them, some signals from other cells within the ovary and some from outside the ovary. In addition, the granulosa cells receive and respond to signals from the developing oocytes. In this way, the development of the follicle and the maturing oocyte is coordinated to ensure that the ovulated egg is both healthy and ready (at the correct stage of the cell cycle) to receive the sperm. The interactions that occur in the ovary are clearly complex. Oocytes and surrounding granulosa cells maintain functional gap junctions between themselves. These gap junctions account for the vast majority of metabolite influx into the oocyte required for oocyte growth. The somatic cells of the follicle are also believed to play an important role in maintaining oocytes in meiotic arrest prior to the surge in luteinizing hormone (LH). The communication between the oocyte and the follicle cells is not one-way. Compelling evidence suggests that the oocyte also signals to granulosa cells to regulate their growth and many aspects of their physiology. For example, the oocyte secretes paracrine factors
156
Donovan and de Miguel
such as growth-differentiation-factor-9 (GDF-9) (64), which regulate granulosa-cell proliferation, suppress LH-receptor mRNA production by granulosa cells, inhibit granulosa-cell production of urokinase plasminogen activator, and regulate other functions of the somatic cells in the ovary. It is apparent that the follicle should not be regarded simply as a structure in which the nurses (granulosa cells) look after the docile patient (the oocyte), but rather one in which the patient has a telephone and call button, and it does not hesitate to use them. What are the factors that participate in the signaling between the granulosa and the oocyte cells? The female infertility seen in some Sl mutants that are otherwise viable suggests that, in addition to its role during embryonic and fetal development, KL also plays an important role in adult gametogenesis. In situ hybridization and immunocytochemical studies of c-kit and KL mRNA and protein in the ovary give a clear picture of the cell types expressing both the receptor and its ligand (30,65–67). Oocytes express c-kit mRNA and protein at all stages of follicle development, and the receptor is also expressed in ovulated eggs. The c-kit receptor is also found to be expressed in interstitial cells and theca cells (68). The granulosa cells surrounding the oocyte express KL in every mammal examined thus far. In mice, KL expression is low in primordial and primary follicles, and in granulosa cells surrounding the ovulated oocyte. However, soon after the period of oocyte growth (i.e., the primary follicle through the preovulatory follicle), KL mRNA levels increase and are regulated in a hormonally dependent manner (69). Taken together, these data suggest that KL could play an important role in oocyte growth. Consistent with these observations, mice carrying mutations in the Sl gene exhibit defects in oogenesis. For example, Slpanda (Slpan) mice have DNA rearrangements in the Sl gene-promoter region that reduces KL expression during development and in the adult mouse (70). Defective KL mRNA expression in Slpan animals causes sterility by influencing the initiation and maintenance of ovarian-follicle development. The observed arrest in follicle development occurs at the primary-follicle stage of development. Similar defects, which are found in Slcontrasted (Slcon) mice, also affect ovarianfollicle development (70). These data demonstrate a requirement for KL in follicle development. Microinjection of the ACK2 anti-c-kit antibody into female mice disrupts oogenesis, and provides important information on the role of the c-kit signaling pathways in the ovary (66). These studies suggest that c-kit is involved in the onset of primordial follicle development and primordial follicle growth consistent with the defects seen in several Sl mutants. In mice injected with anti-c-kit antibody every 2 d for the first 2 wk after birth, oocytes were surrounded by a single layer of granulosa cells but these cells were not synthesizing DNA (66). This suggests that the granulosa cells were not actively proliferating. Nevertheless, in some cases, granulosa cells differentiated to take on a cuboidal shape. However, many follicles were observed to have degenerated, and the oocytes were lost (66). When the regimen of anti-c-kit antibody injection was changed so that the antibody was not injected until 2 d after birth, primary-follicle development was only slightly disturbed. The conclusion from these studies was that c-kit function is critical for primary follicle development during the first 5 d of postnatal life (66). These studies also suggested an important role for the c-kit signaling pathway in antral-follicle development and function. Thus, mice injected with the ACK-2 antibody had reduced numbers of antral follicles by comparison with matched controls. Injection of the ACK-2 antibody between postnatal d 10 and 14 inhibited granulosa-cell proliferation, and antrum
Chapter 7/Role of the C-Kit Ligand Axis
157
formation was severely perturbed (66). Once antral follicles are formed, some of these large follicles will mature to the ovulatory stage. Blocking c-kit signaling via ACK-2 injection between d 10 and d 14 caused antral-follicle degeneration and inhibition of follicular fluid formation (66). This result suggests that the c-kit/KL signal is also required for the maturation of antral follicles. Previous in vitro studies suggested that the c-kit signaling pathway plays an important role in oocyte growth. For example, when follicles are cultured in the presence of soluble KL, an increase in oocyte diameter is observed (71). Detailed analysis of KL mRNA levels in developing and maturing ovarian follicles suggests that the oocyte regulates both the type and level of KL mRNA expressed by surrounding follicle cells. For example, fully grown oocytes were found to reduce the level of KL mRNA in preantral granulosa cells, and also, increased the ratio of KL-1 mRNA to KL-2 mRNA (72). Other oocytemediated changes in KL mRNA expression were appropriate to the stage of folliculogenesis (72). Therefore, the developmental regulated expression of c-kit in the oocyte and KL in the surrounding follicle cells provides a nice mechanism for crosstalk between the follicle cells and the oocyte. In response to KL, the oocyte develops or matures and sends a signal back to the follicle (granulosa) cells. Follicle cells respond by modifying the amount or type of KL they produce, which in turn affects the oocyte. In this way, the follicle cells determine which stage of development the oocyte has reached and respond accordingly, and vice versa. How does the signal transduced by the c-kit receptor, which is present in the oocyte, regulate granulosa cell function? One attractive candidate for a signal produced by oocytes and which would act on granulosa cells is GDF-9 (73,74). GDF-9 is produced by the oocyte, and binds to receptors present on granulosa cells. In female mice lacking GDF-9, follicles with intact oocytes contain only a single layer of granulosa cells, similar to the Sl mutant mice (75). Although oocyte levels of c-kit mRNA appear normal in GDF-9-deficient mice, KL levels are greatly increased (64). These data suggest that KL may be regulated in a paracrine fashion by GDF-9. Interestingly, the oocytes in GDF-9 knockout mice have defects in meiotic competence (abnormal germinal-vesicle breakdown and spontaneous parthenogenetic activation), and demonstrate an increased rate of growth (75,76). Although the oocyte undoubtedly plays an important role in regulating KL mRNA levels in granulosa cells, other factors not derived from oocytes are also likely to play an important role in this regulation, including signals emanating from ovarian theca cells and extragonadal factors such as FSH. This is supported by the finding that stimulation of the LH receptor in theca cells, via human chorionic gonadotropin (hCG) and equine chorionic gonadotropin (eCG) treatment results in increased levels of KL mRNA in certain granulosa-cell populations (68). A growing body of evidence suggests that the c-kit signal-transduction pathway also plays a role in regulating the meiotic cell cycle in mammal oocytes in the rat, and that activation of the c-kit receptor results in a delay in the rate of oocyte meiosis (77). Thus, KL signaling may be one of the factors responsible for maintaining oocytes in meiotic arrest during their growth period. When rat oocytes are injected with c-kit antisense oligonucleotides, c-kit levels decline and the oocytes show an increased ability to resume meiosis (78). In contrast, oocytes cultured in the presence of soluble KL are delayed in their ability to resume meiosis (78). The changes in KL-1 and KL-2 mRNA levels and ratios in developing follicles described here may provide a mechanism for regulating meiotic resumption. It is presumed that membrane-bound forms of KL, when bound to the c-kit receptor, prevent c-kit internalization. Membrane-bound forms of KL may also
158
Donovan and de Miguel
send a quantitatively and qualitatively distinct signal to cells than the soluble form of KL (79). Thus, a switch in production from membrane-bound to soluble c-kit by granulosa cells may be one of the signals that triggers the resumption of meiosis in mammals. The analysis of the role of the c-kit/KL axis in female germline development reinforces the idea that these two proteins play multiple roles at different stages of germ-cell development. One of the challenges ahead will be to decipher how a single receptor, hardwired into different cell types, can give very different responses.
COULD GONADAL TUMORS BE A CONSEQUENCE OF C-KIT/KL DYSREGULATION? While compelling evidence has been provided for the role of c-kit and KL in normal germline development, little is known about the role of these proteins in germ-cell tumor formation or in the development of gonadal tumors. Loss of germ cells from the ovary is associated with the development of epithelial ovarian tumors, including tubular adenomas. This is has been suggested to result from overproduction of pituitary gonadotrophin in response to reduced germ-cell numbers, which in turn causes overstimulation of the gonad. Such a phenotype is seen in both W and Sl mutants that are viable and sterile (42). One other mechanism in which somatic cells of the ovary may become transformed is through constitutive expression of both c-kit and its ligand. In some forms of ovarian cancer (serous adenocarcinoma), both c-kit and KL proteins have been detected histochemically in the same cell type (80). This could result in autocrine activation of the c-kit receptor that would be expected to drive cell-cycle progression and lead to cellular transformation. In some germ-cell tumors of the ovary (dysgerminomas), c-kit is expressed in malignant cells while the surrounding connective tissue expresses KL. Thus, the c-kit signaling pathway may play an important role—not only in normal development of the ovary, but also in development of ovarian tumors. Curiously, some mutations at the Sl locus also increase the incidence of testicular teratoma and teratocarcinoma in mice (81). This observation is puxxling, since KL is required for PGC survival (37). Loss of one allele of Sl should result in loss of PGCs rather than their extended proliferation. PGC numbers in the developing embryo may be strictly regulated, so that evolutionary pressure ensures that the gonad is fully populated with germ cells. In this scenario, reduced PGC survival may cause the remaining PGCs to continue to proliferate in order to restore PGC numbers. Interestingly, in mouse mutants in which germ-cell numbers are reduced, extended proliferation of germ cells is observed. Germ-cell hyperplasia may predispose the cells to transformation, as it does in other lineages (82). Some evidence for this also comes from studies in which PGC numbers were reduced by treatment of embryos with mitomycin C (83). Following treatment with mitomycin C, embryo size and the number of PGCs are greatly reduced. However, after a few days of development, PGC numbers recover somewhat (83). These data suggest that there is some mechanism for monitoring and counting PGC numbers in the developing gonad. In humans, testicular cancer incidence correlates with conditions in which the gonads are not well-developed (for review see ref. 3), such as cryptorchidism (84), gonadal dysgenesis (85), androgen insensitivity syndrome (86), testicular atrophy (87), or infertility (88). It is now well-accepted that CIS (carcinoma in situ of the testis) is the precursor of most germ-cell testicular cancers (for review see ref. 89), with the exception of spermatocytic seminoma (90). CIS cells are
Chapter 7/Role of the C-Kit Ligand Axis
159
thought to be derived from gonocytes, and in fact, they show similar morphological and immunohistochemical characteristics (91). Several reports also suggest involvement of the c-kit pathway in the origin of CIS. It has been hypothesized that overexpression (or prolonged expression) of c-kit by gonocytes may lead to abnormal cell divisions and subsequently to their transformation (92,93). To confirm this hypothesis, an activating mutation in the kinase domain has been identified in the c-kit gene in germ-cell tumors in a small number of cases (94), which produces a c-kit protein that is constitutively active. These data highlight the potential importance of the c-kit signal transduction pathway in gonadal tumors of both germ-cell and somatic-cell origin. Further definition of the role of this signaling pathway in gonadal tumors is necessary. Interestingly, disruption of the c-kit-signal transduction pathway may be an important method for treating testicular tumors (95), and possibly other tumors in which the c-kit signaltransduction pathway is disturbed.
FUTURE PROSPECTS The importance of fertility in human populations is likely to make the study of the role of the c-kit/KL signaling pathway in gametogenesis an enduring one. The c-kit/KL signaling pathway is undoubtedly one of the key pathways involved in regulation of gametogenesis. Moreover, it plays an important role at many different stages of gametogenesis. Several areas of research are likely to play an important role in our understanding of the role that c-kit and KL play in gametogenesis. First, studies on the signaling pathway that lies downstream of c-kit receptor will probably yield important information on how this one signaling protein can effect such different responses at different stages of germ-cell development. A key question is how the c-kit receptor is hardwired within germ cells at different stages of development. Second, targeting of the c-kit gene with different mutations via homologous recombination in ES cells will certainly identify the residues within the protein responsible for defined functions within different cell types (26). Combined with cell -type-specific deletions (mediated by Lox-Cre), this approach will undoubtedly refine our understanding of the biology of the c-kit response. Third, improvements in the in vitro culture conditions for germ cells at all stages of development will further clarify the role of the c-kit/KL axis in germline development. Fourth, the further development of transplantation techniques for male germ cells (96,97) will allow many of the roles of KL in male spermatogonial survival and proliferation to be addressed. The development of the mammalian germline is a complex process. The developmental processes involved include migration, survival, proliferation, growth, and differentiation. Many different types of somatic cells may be involved, and these cells may also migrate, proliferate, and differentiate in order to fulfill their function in support of the germ cells. One striking feature of these processes is the central role of the c-kit receptor and its ligand, KL. Although many other factors are involved in germline development, the study of the c-kit/KL axis is likely to continue to be a central feature of research in mammalian gametogenesis.
ACKNOWLEDGMENTS We would like to thank Mary Bedell for many helpful discussions and Marty Matzuk for inviting us to write this review and for his patience. Work in the author’s laboratory
160
Donovan and de Miguel
was supported in part by a Cancer Center Core Grant (P30CA56036) from the National Cancer Institute.
REFERENCES 1. McLaren A. Germ Cells and Soma: A New Look at an Old Problem. Yale Univeristy Press, New Haven, CT, 1981. 2. Bondy CA, Nelson LM, Kalantaridou SN. The genetic origins of ovarian failure. J Womens Health 1998;7(10):1225–1229. 3. Skakkebaek NE, Rajpert-De Meyts E, Jorgensen N, Carlsen E, Petersen PM, Giwercman A, et al. Germ cell cancer and disorders of spermatogenesis: an environmental connection? Apmis 1998;106(1):3–11; discussion 12. 4. Schottenfeld D, Warshauer ME, Sherlock S, Zauber AG, Leder M, Payne R. The epidemiology of testicular cancer in young adults. Am J Epidemiol 1980;112(2):232–246. 5. Osterlind A. Diverging trends in incidence and mortality of testicular cancer in Denmark, 1943-1982. Brit J Cancer 1996;53(4):501–505. 6. Bjorge T, Engeland A, Hansen S, Trope CG. Trends in the incidence of ovarian cancer and borderline tumours in Norway, 1954-1993. Int J Cancer 1997;71(5):780–786. 7. Lawson KA, Hage WJ. Clonal analysis of the origin of primordial germ cells in the mouse. Ciba Foundation Symposium, 1994;182:68–84; discussion 84–91. 8. Donovan PJ, Stott D, Cairns LA., Heasman J, Wylie CC. Migratory and postmigratory mouse primordial germ cells behave differently in culture. Cell 1986;44(6):831–838. 9. Paniagua R, Nistal M. Morphological and histometric study of human spermatogonia from birth to the onset of puberty. J Anat 1984;139(Pt 3):535–552. 10. Vergouwen RP, Jacobs SG, Huiskamp R, Davids JA, de Rooij DG. Proliferative activity of gonocytes, Sertoli cells and interstitial cells during testicular development in mice. J Reprod Fertil 1991; 93(1):233–243. 11. Hilscher B, Hilscher W, Bulthoff-Ohnolz B, Kramer U, Birke A, Pelzer H, et al. Kinetics of gametogenesis. I. Comparative histological and autoradiographic studies of oocytes and transitional prospermatogonia during oogenesis and prespermatogenesis. Cell Tissue Res 1974;154(4):443–470. 12. Tilly JL. Apoptosis and ovarian function. Rev Reprod 1996;1(3):162–172. 13. Kaipia A, Hsueh AJ. Regulation of ovarian follicle atresia. Ann Rev Physiol 1997;59:349–363. 14. Braun RE. Every sperm is sacred—or is it? Nat Genet 1998;18(3):202–204. 15. Furuchi T, Masuko K, Nishimune Y, Obinata M, Matsui Y. Inhibition of testicular germ cell apoptosis and differentiation in mice misexpressing Bcl-2 in spermatogonia. Development 1996;122(6):1703–1709. 16. De Rooij DG, Van Dissel-Emiliani FM, Van Pelt AM. Regulation of spermatogonial proliferation. Ann NY Acad Sci 1989;564:140–153. 17. Matsui Y. Regulation of germ cell death in mammalian gonads. APMIS 1998;106(1):142–147; discussion 147,148. 18. Geissler EN, Ryan MA, Housman DE. The dominant-white spotting (W) locus of the mouse encodes the c-kit proto-oncogene. Cell, 1988;55(1):185–192. 19. Chabot B, Stephenson DA, Chapman VM, Besmer P, Bernstein A. The proto-oncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus. Nature 1988; 335(6185):88,89. 20. Anderson DM, Lyman SD, Baird A, Wignall JM, Eisenman J, Rauch C, et al. Molecular cloning of mast cell growth factor, a hematopoietin that is active in both membrane bound and soluble forms. Cell 1990;63(1):235–243. 21. Zsebo KM, Williams DA, Geissler EN, Broudy VC, Martin FH, Atkins HL, et al. Stem cell factor is encoded at the Sl locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor. Cell 1990;63(1):213–224. 22. Copeland NG, Gilbert DJ, Cho BC, Donovan PJ, Jenkins NA, Cosman D, Anderson D, Lyman SD, Williams DE. Mast cell growth factor maps near the steel locus on mouse chromosome 10 and is deleted in a number of steel alleles. Cell 1990;63(1):175–183. 23. Huang E, Nocka K, Beier DR, Chu TY, Buck J, Lahm HW, et al. The hematopoietic growth factor KL is encoded by the Sl locus and is the ligand of the c-kit receptor, the gene product of the W locus. Cell 1990;63(1):225–233. 24. Huang EJ, Nocka KH, Buck J, Besmer P. Differential expression and processing of two cell associated forms of the kit-ligand: KL-1 and KL-2. Mol Biol Cell 1992;3(3):349–362.
Chapter 7/Role of the C-Kit Ligand Axis
161
25. Majumdar MK, Feng L, Medlock E Toksoz D, Williams DA. Identification and mutation of primary and secondary proteolytic cleavage sites in murine stem cell factor cDNA yields biologically active, cell-associated protein. J Biol Chem 1994;269(2):1237–1242. 26. Tajima Y, Moore MA, Soares V, Ono M, Kissel H, Besmer P. Consequences of exclusive expression in vivo of Kit-ligand lacking the major proteolytic cleavage site. Proc Natl Acad Sci USA 1998;95(20):11,903–11,908. 27. Lev S, Blechman JM, Givol D, Yarden Y. Steel factor and c-kit protooncogene: genetic lessons in signal transduction. Crit Rev Oncogenesis 1994;5(2–3):141–168. 28. Besmer P, Manova K, Duttlinger R, Huang EJ, Packer A, Gyssler C, et al The kit-ligand (steel factor) and its receptor c-kit/W: pleiotropic roles in gametogenesis and melanogenesis. Development (Suppl) 1993;125–137. 29. Silvers WK. The Coat Colors of Mice. Springer-Verlag, New York, NY, 1979. 30. Matsui Y, Zsebo KM, Hogan BL. Embryonic expression of a haematopoietic growth factor encoded by the Sl locus and the ligand for c-kit. Nature 1990;347(6294):667–669. 31. Nocka K, Majumder S, Chabot B, Ray P Cervone M, Bernstein A, et al. Expression of c-kit gene products in known cellular targets of W mutations in normal and W mutant mice—evidence for an impaired c-kit kinase in mutant mice. Genes Dev 1989;3(6):816–826. 32. Keshet E, Lyman SD, Williams DE, Anderson DM, Jenkins NA, Copeland NG, et al. Embryonic RNA expression patterns of the c-kit receptor and its cognate ligand suggest multiple functional roles in mouse development. EMBO J 1991;10(9):2425–2435. 33. Mintz B. Embryological development of primordial germ cells in the mouse: influence of a new mutation, Wj. J Embryol Exp Morphol 1957;5:396–406. 34. Mintz B, Russell ES. Gene-induced embryological modifications of primordial germ cells in the mouse. J Exp Morphol 1957;134:207–237. 35. Buehr M, McLaren A, Bartley A, Darling S. Proliferation and migration of primordial germ cells in We/We mouse embryos. Dev Dyn 1993;198(3):182–189. 36. McCoshen JA, McCallion DJ. A study of the primordial germ cells during their migratory phase in Steel mutant mice. Experientia 1975;31(5):589,590. 37. Dolci S, Williams DE, Ernst MK, Resnick JL, Brannan CI, Lock LF, et al. Requirement for mast cell growth factor for primordial germ cell survival in culture. Nature 1991;352(6338):809–811. 38. Matsui Y, Toksoz D, Nishikawa S, Williams D, Zsebo K, Hogan BL. Effect of Steel factor and leukaemia inhibitory factor on murine primordial germ cells in culture. Nature 1991;353(6346):750–752. 39. Godin I, Deed R, Cooke J, Zsebo K, Dexter M, Wylie CC. Effects of the steel gene product on mouse primordial germ cells in culture. Nature 1991;352(6338):807–809. 40. Brannan CI, Lyman SD, Williams DE, Eisenman J, Anderson DM, Cosman D, et al. Steel-Dickie mutation encodes a c-kit ligand lacking transmembrane and cytoplasmic domains. Proc Natl Acad Sci USA 1991;88(11):4671–4674. 41. Flanagan JG, Chan DC, Leder P. Transmembrane form of the kit ligand growth factor is determined by alternative splicing and is missing in the Sld mutant. Cell 1991;64(5):1025–1035. 42. Brannan CI, Bedell MA, Resnick JL, Eppig JJ, Handel MA, Williams DE, et al. Developmental abnormalities in Steel17H mice result from a splicing defect in the steel factor cytoplasmic tail. Genes Dev 1992;6(10):1832–1842. 43. Orth JM, Qiu J, Jester WF Jr, Pilder S. Expression of the c-kit gene is critical for migration of neonatal rat gonocytes in vitro. Biol Reprod 1997;57(3):676–683. 44. van Haaster LH., de Rooij DG. Spermatogenesis is accelerated in the immature Djungarian and Chinese hamster and rat. Biol Reprod 1993;49(6):1229–1235. 45. Vitale R, Fawcett DW, Dym M. The normal development of the blood-testis barrier and the effects of clomiphene and estrogen treatment. Anat Rec 1973;176(3):331–344. 46. Yoshinaga K, Nishikawa S, Ogawa M, Hayashi S, Kunisada T, Fujimoto T. Role of c-kit in mouse spermatogenesis: identification of spermatogonia as a specific site of c-kit expression and function. Development 1991;113(2):689–699. 46a. Blume-Jensen P, Janknecht R, Hunter T. The kit receptor promotes cell survival via activation of PI 3-kinase and subsequent Akt-mediated phosphorylation of Bad and Ser 136. Curr Biol 1998;8(13):779–782. 46b. Blume-Jensen P, Jiang G, Hyman R, Lee KF, O’Gorman S, Hunter V. Kit/stem cell factor receptorinduced activation of phosphatildylinositol 3'-kinase is essential for male fertility. Nat Gene 2000;24(2):157–162. 46c. Kissel H, Timokhina I, Hardy MP, Rothschild G, Tjima T, Soares V, Angeles M, et al. Point mutation in kit receptor tyrosine kinase reveals essential roles for kit signaling in spermatogenesis and oogenesis without affectivn other kit responses. EMBO J 1000;19(6);1312–1326.
162
Donovan and de Miguel
47. Ding HF, Fisher DE. Mechanisms of p53-mediated apoptosis. Crit Rev Oncogenesis 1998;9(1):83–98. 48. Steele RJ, Thompson AM, Hall PA, Lane DP. The p53 tumour suppressor gene. Brit J Surg 1998;85(11):1460–1467. 49. Bates S, Vousden KH. Mechanisms of p53-mediated apoptosis. Cell Mol Life Sci 1999;55(1):28–37. 50. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr, Butel JS, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992;356(6366):215–221. 51. Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT, et al. Tumor spectrum analysis in p53-mutant mice. Curr Biol 1994;4(1):1–7. 52. Jordan SA, Speed RM, Bernex F, Jackson IJ. Deficiency of Trp53 rescues the male fertility defects of KitW-v mice but has no effect on the survival of melanocytes and mast cells. Dev Biol 1999;215:78–90. 53. Kapur R, Cooper R, Xiao X Weiss MJ, Donovan P, Williams DA. The presence of novel amino acids in the cytoplasmic domain of stem cell factor results in hematopoietic defects in Steel(17H) mice. Blood 1999;94(6):1915–1925. 54. Wehrle-Haller B, Weston JA. Altered cell-surface targeting of stem cell factor causes loss of melanocyte precursors in Steel17H mutant mice. Dev Biol 1999;210(1):71–86. 55. Vincent S, Segretain D, Nishikawa S, Nishikawa SI, Sage J, Cuzin F, et al. Stage-specific expression of the Kit receptor and its ligand (KL) during male gametogenesis in the mouse: a Kit-KL interaction critical for meiosis. Development 1998;125(22):4585–4593. 56. Rossi P, Marziali G, Albanesi C, Charlesworth A, Geremia R, Sorrentino V. A novel c-kit transcript, potentially encoding a truncated receptor, originates within a kit gene intron in mouse spermatids. Dev Biol 1992;152(1):203–207. 57. Sandlow JI, Feng HL, Sandra A. Localization and expression of the c-kit receptor protein in human and rodent testis and sperm. Urology 1997;49(3):494–500. 58. Albanesi C, Geremia R, Giorgio M, Dolci S, Sette C, Rossi P. A cell- and developmental stage-specific promoter drives the expression of a truncated c-kit protein during mouse spermatid elongation. Development 1996;122(4):1291–1302. 59. Sette C, Bevilacqua A, Bianchini A, Mangia F, Geremia R, Rossi P. Parthenogenetic activation of mouse eggs by microinjection of a truncated c-kit tyrosine kinase present in spermatozoa. Development 1997;124(11):2267–2274. 60. Sandlow JI, Feng HL, Zheng LJ, Sandra A. Migration and ultrastructural localization of the c-kit receptor protein in spermatogenic cells and spermatozoa of the mouse. J Urol 1999;161(5):1676–1680. 61. Feng H, Sandlow JI, Sandra A. The c-kit receptor and its possible signaling transduction pathway in mouse spermatozoa. Molecular Reproduction & Development, 1998;49(3):317–326. 62. Eppig JJ, Chesnel F, Hirao Y, O’Brien MJ, Pendola FL, Watanabe S, et al. Oocyte control of granulosa cell development: how and why. Human Reprod 1997;12(11 Suppl):127–132. 63. Buccione R, Schroeder AC, Eppig JJ. Interactions between somatic cells and germ cells throughout mammalian oogenesis. Biol Reprod 1990;43(4):543–547. 64. Elvin JA, Clark AT, Wang P, Wolfman NM, Matzuk MM. Paracrine actions of growth differentiation factor-9 in the mammalian ovary. Mol Endocrinol 1999;13(6):1035–1048. 65. Manova K, Nocka K, Besmer P, Bachvarova RF. Gonadal expression of c-kit encoded at the W locus of the mouse. Development 1990;110(4):1057–1069. 66. Yoshida H, Takakura N, Kataoka H, Kunisada T, Okamura H, Nishikawa SI. Stepwise requirement of c-kit tyrosine kinase in mouse ovarian follicle development. Dev Biol 1997;184(1):122–137. 67. Keshet E, Lyman SD, et al. Embryonic RNA expression patterns of the c-kits receptor and its cognate ligand suggest multiple functional roles in mouse development. EMBO J 1991;10(9):2425–2435. 68. Parrott JA, Skinner MK. Direct actions of kit-ligand on theca cell growth and differentiation during follicle development. Endocrinology 1997;138(9):3819–3827. 69. Motro B, Bernstein A. Dynamic changes in ovarian c-kit and Steel expression during the estrous reproductive cycle. Dev Dyn 1993;197(1):69–79. 70. Bedell MA, Brannan CI, Evans EP, Copeland NG, Jenkins NA, Donovan PJ. DNA rearrangements located over 100 kb 5' of the Steel (Sl)-coding region in Steel-panda and Steel-contrasted mice deregulate Sl expression and cause female sterility by disrupting ovarian follicle development. Genes Dev 1995;9(4):455–470. 71. Packer AI, Hsu YC, Besmer P, Bachvarova RF. The ligand of the c-kit receptor promotes oocyte growth. Dev Biol 1994;161(1):194–205. 72. Joyce IM, Pendola FL, Wiggelsworth K, Eppig JJ. Oocyte regulation of Kit ligand expression in mouse ovarian follicles. Dev Biol 1999;214:342–353.
Chapter 7/Role of the C-Kit Ligand Axis
163
73. McPherron AC, Lee SJ. GDF-3 and GDF-9: two new members of the transforming growth factor-beta superfamily containing a novel pattern of cysteines. J Biol Chem 1993;268(5):3444–3449. 74. McGrath SA, Esquela AF, Lee SJ. Oocyte-specific expression of growth/differentiation factor-9. Mol Endocrinol 1995;9(1):131–136. 75. Dong J, Albertini DF, Nishimori K, Kumar TR, Lu N, Matzuk MM. Growth differentiation factor-9 is required during early ovarian folliculogenesis. Nature, 1996;383(6600):531–535. 76. Carabatsos MJ, Elvin J, Matzuk MM, Albertini DF. Characterization of oocyte and follicle development in growth differentiation factor-9 deficient mice. Dev Biol 1998;204:373–384. 77. Ismail RS, Okawara Y, Fryer JN, Vanderhyden BC. Hormonal regulation of the ligand for c-kit in the rat ovary and its effects on spontaneous oocyte meiotic maturation. Mol Reprod Dev 1996;43(4):458–469. 78. Ismail RS, Dube M, Vanderhyden BC. Hormonally regulated expression and alternative splicing of kit ligand may regulate kit-induced inhibition of meiosis in rat oocytes. Dev Biol 1997; 184(2):333–342. 79. Miyazawa K, Williams DA, Gotoh A, Nishimaki J, Broxmeyer HE, Toyama K. Membrane-bound Steel factor induces more persistent tyrosine kinase activation and longer life span of c-kit gene-encoded protein than its soluble form. Blood 1995;85(3):641–649. 80. Inoue M, Kyo S, Fujita M, Enomoto T, Kondoh G. Coexpression of the c-kit receptor and the stem cell factor in gynecological tumors. Cancer Res 1994;54(11):3049–3053. 81. Stevens LC. Genetic influences on teratocarcinogenesis and parthenogenesis. Prog Clin Biol Res 1981;45:93–104. 82. Noguchi T, Stevens LC. Primordial germ cell proliferation in fetal testes in mouse strains with high and low incidences of congenital testicular teratomas. J Natl Cancer Inst 1982;69(4):907–913. 83. Tam PP, Snow MH. Proliferation and migration of primordial germ cells during compensatory growth in mouse embryos. J Embryol Exp Morphol 1981;64:133–147. 84. Moller H, Prener A, Skakkebaek NE. Testicular cancer, cryptorchidism, inguinal hernia, testicular atrophy, and genital malformations: case-control studies in Denmark. Cancer Causes Control 1996;7(2):264–274. 85. Muller J, Skakkebaek NE. Gonadal malignancy in individuals with sex chromosome anomalies. Birth Defects: Original Article Series, 1990;26(4):247–255. 86. Collins GM, Kim DU, Logrono R, Rickert RR, Zablow A, Breen JL. Pure seminoma arising in androgen insensitivity syndrome (testicular feminization syndrome): a case report and review of the literature. Mod Pathol 1993;6(1):89–93. 87. Giwercman A, Lenz S, Skakkebaek NE. Carcinoma in situ in atrophic testis: biopsy based on abnormal ultrasound pattern. Brit J Urol 1993;72(1):118–120. 88. Petersen PM, Skakkebaek NE., Giwercman A. Gonadal function in men with testicular cancer: biological and clinical aspects. Apmis 1998;106(1):24–34; discussion 34–36. 89. Skakkebaek NE, Berthelsen JG, Giwercman A, Muller J. Carcinoma-in-situ of the testis: possible origin from gonocytes and precursor of all types of germ cell tumours except spermatocytoma. Int J Androl 1987;10(1):19–28. 90. Muller J. Abnormal infantile germ cells and development of carcinoma-in-situ in maldeveloped testes: a stereological and densitometric study. Int J Androl 1987;10(3):543–567. 91. Meyts ER, Jorgensen N, Muller J, Skakkebaek NE. Prolonged expression of the c-kit receptor in germ cells of intersex fetal testes. J Pathol 1996;178(2):166–169. 92. Rajpert-De Meyts E, Jorgensen N, Brondum-Nielsen K, Muller J, Skakkebaek NE. Developmental arrest of germ cells in the pathogenesis of germ cell neoplasia. Apmis 1998;106(1):198–204; discussion 204–206. 93. Jorgensen N, Giwercman A, Muller J, Skakkebaek NE. Immunohistochemical markers of carcinoma in situ of the testis also expressed in normal infantile germ cells. Histopathology 1993;22(4):373–378. 94. Tian Q, Frierson HF Jr, Krystal GW, Moskaluk CA. Activating c-kit gene mutations in human germ cell tumors. Am J Pathol 1999;154(6):1643–1647. 95. Li Q, Kondoh G, Inafuku S, Nishimune Y, Hakura A. Abrogation of c-kit/Steel factor-dependent tumorigenesis by kinase defective mutants of the c-kit receptor: c-kit kinase defective mutants as candidate tools for cancer gene therapy. Cancer Res 1996;56(19):4343–4346. 96. Brinster RL, Avarbock MR. Germline transmission of donor haplotype following spermatogonial transplantation. Proc Natl Acad Sci USA 1994;91(24):11,303–11,307. 97. Brinster RL, Zimmermann JW. Spermatogenesis following male germ-cell transplantation. Proc Natl Acad Sci USA 1994;91(24):11,298–11,302.
Chapter 8/Steroidogenesis
8
165
Gene Knockout Approaches to Steroidogenesis Tomonobu Hasegawa, MD, PHD, Liping Zhao, PHD, Kathleen M. Caron, PHD, Morag Young, PHD, and Keith L. Parker, MD, PHD CONTENTS INTRODUCTION STAR KNOCKOUT MICE SF-1 KNOCKOUT MICE SUMMARY AND PERSPECTIVES ACKNOWLEDGMENTS REFERENCES
INTRODUCTION Genetic disorders in human patients—and to a lesser degree, in laboratory animals— have provided prismatic insights into the mechanisms of steroid hormone biosynthesis. These studies are restricted to spontaneously arising mutations, and often are hampered by ethical limitations on human experimentation. Gene targeting in mouse embryonic stem (ES) cells—ultimately producing knockout mice—has expanded considerably the number of genes whose function can be evaluated in vivo. This chapter focuses on knockout mouse studies that have defined the roles of two essential components of steroidogenesis: the transcription factor steroidogenic factor 1 (SF-1) and a protein that is required for cholesterol delivery to the steroidogenic complex, the steroidogenic acute regulatory protein (StAR). The regulated production of steroid hormones involves complex, reciprocal interactions among the hypothalamus, anterior pituitary, and primary steroidogenic tissues, and defects at multiple levels can impair steroidogenesis. Figure 1 outlines the factors that control the production of steroid hormones in the adrenal cortex. Analyses of human patients with mutations that impair various steps in the adrenal and gonadal pathways have provided key insights into the roles of many of these components (1,2). These
From: Contemporary Endocrinology: Transgenics in Endocrinology Edited by: M. Matzuk, C. W. Brown, and T. R. Kumar © Humana Press Inc., Totowa, NJ
165
166
Hasegawa et al.
Fig. 1. Schematic overview of the multiple steps in adrenal steroidogenesis. A diagram of the different levels involved in the regulation of steroid hormone production by the adrenal cortex is shown. CRH, corticotropin-releasing hormone; ACTH, corticotropin; ACTH-R, ACTH receptor; SR-B1, high-density lipoprotein receptor; SF-1, steroidogenic factor 1; StAR, steroidogenic acute regulatory protein; P450scc, cholesterol side-chain cleavage enzyme.
human studies—coupled with cell-culture analyses in steroidogenic cells from different species—provide a framework for understanding the essential steps in steroid production. Experiments remain that cannot be performed in humans because of ethical considerations. In addition, evolving technologies for transgenesis and gene knockouts have enormously expanded our ability to examine in vivo the effects of mutating specific components of the steroidogenic complex.
StAR KNOCKOUT MICE As shown in Fig. 1, one essential step in steroidogenesis is the translocation of cholesterol from the cytoplasm to the inner mitochondrial membrane, where the cholesterol side-chain cleavage enzyme (P450scc) catalyzes the first committed reactions in steroidogenesis. The steroidogenic acute regulatory protein (StAR), a 30-kDa mitochondrial phosphoprotein, was initially isolated because its expression within steroidogenic
Chapter 8/Steroidogenesis
167
cells was rapidly induced by trophic hormones (3). These findings suggested that StAR may contribute to steroidogenesis. Dramatic confirmation of the essential role of StAR in these processes has come from analyses of human patients with congenital lipoid adrenal hyperplasia (lipoid CAH), an autosomal recessive disorder characterized by defects in all classes of steroid hormones (reviewed in 4). Lipoid CAH was associated with mutations in StAR that precluded its function in cell transfection models of steroidogenesis. Certain features of the lipoid CAH phenotype were puzzling: the ratio of male to female patients (3:1) diverged from that predicted for an autosomal recessive trait. Moreover, some 46 XX patients underwent menarche with breast development at the normal age of puberty, strongly suggesting that they retained some capacity for estrogen biosynthesis (5). Based in part on these sex-specific differences in gonadal pathology, Miller, Strauss, and colleagues proposed a two-hit model of the pathogenesis of StAR deficiency (4). According to this model, steroidogenic cells lacking StAR initially retain some capacity for StAR-independent steroidogenesis. Over time, inadequate steroidogenesis leads to elevated levels of trophic hormones, which in turn stimulate progressive accumulation of lipids within the steroidogenic cells and ultimately cause their death. The ovaries, which are not steroidogenically active in utero, maintain some capacity for steroidogenesis that becomes apparent at the time of puberty. To explore the roles of StAR in a system amenable to experimental manipulation, we used targeted gene disruption to create StAR knockout mice (6). At birth, StAR knockout mice were indistinguishable from wild-type littermates, with an equal ratio of genetic males and females, but all pups had female external genitalia. A subset (~30–40%) exhibited signs of respiratory distress and died within 24 h after birth; the rest failed to grow normally and died within 2 wk after birth from adrenocortical insufficiency. Hormone assays revealed severe defects in adrenal steroids, and elevated ACTH levels consistent with a loss of negative feedback regulation at hypothalamic-pituitary levels. In contrast, gonadal hormones did not differ significantly from levels in wild-type littermates in the prepubertal state. Histologically, the adrenal cortex of newborn StAR knockout mice contained striking lipid deposits with loss of normal cortical architecture (Fig. 2). The gonads were relatively spared, with no overt histological abnormalities, minimal lipid deposits in the steroidogenic compartment of the testis, and none in the ovary. In striking support of the two-hit model, StAR knockout mice kept alive with corticosteroid replacement therapy developed marked abnormalities of the ovaries, including a lack of corpora lutea and marked hyperplasia of lipid-engorged theca cells (6a). These StAR knockout mice may provide a useful model system for determining the mechanisms that mediate StAR’s essential roles in regulated steroidogenesis. For example, immortalized cell lines derived from the steroidogenic organs of StAR knockout mice should provide an ideal system for exploring the structure-function aspects of StAR within actual steroidogenic cells. Similarly, these mice may provide a system for studying and identifying the actions of other proteins involved in cholesterol translocation within steroidogenic cells. Finally, the finding that StAR is expressed in discrete brain regions (7) suggests that further analyses of these knockout mice may reveal roles of StAR outside of the classical steroidogenic tissues.
168
Hasegawa et al.
Fig. 2. Histology of the adrenal gland and gonads from newborn wild-type (WT) and StAR knockout (KO) mice. Steroidogenic organs were isolated from WT and StAR KO mice1–6 d after birth, and sections were stained with oil red O and hematoxylin. (Top panels) Adrenal sections. (Middle panels) Testis sections. (Bottom panels) Ovary sections. The arrows point to areas of lipid deposits in the adrenal cortex and testis.
SF-1 KNOCKOUT MICE SF-1 initially was identified as a transcription factor that regulated the cell-specific expression of the cytochrome P450 steroid hydroxylases that catalyze most steroidogenic conversions (8,9). When a cDNA encoding SF-1 was isolated, its sequence established SF-1 as a member of the nuclear hormone-receptor family that mediates transcriptional regulation by steroid hormones, thyroid hormone, vitamin D, and retinoids. Subsequent studies have shown that SF-1 regulates adrenal and gonadal expression of many genes
Chapter 8/Steroidogenesis
169
involved in steroidogenesis, including 3`-hydroxysteroid dehydrogenase, the ACTH receptor, StAR, and the high-density lipoprotein receptor SR-B1 (reviewed in 10). Analyses of reporter genes driven by the Müllerian-inhibiting substance (MIS) promoter region in transfected Sertoli cells and transgenic mice suggest that SF-1 also regulates expression of the MIS gene (11–13). Thus, SF-1 regulates the production of both essential hormones in male sexual differentiation: androgens and MIS. To explore the link between SF-1 and steroidogenesis during endocrine development, the spatio-temporal profile of its expression during embryogenesis was examined (12,14). SF-1 is expressed in both male and female mouse embryos from the very earliest stages of gonadogenesis, when the intermediate mesoderm condenses to form the urogenital ridge. As the testes differentiate, SF-1 expression localizes to both the interstitial region—where Leydig cells produce androgens—and the testicular cords, where Sertoli cells express MIS. In the ovaries, in contrast, SF-1 transcripts decrease just as sexual differentiation is taking place, suggesting that persistent SF-1 expression could impair female sexual differentiation. In addition to the primary steroidogenic tissues, SF-1 transcripts also are detected in the anterior pituitary and hypothalamus, suggesting that SF-1 regulates the endocrine axis at other levels. Analyses of SF-1 knockout mice has confirmed the essential roles of SF-1 at all three levels of the hypothalamic-pituitary-steroidogenic organ axis (15–19). Although the very earliest stages of gonadal development appeared intact, newborn SF-1 knockout mice exhibited adrenal and gonadal agenesis (Fig. 3). As a consequence of gonadal degeneration, before androgens and MIS are normally produced, male-to-female sex reversal of the internal and external urogenital tracts also occurred. SF-1 knockout mice also had impaired expression of a number of markers of gonadotropes—the cells in the anterior pituitary gland that regulate gonadal steroidogenesis—and they lacked the ventromedial hypothalamic nucleus (Fig. 4)—a cell group in the medial hypothalamus linked to feeding and reproductive behaviors. Although their GnRH neurons were normal in number and location, the impaired gonadotropin expression in SF-1 knockout mice raises the possibility that the VMH contributes to normal GnRH release. Finally, although the molecular basis is yet to be defined, the spleens of SF-1 knockout mice were hypoplastic and contained irregularly distributed clusters of erythrocytes, reflecting impaired erythropoiesis (20). The human SF-1 gene, located on chromosome 9q33 (21), shares extensive homology with its mouse counterpart (22,23) and is expressed in many of the same sites (24,25). A recent report described a human subject with adrenal insufficiency and 46, XY sex reversal associated with a mutation in one allele of SF-1 that precludes DNA-binding (26). The mutated SF-1 protein did not exhibit dominant negative activity when coexpressed with wild-type protein, suggesting that the human disorder results from haploinsufficiency of SF-1. It remains possible, however, that the “normal” allele has a mutation that was undetected, or that a somatic mutation arose during early development. In either case, although its potential roles in the human VMH and the pituitary have not yet been established, these studies indicate that SF-1 in humans also plays essential roles in gonadal and adrenal development and function. Another important goal for future studies is to identify the specific target genes through which SF-1 exerts its profound effects on endocrine development. Although a number of SF-1 target genes in the adrenal cortex and gonads have been identified, none of them alone can explain the loss of the adrenal glands and gonads. Moreover, no target genes
170
Hasegawa et al.
Fig. 3. Newborn SF-1 knockout mice lack adrenal glands and gonads and have female internal genitalia. SF-1 knockout mice (left) and wild-type littermates (right) were sacrificed and their genitourinary tracts were dissected. (A) SF-1 knockout female. (B) Wild-type female. (C) SF-1 knockout male. (D) Wild-type male. The scale bar = 1 mm. Reprinted with permission from ref. (15). k, kidney; a, adrenal; o, ovary; t, testis; e, epididymis; od, oviduct.
of SF-1 within the VMH have been identified. The definition of additional target genes— some of which presumably impinge on the cell cycle/proliferation pathways—will undoubtedly provide important new insights into SF-1 function.
SUMMARY AND PERSPECTIVES As outlined in this chapter, evolving technologies for creating knockout mice are providing exciting new approaches to explore the in vivo roles of various genes in the regulated production of steroid hormones. In particular, rapid advancements with tissuespecific knockouts using the bacteriophage Cre recombinase should provide major new insights into the precise roles of various genes within specific tissues. For example, VMH-specific disruption of SF-1 would provide a sophisticated system for defining the
Chapter 8/Steroidogenesis
171
Fig. 4. SF-1 knockout mice lack the ventromedial hypothalamic nucleus. Coronal sections from wild-type (lower left) and SF-1 knockout male mice (upper right) and SF-1 knockout female mice (lower right) were stained with cresyl violet and photomicrographs were taken. A schematic diagram of the anatomical regions found within these sections is shown (upper left). The scale bar = 200 µm. mt, mammillothalamic tract; Do, dorsal hypothalamic nucleus; 3V, third ventricle; DMH, dorsomedial hypothalamic nucleus; VMH, ventromedial hypothalamic nucleus; Arc, arcuate nucleus; ME, median eminence. Modified with permission from ref. (19).
physiological functions of the VMH in the setting of normal levels of adrenal and gonadal steroids. Alternatively, transgenic rescue of the StAR knockout mice with wild-type and mutated StAR transgenes should permit a successful dissection of structure-function aspects of StAR in facilitating cholesterol translocation within steroidogenic tissues.
ACKNOWLEDGMENTS Work in the authors’ laboratory was supported by the Howard Hughes Medical Institute and by NIH grants HL48460 and DK55480.
REFERENCES 1. Donohoue PA, Parker KL, Migeon CJ. Congenital adrenal hyperplasia. In: Scriver CR, Beaudet LL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. McGraw-Hill, New York, NY, 2001; pp. 4077–4116. 2. Adashi EY, Hennebold JD. Single gene mutations resulting in reproductive dysfunction in women. N Engl J Med 1999;340:709–718. 3. Clark BJ, Wells J, King SR, Stocco DM. The purification, cloning, and expression of a novel luteinizing hormone-induced mitochondrial protein in MA-10 mouse Leydig tumor cells. Characterization of the steroidogenic acute regulatory protein (StAR). J Biol Chem 1994;269:28,314–28,322. 4. Bose HS, Sugawara T, Strauss JF 3rd, Miller WL. The pathophysiology and genetics of congenital lipoid adrenal hyperplasia. N Engl J Med 1996;335:1870–1878.
172
Hasegawa et al.
5. Bose HS, Pescovitz OH, Miller WL. Spontaneous feminization in a 46,XX female patient with congenital lipoid adrenal hyperplasia due to a homozygous frameshift mutation in the steroidogenic acute regulatory protein. J Clin Endocrinol Metab 1997;82:1511–1515. 6. Caron KM, Soo S-C, Clark BJ, Stocco DM, Wetsel W, Parker KL Targeted disruption of the mouse gene encoding the steroidogenic acute regulatory protein provides insights into congenital lipoid adrenal hyperplasia. Proc Natl Acad Sci USA 1997;94:11,540–11,545. 6a. Hasegawa T, Zhao L, Caron K, et al. Developmental roles of the steroidogenic acute regulatory protein (StAR) as revealed by StAR knockout mice. Mol Endocrinol 2000;14:1462–1471. 7. Furukawa A, Miyatake A, Ohnishi T, Ichikawa Y. Steroidogenic acute regulatory protein (StAR) transcripts constitutively expressed in the adult rat central nervous system: colocalization of StAR, cytochrome P-450SCC (CYP XIA1), and 3 beta-hydroxysteroid dehydrogenase in the rat brain. J Neurochem 1998;71:2231–2238. 8. Lala DS, Rice DA, Parker KL. Steroidogenic factor I, a key regulator of steroidogenic enzyme expression, is the mouse homolog of fushi tarazu-factor I. Mol Endocrinol 1992;6:1278–1287. 9. Morohashi K, Honda S, Inomata Y, Handa H, Omura T. A common trans-acting factor, Ad4-binding protein, to the promoters of steroidogenic P-450s. J Biol Chem 1992;267:17,913–17,919. 10. Parker KL, Schimmer BP. Steroidogenic factor 1: a key determinant of endocrine development and function. Endocr Rev 1997;18:361–377. 11. Shen W-H, Moore CCD, Ikeda Y, Parker KL, Ingraham HA. Nuclear receptor steroidogenic factor 1 regulates MIS gene expression: a link to the sex determination cascade. Cell 1994;77:651–661. 12. Hatano O, Takayama K, Imai T, Waterman MR, Takakusu A, Omura T. Morohashi K. Sex-dependent expression of a transcription factor, Ad4BP, regulating steroidogenic P-450 genes in the gonads during prenatal and postnatal rat development. Development 1994;120:2787–2797. 13. Giuili G, Shen W-H, Ingraham HA. The nuclear receptor SF-1 mediates sexually dimorphic expression of Mullerian Inhibiting Substance, in vivo. Development 1997;124:1799–1807. 14. Ikeda Y, Shen W-H, Ingraham HA, Parker KL. Developmental expression of mouse steroidogenic factor 1, an essential regulator of the steroid hydroxylases. Mol Endocrinol 1994;8:654–662. 15. Luo X, Ikeda Y, Parker KL. A cell-specific nuclear receptor is essential for adrenal and gonadal development and sexual differentiation. Cell 1994;77:481–490. 16. Sadovsky Y. Crawford PA, Woodson KG, Polish JA, Clements MA, Tourtellotte LM. et al. Mice deficient in the orphan receptor steroidogenic factor 1 lack adrenal glands and gonads but express P450 side-chain-cleavage enzyme in the placenta and have normal embryonic serum levels of corticosteroids. Proc Natl Acad Sci USA 1995;92:10,939–10,943. 17. Shinoda K, Lei H, Yoshii H, Nomura M, Nagano M, Shiba H, Sasaki H, Osawa Y, Ninomiya Y, Niwa O, Morohashi K-I. Developmental defects in the ventromedial hypothalamic nucleus and pituitary gonadotroph in the Ftz-F1 disrupted mice. Dev Dyn 1995;204:22–29. 18. Ingraham HA, Lala DS, Ikeda Y, Luo X, Shen W-H, Nachtigal MW, et al. The nuclear receptor SF-1 acts at multiple levels of the reproductive axis. Genes Dev 1994;8:2302–2312. 19. Ikeda Y, Luo X, Abbud R, Nilson JH, Parker KL. The nuclear receptor steroidogenic factor 1 is essential for the formation of the ventromedial hypothalamic nucleus. Mol Endocrinol 1995;9:478–486. 20. Morohashi K, Tsuboi-Asai H, Matsushita S, Suda, M, Nakashima M, Sasano H, Hataba Y, Li CL, Fukata J, Irie J, Watanabe T, Nagura H, Li E. Structural and functional abnormalities in the spleen of an mFtz-F1 gene-disrupted mouse. Blood 1999;93:1586–1594. 21. Taketo M, Parker KL, Howare TA, Tsukiyama R, Wong M, Niwa O, et al. Homologs of Drosophila FushiTatzu Factor 1 map to mouse chromosome 2 and human chromosome 9q33. Genomics 1995;25:565–567. 22. Oba K, Yanase T, Nomura M, Morohashi K, Takayanagi R, Nawata H. Structural characterization of human Ad4BP (SF-1) gene. Biochem Biophys Res Commun 1996;226:261–267. 23. Wong M, Ramayya MS, Chrousos GP, Driggers PH, Parker KL. Cloning and sequence analysis of the human gene encoding steroidogenic factor 1. J Mol Endocrinol 1996;17:139–147. 24. Ramayya MS, Zhou J, Kino T, Segars JH, Bondy CA, Chrousos GP. Steroidogenic factor 1 messenger ribonucleic acid expression in steroidogenic and nonsteroidogenic human tissues: Northern blot and in situ hybridization studies. J Clin Endocrinol Metab 1997;82:1799–1806. 25. Hanley NA, Ball SG, Clement-Jones M, Hagan DM, Strachan T, Lindsay S, et al. Expression of steroidogenic factor 1 and Wilm’s tumor 1 during early human gonadal development and sex determination. Mech Dev 1999;87:175–180. 26. Achermann JC, Ito M, Ito M, Hindmarsh PC, Jameson JL. A mutation in the gene encoding steroidogenic factor-1 causes XY sex reversal and adrenal failure in humans. Nat Genet 1999;22:125,126.
Chapter 9/Progesterone Action In Vivo
9
173
The Progesterone Receptor Knockout Mouse Model New Insights into Progesterone Action In Vivo
John P. Lydon, PHD, Selma Soyal, PHD, Bert W. O’Malley, MD, and Preeti M. Ismail, PHD CONTENTS INTRODUCTION OVARIAN FOLLICULAR RUPTURE IS CRITICALLY DEPENDENT ON PR FUNCTION AN ESSENTIAL ROLE FOR PR IN SEXUAL BEHAVIOR NEW PERSPECTIVES ON PROGESTERONE ACTION IN THE UTERUS PROGESTERONE IS ESSENTIAL FOR MAMMARY-GLAND PROLIFERATION AND D IFFERENTIATION FUTURE PROSPECTIVES CONCLUSIONS ACKNOWLEDGMENTS REFERENCES
INTRODUCTION Historical Perspective During the first decade of the twentieth centry, a series of classic experiments performed by the noted European embryologists Fraenkel, Loeb, Bouin, and Ancel unequivocally demonstrated the essential role of the corpus luteum in the establishment and maintenance of pregnancy (reviewed in 1,2). Subsequent investigations in the 1920s revealed that organic extracts of the corpus luteum were able to elicit the distinctive histological and physiological phenotype of the endometrium (termed “progestational proliferation”), characteristic of early pregnancy in ovariectomized (OVX) rabbits (reviewed in 3). If the animals were mated 1 d prior to ovariectomy, chronic administration of these extracts was sufficient to maintain normal development of the embryo to term. In the early 1930s, the “internal secretion” of the corpus luteum, responsible for these utero-morphic changes was identified and purified by Willard M. Allen at the University of Rochester, NY, which he names “progestrin,” a substance that favors gestation (4). The discovery of progestin, or progesterone, heralded a new era in From: Contemporary Endocrinology: Transgenics in Endocrinology Edited by: M. Matzuk, C. W. Brown, and T. R. Kumar © Humana Press Inc., Totowa, NJ
173
174
Lydon et al.
reproductive medicine, and it was initially envisioned that the hormone would be used to reduce or inhibit such female fertility disorders as spontaneous miscarriages in women at high risk (reviewed in 5). Ironically, during the following decades, the use of progesterone (in derivative form) as a female contraceptive agent (“the pill”) would overshadow its original promise as a fertility drug (6,7). Although progesterone’s role as an indispensable steroid hormone in female fertility was firmly established during the first half of the twentieth century, defining its mechanism of action has been a preoccupation for many molecular endocrinologists for the last 30–40 yr. Influenced by the seminal investigations of Jacob and Monod in 1961 (8), which set the basic tenets of gene regulation, studies on the rat uterus by Jensen and Gorski (9–11) and on the chick oviduct model by O’Malley et al. (12,13) provided the essential support for the existence of a specific intracellular binding protein (“the receptor”) for estrogen and progesterone, respectively. The identification of the progesterone receptor in the late 1960s has provided not only the molecular lynch-pin upon which our modern concepts of progesterone’s mechanism of action are founded, but has had far-reaching implications for the design and application of progestin and antiprogestin clinical therapies for such target tissues as the uterus, the mammary gland, and the brain.
The Progesterone Receptor Most of the physiological effects of progesterone are now known to be mediated by a specific intracellular transcription factor termed the progesterone receptor (PR) (14,15). As for all classical steroid hormone receptors, the PR is believed to undergo an “activation step” upon ligand binding, which permits the activated ligand/receptor complex to interact effectively with specific response elements located in the promoters of target genes, the activation or repression of which manifests the progesterone-extracellular signal into an appropriate physiological response (16,17). Although many steps in the mechanism of PR action have been elucidated, the specific target genes for this receptor have not yet been defined. The first cloning of PR (18,19) revealed it as a member of the nuclear-receptor superfamily of transcription factors, which now includes receptors for a number of potent effector molecules including steroids, retinoids, prostanoids, thyroid hormone, and vitamin D3, as well as an orphan-receptor subfamily for which ligands have not yet been assigned (16,17,20). Members of this superfamily are characterized by a common structural motif that is organized into defined domains in terms of structure and function, suggesting a common underlying mechanism of action (16,17); see Fig. 1. An additional level of complexity concerning PR action is reflected in the existence of two naturally occurring ligand-binding forms of this receptor, termed PRA and PRB (14,15); (Fig. 1). PRA and PRB are believed to arise as a result of either alternative initiation of translation from a single mRNA (21) or by alternate transcription from promoters within the same gene (22,23). These receptor isoforms differ only in that PRB contains a short additional stretch of amino acids at the amino terminus of the receptor (21). Recent in vitro studies have implicated differential transactivation functions for these receptor isoforms (24–26); the net result of these differences would be to further expand the physiological responses of PR to progesterone. Although these studies have fostered much discussion concerning the individual functions of the A and B forms of PR, the evolutionary, developmental, and physiological significance of these findings is only now being elucidated. Selective ablation of PR-A function in mice
Chapter 9/Progesterone Action In Vivo
175
Fig. 1. The mouse progesterone-receptor (PR) contains common structural domain motifs that are shared by members of the nuclear-receptor superfamily. PR contains a long N-terminus region (A/B), a short DNA-binding domain (C) and hinge region (D), a ligand-binding domain, and a short C-terminus (F). The PR is unique because it is composed of two isoforms, PRA and PRB . PRB is structurally identical to PRA, except for a 165 amino-acid extension at the N-terminus. Numbers in parentheses denote amino-acid number; METB and META are the initiating methionines for PRB and PRA respectively.
recently demonstrated that the PR-B subtype regulates a subset of reproductive functions of progesterone, thereby supporing the concept that these receptor isoforms are functionally distinct in vivo (26a). In most physiological contexts, the PR is transactivated by estrogen via its cognate receptor—the estrogen receptor (ER)—implying that many of the observed physiological responses attributed to progesterone may be caused by the combined effects of progesterone and estrogen. The close temporal and spatial overlap in the functional activities of ER and PR, have made it difficult to achieve a fuller understanding of progesterone’s direct involvement in many physiological systems because of the complexity of estrogen’s influence. A major challenge in reproductive endocrinology has been to define and characterize those physiological responses that are specifically attributable to progesterone and/or estrogen in vivo.
The Progesterone Receptor Knockout Mouse Model To address the physiological significance of PR function in vivo and to gain insight into progesterone’s functional interrelationship with estrogen, a progesterone-receptor knockout (PRKO) mouse model was generated, in which both forms of PR (A and B) were simultaneously ablated through gene-targeting techniques (27). Both male and female mice, heterozygotes and homozygotes for the PRKO mutation, developed to adulthood and at normal Mendelian frequencies. Interestingly, previous investigations have demonstrated the existence of transcripts for PR as well as for ER during the initial stages of mouse blastocyst development (28), suggesting an obligate requirement for these nuclear receptors in embryogenesis. However, the first studies on the PRKO mouse revealed that embryonic-derived PR, like the ER (29), is not essential for embryonic survival, and is not required for prenatal morphogenesis of the female reproductive system. General anatomical investigations have not revealed discernible differences in organ morphology between the PRKO homozygotes and their wild-type or heterozygote siblings (PRKO homozygote = PRKO). However, as anticipated, female PRKO mice were shown to be infertile in crosses with sexually experienced wild-type males. In contrast,
176
Lydon et al.
male PRKO mice proved to be as fertile as their wild-type and heterozygote litter mates; interestingly, the estrogen receptor-_ knockout (ERKO) male has been shown to be infertile (29). As will be appreciated in the ensuing sections, apart from representing the ultimate means of dissecting estrogen vs progesterone effects in vivo, the PRKO mouse has provided a wealth of biological information concerning progesterone’s role in female fertility. The expanded panoply of physiological responses attributed to progesterone as a result of these studies has underscored the essential role of PR as a central coordinator of a number of reproductive systems that collectively ensure female fertility, and ultimately, species survival. Finally, recognizing the clear phylogenetic differences between humans and mice, we believe that the PRKO mouse—a eutherian mammal like the human—holds great promise for the future as a valid experimental system with which to evaluate the controversial involvement of progesterone in human cancers such as that of the uterus and breast.
OVARIAN FOLLICULAR RUPTURE IS CRITICALLY DEPENDENT ON PR FUNCTION Induced by the preovulatory gonadotropin surge, ovulation culminates with the rupture and subsequent luteinization of the preovulatory follicle, expulsion of the cumulusoocyte complex, and resumption of oocyte meiosis. The biochemical and molecular events that define this process are precisely regulated throughout the hypothalamicpituitary-ovarian axis by the individual and integrative actions of hypothalamic gonadotropin-releasing hormone (GnRH), the pituitary gonadotropins: follicle-stimulating hormone (FSH) and luteinizing hormone (LH), and the ovarian steroids: estradiol and progesterone (reviewed in 30,31).
The PR Regulates the Generation of the LH Surge Estradiol, secreted from the maturing follicle, was originally assumed to be the primary steroidal trigger in the manifestation of the preovulatory LH surge. However, this assumption was subsequently challenged by the observation that the estrogen-induced LH surge elicited in the OVX mouse could never attain the level or the duration normally observed at proestrus (reviewed in ref. 32). Further experiments demonstrated that the addition of progesterone to the above hormone treatment was necessary to fully reinstate the proestrus LH surge, thereby implicating the unique importance of preovulatory progesterone in this process (33). As further support for this concept, the administration of progesterone-synthesis inhibitors (34) or PR antagonists (35) to intact rats on the morning of proestrus was shown to significantly attenuate the LH surge. With the advent of the PRKO mouse (27), more recent investigations have unequivocally established not only the pivotal role of PR in the generation of the LH surge, but have confirmed that this receptor mediates its regulatory effects at all levels of the hypothalamic-pituitary-ovarian axis through various mechanisms of action. Initial investigations into the PRKO reproductive phenotype revealed that, unlike the normal mouse, the PRKO female was incapable of exhibiting the LH surge when exposed to male mouse odor (36). In addition, vaginal-smear cytology revealed the absence of a normal estrous cycle in these mice. To determine whether the failure of the PRKO mouse to generate the LH surge was caused by an inherent inability of the PRKO hypothalamus
Chapter 9/Progesterone Action In Vivo
177
Fig. 2. Effect of estrogen priming on plasma LH levels of OVX wild-type and PRKO mice. Estrogen-primed (+ E2) OVX wild-type mice exhibited an LH surge (a; p < 0.05, n = 8) in comparison to unprimed OVX wild-type mice (OVX; n = 8). Plasma LH levels in unprimed ovariectomized PRKO mice (OVX; n = 8) were similar to their wild-type counterparts, whereas estrogen-priming (+ E2; n = 8) led to a significant (b; p < 0.05 below PRKO OVX) decrement in LH release. Reproduced with permission of Chappell et al. (37).
and/or pituitary to interpret the estradiol signal, OVX PRKO and wild-type mice were evaluated for their capacity to evoke the LH surge in response to exogenous estradiol (ref. 37 and Fig. 2). While a significant estrogen-induced LH surge was elicited in the wild-type mouse, the PRKO female failed to display such a surge. Instead, LH levels in response to estrogen administration were significantly decreased in the PRKO female in comparison to no hormone treatment, suggesting that the estrogen-induced negativefeedback influence on LH secretion remained intact in the PRKO female despite the absence of estrogen-positive feedback effects. These results further suggested that one point of divergence between the negative and positive effects of estrogen on LH secretion may be mediated at the level of PR, where PR mediates estradiol-positive feedback effects and PR-independent signaling pathways are responsible for estradiol-negativefeedback actions. Since ovariectomy resulted in the removal of assayable serum progesterone, it was logical to conclude that the LH surge observed in the estrogen-primed OVX wild-type mouse was not dependent on circulating progesterone. However, as noted previously, progesterone is required for the full proestrus LH surge to occur. Intriguingly, the PRKO mouse was incapable of exhibiting the estrogen-induced LH surge, suggesting that estrogen requires PR to elicit the LH surge, but not its ligand. Recently, ligand-independent activation of PR by intracellular second messenger pathways has been implicated in the modulation of female rodent sexual receptivity and behavior (38,39). Moreover, from recent in vitro studies, Turgeon and Waring have
178
Lydon et al.
Fig. 3. Plasma LH levels in wild-type and PRKO mice given either one or two pulses of exogenous GnRH. One pulse of GnRH (10) given to estrogen-primed ovariectomized WT and PRKO mice elicited significant (a; p < 0.001) increases in LH above ovariectomized estrogen-primed controls in both test groups. E-primed, ovariectomized WT mice given two pulses of GnRH 60 minutes apart (20) exhibited a significant (b; p < 0.001) additional increase in LH, whereas no further elevation in LH was observed in estrogen-primed ovariectomized PRKO mice. Reproduced with permission of Chappell et al. (37).
proposed that ligand-independent activation of PR is also essential for the GnRH selfpriming mechanism known to occur in the pituitary gonadotrope (40–43). The GnRH self-priming mechanism is defined as the increase in the magnitude of the pituitary gonadotrope LH response to successive GnRH stimulation, and has been shown to occur in rats (44), sheep (45), and humans (46). To determine whether the PRKO pituitary could mount a GnRH self-priming response, estrogen-primed OVX wild-type and PRKO mice were administered either one or two injections of GnRH (37). In the case of the wild-type mouse, a significant GnRH selfpriming response was elicited, as the second of two LH responses were at least twofold greater than the first (Fig. 3). Conversely, in the PRKO females, the second of the two consecutive GnRH injections failed to induce an additional increase in LH secretion. These results provided compelling in vivo evidence for an obligate requirement for ligand-independent activation of PR in the pituitary GnRH-self-priming response. Furthermore, the dependency of the GnRH-self-priming mechanism on estrogen priming underscored the physiological importance of estrogen-induced PRs in this process. Indeed, in response to increasing levels of ovarian estrogen, PR mRNA levels are elevated in the pituitary as well as in the hypothalamus, particularly in the arcuate and medial
Chapter 9/Progesterone Action In Vivo
179
Fig. 4. Effect of estrogen-priming on plasma FSH levels of OVX wild-type and PRKO females. FSH levels were elevated in estrogen-primed OVX wild-type mice (+E2; p < 0.05, n = 8) in comparison to unprimed OVX wild-type mice (OVX; n = 8). Unprimed OVX PRKO mice (OVX; n = 8) exhibited plasma FSH levels similar to unprimed OVX wild-type mice; additionally, no elevation was observed in estrogen-primed OVX PRKO mice (+E2; n = 8) vs unprimed OVX PRKO controls. Reproduced with permission of Chappell et al. (37).
preoptic nucleus (47–51). Whether the defect in LH-surge secretion in the PRKO female can be explained solely by the loss of GnRH self-priming in the pituitary or the absence of hypothalamic GnRH surges, or caused by a defect in both mechanisms, awaits further investigation. Current studies have focused on determining whether the PRKO hypothalamus can exhibit an actual GnRH surge. Although PR expression has not been detected in GnRH neurons (52), PR-containing neurons are known to innervate this neuronal group, suggesting that PR in combination with other potent regulators of GnRH release—i.e., neuropeptide Y (NPY) (35,53), galanin (54,55), catecholamines (52,56), glutamate (57), and gamma-aminobutyric acid (58)—may indirectly modulate hypothalamic GnRH secretion. In addition to the absence of an LH surge and estrous cyclicity, PRKO-serum LH levels were found to be two- to threefold over normal basal (metestrus) values, confirming the negative-feedback control that progesterone exerts on LH secretion outside the LH-surge event (36). Consistent with previous investigations, FSH levels in OVX wildtype and PRKO mice were significantly elevated, and this increase was not reduced by estrogen-priming; in accordance with studies in the rat demonstrating that estrogen alone was insufficient as a negative-feedback regulator of FSH release in the absence of ovarian-derived inhibin. Because of the absence of a full negative-feedback effect on FSH secretion, the characteristic FSH surge in the wild-type mouse was difficult to discern—result of high background levels of FSH (Fig. 4). However, a small yet signifi-
180
Lydon et al.
cant FSH increase was observed in estrogen-primed OVX wild-type mice that was not observed in similarly treated PRKO mice, suggesting, as for the LH surge, that the estrogen-primed FSH surge requires PR (Fig. 4).
An Intraovarian Role for PR Action In addition to PR’s involvement in the manifestation of the preovulatory gonadotropin surge, an intra-ovarian role for progesterone and its receptor has been implicated in the mediation of the LH-induced ovulation event (follicular rupture). In response to the LH surge, progesterone levels increase in the proestrous follicle, and are further elevated in the corpus luteum during diestrous and pregnancy (59). Antibodies to progesterone (60) or inhibitors of its synthesis (61,62) were shown to reduce the number of ovulations in the gonadotropin-induced rat model. Further studies by van der Schoot et al. (63) and Sanchez-Criado (64) have demonstrated that the PR antagonist RU486 could inhibit ovulations in the rat, implicating intra-ovarian PR in this process. Interestingly, histological examination of these ovaries revealed the presence of unruptured follicles exhibiting clear signs of luteinization. In these experiments, however, the PR antagonist also blocked the LH surge, making it difficult to dissociate any intrinsic ovarian effects from those of disrupted LH secretion. To obviate this problem, Loutradis et al. (65) subsequently used RU486 in combination with gonadotropin treatment, and found that ovulation was blocked by the antagonist. However, the block in ovulation did not occur if the antagonist was administered prior to, or 4 h after, gonadotropin treatment, providing a more convincing argument in favor of an intra-ovarian role for PR during the periovulatory period. As further support for this hypothesis, recent molecular approaches demonstrated that granulosa-cell PR expression was both temporally restricted to the rodent periovulatory period and dependent upon ovulatory (but not basal) levels of LH (66,67). That PR is a critical factor in the rupture of the preovulatory follicle recently has been demonstrated in vivo by the striking ovarian phenotype exhibited by the gonadotropinprimed PRKO mouse (27). Despite exposure to superovulatory levels of gonadotropins, the PRKO mouse failed to ovulate, as first evidenced by the absence of oocytes in the oviduct (see Table 1). Closer histological examination of the PRKO ovaries revealed that although follicular development apparently progressed to the pre-ovulatory stage, follicular rupture was effectively eliminated (Fig. 5). Despite the absence of ovulation, granulosa cells within the unruptured PRKO follicle responded to the LH surge, as evidenced by cumulus expansion and subsequent expression of specific biochemical markers of the luteal-cell phenotype (i.e., the cytochrome P450 cholesterol side-chain cleavage). The presence of an apparently functional corpus luteum in the PRKO ovary may explain, in part, the equivalent levels of serum progesterone observed in the PRKO and wild-type mouse (36). The existence of oocytes in the PRKO ovary prompted the question as to whether oocyte maturation and/or function required the PR. If this was the case, PR involvement in oocyte development would probably occur by PR-initiated paracrine signals emanating from preovulatory granulosa cells, since PR expression is restricted to the granulosa cells of the rodent follicle at proestrus. To answer this question, cumulus-ooycte cell complexes (arrested in prophase 1 of meiosis), isolated from large antral follicles of PRKO and WT ovaries, were evaluated for their capacity to mature to metaphase II of meiosis and be fertilized in vitro. These experiments demonstrated that PRKO oocytes
Chapter 9/Progesterone Action In Vivo
181 Table 1
Oocytes and Embryos Produced Following Superovulation Group
Oocytes
1-Cell stage
2-Cell stage
N
WT PRKO
11 ± 3 0
13 ± 2 0
1 0
6 6
Ovarian function was assayed by determining the ovary’s response to superovulatory doses of the gonadotropins PMSG and hCG (27). Following hCG treatment, mice were placed overnight with sexually experienced wild-type males. Oocytes and embryos were flushed from both oviducts of each animal 24 h following hCG administration, and examined and counted using a dissecting microscope. The data are means ± standard deviation. Reproduced with permission from Lydon et al. (27).
Fig. 5. Differential ovarian responses to superovulatory levels of gonadotropins in the PRKO and wild-type mouse. (A) A section of a typical wild-type ovary following treatment with pregnant mare serum gonadotropin (PMSG) followed by human chorionic gonadotropin (hCG) (see ref. 27 for more details). Note the presence of numerous corpora lutea (CL) following ovulation; scale bar: 100 µm. (B) A typical section through the PRKO ovary following an identical superovulatory treatment regimen. Note the unusual presence of an entrapped oocyte within a CL (indicated by arrow). (C and D) Higher magnifications of the corpora lutea in A and B, respectively; scale bar: 5 µm. Reproduced with permission of Lydon et al. (27).
retained the capability to be fertilized. In addition, the resultant embryos were able to progress to the 2-cell stage and blastocyst-stage at normal frequencies (Table 2). Indeed, pronuclear-stage embryos, derived from PRKO oocytes and transferred to foster mothers, were able to develop to term, demonstrating that PR function is not essential for oocyte maturation, fertilization, or early embryonic development.
182
Lydon et al. Table 2 In Vitro Fertilization of Wild-Type and PRKO a Oocytes Oocyte genotype
Wild-type
PRKO
Oocytes fertilized in vitro that reached the 2-cell stage Experiment 1 90% n = 30 89% n = 300 Experiment 2 91% n = 43 88% n = 265 Experiment 3 59% n = 82 92% n = 136 2-Cell embryos that reached the blastocyst stage Experiment 1 93% n = 27 94% n = 267 Experiment 2 79% n = 39 86% n = 233 Experiment 3 83% n = 48 90% n = 125 a
Personal communication from Dr. Joanne Richards, Department of Molecular and Cellular Biology, Baylor College of Medicine.
The current challenge is to define the signaling pathways through which PR mediates the physiological effects that enable follicular rupture to occur. Evidence suggests that dissolution of the follicular wall and the discharge of the oocyte is subsequent to a prostaglandin-mediated cascade of proteolytic reactions (68). Because the preovulatory increase in progesterone precedes the rise in prostaglandins, it has been suggested that progesterone may regulate prostaglandin synthesis and/or ovarian proteolytic activity as a prelude to follicular rupture (69–71). Because the PRKO ovarian phenotype is restricted to a functional defect in follicular-wall rupture, this animal offers an attractive approach to evaluating the expression profiles for those ovarian-gene products previously implicated to be regulated by progesterone and proposed as having a role in follicular rupture (reviewed in 72). Furthermore, the PRKO mouse in conjunction with differential cDNA cloning strategies, such as differential-display polymerase chain reaction (PCR), subtractive hybridization, and/or screening of gene-arrayed libraries may prove useful in identifying and isolating novel downstream PR-target gene(s) that are essential and specific for the final stages of ovulation. Unlike past attempts to develop contraceptive strategies based on directly disabling PR function (73), with the inherent side effects of PR-antagonism outside the ovary, these screening approaches may provide molecular targets exclusive to the ovary, and therefore may present safer routes for new contraceptive therapeutic strategies in the future.
AN ESSENTIAL ROLE FOR PR IN SEXUAL BEHAVIOR Female Sexual Behavior Steroid autoradiography (48) and in situ hybridization (74) have demonstrated that PR expression in the female rodent brain is primarily concentrated in the pre-optic area (POA)—the hypothalamus and the amygdala. These brain areas have long been associated with a female sexual response exhibited by rodents, termed lordosis. The lordosis response is characterized by a pronounced dorsoflexive posture consisting of a concave arching of the back with the rump and head elevated, which serves to solicit and to facilitate copulation by the male. The ventral medial nucleus of the hypothalamus
Chapter 9/Progesterone Action In Vivo
183
Fig. 6. Comparative responses to Estrogen (E), E+ Progesterone (P), and E+ the dopamine D1 agonist, SKF38393 (SKF) on lordosis behavior in wild-type and PRKO females in the presence of sexually experienced wild-type male mice. E, E+P, or E + SKF were directly administered into the third cerebral ventricle of wild-type and PRKO females. Control mice received vehicle (saline). Note the statistically significant differences in lordosis behavior exhibited by estrogen-primed wild-type and PRKO females in response to either P or the dopamine agonist (*, p < 0.001). Reproduced with permission of Mani et al. (38).
(VMNH) is primarily responsible for synchronizing the induction of this behavior with the onset of proestrus, and the net result is to optimize the potential for fertilization to occur (75). Both estrogen and progesterone have been shown to play pivotal roles in eliciting this behavior (76). In the case of the OVX adult rat, progesterone was required under physiological estrogen-priming conditions to induce lordosis (77). In these studies, PR was induced by estrogen in the VMNH, and its induction temporally coincided with the induction of lordosis. Furthermore, the inhibition of this progesterone-facilitated sexual behavior by the progesterone antagonist RU486 (78,79), as well as antisense oligonucleotides to PR mRNA (80–82) indicated an important role for hypothalamic PRs in the manifestation of this behavior. As a critical in vivo validation of these observations, the PRKO female was evaluated for lordosis response capability (27,38). Unlike normal females, the OVX PRKO mouse, sequentially administered estrogen and progesterone, was unable to exhibit a lordosis response when placed proximal to a sexually experienced male (Fig. 6). This behavioral impairment confirmed recent findings describing the inability of progesterone to elicit a lordosis response in estrogen-primed OVX rats that were previously administered PR antisense oligonucleotides, either intracerebroventrically or into the VMNH. This PRKO study underscored the essential role played by PR in female sexual behavior, and reiterated the functional versatility of this receptor in ensuring female fertility. Previous in vitro studies have demonstrated that PR can be transactivated in a ligandindependent manner by dopamine, a catecholamine neurotransmitter (83). Using a spec-
184
Lydon et al.
trum of dopaminergic agonists, the ligand-independent activation of PR by this neurotransmitter was specifically mediated through the dopamine D1 receptor subtype. Because dopamine has been implicated in the elaboration of rodent sexual behavior (84–86), recent efforts have focused on evaluating the physiological significance of ligand-independent activation of PR by dopamine in the generation of the lordosis response. Using antisense oligonucleotides to PR mRNA, administered into the third intracerebral ventricle of rats, we recently reported the elimination of dopamine-induced sexual behavior, providing strong support for the proposal that dopamine requires the presence of PR to induce lordosis (87). Based on these studies, we hypothesized the existence of a cross-communication pathway between cell-membrane receptors for dopamine and intracellular PR. Furthermore, this dual mode of PR activation may represent a critical mechanism by which neurotransmitter signaling impacts steroid receptor-dependent gene expression that is essential for behavioral responses. To unequivocally demonstrate that unoccupied PR is essential for dopamine-initiated sexual behavior in vivo, the estrogen-primed OVX PRKO female was tested for its ability to display sexual behavior in response to dopamine (38). Although wild-type mice exhibited a robust sexual behavioral response as a result of dopamine administration, the PRKO female failed to elicit this behavior (Fig. 6). The inability of both progesterone and dopamine to elicit sexual behavior in the PRKO female provides definitive in vivo evidence for the proposal that PR is an important point of convergence through which steroid and neurotransmitter signaling pathways regulate sexual behavior. Although the precise molecular mechanism(s) by which dopamine modulates PR activity remain undefined, it has been suggested that phosphorylation of the receptor and/or its coactivator may be involved (88,89). The behavioral phenotype exhibited by the PRKO female provides a clear indication of an abnormality of the neuroendocrine system. Although gross histopathological defects have not been detected in the PRKO brain, we speculate that the brain lesion will be subtle and may be associated with a defect in a “PR-induced” developmental event during the establishment of neuronal networks in prenatal life (90). However, we know that the pathway for lordosis itself is intact, since a vigorous response occurs following serotonin administration. Serotonin is known to operate independently of PR (38). It is also quite possible that the neuroanatomical defect occurs in ongoing transient and reversible “organizational events” (synaptic plasticity), such as the fluctuations in dendritic spine density that have been reported to occur in the VMNH of the adult female in response to changes in the levels of estrogen and progesterone during the estrous cycle (91).
Does the PR have a Role in Male Sexual Behavior? Historically, progesterone has not been considered to exert significant effects in mammalian male sexual behavior. However, initial studies with birds and rodents suggested that progesterone administration may even inhibit sexual behavior in these species (92–95). Indeed, these results have served as a rationale for the use of pharmacological doses of progestins in the chemical castration of sex offenders (96,97). That progesterone might exhibit bona fide physiological effects in male sexual behavior was first indicated by the distinct diurnal variation in the secretion profile for progesterone in male rats (98) and humans (99). Moreover, investigations with a number of lizard species have shown that administration of progesterone will induce typical courtship and copulatory behaviors in castrated males (100–104). Using the reptilian model, investigators have
Chapter 9/Progesterone Action In Vivo
185
demonstrated that progesterone synergizes with testosterone to induce the male sexual behavioral response (101–103), in much the same way that progesterone synergizes with estrogen in the elaboration of female sexual behavior (75). Reptilian male behavioral studies have prompted a reevaluation of progesterone’s involvement in male sexual behavior in the mammal. Recent investigations have demonstrated that the systemic administration of progesterone to physiological levels or the direct delivery of progesterone to the POA induced the classical male sexual behavioral response in intact and castrated rats (105,106). The POA is generally considered the neuroanatomical structure primarily responsible for regulating male sexual behavioral responses. Furthermore, as observed in the lizard, the manifestation of the male sexual behavior depended upon functional synergy between testosterone and progesterone (105). To date, the majority of information on progesterone’s role in male sexual behavior has been drawn from the investigation of reptilian models. From these experiments, it has been hypothesized that progesterone may function by sensitizing the POA to androgens (104). Indeed, the recent observation that direct administration of progesterone to the rat POA stimulates male-typical sex behavior, while the progesterone antagonist RU486 suppresses this behavioral response (105), provides further support in favor of an important role for PR—particularly POA-derived PR—in male sexual behavior. The PRKO mouse has yet to be extensively utilized to examine PR’s role in male sexual behavior (as measured by mount, intromission, and ejaculation frequencies). However, initial investigations with this mouse model have indicated an important role for PR in this behavior (107). Although a small but significant difference in male sexual behavior was observed between intact wild-type and PRKO males, evaluation of these behavioral measures following castration revealed a profound difference between both test groups (Fig. 7). The observed differences in the responses of the wild-type and PRKO males to castration when provided with prior sexual experience have been attributed to the theory that PR is required for neural circuits modified by “sexual experience” to bypass androgen dependence (107). Previous investigations into rat male sexual behavior have reported that those sexually experienced males manifesting a sexual behavior following castration exhibited preceding surges of dopamine in the POA, whereas castrated males that were unable to display this behavior did not (108). Furthermore, local administration of dopamine agonists into the POA reinstated the copulatory behavior to previously unresponsive castrates (109). As mentioned previously, we have demonstrated that dopamine can induce female sexual behavior through ligand-independent activation of PR in the VMNH (38,81,87,110). By extension, we hypothesize that similar mechanisms may occur in the POA to induce male sexual behaviors. In light of our initial studies with the PRKO male, it is tempting to speculate that sexual experience may enhance dopamine release from the POA—which results in ligand-independent activation of PR—and may cause male sexual behavior to occur. The PRKO male plays an essential role in this hypothesis. Future investigations will focus on testing whether the PRKO male can respond to dopamine, and whether sexually experienced wild-type castrates display a reduction in sexual behavior when administered dopamine antagonists.
NEW PERSPECTIVES ON PROGESTERONE ACTION IN THE UTERUS In response to embryo attachment and subsequent penetration of the uterine epithelial-cell layer and underlying basement membranes, the uterus undergoes profound
186
Lydon et al.
Fig. 7. The comparative effect of sexual experience on male sexual behavior in the WT and PRKO. (A) Mount frequencies of experienced (EXP) and naïve (NAÏVE) WT and PRKO males castrated for 3 wk. (B) Intromission frequencies in 3-wk castrates. Numbers in parentheses refer to sample sizes. Reproduced with permission of Phelps et al. (107).
morphological, cellular, and vascular changes that are precisely regulated by the coordinate actions of progesterone and estrogen (reviewed in 111). The remodeling of the uterus, known as the decidual response, culminates with the generation of the decidua that surrounds the developing fetus and becomes the maternal component of the placenta. Between embryo implantation and parturition, progesterone is believed to maintain the pregnancy state by blocking the responsiveness of the myometrial smooth-muscle layer to such contractile stimuli as prostaglandins and oxytocin, in addition to inhibiting the premature softening and dilation of the cervix (cervical ripening) (reviewed in 112). Superimposed on these effects, progesterone is also implicated in the local suppression of undesirable immunological responses that are elicited within the maternal compartment against the developing fetus (113–115). Together, these distinct regulatory roles further emphasize the pleiotropic nature of progesterone in the establishment and elaboration of the maternal-fetal interface. In defining the dynamic interplay between progesterone and estrogen, both in the development of the receptive uterus and in the subsequent induction of the decidual response, the mouse—the PRKO mouse—has proven to be an invaluable investigative
Chapter 9/Progesterone Action In Vivo
187
tool. During the initial stages of mouse pregnancy, the distinct secretion patterns for progesterone and estrogen have provided some of the most informative clues for their selective contributions to uterine development and function (116–120). For example, during the first 2 d of murine pregnancy, the proliferation of the uterine luminal epithelial-cell layer was shown to coincide with rising levels of pre-ovulatory estrogen. On the third day, uterine stromal cells were found to undergo proliferation in response to progesterone, synthesized and secreted from recently formed corpora lutea. Preimplantation (nidatory) estrogen further augmented this effect on d 4. Embryo implantation occurred later on d 4, and in response to progesterone, uterine epithelial cells switched from a proliferative to a differentiative pathway, while stromal fibroblasts embarked on a program of differentiation to become decidual cells. Collectively, these observations reveal that the spectrum of proliferative and differentiative responses elicited within the uterus is dependent on the synchronized actions of progesterone and estrogen, and that these responses are restricted to distinct cellular compartments of the uterus. In addition to the pregnant mouse, the pseudopregnant, the delayed implantation, and the OVX steroid-treated mouse models have offered more simplified approaches to further dissecting the selective uterine effects of progesterone and estrogen (121–123). In the case of the steroid-treated OVX mouse, whereas exogenous estrogen was shown to stimulate uterine epithelial-cell proliferation, the co-administration of progesterone was found to inhibit estrogen-induced epithelial proliferation in favor of stromal proliferation (123–126). Similar hormone treatments applied to the PRKO mouse have recently highlighted the importance of PR in preventing estrogen-induced uterine epithelial hypertrophy and hyperplasia, stromal edema, and local proinflammatory responses (refs. 27 and 127, and Fig. 8). Interestingly, the uterine defect in the PRKO female was shown to closely correlate with uterine aberrations that occur in rodents (123,128) and in humans (129,130) as a result of unopposed estrogen treatment, and further supports the rationale for including progestins in postmenopausal hormone-replacement therapies (131). Molecular endocrinologists have long recognized that the synergistic and antagonistic actions of estrogen and progesterone are underscored by the mutual regulation of their respective receptors (132–134). In the case of the rodent uterus, in situ radiolabeled steroid binding and recent immunohistochemistry have localized the nuclear receptors for progesterone and estrogen to the epithelial, stromal, and myometrial compartments (135–138). From these studies, an important question has arisen: In the uterus, treated with either estrogen or estrogen plus progesterone, can the expression profiles for ER and PR shed new light on how these hormones regulate uterine proliferation in a compartmentalized, specific fashion? To address this question, immunohistochemical analysis was recently employed in conjunction with the steroid-treated OVX mouse model (138). In the case of the hormonally untreated OVX mouse, uterine PR expression was predominantly localized to the luminal epithelial-cell layer. However, following estrogen administration, PR expression was significantly reduced in the luminal epithelial compartment, but increased in the stromal and myometrial compartments. While estrogen repressed PR expression in the luminal epithelium, expression in the glandular epithelium was unaffected, indicating a differential regulation of PR by estrogen in these epithelial compartments; the glandular epithelium is believed to originate from down-growths of the luminal epithelium. The inclusion of progesterone in the hormonal treatment resulted in a marked reduction in PR expression in all uterine compartments, demonstrating a general negative feedback of PR on its own expression.
188
Lydon et al.
Fig. 8. Wild-type and PRKO uterine responses to E and P treatment. In situ gross anatomy of wildtype (A) and PRKO (B) uteri, following E and P treatment, is indicated by arrows. Note the marked enlarged fluid filled uterus in the PRKO (B). Histological analysis of a representative cross-section of the uterine wall of the hormonally treated wild-type mouse (C) shows the presence of a normal uterine architecture, luminal epithelium (LE), glandular epithelium (GE), stromal-cell layer (S) and myometrium (M); scale bar: 50 µm. Histological analysis of a typical transverse section of the uterine wall of the PRKO, treated with E and P, reveals an abnormal uterine structure. Note the hyperplastic luminal (LE) and hypertrophic glandular (GE) epithelium, loosely arranged stromal layer (S), and the presence of polymorphonuclear (PMN) leucocytes; scale bar: 50 µm. Reproduced with permission of Lydon et al. (27).
The fact that progesterone inhibits estrogen-induced luminal-epithelial proliferation and that the downregulation of PR expression by estrogen in this compartment is matched by its contemporaneous upregulation in the stromal compartment has recently led to an important hypothesis that stromal PRs may exclusively regulate estrogen-induced luminal-epithelial proliferation. If this hypothesis is true, it is conceptually possible that estrogen induction of PR in the stroma sets in motion a control mechanism early on, by which estrogen self-limits its action in a compartmentalized, specific manner. Furthermore, defining the stromal PR population as the exclusive mediators of progesterone’s inhibition of estrogen-induced uterine epithelial proliferation would greatly simplify future studies concerned with identifying those key effector molecules downstream of PR which are involved in this important growth-inhibitory uterine-signaling pathway. This recently confirmed hypothesis could only have been tested by experiments utilizing the PRKO mouse in combination with uterine epithelial-stromal reciprocal transplantation approaches (139). Intriguingly, parallel studies with the ERKO mouse have demonstrated that only stromal ERs are necessary for mediating estrogen’s proliferative signal to the uterine luminal-epithelial compartment (140). Apart from demonstrating the exclusive requirement for stromal PRs in the inhibition of estrogen-induced epithelial proliferation by progesterone, the PRKO mouse studies have raised the following provocative questions: 1) What is the functional significance of epithelial-derived PRs
Chapter 9/Progesterone Action In Vivo
189
Fig. 9. Proposed mechanism of E and P action on uterine epithelial DNA synthesis. Estrogeninduced proliferative and progesterone-induced inhibitory signals are indicated by light and dark arrows, respectively. Estrogen binds to stromal ER and generates a paracrine signal which induces DNA synthesis of uterine epithelium. Progesterone binds to stromal PR, which leads to inhibition of uterine epithelial proliferation. The three possible inhibitory mechanisms are: 1) PR inhibits transcription of ER-dependent paracrine mediators; 2) progesterone-induced gene products antagonize the action of E-induced paracrine mediators through a variety of indirect mechanisms; and 3) progesterone-induced paracrine mediator is a direct inhibitor of epithelial proliferation, such as TGF-`. Reproduced with permission of Kurita et al. (139).
in the uterus? 2) What are the mechanisms by which stromal PRs mediate their growthinhibitory effects to the luminal-epithelial compartment? The physiological relevance of epithelial-derived PR has yet to be elucidated, and may not be answered until an epithelial-specific PRKO mouse is generated. However, a number of mechanistic models have been set forth to explain how stromal PRs may inhibit estrogen-induced proliferation of the luminal-epithelial compartment (139). For example, stromal PRs may directly inhibit the intracellular synthesis or secretion of an estrogen-inducible paracrine factor, activate a paracrine factor that negates the effect of estrogen-induced paracrine mediators through indirect effects, and/or induce a paracrine factor that directly inhibits luminal-epithelial proliferation (summarized in Fig. 9).
190
Lydon et al.
Whether one or all of these models proves to be valid awaits further experimentation; however, the steady increase in the number of potential uterine molecular targets recently reported for progesterone (141–149) offers renewed hope for a more comprehensive molecular explanation for progesterone’s modulation of uterine proliferation and differentiation in the near future. Finally, we believe that understanding the mechanism by which the stromal progesterone-signaling pathway impacts the luminal-epithelial compartment will provide a new perspective on the molecular and cellular processes underlying the pathogenesis of such uterine disorders as endometrial hyperplasias and adenocarcinomas (150).
PROGESTERONE IS ESSENTIAL FOR MAMMARY GLAND PROLIFERATION AND DIFFERENTIATION Implications for Current Breast Cancer Investigations Clinical and epidemiological studies have revealed a close association between breastcancer risk and the cyclical exposure of the mammary gland to ovarian sex steroids that occurs during the premenopausal years (reviewed in 151). This correlation is further substantiated by the fact that inhibition or reduction of such steroidal exposure, (e.g., after oophorectomy, and in late menarche and early menopause), has been demonstrated to markedly reduce breast-cancer risk (152–155). The increase in breast cancer observed with advancing age (Fig. 10) is currently hypothesized to arise from ovarian sex-steroidinduced proliferation of the mammary epithelial cell, which allows for the occurrence and aggregation of genetic changes throughout the reproductive years that result in breast cancer in later life (156). With a primary correlate of breast-cancer risk linked with the cyclical exposure of the mammary epithelial cell to ovarian sex steroids, breastcancer prevention treatments based on suppressing ovarian steroidogenesis are currently being explored (156). Until recently, estrogen was assumed to be the primary ovarian steroid involved in normal proliferation of the human mammary epithelial cell, and was considered important in the advancement of this cell type to a neoplastic state (reviewed in 157). Based in part on its established involvement in the differentiation of the endometrium, ovarian progesterone was assumed to exert anti-estrogenic, therefore antiproliferative, effects in the mammary gland, and was judged to contribute negligible effects to mammary tumorigenesis. However, these assumptions have not adequately explained why the proliferative index for the mammary epithelial compartment is highest during the progesterone-dominant luteal phase of the human menstrual cycle (158), or why progestins included in combined oral contraceptives can prevent ovarian and endometrial cancer but not breast cancers (159). Many of the conflicting reports concerning progesterone’s role in mammarygland development and neoplasia may be partially based on the inherent experimental difficulties in the use of the human as a model system. Despite over fifty million years of divergent evolution between the rodent and human, the developmental biology of the rodent mammary gland is remarkably similar to the human; thus, the rodent model has been established as the experimental system of choice in studying mammary-gland development and function (160,161). In the case of the murine experimental system, the PRKO mouse represents a new expanding subfamily of knockout mouse models that have recently been utilized to explore the various stages of mammary-gland development in an in vivo context
Chapter 9/Progesterone Action In Vivo
191
Fig. 10. Age-incidence rate for breast cancer. The log of age is plotted against the log of breast cancer incidence. The effect of menopause (~ age 50) on the rate at which breast cancer increases is clearly evident. The graph to the right displays the typical hormone profile for E and P during the menstrual cycle of a healthy premenopausal woman. Notice that the luteal phase of the cycle (d 14–28) is coincident with the progesterone peak that follows ovulation as well as the second peak of estrogen. Reproduced (in adapted form) with permission from Spicer et al., Cancer Investigation 1995;13:495–504.
(reviewed in 162). To evaluate the importance of PR in murine mammary-gland proliferation and differentiation, comparative whole-mount analysis revealed that unlike wildtype mice, the PRKO mammary gland failed to develop the typical pregnancy-associated epithelial ductal morphogenesis that consists of extensive dichotomous branching with attendant interductal lobuloalveolar development that occurs in response to exogenous estrogen and progesterone treatment (Fig. 11 and ref. 27). These initial gross morphological studies, in addition to recent molecular analysis (163), unequivocally demonstrate both a proliferative and a differentiative involvement for progesterone and its receptor in this tissue. Previous binding studies using the radiolabeled progestin agonist (3H)-R5020 provided evidence for the existence of progestin-binding sites both in the epithelial and stromal compartments that constitute the mammary gland of the adult virgin mouse (164). Subsequent investigations revealed that these mammary epithelial- and stromalderived progestin binding activities were distinct in their biochemistry and ontogenesis (165). Like the uterus, these results suggested that PR may play an important role in reciprocal homeostatic cell-cell interactions that occur between the epithelial- and stromal-cell populations of the mammary gland that, like the uterus, are essential for normal development and function (166–168). Because breakdown in communication between epithelial- and stromal-cell groups within the mammary gland could potentially lead to inappropriate epithelial-cell proliferation such as neoplasia, and because of the potential involvement of PR in this intercellular communication pathway, the PRKO mouse in combination with established mammary-gland transplantation procedures was used to evaluate the selective contributions of epithelial- and stromal-PR populations to mammary-gland ductal branching and alveologenesis.
192
Lydon et al.
Fig. 11. Removal of PR function results in a defect in mammary gland ductal branching and alveologenesis. Adult (12-wk-old) virgin wild-type (A) and PRKO (B) mammary glands show a similar ductal morphology; scale bar in panel A is 5 mm. The PRKO mammary phenotype is clearly evident when wild-type (C) and PRKO (D) are transplanted into a host mouse that subsequently becomes pregnant; scale bar in panel C is 5 mm. Despite the presence of pregnancy hormones, the PRKO gland (D) does not exhibit the typical pregnancy-associated ductal morphology as displayed by the wild-type transplanted gland (C). (E and F) Higher magnifications of C and D, respectively; scale bar in (E) is 500 µm.
Using this technological approach, we recently demonstrated that the luminal-epithelial compartment of the murine mammary gland is the primary target for the progesterone-induced proliferative signal (169,170). Importantly, the luminal epithelial cell has been considered the primary site for the initial carcinogenic insult (161). Moreover, these findings have provided essential functional support for subsequent immunohistochemical studies that have localized PR expression predominantly to the luminalepithelial cell (171–173). These investigations also offer strong evidence suggesting that the PR-initiated proliferative signal(s) may impact neighboring mammary epithelial cells that lack PR through unidentified paracrine factor(s) (170).
Chapter 9/Progesterone Action In Vivo
193
From a mechanistic perspective, it is interesting to note that while progesterone exerts its antiproliferative effects on the luminal-epithelial layer of the uterus via stromal PRs, progesterone manifests its proliferative and differentiative effects in the mammary gland through epithelial-derived PRs. These observations may eventually explain the differential actions of this steroid on these two progesterone-target tissues. Although these recent findings represent important advances in our current understanding of progesterone’s role in normal mammary-gland development, defining its controversial involvement in mammary tumorigenesis has proven to be one of the more challenging research areas in mammary-gland biology. However, a number of reports have implicated a role for progestins in the active progression of certain carcinogeninduced mammary tumors in the rat and mouse (174–178). These observations have underscored the necessity to better understand progesterone’s participation in mammary-gland tumor progression, in order develop a more rational basis for the current use of progestins in contraception and postmenopausal hormone replacement therapies and also to enable the design of novel diagnostic approaches and/or therapies for the future treatment and prevention of breast cancer. Because of the uncertainties regarding the involvement of progesterone during mammary-gland tumorigenesis coupled with the widespread clinical use of progestins, the PRKO mouse model is currently being utilized to directly evaluate whether PR has an important role in mammary tumorigenesis in vivo distinct from ER’s effects. Recent results clearly demonstrate the importance of progesterone-induced proliferative signals in mammary tumorigenesis. Using a chemical carcinogen-induced rodent mammary tumor model, we recently demonstrated that the PRKO mouse is significantly less susceptible to mammary tumorigenesis than normal mice, supporting a critical involvement for progesterone receptor function in this cancer (178a). Finally, we predict that the PRKO mouse model will be an essential research tool in the identification and isolation of novel molecular targets for PR in the mammary gland, with attendant implications for mammary-gland development, and mammary tumorigenesis. From a developmental perspective, branching morphogenesis is a recurrent theme in the ontogenesis of many organ systems during embryonic development. Since the expression of a number of these developmental genes has been reported in the adult mammary gland (179), we anticipate that the PRKO mouse will be important in evaluating whether progesterone signaling converges with these developmental pathways to induce ductal branching and alveologenesis in the adult gland.
FUTURE PERSPECTIVES To date, most research on progesterone action has concentrated on elucidating the mechanism by which this hormone modulates various aspects of female reproduction. However, an increasing number of reports have suggested progesterone’s involvement in many diverse physiological systems that are apparently unrelated to female reproduction. Because PR’s role is uncertain for many of these systems, we believe that the PRKO mouse model will be a powerful investigative tool in reaching a more comprehensive understanding of the relevant role of progesterone and its receptor in these areas. For example, neurobiologists have previously detected PR in the adult brain of the male rat at levels equating those in the female (180). A more detailed investigation has revealed that the most significant differences in PR levels between the male and female
194
Lydon et al.
adult rodent brain are restricted to differences in estrogen-induced PR in the VMNH, a region of the female brain involved in the induction of lordosis. Moreover, the physiological significance of equivalent levels of this nuclear receptor in regions of the female and male brain, other than the VMNH, is one of the more challenging questions concerning the neurobiology of this steroid. Intriguingly, recent PR-immunohistochemistry has revealed a significantly higher level of PR in the medial pre-optic nucleus (MPN) in the male fetal and neonatal rat, as compared to the female. The MPN is considered one of the most sexually dimorphic structures in the rodent, and is involved in many sexually differentiated behaviors (181). Based on these observations, it has been proposed that during pregnancy, high levels of maternally derived progesterone may exert sexual differentiative effects on the developing fetal CNS, and that PRs in the fetal MPN would mediate these effects (181). The existence of PRs in the CA1 hippocampal neurons (182) and the finding that progesterone in concert with estrogen may regulate synaptic plasticity in this region (183) are of particular interest. Because this brain region controls learning and other cognitive skills (184), functional roles for these gonadal hormones in behaviors other than lordosis (i.e., cognition, learning, and memory) cannot be discounted (185,186). In addition to evaluating the role of ovarian-derived progesterone on neuronal development and function, recent biochemical and electrophysiological investigations have underscored the physiological importance of neuronal-derived progesterone in local neuronal effects (187). For example, Baulieu et al. have recently demonstrated that progesterone and its metabolic derivatives (classified as “neurosteroids”) are synthesized within glial (188) and Schwann (189) cells of the central and peripheral nervous systems, respectively. Furthermore, through in vitro studies, these neurosteroids have been shown to exert changes on local neurotransmission (188) as well as nerve morphology (189) through either the classical PR-signaling pathway (189) or through less clearly understood rapid membrane effects (nongenomic) (190). Clearly, the PRKO mouse model would be extremely useful in substantiating these observations within an in vivo context. From a clinical perspective, further studies on progesterone’s role in brain development and function will be essential, as progesterone has been proposed as an alternative method to limit the extent of neuronal damage induced by delayed injury processes following cortical injury (186,191–193). Progesterone’s neuroprotective effects have been reported to include improved blood-brain barrier integrity, containment of free-radical-induced lipid peroxidation, and a significant reduction in cerebral edema (186,191–194). Progesterone holds particular promise as a valid treatment regimen for brain injury, as it is equally effective at reducing cerebral edema in both males and females (192) without attendant undesirable side effects observed thus far. Whether PR mediates some or all of these progesterone-initiated neuroprotective effects is unclear. However, the utilization of the PRKO mouse model in conjunction with an ablation model of cortical injury (195) will be essential in addressing this question. In addition to its proposed role in the nervous system, progesterone has been implicated to have a physiological role in cardiovascular biology. Premenopausal women have a significantly lower risk (ratio 1:10) of cardiovascular disease than men of equivalent age. However, this protection diminishes in the postmenopausal woman. At age 75, the incidence is essentially the same in both sexes, with cardiovascular disease the leading cause of mortality/morbidity in women by age 60 (reviewed in 196). Because natural and surgical (bilateral oophorectomy) menopause accelerates the development
Chapter 9/Progesterone Action In Vivo
195
of coronary heart disease, ovarian hormones have been implicated in protection against cardiovascular disease in premenopausal women (197). Previously, estrogen replacement therapy has been shown to reduce cardiovascular mortality in premenopausal women by an average of 50% (198–200). It is believed that approx 25–50% of the cardioprotection afforded by estrogen can be attributed to beneficial changes in serum lipoprotein levels, while the remainder of this protection is associated, in part, with direct effects of estrogen on the cardiovascular system (199–201). Because estrogen monotherapy has been linked to increases in the risk of endometrial cancer (202), progestins have usually been included to reduce this risk (203). The role of progesterone in combination with estrogen in cardioprotection is currently controversial. A number of previous investigations have proposed that progestins counteract the beneficial anitiatherogenic effects of estrogen by its negative influence on serum lipids, particularly HDL cholesterol (204). However, these findings have recently been challenged (205), and as mentioned previously, estrogen-induced beneficial effects on serum lipoproteins accounts for less than 50% of the total cardioprotective effects of this hormone. Recent studies have demonstrated that those postmenopausal women, using both estrogen and progesterone replacement, exhibited a significantly lower incidence of cardiovascular deaths than those using estrogen monotherapy (206). These observations support a beneficial role for progesterone in cardiovascular disease. As further support for this proposal, PRs as well as ERs have been detected in the vasculature of humans and other mammals (207–209). Indeed, recent studies on the proliferation of arterial smooth-muscle cells (an important constituent of atherosclerotic plaques) suggest that progesterone exerts beneficial effects in this process (209). To unequivocally define progesterone’s role in atherosclerotic cardiovascular disease, the PRKO mouse will provide a powerful new approach in determining PR’s role in these processes that are distinct from ER-mediated effects. We believe that the introduction of the PRKO mutation into existing mouse models for atherosclerosis (210), as well as its use in combination with current carotid-artery injury paradigms (211), will provide further insight into the mechanisms by which progesterone exerts its implicated atherosclerotic-protective effects. In the case of bone homeostasis, inappropriate bone loss that occurs as a result of the onset of menopause is known to be associated with contemporaneous decreases in serum estrogen levels, as evidenced by the beneficial effects of estrogen replacement therapies in reversing this effect (212). Interestingly, with the addition of progesterone to such hormonal replacement therapies, a number of biochemical and morphometric investigations have offered support for the proposal that progesterone may synergistically interact with estrogen in some aspect of bone remodeling (213). The recent detection of PRs in osteoblast cells (214) would seem to further support this notion. However, because of the ambiguities concerning the individual roles of PR and ER in this process, we expect that the PRKO mouse will provide a meaningful investigative approach to mechanistically dissect the respective roles of PR and ER in this process. Finally, the PRKO mouse model has provided an experimental platform for investigating the physiological functions of progesterone, as well as representing an unparalleled opportunity to examine the selective effects of estrogen and progesterone in vivo. As mentioned previously, considerable in vitro evidence has suggested that the A and B forms of the PR have distinct regulatory functions. It is conceptually plausible that the differential effects of these receptor isoforms could reflect, at the molecular level, the in
196
Lydon et al.
vivo pleiotropic effects of progesterone action, as recently revealed by the phenotypic analysis of the PRKO mouse. While the significance of these in vitro investigations is well recognized, the in vivo functional relevance for the existence of these receptor isoforms is only now being understood. As for the seemingly intractable problem of dissecting estrogen and progesterone actions in vivo, a new generation of knockout mouse models has likewise been generated to examine the selective in vivo importance of the PRA and PRB isoforms (26a).
CONCLUSIONS Because of the PRKO mouse, many gray areas of progesterone biology have become clearer, and several new findings have been made. Although investigations on the PRKO have yielded great insights into the physiologic effects of progesterone and its receptor, these studies have underscored how little we know about those complex physiological processes that depend on progesterone action. Because of our recent successes with the PRKO mouse, we predict that new derivations of this mouse model (i.e., PRAKO, PRBKO, PR-LacZ, or GFP Knockin, conditional, tissue, and cell-lineage-specific knockouts) will collectively illuminate further the endocrinological effects of this “internal secretion” of the corpus luteum, well into the twenty-first century.
ACKNOWLEDGMENTS For the studies described herein, the technical assistance of Gouqing Ge and Jie Li, Department of Molecular and Cellular Biology, Baylor College of Medicine, is greatly appreciated. This research was supported by NIH Grants CA-77530 (to John P. Lydon) and HD-07857 (to Bert. W. O’Malley).
REFERENCES 1. Corner GW. Oestrus, ovulation and menstruation. Physiol Rev 1923;111:457–482. 2. Frobenius W. Ludwig Fraenkel: ‘spiritus rector’ of the early progesterone research. Eur J Obstet Gynocol 1999;83:115–119. 3. Corner GW, Allen WM. Physiology of the corpus luteum II. Am J Physiol 1929;88:326–339. 4. Allen WM. Physiology of the corpus luteum V. Am J Physiol 1930;92:174–188. 5. Csapo A. Progesterone. Sci Am 1958;198:40–46. 6. Pincus G. Steroid labile reproductive processes in mammals. Harvey Lect. 1966-67;62:165–189. 7. Pincus G. Control of fertility in mammals by hormonal steroids. Anat Rec 1967;157:53–61. 8. Jacob F, Monod J. Genetic regulatory mechanisms in the synthesis of proteins. J Mol Biol 1961;3:318–356. 9. Jensen EV, Jacobson HI. Basic guides to the mechanism of estrogen action. Recent Prog Hormone Res 1962;18:387–414. 10. Jensen EV, Suzuki T, Kawashima T, Stumpf WE, Jungblut PW, DeSombre ER. A two-step mechanism for the integration of estradiol with rat uterus. Proc Natl Acad Sci USA 1968;59:632–638. 11. Toft D, Gorski J. A receptor molecule for estrogens: isolation from the rat uterus and preliminary characterization. Proc Natl Acad Sci USA 1966;55:1574–1581. 12. O’Malley BW, McGuire WL, Kohler PO, Korenman SG. Studies on the mechanism of steroid hormone regulation of synthesis of specific proteins. Recent Prog Hormone Res 1969;25:105–160. 13. O’Malley BW, Sherman MR, Toft DO. Progesterone “receptors” in the cytoplasm and nucleus of chick oviduct target tissue. Proc Natl Acad Sci USA 1970;67:501–508. 14. Schrader WT, O’Malley BW. Progesterone-binding components of chick oviduct. IV. Characterization of purified subunits. J Biol Chem 1972;247:51–59. 15. Horwitz KB, Alexander PS. In situ photolinked nuclear progesterone receptors of human breast cancer cells: subunit molecular weights after transformation and translocation. Endocrinology 1983;113:2195–2201.
Chapter 9/Progesterone Action In Vivo
197
16. Tsai M-J, O’Malley BW. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Ann Rev Biochem 1994;63:451–486. 17. Mangelsdorf DJ, Thummel C, Beato M, Herrlich G, Schutz G, Umesono K, et al. The nuclear receptor superfamily: the second decade. Cell 1995;83:835–839. 18. Conneely OM, Sullivan WP, Toft DO, Birnbaumer M, Cook RG, Maxwell BL, et al. Molecular cloning of the chicken progesterone receptor. Science 1986;233:767–770. 19. Jeltsch JM, Krozowski Z, Quirin-Stricker C, Gronemyer H, Simpson RJ, Garnier JM, et al. Cloning of the chicken progesterone receptor. Proc Natl Acad Sci USA 1986;83:5424–5428. 20. Kliewer SA, Lehmann JM, Willson TM. Orphan nuclear receptors: shifting endocrinology into reverse. Science 1999;284:757–760. 21. Conneely OM, Maxwell BL, Toft DO, Schrader WT, O’Malley BW. The A and B forms of the chicken progesterone receptor arise by alternate initiation of translation of a unique mRNA. Biochem Biophys Res Commun 1987;149:493–501. 22. Kastner P, Krust A, Turcotte B, Strupp U, Tora L, Gronemeyer H, et al. Two distinct estrogenregulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J 1990;9:1603–1614. 23. Kraus WL, Montano MM, Katzenellenbogen BS. Identification of multiple, widely spaced estrogenresponsive regions in the rat progesterone receptor gene. Mol Endocrinol 1994;8:952–969. 24. Vegeto E, Shahbaz MM, Wen DX, Goldman ME, O’Malley BW, McDonnell DP. Human progesterone receptor A form is a cell and promoter specific repressor of human progesterone receptor B function. Mol Endocrinol 1993;7:1244–1255. 25. Tung L, Mohamed MK, Hoeffler JP, Takimoto GS, Horwitz KB. Antagonist-occupied human progesterone B-receptors activate transcription without binding to progesterone response elements and are dominantly inhibited by A-receptors. Mol Endocrinol 1993;7:1256–1265. 26. Sartorius CA, Groshong SD, Miller LA, Powell RL, Tung L, Takimoto GS, et al. New T47D breast cancer cell lines for the independent study of progesterone B- and A-receptors: only antiprogestinoccupied B-receptors are switched to transcriptional agonists by cAMP. Cancer Res 1994;54: 3868–3877. 26a. Mulac-Jericivic B, Mullinax RA, DeMayo FJ, Lydon JP, Connelly OM. Subgroup of reproductive functions of progesterone mediated by progesterone receptor-b isoform. Science 2000;289:1751–1758. 27. Lydon JP, DeMayo FJ, Funk CR, Mani SK, Hughes AR, Montgomery Jr. CA, et al. Mice lacking progesterone receptors exhibit pleiotropic reproductive abnormalities. Genes Dev 1995;9:2266–2278. 28. Hou Q, Gorski J. Estrogen receptor and progesterone receptor genes are expressed differentially in mouse embryos during preimplantation development. Proc Natl Acad Sci USA 1993;90:9460–9464. 29. Lubahn DB, Moyer JS, Golding TS, Couse JF, Korach KS, Smithies O. Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene. Proc Natl Acad Sci USA 1993;11:162–166. 30. Freeman ME. The neuroendocrine control of the ovarian cycle of the rat. In: Knobil E, Neill JD, editors. The Physiology of Reproduction. Raven Press, New York, NY, 1994. pp. 613–658. 31. Hotchkiss J, Knobil E. The menstrual cycle and its neuroendocrine control. In: Knobil E, Neill JD, editors. The Physiology of Reproduction. Raven Press, New York, NY, 1994. pp. 711–750. 32. Mahesh VB, Brann DW. Regulation of the preovulatory gonadotropin surge by endogenous steroids. Steroids 1998;63:616–629. 33. Krey LC, Tyrey L, Everett JW. The estrogen-induced advance in the cyclic LH surge in the rat: dependency on ovarian progesterone secretion. Endocrinology 1973;93:385–390. 34. DePaolo LV. Attenuation of preovulatory gonadotropin surges by epostane: a new inhibitor of 3 `-hydroxysteroid dehydrogenase. J Endocrinol 1988;118:59–68. 35. Bauer-Dantoin AC, Tabesh B, Norgle JR, Levine JE. RU486 administration blocks neuropeptide Y potentiation of luteinizing hormone (LH)-releasing hormone-induced LH surges in proestrous rats. Endocrinology 1993;133:2418–2423. 36. Chappell PE, Lydon JP, Conneely OM, O’Malley BW, Levine JE. Endocrine defects in mice carrying a null mutation for the progesterone receptor gene. Endocrinology 1997;138:4147–4152. 37. Chappell P, Schneider JS, Kim P, Xu M, Lydon JP, O’Malley BW, et al. Absence of LH surges and GnRH self-priming in ovariectomized (ovx), estrogen (E2)-treated, progesterone receptor knockout (PRKO) mice. Endocrinology 1999;140:3653–3658. 38. Mani SK, Allen JMC, Lydon JP, Mulac-Jericevic B, Blaustein JD, DeMayo FJ, et al. Dopamine requires the unoccupied progesterone receptor to induce sexual behavior in mice. Mol Endocrinol 1996;10:1728–1737.
198
Lydon et al.
39. Auger AP, Moffatt CA, Blaustein JD. Progesterone-independent activation of rat brain progestin receptors by reproductive stimuli. Endocrinology 1997;138:511–514. 40. Turgeon JL, Waring DW. Luteinizing hormone-releasing hormone-induced luteininzing hormone secretion in vitro: cyclic changes in responsiveness and self-priming. Endocrinology 1980;106:1430–1436. 41. Turgeon JL, Waring DW. Rapid augmentation by progesterone of agonist-stimulated luteinizing hormone secretion by cultured pituitary cells. Endocrinology 1990;127:773–780. 42. Turgeon JL, Waring DW. A pathway for luteinizing hormone releasing-hormone self-potentiation: cross-talk with the progesterone receptor. Endocrinology 1992;130:3275–3282. 43. Turgeon JL, Waring DW. Activation of the progesterone receptor by the gonadotropin-releasing hormone self-priming signaling pathway. Mol Endocrinol 1994;8:860–869. 44. Alyer MS, Fink G, Greig F. Changes in the sensitivity of the pituitary gland to luteinizing hormone releasing factor during the oestrous cycle in the rat. J Endocrinol 1974;60:47–54. 45. Phogat JB, Smith RF, Dobson H. Effect of ACTH on gonadotropin releasing hormone-induced luteinizing hormone secretion in vitro. Anim Reprod Sci 1997;48:53–65. 46. Urban RJ, Veldhuis JD, Dufau ML. Estrogen regulates the gonadotropin-releasing hormone-stimulated secretion of biologically active luteinizing hormone. Clin Endocrinol Metab 1991;72:660–668. 47. MacLuskey NJ, McEwen BS. Oestrogen modulates progestin receptor concentrations in some rat brain regions but not in others. Nature 1978;274:276–278. 48. MacLuskey NJ, McEwen BS. Progestin receptors in rat brain: distribution and properties of cytoplasmic progestin-binding sites. Endocrinology 1980;106:192–202. 49. Parsons B, MacLuskey NJ, Krey L, Pfaff DW, McEwen BS. The temporal relationship between estrogen-inducible progestin receptors in the female rat brain and the time course of estrogen activation of mating behavior. Endocrinology 1980;107:774–779. 50. Romano GJ, Krust A, Pfaff DW. Expression and estrogen regulation of progesterone receptor mRNA in neurons of the mediobasal hypothalamus: an in situ hybridization study. Mol Endocrinol 1989;3:1295–1300. 51. Hagihara K, Hirata S, Osada T, Hirai M, Kato J. Distribution of cells containing progesterone receptor mRNA in the female rat di- and telencephalon: an in situ hybridization study. Mol Brain Res 1992;14:239–249. 52. Fox SR, Harlan R, Shivers B, Pfaff DW. Chemical characterization of neuroendocrine targets for progesterone in the female rat brain and pituitary. Neuroendocrinology 1990;51:276–283. 53. Sahu A, Crowley WR, Kalra SP. An opioid-neuropeptide-Y transmission line to luteinizing hormone(LH)-releasing hormone neurons: a role in the induction of LH surge. Endocrinology 1990;126:876–883. 54. Brann DW, Chorich LP, Mahesh VB. Effect of progesterone on galanin mRNA levels in the hypothalamus and the pituitary: correlation with the gonadotropin surge. Neuroendocrinology 1993;58:531–538. 55. Rossmanith WG, Marks DL, Clifton DK, Steiner RA. Induction of galanin mRNA in GnRH neurons by estradiol and its facilitation by progesterone. J Neuroendocrinol 1996;8:185–191. 56. Leranth C, MacLuskey N, Shanabrough M, Naftolin F. Catecholaminergic innervation of luteinizing hormone-releasing hormone and glutamic acid decarboxylase immunopositive neurons in the rat medial preoptic area. An electron-microscopic double immunostaining and degeneration study. Neuroendocrinology 1988;48:591–602. 57. Brann DW, Mahesh VB. Endogenous excitatory amino acid involvement in preovulatory and steroid-induced surge of gonadotropins in the female rat. Endocrinology 1991;128:1541–1547. 58. Unda R, Brann DW, Mahesh VB. Progesterone suppression of glutamic acid decarboxylase (GAD67) mRNA levels in the preoptic area: correlation to the luteinizing hormone surge. Neuroendocrinology 1995;62:562–570. 59. Rothchild I. The regulation of the mammalian corpus luteum. Recent Prog Hormone Res 1981;17:183–298. 60. Mori T, Suzuki A, Nishimura T, Kambegawa A. Inhibition of ovulation in immature rats by antiprogesterone antiserum. J Endocrinol 1977;73:185–186. 61. Lipner H, Greep RO. Inhibition of steroidogenesis at various sites in the biosynthetic pathway in relation to induced ovulation. Endocrinology 1971;88:602–607. 62. Snyder BW, Beecham GD, Schane HP. Inhibition of ovulation in rats with epostane, an inhibitor of 3b-hydroxysteroid dehydrogenase. Proc Soc Exp Biol Med 1984;176:238–242. 63. Van der Schoot P, Bakker GH, Klijn JGM. Effects of the progesterone antagonist RU486 on ovarian activity in the rat. Endocrinology 1987;121:1375–1382.
Chapter 9/Progesterone Action In Vivo
199
64. Sanchez JE, Bellido C, Galiot F, Lopez FJ, Gaytan F. A possible mechanism of the anovulatory action of antiprogesterone RU486 in the rat. Biol Reprod 1990;42:877–886. 65. Loutradis D, Bletsa R, Aravantinos L, Kallianidis K, Michalas S, Psychoyos A. Preovulatory effects of the progesterone antagonist mifepristone (RU486) in mice. Hum Reprod 1991;6:1238–1240. 66. Park-Sarge O-K, Mayo K. Transient expression of progesterone receptor messenger RNA in ovarian granulosa cells after the preovulatory luteinizing hormone surge. Mol Endocrinol 1991;5:967–978. 67. Natraj U, Richards JS. Hormonal regulation localization and functional activity of the progesterone receptor in granulosa cells of rat preovulatory follicles. Endocrinology 1993;133:761–769. 68. Espey LL, Lipner H. Ovulation. In: Knobil E, Neill JD, editors. The Physiology of Reproduction. 2nd ed. Raven Press, New York, NY, 1994. pp. 725–780. 69. Iwamasa J, Shibata S, Tanaka N, Matsuura K, Okamura H. The relationship between ovarian progesterone and proteolytic enzyme activity during ovulation in the gonadotropin-treated immature rat. Biol Reprod 1992;46:309–313. 70. Tanaka N, Espey LL, Stacy S, Okamura H. Epostane and indomethacin actions on ovarian kallikrein and plasminogen activator activities during ovulation in the gonadotropin-primed immature rat. Biol Reprod 1992;46:665–670. 71. Espey LL. Current status of the hypothesis that mammalian ovulation is comparable to an inflammatory reaction. Biol Reprod 1994;50:233–238. 72. Richards JS, Russell DL, Robker RL, Dajee M, Alliston TN. Molecular mechanisms of ovulation and luteinization. Mol Cell Endocrinol 1998;145:47–54. 73. Spitz IM, Croxatto HB, Lahteenmaki P, Heikinheimo O, Bardin CW. Effect of mifepristone on inhibition of ovulation and induction of luteolysis. Hum Reprod 1994;9:69–76. 74. Lauber AH, Romano GJ, Pfaff DW. Sex difference in estradiol regulation of progestin receptor mRNA in rat mediobasal hypothalamus as demonstrated by in situ hybridization. Neuroendocrinology 1991;53:608–613. 75. Pfaff DW, Schwartz-Giblin S, McCarthy MM, Kow L. Cellular and molecular mechanisms of female reproductive behavior. In: Knobil E, Neill JD, editors. The Physiology of Reproduction. Raven Press, New York, NY, 1994. pp. 107–220. 76. Lauber AH, Romano GJ, Pfaff DW. Steroid control of higher brain functions: gene expression for estrogen and progesterone receptor mRNAs in rat brain and possible relations to sexually dimorphic functions. J Steroid Biochem Mol Biol 1991;40:53–62. 77. McEwen BS, Jones K, Pfaff DW. Hormonal control of sexual behavior in the female rat: molecular, cellular and neurochemical studies. Biol Reprod 1987;36:37–45. 78. Brown TJ, Blaustein JD. Abbreviation of the period of sexual behavior in female guinea pigs by the progesterone receptor antagonist RU38486. Brain Res 1986;373:3–113. 79. Vathy IU, Etgen AM, Barfield RJ. Actions of RU38486 on progesterone facilitation and sequential inhibition of rat estrous behavior: correlation with neural progestin receptors. Horm Behav 1989;23:43–56. 80. Pollio G, Xue P, Zanisi A, Maggi A. Antisense oligonucleotide blocks progesterone-induced lordosis behavior in ovariectomized rats. Mol Brain Res 1993;19:135–139. 81. Mani SK, Blaustein JD, Allen JMC. Inhibition of rat sexual behavior by antisense oligonucleotides to the progesterone receptor. Endocrinology 1994;135:1409–1414. 82. Ogawa S, Olazabal UE, Pfaff DW. Effects of intrahypothalamic administration of antisense DNA for progesterone receptor mRNA on reproductive behavior and progesterone immunoreactivity. J Neurosci 1994;14:1766–1774. 83. Power RF, Mani SK, Codina J, Conneely OM, O’Malley BW. Dopaminergic and ligand-independent activation of steroid hormone receptors. Science 1991;254:1636–1639. 84. Foreman MM, Moss RL. Role of hypothalamic dopaminergic receptors in the control of lordosis behavior in the female rat. Physiol Behav 1979;22:282–289. 85. Caggiula AR, Antelman SM, Chiodo LA, Lineberry CG, editors. Brain dopamine and sexual behavior: psychopharmacological and electrophysiological evidence for antagonism between active and passive components. Pergamon Press, New York, NY, 1979. 86. Pfaus JG, Damsma G, Wenkstern D, Fibiger HC. Sexual activity increases dopamine transmission in the nucleus accumbens and striatum of female rats. Brain Res 1995;693:21–30. 87. Mani SK, Allen JMC, Clark JH, Blaustein JD, O’Malley BW. Convergent pathways for steroid hormone-and neurotransmitter-induced rat sexual behavior. Science 1994;265:1246–1249. 88. O’Malley BW, Schrader WT, Mani S, Smith C, Weigel NL, Conneely OM, et al. An alternative ligandindependent pathway for activation of steroid receptors. Recent Prog Horm Res 1995;50:333–347.
200
Lydon et al.
89. Smith CL, Onate SA, Tsai M-J, O’Malley BW. CREB binding protein acts synergistically with steroid coactivator-1 to enhance steroid receptor-dependent transcription. Proc Natl Acad Sci USA 1996;93:8884–8888. 90. Arnold AP, Breedlove SM. Organizational, and activational effects of sex steroids on brain and behavior: a reanalysis. Horm Behav 1985;19:469–498. 91. Frankfurt M, Gould E, Woolley C, McEwen BS. Gonadal steroids modify dendritic spine density in ventromedial hypothalamic neurons: a Golgi study in the adult rat. Neuroendocrinology 1990;51:530–535. 92. Erickson CJ, Bruder RH, Komisaruk BR, Lehrman DS. Selective inhibition of androgen-induced behavior in male ring doves (Streptopelia risoria). Endocrinology 1967;81:39–44. 93. Erpino MJ. Hormonal control of courtship behavior in the pigeon (Columba livia). Anim Behav 1969;1:401–405. 94. Erpino MJ. Temporary inhibition by progesterone of sexual behavior in intact male mice. Horm Behav 1973;4:335–339. 95. Bottoni L, Lucini V, Massa R. Effect of progesterone on the sexual behavior of the male Japanse quail. Gen Comp Endocrinol 1985;57:345–351. 96. Bradford JMW. Treatment of sexual offenders with cyproterone acetate. In: Sitse JMA, editor. The pharmacology and endocrinology of sexual function. Elsevier, New York, 1988, pp. 526–536. 97. Lehne GK. Treatment of sex offenders with medroxyprogesterone acetate. In: Sitse JMA, editor. The pharmacology and endocrinology of sexual function. Elsevier, New York, 1988, pp. 516–525. 98. Kalra PS, Kalra SP. Circadian periodicities of serum androgens, progesterone, gonadotropins and luteinizing hormone-releasing hormone in male rats: The effects of hypothalamic deafferentation, castration and adrenalectomy. Endocrinology 1977;10:1821–1827. 99. Vermueulen A, Verdonck L. Radioimmunoassay of 17 b-hydroxy-5a-androstan-3-one,4-androstene-3, 17-dione, dehydroepiandrosterone, 17-hydroxyprogesterone and progesterone and its application to human male plasma. J Steroid Biochem 1976;7:1–10. 100. Lindzey J, Crews D. Hormonal control of courtship and copulatory behavior in male Cnemidophorus inornatus, a direct sexual ancestor of a unisexual, parthenogenetic lizard. Gen Comp Endocrinol 1986;64:411–418. 101. Lindzey J, Crews D. Effects of progestins on sexual behavior in castrated lizards (Cnemidophoru inornatus). J Endocrinol 1988;119:265–273. 102. Young LJ, Greenberg N, Crews D. The effects of progesterone on sexual behavior in male green anole lizards (Anolis carolinensis). Horm Behav 1991;25:477–488. 103. Lindzey J, Crews D. Interactions between progesterone and androgens in the stimulation of sex behaviors in male little striped whiptail lizards, Cnemidophorous inornatus. Gen Comp Endocrinol 1992;86:52–58. 104. Crews D, Godwin J, Hartman V, Grammer M, Prediger E, Sheppherd R. Intrahypothalamic implantation of progesterone in castrated male whiptail lizards (Cnemidophorus inornatus) elicits courtship and copulatory behavior and affects androgen receptor- and progesterone receptor-mRNA expression in the brain. J Neurosci 1996;16:7347–7352. 105. Witt D, Young L, Crews D. Progesterone modulation of androgen-dependent sexual behavior in male rats. Physiol Behav 1995;57:307–313. 106. Witt DM, Reigada LC, Wengroff BE. Intrahypothalamic progesterone regulates androgen-dependent sexual behavior in male rats. Soc Neurosci Abstr 1997;23:1357. 107. Phelps SM, Lydon JP, O’Malley BW, Crews D. Regulation of male sexual behavior by progesterone receptor, sexual experience, and androgen. Horm Behav 1998;34:294–302. 108. Hull EM, Du J, Lorrain DS, Matuszewich L. Extracellular dopamine in the medial preoptic area: implications for sexual motivation and hormonal control of copulation. J Neurosci 1995;15:7465–7471. 109. Hull EM, Du J, Lorrain DS, Matuszewich L. Testosterone, preoptic dopamine, and copulation in male rats. Brain Res Bull 1997;44:327–333. 110. Mani SK, Blaustein JD, O’Malley BW. Progesterone receptor function from a behavioral perspective. Horm Behav 1997;31:244–255. 111. Dey SK. Implantation. Lippincott-Raven, Philadelphia, PA, 1996. 112. Rothchild I. Role of Progesterone in Initiating and Maintaining Pregnancy. Raven Press, New York, NY, 1983. 113. Grossman CJ. Interactions between the gonadal steroids and the immune system. Science 1985;227:257–261.
Chapter 9/Progesterone Action In Vivo
201
114. Szwkeres-Bartho J, Kinsky R, Chaouat G. The effect of a progesterone-induced immunologic blocking factor on NK-mediated resorption. Am J Reprod Immun Microbiol 1990;24:105–107. 115. Morell V. Zeroing in on how hormones affect the immune response. Science 1995;269:773–775. 116. Finn CA, Martin L. Patterns of cell division in the mouse uterus during early pregnancy. J Endocrinol 1967;39:593–597. 117. Finn CA, Martin L. Hormone secretion during early pregnancy in the mouse. J Endocrinol 1969;45:57–65. 118. Finn CA, Martin L. The role of the oestrogen secreted before oestrus in the preparation of the uterus for implantation in the mouse. J Endocrinol 1970;47:431–438. 119. Finn CA, Martin L. The onset of progesterone secretion during pregnancy in the mouse. J Reprod Fert 1971;25:299,300. 120. Finn CA, Martin L. The control of implantation. J Reprod Fert 1974;39:195–206. 121. Yoshinaga K, Adams CE. Delayed implantation in the spayed, progesterone treated adult mouse. J Reprod 1966;12:593–595. 122. Psychoyos A. Endocrine control of egg implantation. In: Greep RO, Astwood EG, Geiger SR, editors. Handbook of Physiology. American Physiological Society, Washington, DC, 1973, pp. 187–215. 123. Martin L, Finn CA, Trinder G. Hypertrophy and hyperplasia in the mouse uterus after oestrogen treatment: an autoradiographic study. J Endocr 1973;56:133–144. 124. Martin L, Finn CA, Carter J. Effects of progesterone and oestradiol-17b on the luminal epithelium of the mouse uterus. J Reprod Fert 1970;21:461–469. 125. Martin L, Finn CA, Trinder G. DNA synthesis in the endometrium of progesterone-treated mice. J Endocrinol 1973;56:303–307. 126. Martin L, Finn CA. The inhibition by progesterone of uterine epithelial proliferation in the mouse. J Endocrinol 1973;57:549–554. 127. Tibbetts TA, Conneely OM, O’Malley BW. Progesterone via its receptor antagonizes the proinflammatory activity of estrogen in the mouse uterus. Biol Reprod 1999;60:1158–1165. 128. Quarmby VE, Korach KS. The influence of 17b-estradiol on patterns of cell division in the uterus. Endocrinology 1984;114:694–702. 129. Whitehead MI. The effects of estrogen and progesterone on the postmenopausal endometrium. Maturitas 1978;9:309–313. 130. Gelfand MM, Ferenczy A. A prospective 1-year study of estrogen and progestin in postmenopausal women: effects on the endometrium. Obstet Gynecol 1989;74:398–402. 131. Greenblatt RB, Gambrell RD, Stoddard LD. The protective role of progesterone in the prevention of endometrial cancer. Path Res Pract 1982;174:297–318. 132. Jensen EV, DeSombre ER. Mechanism of action of the female sex hormones. Annu Rev Biochem 1972;41:203–230. 133. Hsueh AJW, Peck Jr EJ, Clark JH. Progesterone antagonism of the oestrogen receptor and oestrogeninduced uterine growth. Nature 1975;254:337–339. 134. Katzenellenbogen BS. Dynamics of steroid hormone receptor action. Annu Rev Physiol 1980;42:17–36. 135. Yamashita S, Newbold RR, McLachlan JA, Korach KS. Developmental pattern of estrogen receptor expression in female mouse genital tracts. Endocrinology 1989;125:2888–2896. 136. Murakami R, Shughrue PJ, Stumpf WE, Elger W, Schulze P-E. Distribution of progestin-binding cells in estrogen-treated and untreated neonatal mouse uterus and oviduct: autoradiographic study with [125I] progestin. Histochemistry 1990;94:155–159. 137. Parczyk K, Madjno R, Michna H, Nishino Y, Schneider M. Progesterone receptor repression by estrogens in rat uterine epithelial cells. J Steroid Biochem Mol Biol 1997;63:309–316. 138. Tibbetts TA, Mendoza-Meneses M, O’Malley BW, Conneely OM. Mutual and intercompartmental regulation of estrogen receptor and progesterone receptor expression in the mouse uterus. Biol Reprod 1998;59:1143–1152. 139. Kurita T, Young P, Brody JR, Lydon JP, O’Malley BW, Cunha GR. Stromal progesterone receptors mediate the inhibitory effects of progesterone on estrogen-induced uterine epithelial cell deoxyribonucleic acid synthesis. Endocrinology 1998;139:4708–4713. 140. Cooke PS, Buchanan DL, Young P, Setiawan T, Brody J, Korach KS, et al. Stromal estrogen receptors mediate mitogenic effects of estradiol on uterine epithelium. Proc Natl Acad Sci USA 1997;94:6535–6540. 141. Das SK, Chakraborty I, Paria BC, Wang XN, Plowman G, Dey SK. Amphiregulin is an implantationspecific and progesterone-regulated gene in the mouse uterus. Mol Endocrinol 1995;9:691–705.
202
Lydon et al.
142. Bruner KL, Rodgers WH, Gold LI, Korc M, Hargrove JT, Matrisian LM, et al. Transforming growth factor b mediates the progesterone suppression of an epithelial metalloproteinase by adjacent stroma in the human endometrium. Proc Natl Acad Sci USA 1995;92:7362–7366. 143. Surveyor GA, Gendler SJ, Pemberton L, Das SK, Wegner CC, Dey SK, et al. Expression and steroid hormonal control of muc-1 in the mouse uterus. Endocrinology 1995;136:3639–3647. 144. Iruela-Arispe ML, Porter P, Bornstein P, Sage EH. Thrombospondin-1, an inhibitor of angiogenesis, is regulated by progesterone in the human endometrium. J Clin Invest 1996;97:403–412. 145. Rider V, Carlone DL, Foster RT. Oestrogen and progesterone control basic fibroblast growth factor mRNA in the rat uterus. J Endocrinol 1997;154:75–84. 146. Ma L, Benson GV, Hyunjung L, Dey SK, Mass RL. Abdominal B (AbdB) hoxa genes: regulation in adult uterus by estrogen and progesterone and repression in Mullerian duct by synthetic estrogen diethylstilbestrol (DES). Dev Biol 1998;197:141–154. 147. Chen GTC, Getsios S, MacCalman CD. 17b-Estradiol potentiates the stimulatory effects of progesterone on cadherin-11 expression in cultured human endometrial stromal cells. Endocrinology 1998;139:3512–3519. 148. Zhu L-J, Cullinan-Bove K, Polihronis M, Bagchi MK, Bagchi IC. Calcitonin is a progesteroneregulated marker that forecasts the receptive state of endometrium during implantation. Endocrinology 1998;139:3923–3934. 149. Kumar S, Zhu L-J, Polihronis M, Cameron ST, Baird DT, Schatz F, et al. Progesterone induces calcitonin gene expression in human endometrium within the putative window of implantation. J Clin Endocrinol Meta 1998;83:4443–4450. 150. Vellios F. Endometrial hyperplasia and carcinoma in situ. Gynecol Oncol 1974;2:152–161. 151. Russo IH, Russo J. Role of hormones in mammary cancer initiation and progression. J Mam Gland Biol Neoplasia 1998;3:49–61. 152. Hirayama T, Wynder EL. A study of epidemiology of cancer of the breast. II. The influence of hysterectomy. Cancer 1962;15:28–38. 153. Feinleib M. Breast cancer and artificial menopause. J Natl Cancer Inst 1968;41:315–329. 154. Trichopoulos D, MacMahon B, Cole P. Menopause and breast cancer. J Natl Cancer Inst 1972;48:605–613. 155. Henderson BE, Ross RK, Judd HL, Krailo MD, Pike MC. Do regular ovulatory cycles increase breast cancer risk? Cancer 1985;56:1206–1208. 156. Henderson BE, Ross RK, Pike MC. Hormonal chemoprevention of cancer in women. Science 1993;259:633–638. 157. Clarke CL, Sutherland RL. Progestin regulation of cellular proliferation. Endocrine Rev 1990;11:266–300. 158. Anderson TS, Ferguson JP, Raab GM. Cell turnover in the “resting” human breast : Influence of parity, contraceptive pill, age and laterality. Brit J Cancer 1982;46:376–382. 159. Pike MC, Spicer DV, editors. Contraception. Springer-Verlag, New York, NY, 1993. 160. Medina D. The mammary gland: a unique organ for the study of development and tumorigenesis. J Mammary Gland Biol Neoplasia 1996;1:5–19. 161. Cardiff RD, Wellings SR. The comparative pathology of human and mouse mammary glands. J Mammary Gland Biol Neoplasia 1999;4:105–122. 162. Hennighausen L, Robinson GW. Think globally, act locally: the making of a mouse mammary gland. Genes Dev 1998;12:449–455. 163. Said TK, Conneely OM, Medina D, O’Malley BW, Lydon JP. Progesterone, in addition to estrogen, induces cyclin D1 expression in the murine mammary epithelial cell, in vivo. Endocrinology 1997;138:3933–3939. 164. Haslam SZ, Shyamala G. Relative distribution of estrogen and progesterone receptors among the epithelial, adipose, and connective tissue components of the normal mammary gland. Endocrinology 1981;108:825–830. 165. Haslam SZ. The ontogeny of mouse mammary gland responsiveness to ovarian steroid hormones. Endocrinology 1989;125:2766–2772. 166. Cunha GR. Role of mesenchymal-epithelial interactions in normal and abnormal development of the mammary gland and prostate. Cancer 1994;74:1030–1044. 167. Cunha GR, Yom YK. Role of mesenchymal-epithelial interactions in mammary gland development. J Mammary Gland Biol Neoplasia 1996;1:5–19. 168. Cunha GR, Young P, Hom YK, Cooke PS, Taylor JA, Lubahn DB. Elucidation of a role for stromal steroid hormone receptors in mammary gland growth and development using tissue recombinants. J Mammary Gland Biol Neoplasia 1997;2:393–402.
Chapter 9/Progesterone Action In Vivo
203
169. Humphreys RC, Lydon JP, O’Malley BW, Rosen JM. Use of PRKO mice to study the role of progesterone in mammary gland development. J Mammary Gland Biol Neoplasia 1997;2:343–354. 170. Brisken C, Park S, Vass T, Lydon JP, O’Malley BW, Weinberg RA. A paracrine role for the epithelial progesterone receptor in mammary gland development. Proc Natl Acad Sci USA 1998;95:5076–5081. 171. Silberstein GB, Van Horn K, Shyamala G, Daniel CW. Progesterone receptors in the mouse mammary duct: distribution and developmental regulation. Cell Growth Differen 1996;7:945–952. 172. Shyamala G, Barcellos-Hoff MH, Toft D, Yang X. In situ localization of progesterone receptors in normal mouse mammary glands : absence of receptors in the connective and adipose stroma and a heterogeneous distribution in the epithelium. J Steroid Biochem Mol Biol 1997;63:251–259. 173. Shyamala G. Progesterone signaling and mammary gland morphogenesis. J Mammary Gland Biol Neoplasia 1999;4:89–104. 174. Jull JW. The effects of oestrogens and progesterone on the chemical induction of mammary cancer in mice of the IF strain. J Path Bact 1954;68:547–559. 175. Jabara AG, Harcourt AG. Effects of progesterone, ovariectomy and adrenalectomy on mammary tumors induced by 7, 12-dimethylbenz(a)anthracene in Sprague-Dawley rats. Pathology 1971;3:209–214. 176. Welsch CW. Host factors affecting the growth of carcinogen-induced rat mammary carcinomas: a review and tribute to Charles Brenton Huggins. Cancer Res 1985;45:3415–3443. 177. Robinson SP, Jordan VC. Reversal of antitumor effects of tamoxifen by progesterone in the 7, 12dimethylbenzanthracene-induced rat mammary carcinoma model. Cancer Res 1987;47:5386–5390. 178. Russo IH, Russo J. Progestagens and mammary gland development: differentiation versus carcinogenesis. Acta Endocrinol 1991;125:7–12. 178a. Lydon JP, Ge G, Kittrell FS, Medina D, O’Malley BW. Murine mammary gland carcinogenesis is critically dependent on progesterone receptor function. Cancer Res 1999;59:4276–4284. 179. Daniel CW, Smith GH. The mammary gland: a model for development. J Mammary Gland Biol Neoplasia 1999;4:3–8. 180. McEwen BS. Genomic regulation of sexual behavior. J Steroid Biochem 1988;30:179–183. 181. Wagner CK, Nakayama AY, De Vries GJ. Potential role of maternal progesterone in the sexual differentiation of the brain. Endocrinology 1998;139:3658–3661. 182. Parsons B, Rainbow TC, Maclusky NJ, McEwen BS. Progestin receptor levels in rat hypothalamus and limbic nuclei. J Neurosci 1982;12:2549–2554. 183. Gould E, Woolley C, Frankfurt M, McEwen BS. Gonadal steroids regulate dendritic spine density in hippocampal pyramidal cells in adulthood. J Neurosci 1990;10:1286–1291. 184. Olton DDS. Memory functions and the hippocampus. In: Seifert W, editor. Neurobiology of the Hippocampus. Academic Press, London, UK, 1983, pp. 335–373. 185. Williams CL, Meck WH. The organizational effects of gonadal steroids on sexually dimorphic spatial ability. Psychoneuroendocrinology 1991;16:155–176. 186. Roof RL, Duvdevani R, Braswell L, Stein DG. Progesterone facilitates cognitive recovery and reduces secondary neuronal loss caused by cortical contusion injury in male rats. Exp Neurol 1994;129:64–69. 187. Akwa Y, Young J, Kaggadj K, Sancho MJ, Zucman D, Vourc’H C, et al. Neurosteroids: biosynthesis, metabolism and function of pregnenolone and dehydroepiandrosterone in the brain. J Steroid Biochem Mol Biol 1991;40:71–81. 188. LeGoascogne C, Robel P, Gouezou M, Waterman M. Neurosteroids: cytochrome p-450scc in rat brain. Science 1987;237:1212–1215. 189. Koenig HL, Schumacher M, Ferzaz B, DoThi AN, Ressouches A, Guennoun R, et al. Progesterone synthesis and myelin formation by Schwann cells. Science 1995;268:1500–1503. 190. Paul SM, Purdy RH. Neuroactive steroids. FASEB J 1992;6:2311–2322. 191. Betz AL, Coester HC. Effects of steroids on edema and sodium uptake of the brain during focal ischemia in rats. Stroke 1990;21:199–204. 192. Roof RL, Duvdevani R, Stein DG. Progesterone treatment attenuates brain edema following contusion injury in male and female rats. Rest Neurol Neurosci 1992;4:425–427. 193. Zuccarello M, Anderson D. Interaction between free radicals and excitatory amino acids in the blood-brain barrier disruption after iron injury in the rat. J Neurotrauma 1993;10:397–403. 194. Yu WH. Survival of motoneurons following axotomy is enhanced by lactation or progesterone treatment. Brain Res 1989;491:379–382. 195. Asbury ET, Fritts ME, Horton JE, Isaac WL. Progesterone facilitates the acquisition of avoidance learning and protects against subcortical neuronal death following prefrontal cortex ablation in the rat. Behav Brain Res 1998;97:99–106.
204
Lydon et al.
196. Bruckert E, Turpin G. Estrogens and progestins in postmenopausal women: influence on lipid parameters and cardiovascular risk. Horm Res 1995;43:100–103. 197. Godsland IF, Wynn V, Crook D, Miller NE. Sex, plasma lipoproteins, and atherosclerosis-prevailing assumptions and outstanding questions. Am Heart J 1987;114:1467–1503. 198. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991;20:47–63. 199. Barrett-Connor E, Bush TL. Estrogen and coronary heart disease in women. JAMA 1991;265:1861–1867. 200. Sullivan JM, Fowlkes LP. The clinical aspects of estrogen and cardiovascular system. Obstet Gynecol 1996;87(suppl.):36–43. 201. Wahl PW, Walden CE, Knapp RH, Wallace R, Rifkind B. Effect of estrogen/progesterone potency on lipid/lipoprotein cholesterol. N Engl J Med 1983;308:862–867. 202. Report. C. Estrogen replacement therapy in the menopause. JAMA 1983;249:359–361. 203. Persson I, Adami HO, Bergkvist L, Lindgreen A, Petterson B, Hoover R, et al. Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progesterone: results of a prospective study. Br Med J 1989;298:147–151. 204. Hirvonen E, Malkonen M, Manninen V. Effects of different progestogen on lipoproteins during postmenopausal therapy. N Engl J Med 1981;304:560–563. 205. Cheng W, Lau OD, Abumrad NA. Two antiatherogenic effects of progesterone on human macrophages; inhibition of cholesteryl ester synthesis and block of its enhancement by glucocorticoids. J Clin Endo Met 1999;84:265–271. 206. Grodstein F, Stampfer MJ, Manson JE, al. e. Post menopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996;335:453–461. 207. Ingegno MD, Money SR, Thelmo W, Greene GL, Davidian M, Jaffe BM, et al. Progesterone receptors in the human heart and great vessels. Lab Invest 1988;59:353–356. 208. Knauthe R, Diel P, Hegele-Hartung C, Engelhaupt A, Fritzemeier K-H. Sexual dimorphism of steroid hormone receptor messenger ribonucleic acid expression and hormonal regulation in rat vascular tissue. Endocrinology 1996;137:3220–3227. 209. Lee W-S, Harder JA, Yoshizumi M, Lee M-E, Haber E. Progesterone inhibits arterial smooth muscle cell proliferation. Nat Med 1997;3:1005–1008. 210. Bourassa KP-A, Milos PM, Gaynor BJ, Breslow JL, Aiello RJ. Estrogen reduces atherosclerotic lesion development in apolipoprotein E-deficient mice. Proc Natl Acad Sci USA 1996;93:10,002–10,027. 211. Iafrati MD, Karas RH, Aronovitz M, Kim S, Sullivan Jr. TR, Lubahn DB, et al. Estrogen inhibits the vascular injury response in estrogen receptor a-deficient mice. Nat Med 1997;3:545–548. 212. Hutchinson T, Polansky S, Feinstein A. Post-menopausal oestrogens protect against fractures of hip and distal radius: a case-control study. Lancet 1979;2:705–709. 213. Bain SD, Jensen E, Celino DL, Bailey MC, Lantry MM, Edwards MW. High-dose gestagens modulate bone resorption and formation and enhance estrogen-induced endosteal bone formation in the ovariectomized mouse. J Bone Mineral Res 1993;8:219–229. 214. Prior JC. Progesterone as a bone-trophic hormone. Endocrine Rev 1990;11:386–398.
Chapter 10/Knockout and Transgenic Mouse Models
10
205
Knockout and Transgenic Mouse Models that Have Contributed to the Understanding of Normal Mammary Gland Development Tiffany N. Seagroves, PHD and Jeffrey M. Rosen, PHD CONTENTS INTRODUCTION THE MAMMARY GLAND AS A MODEL SYSTEM OF DEVELOPMENT SIGNIFICANCE OF UNDERSTANDING THE GENETIC PATHWAYS CONTROLLING NORMAL MAMMARY GLAND DEVELOPMENT TECHNOLOGIES TO INVESTIGATE MAMMARY GLAND DEVELOPMENT GENERAL MORPHOLOGY OF EMBRYONIC MOUSE MAMMARY GLAND DEVELOPMENT GENERAL MORPHOLOGY OF POSTNATAL MOUSE MAMMARY GLAND DEVELOPMENT CONTROL OF EMBRYONIC DEVELOPMENT DUCTAL MORPHOGENESIS LOBULOALVEOLAR DEVELOPMENT, PROLIFERATION, AND DIFFERENTIATION IN RESPONSE TO PREGNANCY CONTROL OF LACTATION REGRESSION AND REMODELING DURING INVOLUTION SUMMARY OF KNOCKOUT AND TRANSGENIC MICE REFERENCES
INTRODUCTION The Mammary Gland as a Model System of Development The mammary gland in mice is in many ways analogous to the Drosophila eye as a target organ that can be readily manipulated to dissect information about the function of genes and signaling pathways during development. The majority of mammary-gland development occurs postnatally, and therefore can be manipulated without the problems of embryonic lethality observed in many other organ systems. Classically, the mammary From: Contemporary Endocrinology: Transgenics in Endocrinology Edited by: M. Matzuk, C. W. Brown, and T. R. Kumar © Humana Press Inc., Totowa, NJ
205
206
Seagroves and Rosen
gland has been a model system for endocrinologists. Yet, new technologies developed within the past 30 yr have transformed the mammary gland into a powerful genetic model system. Basic developmental biological processes—including ductal morphogenesis and patterning, proliferation, differentiation, and apoptosis as well as stromal-epithelial interactions—may be studied using a combination of classical biological techniques coupled with the sophisticated methods of modern mouse genetics. There are several advantages to the use of the mammary gland as a model system to study development. First, the mammary gland is not essential for survival of individual mice. More importantly, since rodents contain multiple pairs of glands, one or multiple glands may be biopsied from the same animal over the course of development, decreasing animal-to-animal experimental variability. Second, in contrast to most organ systems, the mammary gland develops primarily after birth, eliminating the need to harvest delicate embryos at precise stages of pregnancy. Third, multiple techniques exist to assay the epithelial or stromal contribution of a particular gene to mammary development, allowing complex signaling pathways to be dissected.
Significance of Understanding the Genetic Pathways Controlling Normal Mammary Gland Development Breast cancer is the most frequently diagnosed cancer for women in the United States, projected to affect 1 in 8 women over their lifetime (1,2). In the past three decades since the initiation of the “War on Cancer,” the vast majority of National Institute of Health (NIH)-funded research has been performed using established human breast-cancer cell lines, often derived from pleural effusions of breast-cancer patients. These cell lines are routinely genetically unstable, and contain a plethora of genetic alterations. In 1998, the priorities of the National Cancer Institute (NCI) were changed with regards to the funding of breast-cancer research. An emphasis on “… a more complete understanding of the normal mammary gland at each stage of development will…be a critical underpinning of continued advances in detecting, preventing and treating breast cancer...The principal scientific need in this field now is to focus studies on the early transitions from the normal to the malignant state in human and rodent model systems.” Therefore, the NCI recommended: “to increase funding for projects that integrate knowledge of cell signaling with whole organ biology for the development (of) in vitro models of breast differentiation, experimental xenograft systems and transgenic/knock-out mouse models.” As this chapter demonstrates, gene-deleted or “knockout” and transgenic mice have already elucidated several basic mechanisms that control normal mammary morphogenesis. Furthermore, several transgenic and knockout mouse models mimic the pathology observed in breast cancers (3). The results of these and future studies will certainly impact breast cancer diagnosis, prognosis and treatment protocols.
Technologies to Investigate Mammary Gland Development Multiple technologies exist to analyze mammary development and physiology following deletion, overexpression, or direct delivery of a gene product of interest. Many of these techniques are reviewed in ref. 4. Often, the first clue that a gene is contributing to mammary development is the failure of knockout mice to support their litters at lactation. Several key regulators of mammary development have been serendipitously identified in mice that were created for other reasons. Genes can be targeted (and overexpressed) in the mammary epithelium under the control of the mouse mammary-
Chapter 10/Knockout and Transgenic Mouse Models
207
tumor virus (MMTV) or milk-protein gene promoters, such as `-casein, whey acidic protein (WAP), `-lactoglobulin, or _-lactalbumin (5). All of these promoters will direct transgene expression primarily during pregnancy and lactation in a temporal and hormonally regulated fashion. Occasionally, the MMTV and the WAP promoters may be expressed at sufficient levels in virgin mice to influence ductal morphogenesis (6–8). The response of the mammary gland to systemic administration of exogenous growth factors, steroid hormones, or polypeptides may be assayed by subcutaneous (sc) interscapular implantation of beeswax pellets containing the gene product of interest, or using Alzet mini-pumps. Alternatively, factors diluted into saline solutions or sesame oil may be injected subcutaneously behind the neck. To assess localized responses, smaller ethylene/vinyl acetate copolymer (Evac) pellets containing the factor of interest may be directly implanted into a mammary gland (9). Implantation of blank Evac pellets within the contralateral gland of the same animal allows direct comparison of efficacy of treatment, and eliminates concerns of animal-to-animal variability. Other technologies rely on the intrinsic ability of the mammary gland to regenerate. The mammary epithelial cells (MEC) are capable of completing multiple cycles of reproductive development, including proliferation and differentiation during pregnancy, secretion of milk at lactation, and massive apoptosis during involution. During successive pregnancies, these processes will be repeated. The dramatic increase in the number of MEC that occur during each pregnancy suggests that stem-cell populations exist in the mammary gland. Based on the results of serial dilution experiments, it is hypothesized that approx 1 in every 2,500 MEC is a stem cell (10–12). Transplantation techniques developed by DeOme et al. rely on the ability of MEC to repopulate a host fat pad that has been surgically “cleared” of its endogenous epithelium (13). A schematic of the transplantation protocol is presented in Fig. 1. Following removal of the host’s endogenous epithelium, small portions (1 × 1mm) of donor mammary tissue, averaging approx 4600 MEC (10), are inserted into a pocket created within the host fat pad. After a period of outgrowth, typically 6–8 wk posttransplantation, the ductal network has reorganized, growing away from the site of the transplant to the edges of the fat pad (Fig. 1). Serial transplantation is usually possible for up to five generations from tissue that has regenerated from the original transplanted graft (14). In 1988, Sheffield et al. described successful transplantation of human breast epithelium into cleared fat pads of athymic nude mice, providing another application of transplantation to breast-cancer research (15). This transplantation technology has provided multiple assays to analyze phenotypes observed in knockout and transgenic mouse models (16). First, defects in development may be assigned to either the epithelial or stromal compartments of the mammary gland through reciprocal transplantation. For example, mammary epithelium isolated from knockout mice may be transplanted into the cleared fat pads of wild-type hosts and conversely, wild-type epithelium may be transplanted into the cleared fat pads of knockout hosts (17,18). If the knockout tissue fails to develop normally in the wild-type fat pad, the defect is MEC autonomous. Conversely, if the wild-type epithelium does not develop within the knockout stroma, the defect resides in the stromal compartment. To control for defects attributed to transplantation, such as disruption of the connection to the nipple, development of the transplanted outgrowths may be compared to development of an endogenous thoracic gland present in the host. Although mature females are used most often as the donors for transplantation, the mammary anlage may also be rescued from embryos and transplanted into 3-wk old hosts as early as embryonic (E) d 12.0. This
208
Seagroves and Rosen
Fig. 1. Transplantation of cells or epithelium into the cleared inguinal (#4) fat pads of 3-wk-old hosts. By 3 wk of age, the ducts have grown just to the lymph node (dark circle, one-third down fat pad from the nipple). To “clear” the fat pad, the endogenous epithelium is cut away (solid line) from the remaining fat pad just beyond the lymph node. The nipple and area of skin where epithelium was removed is then cauterized (dashed lines). A small piece of epithelium is placed into a small pocket of the remaining fat pad (gray oval). Alternatively, MEC may be injected into the cleared fat pad. Normal epithelium will grow out to the edges of the “cleared” fat pad within 6–8 wk posttransplantation.
circumvents problems with embryonic and neonatal lethality often encountered with knockout mice. Second, transplantation of donor epithelium isolated from knockout mice into wild-type host fat pads may separate systemic from mammary-intrinsic developmental defects. Third, cleared mammary fat pads may be injected with purified preparations of MEC that have been genetically manipulated in vitro. Reciprocal epithelial-stromal interactions may also be investigated by transplantation under the kidney capsule. This technique, developed by the Cunha laboratory (19), has provided clues to several factors controlling embryonic and postnatal mammary gland development. Since athymic nude mice are used as the hosts of the recombined tissues, the genetic background of the epithelium and stroma does not have to be similar. Using these transplantation methods, complex biological questions can be addressed. Organ and tissue-culture techniques have been developed to investigate mammarygland development in vitro within a controlled physical environment (reviewed in 20,21). The culture of explanted mammary tissue facilitated investigation of the specific contributions of the hormones and growth factors required for mammary-gland development and differentiation (22). More recently, protocols for isolating pure preparations
Chapter 10/Knockout and Transgenic Mouse Models
209
of MEC by collagenase/trypsin digestion of whole mammary glands of virgin or pregnant mice have been developed (reviewed in 21). Several methods exist to experimentally manipulate primary MEC. Primary MEC transduced with retroviruses in vitro may be re-introduced into the cleared fat pads of hosts to study development in vivo. This technique is a faster, cheaper alternative to producing transgenic mice, but lack of a phenotype may result from a failure to effectively transduce the stem-cell population of MEC. In addition, primary MEC may be cultured for up to 10 d before entering crisis, facilitating investigation of cell-signaling pathways (21). Although primary MEC must be prepared for each experiment, it is likely that cell-signaling events in freshly isolated primary MEC are more physiologically relevant to normal mammary development than those observed in established cell lines. Since traditional knockout mouse models fail to address questions regarding gene deletion at particular stages of development, new technologies have been created to delete genes in a tissue-specific and/or temporal manner. The most prevalent method is based on the Cre-lox system described in P1 bacteriophage, which involves Cre recombinase-mediated deletion of DNA fragments that are flanked by lox-P sites (“floxed”) (23). Floxed DNA is then introduced by homologous recombination into embryonic stem (ES) cells. Gene-targeted mice heterozygous for the floxed allele are bred to homozygosity. Upon addition of Cre, both copies of a gene will be deleted. Once a gene has been successfully floxed and introduced in mice, there are two methods to induce Cre expression. First, mice that carry floxed alleles may be crossed to transgenic mice that express Cre via tissue-specific promoters. For example, transgenic lines of mice that express Cre recombinase via the MMTV, WAP, and `-lactoglobulin promoters have been created (24,25). Alternatively, primary MEC may be prepared from floxed mice, transduced with Cre via adenovirus infection and transplanted into the cleared fat pad of host mice (25a). Utilization of the Cre/lox system will further refine the ability of the mammary gland to reveal mechanisms of development.
General Morphology of Embryonic Mouse Mammary Gland Development Mammary rudiments appear as epidermal thickenings on either side of the trunk, referred to as the “milk streak,” by E 12.0 (26). Dense mammary mesenchyme, composed of 2–3 layers of tightly packed fibroblasts, envelops the developing mammary bud, appearing at E 13.0. The functions of this mesenchyme are to support growth of the epithelial bud and to regulate sexual dimorphism of the gland in response to testosterone. Posterior to the dense mammary mesenchyme lies the future fat pad, which is composed of preadipocytes (26). By E 14.0, the dense mammary mesenchyme expresses relatively high levels of androgen receptor (AR) (26). Androgens secreted by the testes in the male induce active regression of the mammary epithelial bud (27). In females the anlage continues to grow very slowly until E 16, when proliferation increases, and the cord of the mammary epithelium begins to grow into the surrounding fat pad, opening to the nipple (26). By birth, a primary duct connected to the nipple containing 12–15 small branches of ductal epithelium is present. An excellent mini-review of embryonic mammary development can be found on the world wide web (www) at http://mammary. nih.gov/atlas/wholemounts/normal/slides/main.html. From birth to approx 3 wk of age, the ductal epithelium grows slowly in proportion to the increase in size of the entire animal (28). By 3 wk of age, the ductal tree has extended out to the lymph node in the inguinal (#4) gland that marks the first one-third of the mammary fat pad. If cleared
210
Seagroves and Rosen
Fig. 2. Histology of ductal morphology in nulliparous female mice. Whole mounts (A,C) or H&E-stained sections (B,D) of inguinal (#4) mammary glands prepared from 6-wk-old (juvenile; A,B) or 12-wk-old (mature; C,D) pure C57/Bl6 mice were digitally captured at 10× (A,B) or 4× (C,D) microscopic magnification. The arrows indicate either the epithelial cells (large arrows) or the dense layer of extracellular matrix surrounding the epithelial cells (small arrows).
of endogenous epithelium, the remaining two-thirds of the mammary stroma may be used as the site of transplanted tissue or cells, as previously described.
General Morphology of Postnatal Mouse Mammary Gland Development The majority of postnatal development begins at 3 wk of age, at the onset of puberty. Postnatal development consists of four tightly regulated stages: ductal outgrowth into the stromal fat pad from 3–9 wk of age, lobuloalveolar proliferation and differentiation during pregnancy, synthesis and secretion of milk at lactation, and involution of the secretory epithelium following weaning. Each stage depends on a critical balance between proliferation, differentiation, and apoptosis. With the advent of knockout and transgenic mice models, the specific contributions of hormones, growth factors, and cellsignaling pathways began to be mapped to these stages of mammary development (29). Rapid development of the rudimentary ductal epithelium is initiated in response to increasing levels of circulating hormones synthesized by the pituitary gland and the ovary, such as estrogen, progesterone, and growth hormone (GH) (30). Other growth factors, such as epidermal growth factor (EGF) and insulin-like growth factor (IGF)-I, have also been demonstrated to stimulate ductal morphogenesis (31,32). Ductal morphogenesis progresses through a balance between proliferation and apoptosis with multilayered club-shaped structures known as terminal end buds (TEB) (Fig. 2A–B). The TEB is composed of two predominant epithelial-cell types. The outermost layer of cells,
Chapter 10/Knockout and Transgenic Mouse Models
211
known as cap cells, are in close contact with the basement membrane at the distal portion of the end bud. Proliferation occurs primarily in these distal-cell layers (33). Cap cells lack differentiated features and intracellular junctions, and are not polarized (30). Programmed cell death occurs within the more proximal innermost cell layers of the TEB known as body cells (33), resulting in the formation of a hollow duct composed of a single layer of luminal-epithelial cells. As the ducts approach the edges of the fat pad, by approx 8–9 wk of age, the TEBs disappear, signaling the end of ductal morphogenesis (Fig. 2C). The virgin gland remains relatively quiescent until the onset of pregnancy or the administration of exogenous hormones such as estrogen and progesterone. The rapidly proliferating cap cells of the TEB are hypothesized to be targets of carcinogenic agents (34), since pregnancy or the administration of hormones that accompany pregnancy are protective against cancer in both rodent and human (female) models (1,35,36). The MEC are surrounded by an outer layer of myoepithelial cells that will contract to express milk through the nipple during lactation. The function of the myoepithelial cells in the nulliparous animal is unknown (30). Epithelial cells may be distinguished from myoepithelial cells in two ways. First, myoepithelial cells, which line the single layer of luminal-epithelial cells, are thin and spindle-shaped in contrast to the columnar appearance of epithelial cells. Second, they can be distinguished by expression of specific cytokeratin intermediate filaments. Ductal luminal or secretory epithelial cells express cytokeratins 8 and 18 (K8 & K18), whereas cytokeratin 14 (K14) is expressed only in myoepithelial cells (37). Pregnancy induces proliferation of the secretory units of the mammary gland—the alveoli—which originate from putative ductal progenitor cells and proliferate to eventually fill the entire stromal fat pad. The gestation period of most mouse strains is between 19–21 d and can be divided into three major stages of development: “early” (0–10 d), “mid-” (10–15 d), or “late” pregnancy (15 d until parturition). The highest rates of DNA synthesis in the ductal epithelium are observed at d 3 of pregnancy, before decreasing and being observed primarily in the developing alveoli (38). Proliferation of alveoli per total number of MEC is maximal during the early pregnancy, from d 6–10 (38). By d 6 of pregnancy, fine secondary/tertiary branches with clusters of alveoli are apparent (Fig. 3A,B). By 10 d of pregnancy, the alveoli have begun to appear uniformly along the ductal network (Fig. 3C,D). Concurrent with proliferation, alveoli begin to functionally differentiate at mid-pregnancy, as assayed by the synthesis milk-protein genes, such as `-casein and WAP (39). The accumulation of proteinaceous and lipid secretory products is evident in the lumen of the alveoli of hematoxylin and eosin (H&E)-stained sections prepared from 15-d pregnant female (Fig. 3E,F). At this stage of pregnancy, alveoli have begun to fill in the “spaces” between the alveoli-lined ducts. By d 18 of pregnancy, the MEC population of the mammary gland accounts for approx 90% of all cells (40); the entire fat pad has become filled with alveoli. During lactation, the secretory epithelium maximally produces and secretes milk. Accumulation of milk distends the alveoli, flattening the epithelial cells into tightly packed rings of cells with large lumens (Fig. 3G). At involution, following the weaning of pups, extensive tissue remodeling and apoptosis of the secretory epithelium occurs, until the gland contains the simple ductal network seen in the virgin. The collapsed nature and disorganization of the MEC typical of an involuting gland 4 d following forced removal of a litter is shown in Fig. 3H. These stages of mammary development
212
Seagroves and Rosen
Fig. 3. Histology of the inguinal mammary gland during pregnancy, lactation and involution. Whole mounts (A,C,E) and/or H&E-stained sections (B,D,F–H) were prepared from 6-d pregnant (A,B), 10-d pregnant (C,D), 15-d pregnant (E,F), 1-d lactating (G) or 4-d forced involuted (H) pure C57BL/6 mice. Note the increase in secretory products in the lumen of alveoli at 15 d of pregnancy (F), the distended lumen during lactation (G) and the collapsed, disorganized structure of the alveoli during involution (H). All images were digitally captured at 10× (A,C,E) or 20× (B,D,F–H) magnification.
may be reviewed in more detail online on the “Biology of the Mammary Gland” home page, sponsored by the NIH at http://mammary.nih.gov. The mammary gland is capable of repeating the process of pregnancy, lactation, and regression to a more virgin-like state multiple times. Involution of the gland naturally proceeds as neonates begin to eat solid food (41), or can either be induced by forced removal of the entire litter or by physically sealing individual nipples, resulting in
Chapter 10/Knockout and Transgenic Mouse Models
213
accumulation of milk or “milk stasis” in the sealed gland (42). In the natural weaning model, milk stasis does not occur, presumably because of a systemic feedback mechanism (42). By either method, the process of regression occurs in two stages: a proteinaseindependent initiation of programmed cell death of epithelial cells, and a tissue remodeling resulting from increased expression of extracellular matrix degrading proteases (42–44). Apoptosis is induced within 24 h of forced involution or teat sealing and is observed as early as d 16 of natural weaning (42). By d 22 of natural weaning, the DNA content is one-half that observed at d 16 (42). As the epithelial cells die, they are sloughed into the lumen, and are phagocytosed by macrophages that increase at d 3 and are maximal at d 10 (43). In forced involution models, by d 4, extensive tissue remodeling is obvious in histological preparations, and the alveoli have collapsed and appear disorganized (Fig. 3H). By d 8 of involution, very few clusters of alveoli remain. In most mice strains, relatively little epithelium is present by d 10 of involution (43). Mice that are pregnant upon natural weaning of their first litter transiently exhibit increased levels of apoptosis, but do not undergo the second phase of involution— tissue remodeling (42,44). Lactation can be restored in the forced involution model if pups are returned to the mother within 2 d, but involution proceeds when pups are removed for 3 d (44). The mechanism of this commitment to involution is not well-defined.
Control of Embryonic Development In comparison to postnatal mammary gland development, very few knockout or transgenic mice have been reported to have defects in embryonic development. Some of the genes implicated in embryonic mammary development are presented in Fig. 4. Presumably, disruption of genes that mediate epithelial-mesenchymal interactions would result in embryonic defects. Two such mouse models have been reported, p63 –/– (45,46) and lymphoid-enhancer factor (Lef)-1 –/– (47) mice. p63, a homolog of the tumorsuppressor gene p53 , is expressed in ectodermally-derived tissues of the embryo (45). Mice lacking p63 die shortly after birth, most likely a result of dehydration caused by poorly differentiated skin. Newborn mice do not have limbs (or have truncated limbs), and have no hair follicles or teeth. No mammary buds form in p63 –/– mice. Interestingly, the p63 –/– mice fail to induce expression of another gene that has been implicated in embryonic development, Lef-1 (45). LEF-1 is a sequence-specific DNA-binding protein that belongs to the T cell factor (TCF) subset of the high-mobility group (HMG) family of proteins (48). Lef-1 is expressed in several developing tissues in the embryo, but is restricted to lymphoid tissues in adult animals (48). Similar to p63 –/– mice, mice lacking Lef-1 do not form tissues that require ectoderm-mesenchymal interactions such as teeth and whiskers (48). In contrast to p63 –/– mice, Lef-1 –/– mice do form mammary buds; however, the buds are arrested and do not progress to ductal development (48). LEF-1 mediates Wnt signaling pathways and may be activated by bone morphogenetic protein (BMP)-4 (49). BMP-4 is expressed in the fetal mesenchyme surrounding the mammary bud, indicating that BMP-4 expressed in the mammary stroma may induce expression of Lef-1 in the mammary epithelium (50). Intriguingly, LEF-1 and other TCF family members may directly induce cyclin D1 expression (51). Therefore, mammary development may be arrested in Lef-1 –/– mice because the mammary bud fails to proliferate to form the primary duct. During embryogenesis, LEF-1 expression partially overlaps with expression of Alx-4, a protein identified in a screen for retinoblastoma (Rb) interacting proteins (52).
214
Seagroves and Rosen
Fig. 4. Genes that are implicated in regulation of embryonic mammary gland development. Ep, epidermis; MB, mammary bud; MM, mammary mesenchyme; FPM, fat-pad mesenchyme. This figure was adapted and reprinted with permission from CW Daniel and Plenum Publishing (63).
Alx-4 , a paired like (PL) homeodomain protein, is expressed in the mesenchyme directly surrounding the ductal epithelium and TEBs in 5-wk-old virgin mice (53). Deletion of LEF-1 may also perturb Alx-4 expression, resulting in deregulated control of proliferation. Mice lacking Alx-4 exhibit normal mammary-gland development, possibly caused by compensation by other PL family members (53). In humans, inherited dominant mutations of the TBX-3, a member of the T-box (tbx) family of transcription factors, results in ulnar-mammary syndrome, in which the breasts are severely underdeveloped or lacking (54). The expression of some Tbx family members has been localized to the mammary anlage during mouse embryonic development (55). Two genes related to the muscle segment homeobox (msh) gene, Msx-1 and Msx-2, have also been implicated in epithelial-mesenchymal interactions (56). Msx-1 is expressed in the epithelial bud, whereas Msx-2 is expressed in the epithelium and mesenchyme of the embryonic mammary gland (50). Deletion of Msx-1 does not alter mammary-gland development, as the newborn mammary gland is unaltered (50). However, Msx-2 expression may be sufficient to compensate. Parathyroid-hormone related protein (PTHrP) and its receptor, first implicated in hypercalcemia that develops in many types of cancer (57), are also required for development of the embryonic mammary gland (58). PTHrP mRNA is expressed in the mammary epithelial bud beginning on E 12 and is expressed in developing ducts during ductal morphogenesis (59). The PTHrP receptor is expressed in the dense mammary mesenchyme from E 12 and in the fat-pad precursor cells from E 18, adjacent to developing
Chapter 10/Knockout and Transgenic Mouse Models
215
ducts (59). During bone development, PTHrP appears to be downstream of the BMPs (60), as are several other targets of mammary embryogenesis. Mice lacking PTHrP develop mammary buds, but the mammary anlage fails to undergo branching morphogenesis. The epithelial cells degenerate by birth, resulting in a fat pad devoid of epithelium. Ductal morphogenesis has been partially rescued by crossing K14-PTHrP transgenic mice with the null mice. However, the ducts penetrated very slowly compared to normal litter mates, and were devoid of any fine side branching (61). The mechanisms of positioning and patterning of the multiple pairs of mammary glands in rodents is unknown. During embryonic development, homologs of Drosophila homeotic genes may participate in the simultaneous establishment of the pairs of mammary buds along the milk streak. Particular members of the Iroquois (Irq) and distal-less (Dlx) homeodomain-containing gene families are expressed in the developing mammary gland (62,63). The Iroquois genes (Irx1-3) have been implicated in the development of the mouse nervous system, ear, heart, and limbs (64). Irx-2 is expressed in the mammary epithelium of the developing mouse mammary gland, but its role in development is unknown. However, recent experiments have determined that the human homolog, IRX-2 continues to be expressed during postnatal development within the epithelium of the terminal ductal lobular unit (TDLU) of the mature human breast (65). Several members of the Dlx gene family are expressed in the developing mouse (66,67). Unexpectedly, Dlx-3 expression was localized to the developing mammary glands of transgenic mice expressing lacZ under the control of the Xenopus Dlx-3 promoter. Mice lacking Dlx-3 die at E 9.5 to E 10 of development, preventing analysis of mammary development in this model (68).
Ductal Morphogenesis To date, a majority of transgenic and gene-deleted mice that effect ductal morphogenesis exhibit retarded or delayed morphogenesis compared to their wild-type litter mates. Several of the genes implicated are growth factors or their corresponding receptors. This is not surprising, because the ductal epithelium must proliferate in order to penetrate the fat pad. STEROID HORMONES Classic hormonal ablation experiments have demonstrated that the steroid hormones are required for ductal morphogenesis. Ovariectomy results in regression of the ductal epithelium, but outgrowth can be restored in the TEBs following administration of estrogen (69). Administration of estrogen and progesterone induces DNA synthesis in both TEBs and the ductal epithelium (70). Proliferation of the ductal epithelium is preceded by one round of proliferation in the mammary stroma, leading to a hypothesis as early as 1984 proposing that the mammary fat pad is the site of initial estrogen action (71). Estrogenic compounds can activate either of two estrogen receptors (ER), the classical ER_ and the more recently discovered ER`. ER` shares 95% and 55% percent homology with the DNA-binding and ligand-binding domains of ER_, respectively (72). Both ER_ and ER` mRNAs are expressed in the dense mammary mesenchyme surrounding the mammary bud beginning at d E 12.5 (73). To address the contribution of ER_ to reproductive development, ER_ –/– (_ERKO) mice have been created (74). The _ERKO mice are viable, but do not ovulate or form copora lutea, significantly decreasing the amount of circulating progesterone (75). Confirming hormonal ablation
216
Seagroves and Rosen
studies, deletion of ER_ (_ERKO) impairs ductal morphogenesis (74). At 4 mo of age, the ductal network present in _ERKO females is severely compromised in comparison to wild-type littermates, and no TEBs are present. Chimeric reconstitutions of neonatal wild-type and _ERKO mammary epithelium and stroma grafted under the kidney capsule of ovary-intact mice have demonstrated that extensive ductal outgrowth occurs only in the presence of wild-type stroma (76). These results indicate that stromal ER_ regulates expression of factors that act in a paracrine fashion to stimulate proliferation of the ductal epithelium. Addition of exogenous steroid hormones or prolactin partially restores ductal development and induces lobuloalveolar development in _ERKO mice (75). Upon treatment for 21 d with estrogen and progesterone, ductal morphogenesis and alveolar development are partially rescued in ovariectomized (OVX) _ERKO mice, suggesting that ER` may be able to compensate for lack of ER_. Partial rescue of the _ERKO phenotype is also evident in pituitary-isografted-intact _ERKO mice (75). Pituitary isografts have induced high levels of circulating prolactin and progesterone in ovary-intact wild-type and _ERKO mice (75). Pituitary isografting of OVX mice, however, did not rescue ductal outgrowth, presumably because prolactin partially functions to stimulate ovarian production of progesterone (77), which must synergize with estrogen to induce ductal morphogenesis. In contrast to the distinct defects observed in the nonhormone-stimulated _ERKO mouse, deletion of ER` does not significantly impair ductal outgrowth, lobuloalveolar development, or lactation, implicating ER_ as the primary mediator of estrogenic action in the mammary gland (75). Further experiments will be required to determine a specific role of ER_ vs ER` in the mammary gland. It will be particularly important to perform the hormonal “rescue” experiments for _ERKO/`ERKO double knockout mice to determine whether estrogen is truly required for ductal morphogeneis and/or lobuloalveolar development. Although progesterone acts synergistically with estrogen to induce ductal outgrowth, deletion of the progesterone receptor (PR) does not impair ductal outgrowth (78). LOCAL GROWTH FACTORS THAT INDUCE DUCTAL MORPHOGENESIS Epidermal growth factor (EGF) also stimulates DNA synthesis in OVX nulliparous mice (79). Implantation of pellets containing EGF into the mammary glands of OVX mice induces localized expression of the of EGF receptor (EGFR) in the stroma immediately surrounding the ducts and TEBs, and in the TEB cap cells (31). Similar to the phenotype of the _ERKO mouse, EGFR –/– epithelial-stromal reconstitution experiments have indicated that the presence of EGFR in the stroma is required to induce ductal outgrowth (80). Recent studies have demonstrated that neutralizing antibodies to EGF prevents proliferation of TEBs following ovariectomy and that similar results are obtained when the mammary glands containing antiestrogens are treated with EGF (81). These results have led to the hypothesis that EGF mediates its effects on TEB proliferation partially through the ER (81). In addition, estrogen treatment induces expression of EGFR in the mammary epithelium of sexually mature mice (82). Since EGF- and estrogen-stimulated cell-signaling pathways appear to be closely intertwined, it is not surprising that deletion of either receptor results in retarded ductal morphogenesis. In addition to EGF, other members of the EGF family of growth factors control ductal morphogenesis. For example, overexpression of either amphiregulin or heregulin (neu
Chapter 10/Knockout and Transgenic Mouse Models
217
differentiation factor, NDF) stimulates aberrant proliferation of the ductal epithelium (83,84). Similar to EGF, slow-release pellets containing AR induce ductal outgrowth in OVX mice (83), and MEC manipulated to overexpresss amphiregulin form lobular hyperplasias in a transplant model (83). Mammary glands of sexually mature transgenic mice that overexpress NDF under control of MMTV promoter aberrantly contain TEBs at sexual maturity, which normally disappear when ductal outgrowth is complete. Multiply bred MMTV-NDF mice form adenocarcinomas at approx 12 mo of age (84). Similarly, 100% of all whey acidic protein transforming growth factor _ (WAP-TGF_) transgenic mice develop mammary adenomas, and nulliparous females exhibit precocious development (85). In contrast, mice carrying single deletions of TGF_ (86) or EGF (87) exhibit no gross defects in mammary development. Since mice carrying single deletions of either amphiregulin, EGF, or TGF_ are fertile, it is possible to assay to mammary development of double or triple knockouts. In contrast to EGF and TGF_, deletion of amphiregulin impaired ductal outgrowth and development and approx 20% of the fat pad contained epithelium at 12 wk of age, with TEBs still present (87). However, within TEBs, there were no differences in the levels of DNA synthesis and apoptosis compared to normal litter mates (87); therefore, the defect in ductal elongation cannot be explained by defects in the TEB cell population. Deletion of all three ligands resulted in further impaired ductal development and a failure to complete ductal morphogenesis and fully differentiate during pregnancy—conditions that led to poor survival rates for pups (87). In contrast, EGF/TGF_ double-knockout mice completed lobuloalveolar development, and were capable of supporting their litters. Therefore, amphiregulin is an important regulator of ductal outgrowth, although it acts via an unknown mechanism. In single EGF or TGF_ knockout mice, the overlapping expression of other EGF family members must be sufficient to compensate for their roles in development (88). LOCAL GROWTH FACTORS THAT INHIBIT DUCTAL MORPHOGENESIS Members of the transforming growth factor (TGF)-` superfamily are also implicated in ductal morphogenesis. Ductal elongation is locally impaired in developing mammary glands implanted with Evac pellets that contain either of the three TGF-` ligands (TGF-`1-3) (9,89). In contrast, the formation of alveoli during pregnancy is not compromised (9). Therefore, the TGF-` ligands function as negative regulators of ductal morphogenesis. Transgenic mice expressing TGF`-1 under control of the MMTV promoter exhibit impaired ductal outgrowth and significantly fewer lateral branches than wild-type litter mates, but alveolar development is unaffected (90), consistent with the results from the Evac pellet studies. In contrast, WAP-TGF-`1 transgenic mice failed to support their litters as a result of limited alveolar development during pregnancy (91). The timing of transgene expression exerted by the MMTV vs WAP promoter may contribute to this apparent discrepancy. The expression of a dominant-negative form of the TGF-` receptor type II (DNIIR) under control of MMTV promoter results in premature development of lateral branching and alveoli capable of producing `-casein in the nulliparous mammary gland (92). The overexpression of DNIIR in the mammary stroma also induces increased lateral branching (93). In contrast, another member of the TGF-` superfamily positively induces ductal development. Reciprocal transplantation experiments have confirmed that the presence of inhibin`B is required in the stroma to support normal ductal morphogenesis and lobuloalveolar development (17).
218
Seagroves and Rosen
OTHER FACTORS Premature lateral branching and functional differentiation of the epithelium is also observed in the mammary glands of transgenic mice that overexpress the matrix metalloproteinases (MMPs) stromelysin-1 or matrilysin-1, implicating that an intact basement membrane contributes to suppression of lobuloalveolar development in virgin mice (7,94). Therefore, controlled ductal elongation and lateral branching are significantly influenced by the local concentrations of growth factors and their corresponding receptors and extracellular matrix molecules. In contrast to these models describing retarded or accelerated growth of the ductal epithelium, deletion of the transcription factor CCAAT/enhancer-binding protein(C/EBP)` dramatically increases intraductal spacing, characterized by a severe bloating of the ducts via an unknown mechanism (18,95). The C/EBP` –/– mice also exhibit decreased lateral branching; however, there are no apparent defects in the rate of ductal outgrowth compared to wild-type litter mates. Decreased levels of lateral branching in virgin mammary glands have also been reported for several other gene-deleted mice, including the progesterone receptor (PR), prolactin, and prolactin receptor (PrlR) mouse models (96–98). Since each of these molecules contributes to lateral branching and lobuloalveolar development during pregnancy, these observations are consistent. However, the principal defect resulting from deletion of each of these genes is a failure of alveoli to develop during pregnancy.
Lobuloalveolar Development, Proliferation, and Differentiation in Response to Pregnancy STEROID RECEPTORS AND PROLACTIN For several years, estrogen, progesterone, and prolactin have been implicated as mediators of alveolar development in the mammary gland (99). The minimal hormones required to induce lobuloalveolar development in OVX mice are estrogen and progesterone. Addition of all three hormones synergistically enhances lobuloalveolar development in this model (100). As discussed, exogenous administration of progesterone and prolactin appear to partially rescue lobuloalveolar development in _ERKO mice (75). In contrast, deletion of either PrlR or PR completely inhibits alveolar development and ductal lateral branching, but does not severely compromise the process of ductal outgrowth and bifurcation (96–98). Mature nulliparous females lacking prolactin do not exhibit lateral branching as extensive as their wild-type litter mates (101). The persistence of TEB in animals as old as 5 mo of age is also unusual (97). In addition, the females are sterile (101). However, following mating progesteron-implanted PRL–/– mice exhibited extensive lobulo–alveolar development by d 18 of pregnancy (101a). It is likely that prolactin is absolutely essential for alveolar development since prolactin signals through the prolactin receptor and transplanted epithelium lacking the prolactin receptor does not develop into lobuloalveolar structures in response to a full-term pregnancy (98). In fact, even prolactin-receptor +/– mice do not develop enough alveoli to support their litters of pups at first lactation (102), implying that a threshold of prolactin-receptor expression is required to induce alveolar morphogenesis. At lactation, the alveoli of prolactin-receptor +/– mice are collapsed, and do not synthesize lipids and proteinaceous material associated with milk production (98). During a second preg-
Chapter 10/Knockout and Transgenic Mouse Models
219
nancy, most prolactin-receptor +/– mice are capable of nursing their litters (102). This type of compensation is typical of many knockout mouse models that are fertile (like the prolactin-receptor +/– mouse), and can be bred multiple times. Transplantation of prolactin-receptor –/– epithelium into the cleared fat pads of wild-type hosts has confirmed that the prolactin receptor is required for lateral branching and development of alveoli— absolutely no alveoli formed by d 1 of lactation (98). In the mammary gland, prolactin-mediated signaling induces signal transducers and activators of transcription (STAT)5a and STAT5b tyrosine phosphorylation and translocation to the nucleus through activation of the JAK (Janus kinase)-STAT pathway (103). Unlike the prolactin-receptor –/– mouse, mice lacking STAT5a are fertile, and exhibit a moderate impairment of alveolar development that prevents successful lactation during the first pregnancy (103). However, deletion of STAT5a does not significantly affect expression of `-casein, and only slightly reduces WAP expression, a likely result of compensation by STAT5b (103). In contrast, fertility is compromised in mice lacking STAT5b –/– (104), but the mice which do become pregnant do not display any gross defects in mammary gland morphology (29). Analysis of development of mammary epithelium isolated from mice lacking both STAT5a and STAT5b, rescued by transplantation into normal hosts, has indicated that deletion of both STAT5 genes results in a phenotype very similar , but not identical, to the prolactin-receptor –/– mammary gland (K. Miyoshi and L. Hennighausen, personal communication). Similar to the prolactin receptor, deletion of PR (PRKO) totally inhibits alveolar development (96). In contrast to ER_ –/– mice, the defect in PR-mediated development has been localized to the mammary epithelium (105). Elegant PR +/+ and PRKO-lacZtagged MEC reconstitution experiments have demonstrated that PR acts via a paracrine mechanism to induce alveolar proliferation (105). Alveolar development can be rescued if PRKO MEC mixed with PR +/+ MEC are reconstituted in close proximity within the cleared fat pads of syngeneic hosts (105). Recombination of PR +/+ stroma and PR –/– epithelium indicates that the stroma does not play a critical role in alveolar morphogenesis, further emphasizing the importance of epithelial-epithelial paracrine interactions, rather than epithelial-stromal interactions, in PR action (105). These results support previous studies which suggested by immunohistochemistry that PR was expressed exclusively in the mammary epithelium (106). These studies do not rule out the possibility that progesterone may play some role in the mammary stroma (107). CELL-CYCLE REGULATORS AND TRANSCRIPTION FACTORS Cyclin D1 expression is controlled by extracellular mitogens, increasing and decreasing in response to the presence of growth factors (108). In the mammary gland, synergistic induction of cyclin D1 expression is observed in mice treated with estrogen and progesterone (109). The deletion of PR eliminates this synergism, resulting in decreased cyclin D1 expression, providing one mechanism of impaired development in the PRKO mouse (109). Mice lacking cyclin D1 are incapable of nursing their pups, and have relatively few alveoli compared to wild-type litter mates (110,111). When analyzed by transplantation in pregnant hosts, the defect in the proliferation of alveoli was localized to the epithelium (112). The mammary phenotype is completely rescued if cyclin E is expressed under control of the endogenous cyclin D1 promoter, implying that cyclin E is directly downstream of cyclin D1 (113). The transcription factor C/EBP` is also required for development of alveoli in response to estrogen and progesterone (18,95). Reminiscent of the PRKO and prolactin-receptor
220
Seagroves and Rosen
–/– mice, mice lacking C/EBP` are infertile (114) and C/EBP`, like PR, acts in an epithelial-cell autonomous manner (18,95). Coupled with the marked inhibition of lobuloalveolar development, a transient decrease in proliferation of C/EBP` –/– epithelium transplanted into the cleared fat pads of C/EBP` +/+ mice at d 6 and 16 of pregnancy was previously reported (18). Based on these observations, the expression and localization of PR and its relationship to proliferation was determined in C/EBP` –/– mice. Unexpectedly, PR mRNA and protein were upregulated threefold compared to wild-type litter mates (114a). In addition, the cellular distribution of PR was altered from the normal punctate pattern in wild-type mice to a more uniform pattern in mature C/EBP` –/– mice. The aberrant localization and expression of PR correlated with a dramatic 10-fold decrease in alveolar proliferation in response to treatment with exogenous estrogen and progesterone. Preliminary analysis has also indicated that like PR, expression and cellular localization of prolactin-receptor may be increased/disrupted in C/EBP` –/– mice, implicating C/EBP` as an important mediator of alveolar progenitor-cell fate decisions (114a).
Control of Lactation In most transgenic and knockout models analyzed to date, the failure of a mother to successfully nurse her pups has been directly related to the extent of alveolar development and differentiation of the mammary epithelium observed during pregnancy. However, there are at least five genes which, when deleted, result in impaired secretion of milk from otherwise completely developed alveoli: colonystimulating factor-1 (CSF-1), oxytocin (OT), relaxin, the receptor-like tyrosine phosphatase LAR, and the winged helix/forkhead transcription factor Mf3. At lactation, oxytocin stimulates contraction of the myoepithelial cells in order to express milk through the nipple. The deletion of oxytocin impairs ejection of milk from alveoli, resulting in premature, milk stasis-induced apoptosis (115). The phenotype of mice lacking Mf3 is very similar to that observed for OT, and injections of OT will restore secretion of milk (116). The LAR receptor-like tyrosine phosphatase is an integral membrane protein that contains an intracellular phosphatase domain. The extracellular ligands that activate LAR are unknown. However, it is known that LAR may associate with focal adhesion complexes through its interactions with LAR-interacting protein (LIP)1 (117). During pregnancy, LAR mRNA is expressed at higher levels than other protein tyrosine phosphatases (PTP), such as PTPs, and expression of LAR increases dramatically d 9 to d 16 of pregnancy (118). The number and size of alveoli present in LAR –/– are only slightly reduced compared to LAR +/+ mice, but the alveoli that do form in LAR –/– mice fail to exhibit secretory activity, although the alveolar lumens are not collapsed (118). The ability of LAR to be sequestered to focal adhesion complexes suggests that disruption of LAR may interfere with extracellular to nuclear-matrix signals proposed to be important in the regulation of milk-protein gene expression (119). Deletion of relaxin, implicated in nipple development and myoepithelial-cell contraction (120), results in a phenotype very similar to lack of LAR, except that relaxin –/– mice exhibit dilated ducts and decreased nipple size (121). CSF-1 is a growth factor circulated in the serum that is produced by the uterus at high levels during pregnancy (122). In contrast to most knockout mouse models, in which decreased development is associated with a failure to lactate, mice lack-
Chapter 10/Knockout and Transgenic Mouse Models
221
ing CSF-1 (op/op) display significantly increased numbers of alveoli at lactation compared to wild-type litter mates, but fail to lactate (123). The CSF-1 –/– mice are capable of producing normal levels of milk-protein genes, but the alveoli remain collapsed and the products are not secreted; therefore, the mothers are not able to support their litters (123). Exogenous administration of CSF-1 to mice only partially rescues the lactation defect, most likely caused by the inability to induce circulating levels as high as those produced by the uterus during a normal pregnancy (123).
Regression and Remodeling During Involution THE ROLE OF GLUCOCORTICOIDS Serum levels of glucocorticoids remain high throughout lactation, but decrease from 34 ng/L to 14 ng/L by d 3 of involution (124). It has been established for several years that administration of exogenous hydrocortisone to lactating rats inhibits regression of the mammary epithelium (125). The tissue-remodeling phase, but not the apoptosis phase, of involution can be delayed for up to 10 d by injecting mice daily with glucocorticoids (43). These observations are consistent with induction of several tissue-remodeling proteinases following glucocorticoid withdrawal, including stromelysin-1 (124), urokinase-like plasminogen activator (uPA), and gelatinase A (43). Mammary glands of transgenic mice overexpressing stromelysin-1 undergo premature apoptosis during pregnancy (7), suggesting that the glucocorticoid-mediated suppression of apoptosis during pregnancy and lactation can be overcome by overexpression of factors that mediate the tissue-remodeling phase of involution. CELL DEATH INDUCERS AND INHIBITORS During the first phase of involution, expression of several factors associated with cell death are induced, including p53, bax, and bcl-x-short (42,44). The deletion of p53 in Balb/C inbred mice results in delayed involution and decreased rates of apoptosis (126), but these effects may be strain-specific, because lack of p53 does not significantly impair involution or apoptosis in C57/Bl6 × 129 females (127). Individual members of the bcl2 family may either enhance or inhibit apoptosis (reviewed in ref. 128). The ratios of proto anti-apoptotic factors has been demonstrated to be critical to modulate apoptosis (129). In particular, bcl-2 is anti-apoptotic, whereas bax and bcl-x-short promote cell death (128). The mammary glands of mice lacking bcl-2 develop normally (130), but, as expected, overexpression of bcl-2 under control of the WAP promoter delays apoptosis during involution (131). In addition, a decrease in the percentage of apoptotic cells in the TEB has been reported in juvenile WAP-bcl-2 transgenic mice (33). The effects of Cremediated deletion of bcl-x in the mammary gland resulted in accelerated apoptosis during involution (131a). TRANSCRIPTION FACTORS The Cre-lox-mediated deletion of STAT3 in the mammary gland also results in delayed involution (132a), consistent with previous observations of enhanced STAT3 phosphorylation in sealed, but not in unsealed mammary glands (44). The factors downstream of STAT3 are unknown but IGFBP-5 expression is markedly reduced during involution in the mammary gland of the STAT3 conditional knockout mice (132a). However, expression of the transcription factor C/EBPb, which is dramatically upregulated within 24 h
222
Seagroves and Rosen
of involution (132), is reported to be directly regulated by STAT3 following stimulation by interleukin-6 (IL-6) (133). Mice lacking C/EBPb have been created, and are viable and fertile (134), but analysis of development of the mammary gland has not been reported. GROWTH FACTORS Overexpression of several growth factors delays or impairs involution, including TGF-_ and IGF-I (85,135–137). These observations are not surprising, because IGF-I acts as a cell-survival factor in mammary epithelial cells (138,139). In fact, multiply bred WAP-IGF-I transgenic mice eventually develop mammary tumors, presumably because fewer cells enter apoptosis, allowing accumulation of spontaneous mutations acquired during multiple rounds of proliferation during pregnancy (139a). Tumors have also been observed in transgenic mice overexpressing IGF-II after multiple pregnancies (140). The IGF binding proteins (IGFBPs) may either enhance or attenuate the mitogenic effects of IGF-I or IGF-II (141). Two IGFBPs—IGFBP-3 and IGFBP-5—have been implicated in regulation of involution. The level of IGFBP-5 secreted in milk increases 50-fold during forced involution, and increases 5– to 10-fold specifically in sealed teats compared to open teats (142). WAP-driven overexpression of IGFBP-3 delays involution, presumably because of the augmentation of IGF-I biological activity, although the delay is not as severe as observed in WAP-IGF-I mice (136). These observations may correlate with the expression of IGFBP-5 and IGFBP-3 during normal virgin development. In the TEB of the juvenile mammary gland, relatively high levels of both IGFBP-5 and IGFBP-3 mRNA are expressed (143). The expression of IGFBP-5 mRNA is uniform in all cell layers, whereas expression of IGFBP-3 mRNA appears to be restricted to the outer cell layers that may be coincident with the proliferative cap-cell layer (143). IGFBP-5 may associate with the extracellular matrix (144), presumably to regulate IGF-I biological activity over a short range. Secreted IGFBP-5 in milk may have activities distinct from the IGFBP-5 bound to the extracellular matrix, since bound IGFBP-5 is reported to enhance IGF-I mitogenic activity (144), whereas expression of IGFBP-5 in milk is correlated with induction of apoptosis during involution (142). Alternatively, the effects of IGFBP-5 may be tissue-specific. It is possible that the IGFBP-5 present in the TEB inhibits IGF-I action, as during involution, in order to determine which cell layers proliferate. If the restricted expression pattern of IGFBP-3 mRNA in the TEB does mediate proliferation of the cap-cell layers, the observation of delayed involution in WAP-IGFBP-3 mice would be consistent with this model. In general, deletion of individual genes does not significantly alter involution. In contrast, overexpression of growth factor and anti-apoptotic genes is sufficient to delay—but not halt—involution. Interestingly, some of the same genes that are implicated as factors regulating virgin ductal morphogenesis in TEBs—such as IGFBP-5, IGFBP-3, and bcl-2—also appear to be important for the induction of apoptosis during involution.
Summary of Knockout and Transgenic Models In summary, the mouse models described here have confirmed the results derived from classical endocrinology experiments demonstrating that hormones control mammary-gland development and differentiation. In addition, they have also provided clues
Chapter 10/Knockout and Transgenic Mouse Models
223
Fig. 5. A partial list of genes regulating the progression of mouse mammary-gland development, differentiation, lactation, and remodeling. The large arrow indicates regression of epithelial cells during involution to a more virgin-like state in which the mammary gland contains primarily ductal epithelium. This figure was adapted and reprinted with permission from Cold Spring Harbor Laboratory Press (29).
to the some of the cell-signaling pathways that mediate mammary-gland development. A partial list of some the factors controlling postnatal mammary-gland development is presented in Fig. 5. This is an exciting time in mammary-gland biology. We now have the techniques required to answer critical and mechanistic questions. The many technical advantages that the mammary gland offers in combination with the sophisticated genetic manipulations available in the field of mammary gland research should provide an impetus for more investigators